Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases

ABSTRACT

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.

The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.

Vasopressin is an endogenous hormone which exerts various effects on organs and tissues. It is suspected that the vasopressin system is involved in various pathological states such as, for example, heart failure and high blood pressure. At present, three receptors (V1a, V1b or V3 and V2) via which vasopressin mediates its numerous effects are known. Antagonists of these receptors are therefore being investigated as possible new therapeutic approaches for the treatment of diseases (M. Thibonnier, Exp. Opin. Invest. Drugs 1998, 7(5), 729-740; T. Ryckmans, Current Opinion in Drug Discovery & Development 13 (2010), 538-547; G. Decaux et al., Lancet 371 (2008), 1624-1632; R. Lemmens-Gruber, M. Kamyar, Cell. Mol. Life Sci. 63 (2006), 1766-1779).

1-(Het)Arylsulfonyl-1,3-dihydro-2H-indol-2-ones have previously been described as ligands of vasopressin receptors, for example in WO 2005/030755, WO 2006/005609, WO 2006/080574, WO 2008/080970, WO 2008/080971, WO 2008/080972, WO 2008/080973, WO 2009/071687, WO 2009/071689, WO 2009/071690, WO2009/071691, WO 2009/083559, WO 2010/009775 or WO 2010/142739.

Besides the binding affinity for the vasopressin V1b receptor, further properties may be advantageous for the treatment and/or prophylaxis of vasopressin-related disorders, such as, for example:

1.) a selectivity for the vasopressin V1b receptor compared with the vasopressin V1a receptor, i.e. the quotient of the binding affinity for the V1a receptor (Ki(V1a) (determined in the unit “nanomolar (nM)”) and the binding affinity for the V1b receptor (Ki(V1b)) (determined in the unit “nanomolar (nM)”). A larger quotient Ki(V1a)/Ki(V1b) means a greater V1b selectivity;

2.) a selectivity for the vasopressin V1b receptor compared with the vasopressin V2 receptor, i.e. the quotient of the binding affinity for the V2 receptor (Ki(V2) (determined in the unit “nanomolar (nM)”) and the binding affinity for the V1b receptor (Ki(V1b)) (determined in the unit “nanomolar (nM)”). A larger quotient Ki(V2)/Ki(V1b) means a greater V1b selectivity;

3.) a selectivity for the vasopressin V1b receptor compared with the oxytocin OT receptor, i.e. the quotient of the binding affinity for the OT receptor (Ki(OT) (determined in the unit “nanomolar (nM)”) and the binding affinity for the V1b receptor (Ki(V1b)) (determined in the unit “nanomolar (nM)”). A larger quotient Ki(OT)/Ki(V1b) means a greater V1b selectivity.

4.) the metabolic stability, for example determined from the half-lives, measured in vitro, in liver microsomes from various species (e.g. rat or human);

5.) no or only low inhibition of cytochrome P450 (CYP) enzymes: cytochrome P450 (CYP) is the name for a superfamily of heme proteins having enzymatic activity (oxidase). They are also particularly important for the degradation (metabolism) of foreign substances such as drugs or xenobiotics in mammalian organisms. The principal representatives of the types and subtypes of CYP in the human body are: CYP 1A2, CYP 2C9, CYP 2D6 and CYP 3A4. If CYP 3A4 inhibitors (e.g. grapefruit juice, cimetidine, erythromycin) are used at the same time as medicinal substances which are degraded by this enzyme system and thus compete for the same binding site on the enzyme, the degradation thereof may be slowed down and thus effects and side effects of the administered medicinal substance may be undesirably enhanced;

6.) a suitable solubility in water (in mg/ml);

7.) suitable pharmacokinetics (time course of the concentration of the compound of the invention in plasma or in tissue, for example brain). The pharmacokinetics can be described by the following parameters: half-life (in h), volume of distribution (in l·kg-l), plasma clearance (in l·h-l·kg-l), AUC (area under the curve, area under the concentration-time curve, in ng·h·l-l), oral bioavailability (the dose-normalized ratio of AUC after oral administration and AUC after intravenous administration), the so-called brain-plasma ratio (the ratio of AUC in brain tissue and AUC in plasma);

8.) no or only low blockade of the hERG channel: compounds which block the hERG channel may cause a prolongation of the QT interval and thus lead to serious disturbances of cardiac rhythm (for example so-called “torsade de pointes”). The potential of compounds to block the hERG channel can be determined by means of the displacement assay with radiolabelled dofetilide which is described in the literature (G. J. Diaz et al., Journal of Pharmacological and Toxicological Methods, 50 (2004), 187 199). A smaller IC50 in this dofetilide assay means a greater probability of potent hERG blockade. In addition, the blockade of the hERG channel can be measured by electrophysiological experiments on cells which have been transfected with the hERG channel, by so-called whole-cell patch clamping (G. J. Diaz et al., Journal of Pharmacological and Toxicological Methods, 50 (2004), 187-199).

It was therefore an object of the present invention to provide compounds for the treatment or prophylaxis of various vasopressin-related diseases. The compounds were intended to have a high activity and selectivity, especially a high affinity and selectivity vis-à-vis the vasopressin V1b receptor. In addition, the substance of the invention was intended to have one or more of the aforementioned advantages 1.) to 8.).

The object is achieved by compounds of the formula I

wherein

-   X¹ is N or CH; -   X² is C—R¹ or N; -   R¹ and R², independently of each other, are selected from hydrogen,     halogen, cyano, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl,     C₁-C₃-hydroxyalkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy; -   R³ is selected from hydrogen, halogen, cyano, hydroxyl, C₁-C₃-alkyl,     fluorinated C₁-C₃-alkyl, C₁-C₃-hydroxyalkyl, C₁-C₃-alkoxy and     fluorinated C₁-C₃-alkoxy; -   R⁴ is selected from C₁-C₃-alkoxy; -   R⁵ is selected from hydrogen and C₁-C₃-alkoxy; -   R⁶ is selected from cyano and halogen; -   R⁷ is selected from hydrogen, halogen and cyano; -   R⁸ is selected from hydrogen, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl,     C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl,     C₃-C₇-cycloalkyl, C₃-C₇-halocycloalkyl and phenyl which may carry 1,     2 or 3 substituents selected from halogen, hydroxyl, cyano,     C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; -   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl,     C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio,     C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl,     C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, phenoxy, where the     phenyl moiety may carry 1, 2 or 3 substituents selected from     halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy     and C₁-C₄-haloalkoxy; and a 3-, 4-, 5-, 6- or 7-membered saturated,     partially unsaturated or maximally unsaturated heterocyclic ring     containing 1, 2 or 3 heteroatoms or heteroatom groups selected from     O, N, S, NO, SO and SO₂ as ring members, where the heterocyclic ring     may carry 1, 2 or 3 substituents selected from halogen, hydroxyl,     cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and     C₁-C₄-haloalkoxy; or     -   R⁸ and R⁹, together with the nitrogen atom they are bound to,         form a 3-, 4-, 5-, 6- or 7-membered saturated, partially         unsaturated or maximally unsaturated heterocyclic ring, where         the heterocyclic ring may contain 1 or 2 further heteroatoms or         heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring         members, and where the heterocyclic ring may carry 1 or 2         substituents R¹² and/or 1 or 2 substituents R¹³; where in case         that the heterocyclic ring does not contain 1 or 2 further         heteroatoms or heteroatom groups as ring members, the         heterocyclic ring carries 1 or 2 substituents R¹² and optionally         1 or 2 substituents R¹³; -   R¹⁰ and R¹¹, independently of each other and independently of each     occurrence, are selected from halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl,     C₁-C₄-alkoxy and C₁-C₄-haloalkoxy, with the proviso that R¹⁰ and R¹¹     are not halogen, C₁-C₄-alkoxy or C₁-C₄-haloalkoxy if they are bound     to a carbon atom in α-position to a nitrogen ring atom; or     -   two non-geminal radicals R¹⁰ form together a group —(CH₂)_(n)—,         where n is 1, 2, 3 or 4, where 1 or 2 hydrogen atoms in this         group may be replaced a methyl group; or     -   two non-geminal radicals R¹¹ form together a group —(CH₂)_(n)—,         where n is 1, 2, 3 or 4, where 1 or 2 hydrogen atoms in this         group may be replaced a methyl group; -   each R¹² is independently selected from halogen, hydroxyl,     C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy,     C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio,     C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl,     C₁-C₄-haloalkylsulfonyl, phenoxy, benzyloxy, where the phenyl moiety     in the two last-mentioned radicals may carry 1, 2 or 3 substituents     selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and a 3-, 4-,     5-, 6- or 7-membered saturated, partially unsaturated or maximally     unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or     heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring     members, where the heterocyclic ring may carry 1, 2 or 3     substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;     -   or     -   two radicals R¹², together with the atom(s) they are bound to,         form a 3-, 4-, 5-, 6- or 7-membered saturated, partially         unsaturated or maximally unsaturated heterocyclic ring         containing 1, 2 or 3 heteroatoms or heteroatom groups selected         from O, N, S, NO, SO and SO₂ as ring members, where the         heterocyclic ring may carry 1, 2 or 3 substituents selected from         halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl,         C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; -   each R¹³ is independently selected from halogen, hydroxyl, cyano,     C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl,     C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl,     C₃-C₇-halocycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio,     C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl,     C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, C₁-C₄-alkylcarbonyl,     C₁-C₄-haloalkylcarbonyl, phenyl, phenoxy and a 3-, 4-, 5-, 6- or     7-membered saturated, partially unsaturated or maximally unsaturated     heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom     groups selected from O, N, S, NO, SO and SO₂ as ring members, where     the phenyl moieties or the heterocyclic ring may carry 1, 2 or 3     substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; -   a is 0, 1 or 2; and -   b is 0, 1, 2, 3 or 4;     and the N-oxides, stereoisomers and pharmaceutically acceptable     salts thereof, and the compound of the formula I, wherein at least     one of the atoms has been replaced by its stable, non-radioactive     isotope.

Accordingly, the present invention relates to compounds of the formula I (also “compounds I” hereinafter) and the N-oxides, stereoisomers and the pharmaceutically acceptable salts of the compounds I of the compounds I.

In another aspect, the invention relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of formula I or an N-oxide, a stereoisomer or a pharmaceutically acceptable salt thereof, or comprising at least one compound as defined above or below wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope, preferably wherein at least one hydrogen atom has been replaced by a deuterium atom, in combination with at least one pharmaceutically acceptable carrier and/or auxiliary substance.

In yet another aspect, the invention relates to a compound of formula I or an N-oxide, a stereoisomer or a pharmaceutically acceptable salt thereof for use as a medicament.

In yet another aspect, the invention relates to a compound of formula I or an N-oxide, a stereoisomer or a pharmaceutically acceptable salt thereof for the treatment and/or prophylaxis of vasopressin-related diseases, especially of disorders which respond to the modulation of the vasopressin receptor, in particular of the V1b receptor.

In yet another aspect, the invention relates to the use of a compound of formula I or of an N-oxide, a stereoisomer or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prophylaxis of vasopressin-related diseases; especially of disorders which respond to the modulation of the vasopressin receptor, in particular of the V1b receptor.

The pharmaceutically acceptable salts of compounds of the formula I, which are also referred to as physiologically tolerated salts, are ordinarily obtainable by reacting the free base of the compounds I of the invention (i.e. of the compounds I according to structural formula I) with suitable acids. Examples of suitable acids are listed in “Fortschritte der Arzneimittelforschung”, 1966, Birkhauser Verlag, vol. 10, pp. 224-285. These include for example hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, trifluoroacetic acid, formic acid, maleic acid and fumaric acid.

Halogen in the terms of the present invention is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine and especially fluorine or chlorine.

C₁-C₃-Alkyl is a linear or branched alkyl radical having 1 to 3 carbon atoms, such as methyl, ethyl, n-propyl or isopropyl. C₁-C₄-Alkyl is a linear or branched alkyl radical having 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl.

Fluorinated alkyl is a straight-chain or branched alkyl group having from 1 to 4 (=fluorinated C₁-C₄-alkyl), in particular 1 to 3 carbon atoms (=fluorinated C₁-C₃-alkyl), more preferably 1 or 2 carbon atoms (=fluorinated C₁-C₂-alkyl), wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by fluorine atoms. Examples for fluorinated C₁-C₂-alkyl are fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, (R)-1-fluoroethyl, (S)-1-fluoroethyl, 2-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl and the like. Examples for fluorinated C₁-C₃-alkyl are, apart those mentioned above for fluorinated C₁-C₂-alkyl, 1-fluoropropyl, (R)-1-fluoropropyl, (S)-1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1,1-difluoropropyl, 2,2-difluoropropyl, 3,3-difluoropropyl, 3,3,3-trifluoropropyl, 2-fluoropropyl, 2-fluoro-1-methylethyl, (R)-2-fluoro-1-methylethyl, (S)-2-fluoro-1-methylethyl, 2,2-difluoro-1-methylethyl, (R)-2,2-difluoro-1-methylethyl, (S)-2,2-difluoro-1-methylethyl, 1,2-difluoro-1-methylethyl, (R)-1,2-difluoro-1-methylethyl, (S)-1,2-difluoro-1-methylethyl, 2,2,2-trifluoro-1-methylethyl, (R)-2,2,2-trifluoro-1-methylethyl, (S)-2,2,2-trifluoro-1-methylethyl, 2-fluoro-1-(fluoromethyl)ethyl, 1-(difluoromethyl)-2,2-difluoroethyl and the like. Examples for fluorinated C₁-C₄-alkyl are, apart those mentioned above for fluorinated C₁-C₃-alkyl, 1-fluorobutyl, (R)-1-fluorobutyl, (S)-1-fluorobutyl, 2-fluorobutyl, 3-fluorobutyl, 4-fluorobutyl, 1,1-difluorobutyl, 2,2-difluorobutyl, 3,3-difluorobutyl, 4,4-difluorobutyl, 4,4,4-trifluorobutyl, and the like.

C₁-C₄-Haloalkyl is C₁-C₄-alkyl as defined above wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by a halogen atom. Examples are, apart those mentioned above for fluorinated C₁-C₄-alkyl, chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, 3-chloropropyl, 4-chlorobutyl and the like.

C₁-C₃-Hydroxyalkyl is C₁-C₃-alkyl as defined above wherein one of the hydrogen atoms is replaced by a hydroxyl group. Examples are hydroxymethyl, 1- and 2-hydroxyethyl, 1-, 2- and 3-hydroxy-n-propyl, 1-(hydroxymethyl)-ethyl and the like.

C₃-C₇-Cycloalkyl is a monocyclic saturated hydrocarbon radical having 3 to 7, in particular 3 to 6 (“C₃-C₆-cycloalkyl”) or 3 to 5 (“C₃-C₅-cycloalkyl”) or 3 to 4 (“C₃-C₄-cycloalkyl”) carbon atoms. Examples of C₃-C₄-cycloalkyl comprise cyclopropyl and cyclobutyl. Examples of C₃-C₅-cycloalkyl comprise cyclopropyl, cyclobutyl and cyclopentyl. Examples of C₃-C₆-cycloalkyl comprise cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Examples of C₃-C₇-cycloalkyl comprise cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

C₃-C₇-Halocycloalkyl is a monocyclic saturated hydrocarbon radical having 3 to 7, in particular 3 to 6 (“C₃-C₆-halocycloalkyl”) or 3 to 5 (“C₃-C₅-halocycloalkyl”) or 3 to 4 (“C₃-C₄-halocycloalkyl”) carbon ring members (as mentioned above) in which some or all of the hydrogen atoms are replaced by halogen atoms as mentioned above, in particular fluorine, chlorine and bromine.

C₁-C₃-Alkoxy is a linear or branched alkyl radical linked via an oxygen atom and having 1 to 3 carbon atoms. Examples are methoxy, ethoxy, n-propoxy and isopropoxy. C₁-C₄-Alkoxy is a linear or branched alkyl radical linked via an oxygen atom and having 1 to 4 carbon atoms. Examples are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy and tert-butoxy.

C₁-C₄-Haloalkoxy is C₁-C₄-alkoxy as defined above wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by a halogen atom. Preferably, C₁-C₄-haloalkoxy is fluorinated C₁-C₄-alkoxy. This is a straight-chain or branched alkoxy group having from 1 to 4, in particular 1 to 3 carbon atoms (=fluorinated C₁-C₃-alkoxy), more preferably 1 or 2 carbon atoms (=fluorinated C₁-C₂-alkoxy), wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by fluorine atoms, such as in fluoromethoxy, difluoromethoxy, trifluoromethoxy, 1-fluoroethoxy, (R)-1-fluoroethoxy, (S)-1-fluoroethoxy, 2-fluoroethoxy, 1,1-difluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 1-fluoropropoxy, (R)-1-fluoropropoxy, (S)-1-fluoropropoxy, 2-fluoropropoxy, 3-fluoropropoxy, 1,1-difluoropropoxy, 2,2-difluoropropoxy, 3,3-difluoropropoxy, 3,3,3-trifluoropropoxy, 2-fluoro-1-methylethoxy, (R)-2-fluoro-1-methylethoxy, (S)-2-fluoro-1-methylethoxy, 2,2-difluoro-1-methylethoxy, (R)-2,2-difluoro-1-methylethoxy, (S)-2,2-difluoro-1-methylethoxy, 1,2-difluoro-1-methylethoxy, (R)-1,2-difluoro-1-methylethoxy, (S)-1,2-difluoro-1-methylethoxy, 2,2,2-trifluoro-1-methylethoxy, (R)-2,2,2-trifluoro-1-methylethoxy, (S)-2,2,2-trifluoro-1-methylethoxy, 2-fluoro-1-(fluoromethyl)ethoxy, 1-(difluoromethyl)-2,2-difluoroethoxy, (R)-1-fluorobutoxy, (S)-1-fluorobutoxy, 2-fluorobutoxy, 3-fluorobutoxy, 4-fluorobutoxy, 1,1-difluorobutoxy, 2,2-difluorobutoxy, 3,3-difluorobutoxy, 4,4-difluorobutoxy, 4,4,4-trifluorobutoxy, etc

C₃-C₇-Cycloalkoxy is a monocyclic saturated hydrocarbon radical linked via an oxygen atom and having 3 to 7, in particular 3 to 6 (“C₃-C₆-cycloalkyl”) or 3 to 5 (“C₃-C₅-cycloalkyl”) or 3 to 4 (“C₃-C₄-cycloalkyl”) carbon atoms. Examples of C₃-C₄-cycloalkoxy comprise cyclopropoxy and cyclobutoxy. Examples of C₃-C₅-cycloalkoxy comprise cyclopropoxy, cyclobutoxy and cyclopentoxy. Examples of C₃-C₆-cycloalkoxy comprise cyclopropoxy, cyclobutoxy, cyclopentoxy and cyclohexoxy. Examples of C₃-C₇-cycloalkoxy comprise cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy and cycloheptoxy.

C₃-C₇-Halocycloalkoxy is a monocyclic saturated hydrocarbon radical linked via an oxygen atom and having 3 to 7, in particular 3 to 6 (“C₃-C₆-halocycloalkoxy”) or 3 to 5 (“C₃-C₅-halocycloalkoxy”) or 3 to 4 (“C₃-C₄-halocycloalkoxy”) carbon ring members (as mentioned above) in which some or all of the hydrogen atoms are replaced by halogen atoms as mentioned above, in particular fluorine, chlorine and bromine.

“C₁-C₄-Alkoxy-C₁-C₄-alkyl” refers to a straight-chain or branched alkyl group having 1 to 4 carbon atoms, as defined above, where one hydrogen atom is replaced by a C₁-C₄-alkoxy group, as defined above. Examples are methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, n-butoxymethyl, sec-butoxymethyl, isobutoxymethyl, tert-butoxymethyl, 1-methoxyethyl, 1-ethoxyethyl, 1-propoxyethyl, 1-isopropoxyethyl, 1-n-butoxyethyl, 1-sec-butoxyethyl, 1-isobutoxyethyl, 1-tert-butoxyethyl, 2-methoxyethyl, 2-ethoxyethyl, 2-propoxyethyl, 2-isopropoxyethyl, 2-n-butoxyethyl, 2-sec-butoxyethyl, 2-isobutoxyethyl, 2-tert-butoxyethyl, 1-methoxypropyl, 1-ethoxypropyl, 1-propoxypropyl, 1-isopropoxypropyl, 1-n-butoxypropyl, 1-sec-butoxypropyl, 1-isobutoxypropyl, 1-tert-butoxypropyl, 2-methoxypropyl, 2-ethoxypropyl, 2-propoxypropyl, 2-isopropoxypropyl, 2-n-butoxypropyl, 2-sec-butoxypropyl, 2-isobutoxypropyl, 2-tert-butoxypropyl, 3-methoxypropyl, 3-ethoxypropyl, 3-propoxypropyl, 3-isopropoxypropyl, 3-n-butoxypropyl, 3-sec-butoxypropyl, 3-isobutoxypropyl, 3-tert-butoxypropyl and the like.

C₁-C₄-Haloalkoxy-C₁-C₄-alkyl is a straight-chain or branched alkyl group having from 1 to 4 carbon atoms, wherein one of the hydrogen atoms is replaced by a C₁-C₄-alkoxy group and wherein at least one, e.g. 1, 2, 3, 4 or all of the remaining hydrogen atoms (either in the alkoxy moiety or in the alkyl moiety or in both) are replaced by halogen atoms. Examples are difluoromethoxymethyl (CHF₂OCH₂), trifluoromethoxymethyl, 1-difluoromethoxyethyl, 1-trifluoromethoxyethyl, 2-difluoromethoxyethyl, 2-trifluoromethoxyethyl, difluoro-methoxy-methyl (CH₃OCF₂), 1,1-difluoro-2-methoxyethyl, 2,2-difluoro-2-methoxyethyl and the like.

C₁-C₄-Alkylthio is a C₁-C₄-alkyl group, as defined above, attached via a sulfur atom. Examples are methylthio, ethylthio, n-propylthio, 1-methylethylthio (isopropylthio), butylthio, 1-methylpropylthio (sec-butylthio), 2-methylpropylthio (isobutylthio) or 1,1-dimethylethylthio (tert-butylthio).

C₁-C₄-Haloalkylthio is a C₁-C₄-haloalkyl group, as defined above, attached via a sulfur atom. Examples are SCH₂F, SCHF₂, SCF₃, SCH₂Cl, SCHCl₂, SCCl₃, chlorofluoromethylthio, dichlorofluoromethylthio, chlorodifluoromethylthio, 2-fluoroethylthio, 2-chloroethylthio, 2-bromoethylthio, 2-iodoethylthio, 2,2-difluoroethylthio, 2,2,2-trifluoroethylthio, 2-chloro-2-fluoroethylthio, 2-chloro-2,2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio, 2,2,2-trichloroethylthio, SC₂F₅, 2-fluoropropylthio, 3-fluoropropylthio, 2,2-difluoropropylthio, 2,3-difluoropropylthio, 2-chloropropylthio, 3-chloropropylthio, 2,3-dichloropropylthio, 2-bromopropylthio, 3-bromopropylthio, 3,3,3-trifluoropropylthio, 3,3,3-trichloropropylthio, SCH₂—C₂F₅, SCF₂—C₂F₅, 1-(CH₂F)-2-fluoroethylthio, 1-(CH₂Cl)-2-chloroethylthio, 1-(CH₂Br)-2-bromoethylthio, 4-fluorobutylthio, 4-chlorobutylthio, 4-bromobutylthio or nonafluorobutylthio.

C₁-C₄-Alkylsulfinyl is a C₁-C₁-alkyl group, as defined above, attached via a sulfinyl [S(O)] group. Examples are methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, 1-methylethylsulfinyl (isopropylsulfinyl), butylsulfinyl, 1-methylpropylsulfinyl (sec-butylsulfinyl), 2-methylpropylsulfinyl (isobutylsulfinyl) or 1,1-dimethylethylsulfinyl (tert-butylsulfinyl).

C₁-C₄-Haloalkylsulfinyl is a C₁-C₄-haloalkyl group, as defined above, attached via a sulfinyl [S(O)] group. Examples are S(O)CH₂F, S(O)CHF₂, S(O)CF₃, S(O)CH₂Cl, S(O)CHCl₂, S(O)CCl₃, chlorofluoromethylsulfinyl, dichlorofluoromethylsulfinyl, chlorodifluoromethylsulfinyl, 2-fluoroethylsulfinyl, 2-chloroethylsulfinyl, 2-bromoethylsulfinyl, 2-iodoethylsulfinyl, 2,2-difluoroethylsulfinyl, 2,2,2-trifluoroethylsulfinyl, 2-chloro-2-fluoroethylsulfinyl, 2-chloro-2,2-difluoroethylsulfinyl, 2,2-dichloro-2-fluoroethylsulfinyl, 2,2,2-trichloroethylsulfinyl, S(O)C₂F₅, 2-fluoropropylsulfinyl, 3-fluoropropylsulfinyl, 2,2-difluoropropylsulfinyl, 2,3-difluoropropylsulfinyl, 2-chloropropylsulfinyl, 3-chloropropylsulfinyl, 2,3-dichloropropylsulfinyl, 2-bromopropylsulfinyl, 3-bromopropylsulfinyl, 3,3,3-trifluoropropylsulfinyl, 3,3,3-trichloropropylsulfinyl, S(O)CH₂—C₂F₅, S(O)CF₂—C₂F₅, 1-(CH₂F)-2-fluoroethylsulfinyl, 1-(CH₂Cl)-2-chloroethylsulfinyl, 1-(CH₂Br)-2-bromoethylsulfinyl, 4-fluorobutylsulfinyl, 4-chlorobutylsulfinyl, 4-bromobutylsulfinyl or nonafluorobutylsulfinyl.

C₁-C₄-Alkylsulfonyl is a C₁-C₄-alkyl group, as defined above, attached via a sulfonyl [S(O)₂] group. Examples are methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, 1-methylethylsulfonyl (isopropylsulfonyl), butylsulfonyl, 1-methylpropylsulfonyl (sec-butylsulfonyl), 2-methylpropylsulfonyl (isobutylsulfonyl) or 1,1-dimethylethylsulfonyl (tert-butylsulfonyl).

C₁-C₄-Haloalkylsulfonyl is a C₁-C₄-haloalkyl group, as defined above, attached via a sulfonyl [S(O)₂] group. Examples are S(O)₂CH₂F, S(O)₂CHF₂, S(O)₂CF₃, S(O)₂CH₂Cl, S(O)₂CHCl₂, S(O)₂CCl₃, chlorofluoromethylsulfonyl, dichlorofluoromethylsulfonyl, chlorodifluoromethylsulfonyl, 2-fluoroethylsulfonyl, 2-chloroethylsulfonyl, 2-bromoethylsulfonyl, 2-iodoethylsulfonyl, 2,2-difluoroethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, 2-chloro-2-fluoroethylsulfonyl, 2-chloro-2,2-difluoroethylsulfonyl, 2,2-dichloro-2-fluoroethylsulfonyl, 2,2,2-trichloroethylsulfonyl, S(O)₂C₂F₅, 2-fluoropropylsulfonyl, 3-fluoropropylsulfonyl, 2,2-difluoropropylsulfonyl, 2,3-difluoropropylsulfonyl, 2-chloropropylsulfonyl, 3-chloropropylsulfonyl, 2,3-dichloropropylsulfonyl, 2-bromopropylsulfonyl, 3-bromopropylsulfonyl, 3,3,3-trifluoropropylsulfonyl, 3,3,3-trichloropropylsulfonyl, S(O)₂CH₂—C₂F₅, S(O)₂CF₂—C₂F₅, 1-(CH₂F)-2-fluoroethylsulfonyl, 1-(CH₂Cl)-2-chloroethylsulfonyl, 1-(CH₂Br)-2-bromoethylsulfonyl, 4-fluorobutylsulfonyl, 4-chlorobutylsulfonyl, 4-bromobutylsulfonyl or nonafluorobutylsulfonyl.

C₁-C₄-Alkylcarbonyl is a C₁-C₄-alkyl group, as defined above, attached via a carbonyl [C(═O)] group. Examples are acetyl (methylcarbonyl), propionyl (ethylcarbonyl), propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl and the like.

C₁-C₄-Haloalkylcarbonyl is a C₁-C₄-haloalkyl group, as defined above, attached via a carbonyl [C(═O)] group. Examples are trifluoromethylcarbonyl, 2,2,2-trifluoroethylcarbonyl and the like.

The term “3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members” denotes a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximum unsaturated heteromonocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂, as ring members.

Unsaturated rings contain at least one C—C and/or C—N and/or N—N double bond(s). Maximally unsaturated rings contain as many conjugated C—C and/or C—N and/or N—N double bonds as allowed by the ring size. Maximally unsaturated 5- or 6-membered heterocyclic rings are aromatic. The heterocyclic ring may be attached to the remainder of the molecule via a carbon ring member or via a nitrogen ring member. As a matter of course, the heterocyclic ring contains at least one carbon ring atom. If the ring contains more than one O ring atom, these are not adjacent.

The term “3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximum unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂, as ring members” [wherein “maximum unsaturated” includes also “aromatic”] as used herein denotes monocyclic radicals, the monocyclic radicals being saturated, partially unsaturated or maximum unsaturated (including aromatic). 7-membered rings cannot be aromatic; they are homoaromatic if maximally unsaturated (3 double bonds).

Examples of a 3-, 4-, 5-, 6- or 7-membered saturated heterocyclic ring include: Oxiranyl, thiiranyl, aziridinyl, oxetanyl, thietanyl, azetidinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrazolidin-1-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, pyrazolidin-5-yl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, oxazolidin-2-yl, oxazolidin-3-yl, oxazolidin-4-yl, oxazolidin-5-yl, isoxazolidin-2-yl, isoxazolidin-3-yl, isoxazolidin-4-yl, isoxazolidin-5-yl, thiazolidin-2-yl, thiazolidin-3-yl, thiazolidin-4-yl, thiazolidin-5-yl, isothiazolidin-2-yl, isothiazolidin-3-yl, isothiazolidin-4-yl, isothiazolidin-5-yl, 1,2,4-oxadiazolidin-3-yl, 1,2,4-oxadiazolidin-5-yl, 1,2,4-thiadiazolidin-3-yl, 1,2,4-thiadiazolidin-5-yl, 1,2,4-triazolidin-3-yl, 1,3,4-oxadiazolidin-2-yl, 1,3,4-thiadiazolidin-2-yl, 1,3,4-triazolidin-1-yl, 1,3,4-triazolidin-2-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 1,3-dioxan-5-yl, 1,4-dioxan-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, hexahydropyridazin-3-yl, hexahydropyridazin-4-yl, hexahydropyrimidin-2-yl, hexahydropyrimidin-4-yl, hexahydropyrimidin-5-yl, piperazin-1-yl, piperazin-2-yl, 1,3,5-hexahydrotriazin-1-yl, 1,3,5-hexahydrotriazin-2-yl and 1,2,4-hexahydrotriazin-3-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, thiomorpholin-2-yl, thiomorpholin-3-yl, thiomorpholin-4-yl, 1-oxothiomorpholin-2-yl, 1-oxothiomorpholin-3-yl, 1-oxothiomorpholin-4-yl, 1,1-dioxothiomorpholin-2-yl, 1,1-dioxothiomorpholin-3-yl, 1,1-dioxothiomorpholin-4-yl, azepan-1-, -2-, -3- or -4-yl, oxepan-2-, -3-, -4- or -5-yl, hexahydro-1,3-diazepinyl, hexahydro-1,4-diazepinyl, hexahydro-1,3-oxazepinyl, hexahydro-1,4-oxazepinyl, hexahydro-1,3-dioxepinyl, hexahydro-1,4-dioxepinyl and the like.

Examples of a 3-, 4-, 5-, 6- or 7-membered partially unsaturated heterocyclic ring include: 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl, 2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3-dihydrothien-2-yl, 2,3-dihydrothien-3-yl, 2,4-dihydrothien-2-yl, 2,4-dihydrothien-3-yl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl, 2-isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxazolin-5-yl, 4-isoxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl, 2,3-dihydropyrazol-1-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl, 2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 2-, 3-, 4-, 5- or 6-di- or tetrahydropyridinyl, 3-di- or tetrahydropyridazinyl, 4-di- or tetrahydropyridazinyl, 2-di- or tetrahydropyrimidinyl, 4-di- or tetrahydropyrimidinyl, 5-di- or tetrahydropyrimidinyl, di- or tetrahydropyrazinyl, 1,3,5-di- or tetrahydrotriazin-2-yl, 1,2,4-di- or tetrahydrotriazin-3-yl, 2,3,4,5-tetrahydro[1H]azepin-1-, -2-, -3-, -4-, -5-, -6- or -7-yl, 3,4,5,6-tetrahydro[2H]azepin-2-, -3-, -4-, -5-, -6- or -7-yl-, -2,3,4,7-tetrahydro[1H]azepin-1-, -2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,6,7-tetrahydro[1H]azepin-1-, -2-, -3-, -4-, -5-, -6- or -7-yl, tetrahydrooxepinyl, such as 2,3,4,5-tetrahydro[1H]oxepin-2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,4,7-tetrahydro[1H]oxepin-2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,6,7-tetrahydro[1H]oxepin-2-, -3-, -4-, -5-, -6- or -7-yl, tetrahydro-1,3-diazepinyl, tetrahydro-1,4-diazepinyl, tetrahydro-1,3-oxazepinyl, tetrahydro-1,4-oxazepinyl, tetrahydro-1,3-dioxepinyl and tetrahydro-1,4-dioxepinyl.

Examples for a 3-, 4-, 5-, 6- or 7-membered maximally unsaturated (including aromatic) heterocyclic ring are 5- or 6-membered heteroaromatic rings, such as 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 1,3,4-triazol-1-yl, 1,3,4-triazol-2-yl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 1-oxopyridin-2-yl, 1-oxopyridin-3-yl, 1-oxopyridin-4-yl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl and 2-pyrazinyl, and also homoaromatic radicals, such as 1H-azepine, 1H-[1,3]-diazepine and 1H-[1,4]-diazepine.

The compounds of the invention of the formula I and their N-oxides, stereoisomers and pharmacologically acceptable salts may also be present in the form of solvates or hydrates. Solvates mean in the context of the present invention crystalline forms of the compounds I or of their pharmaceutically acceptable salts which comprise solvent molecules incorporated in the crystal lattice. The solvent molecules are preferably incorporated in stoichiometric ratios. Hydrates are a specific form of solvates; the solvent in this case being water.

The statements made hereinafter concerning suitable and preferred features of the invention, especially concerning the radicals R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, X¹, X², a and b in the compound I, but also concerning the features of the process of the invention and of the use according to the invention apply both taken on their own as well as preferably in any possible combination with one another.

The compounds I are preferably provided in the form of the free base (i.e. according to structural formula I) or in the form of their acid addition salts.

In a preferred embodiment, X² is C—R¹ and R¹, R² and R³, independently of each other, are selected from hydrogen, halogen, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy. More preferably, R¹, R² and R³, independently of each other, are selected from hydrogen, fluorine and methoxy.

In particular, R¹ is selected from hydrogen, fluorine and methoxy.

In particular, R² is selected from hydrogen, fluorine and methoxy.

In particular, R³ is selected from hydrogen and fluorine.

R³ is preferably bound in 3- or 5-position, in particular in 5-position, relative to the 2- and 4-positions of R¹ and R².

In another preferred embodiment, X² is N and R² and R³, independently of each other, are selected from hydrogen, halogen, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy. More preferably, R¹, R² and R³, independently of each other, are selected from hydrogen, fluorine and methoxy.

In this case, R² is preferably selected from hydrogen, fluorine and methoxy, and is in particular methoxy.

In this case, R³ is preferably selected from hydrogen, fluorine and methoxy, and is in particular hydrogen.

Preferably, R⁴ is selected from methoxy and ethoxy.

Preferably, R⁵ is hydrogen or methoxy, and in particular hydrogen.

Preferably, R⁶ is selected from cyano, fluorine and chlorine.

Preferably, R⁷ is selected from hydrogen and fluorine.

In a preferred embodiment,

-   R⁸ is selected from hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl,     C₃-C₆-cycloalkyl and C₃-C₆-halocycloalkyl; -   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl,     C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₃-C₆-cycloalkoxy, C₃-C₆-halocycloalkoxy, and a 3-, 4-, 5- or     6-membered saturated, partially unsaturated or maximally unsaturated     heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups     selected from O, N, S, NO, SO and SO₂ as ring members, where the     heterocyclic ring may carry 1, 2 or 3 substituents selected from     halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy     and C₁-C₄-haloalkoxy; or     -   R⁸ and R⁹, together with the nitrogen atom they are bound to,         form a 3-, 4-, 5- or 6-membered saturated, partially unsaturated         or maximally unsaturated heterocyclic ring, where the         heterocyclic ring may contain 1 or 2 further heteroatoms or         heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring         members, and where the heterocyclic ring may carry 1 or 2         substituents R¹² and/or 1 substituent R¹³; where in case that         the heterocyclic ring does not contain 1 or 2 further         heteroatoms or heteroatom groups as ring members, the         heterocyclic ring carries 1 or 2 substituents R¹² and optionally         1 substituent R¹³; -   each R¹² is independently selected from halogen, hydroxyl,     C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₆-cycloalkoxy,     C₃-C₆-halocycloalkoxy, and a 3-, 4-, 5- or 6-membered saturated,     partially unsaturated or maximally unsaturated heterocyclic ring     containing 1 or 2 heteroatoms or heteroatom groups selected from O,     N, S, NO, SO and SO₂ as ring members, where the heterocyclic ring     may carry 1, 2 or 3 substituents selected from halogen, hydroxyl,     cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and     C₁-C₄-haloalkoxy;     -   or     -   two radicals R¹², together with the atom(s) they are bound to,         form a 3-, 4-, 5- or 6-membered saturated, partially unsaturated         or maximally unsaturated heterocyclic ring containing 1 or 2         heteroatoms or heteroatom groups selected from O, N, S, NO, SO         and SO₂ as ring members, where the heterocyclic ring may carry         1, 2 or 3 substituents selected from halogen, hydroxyl, cyano,         C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;         and -   R¹³ is selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl,     C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl,     C₃-C₆-halocycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio,     C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl,     C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, C₁-C₄-alkylcarbonyl,     C₁-C₄-haloalkylcarbonyl, phenyl, phenoxy and a 3-, 4-, 5- or     6-membered saturated, partially unsaturated or maximally unsaturated     heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom     groups selected from O, N, S, NO, SO and SO₂ as ring members, where     the phenyl moieties or the heterocyclic ring may carry 1, 2 or 3     substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy.

More preferably,

-   R⁸ is selected from hydrogen, C₁-C₄-alkyl, fluorinated C₁-C₄-alkyl,     C₃-C₆-cycloalkyl and fluorinated C₃-C₆-cycloalkyl; -   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated     C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy,     and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring     containing 1 or 2 heteroatoms or heteroatom groups selected from O,     N, S, NO, SO and SO₂ as ring members, where the heterocyclic ring     may carry 1, 2 or 3 substituents selected from halogen, hydroxyl,     cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and     C₁-C₄-haloalkoxy; or     -   R⁸ and R⁹, together with the nitrogen atom they are bound to,         form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,         where the heterocyclic ring may contain 1 or 2 further         heteroatoms or heteroatom groups selected from O, N, S, NO, SO         and SO₂ as ring members, and where the heterocyclic ring may         carry 1 or 2 substituents R¹² and/or 1 substituent R¹³; where in         case that the heterocyclic ring does not contain 1 or 2 further         heteroatoms or heteroatom groups as ring members, the         heterocyclic ring carries 1 or 2 substituents R¹² and optionally         1 substituent R¹³;     -   each R¹² is independently selected from halogen, hydroxyl,         C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or         6-membered saturated heterocyclic ring containing 1 or 2         heteroatoms or heteroatom groups selected from O, N, S, NO, SO         and SO₂ as ring members, where the heterocyclic ring may carry         1, 2 or 3 substituents selected from halogen, hydroxyl, cyano,         C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;         or     -   two radicals R¹², together with the atom(s) they are bound to,         form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring         containing 1 or 2 heteroatoms or heteroatom groups selected from         O, N, S, NO, SO and SO₂ as ring members, where the heterocyclic         ring may carry 1, 2 or 3 substituents selected from halogen,         hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and         C₁-C₄-haloalkoxy; and -   R¹³ is selected halogen, hydroxyl, cyano, C₁-C₄-alkyl, fluorinated     C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated     C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, fluorinated     C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-,     4-, 5- or 6-membered saturated, partially unsaturated or maximally     unsaturated heterocyclic ring containing 1 or 2 heteroatoms or     heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring     members, where the heterocyclic ring may carry 1, 2 or 3     substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy.

In particular,

-   R⁸ is selected from hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl; -   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated     C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy,     and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring     containing 1 oxygen atom as ring member; or     -   R⁸ and R⁹, together with the nitrogen atom they are bound to         form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,         where the heterocyclic ring contains 1 further oxygen atom as         ring member, and where the heterocyclic ring may carry 1 or 2         substituents R¹²; or form a 3-, 4-, 5- or 6-membered saturated         heterocyclic ring which carries 1 or 2 substituents R¹²; and -   each R¹² is independently selected from halogen, hydroxyl,     C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic     ring containing 1 oxygen atom as ring member; or two radicals R¹²     bound to the same carbon ring atom, together with this carbon atom     they are bound to, form a 3-, 4-, 5- or 6-membered saturated     heterocyclic ring containing 1 oxygen atom as ring member.

The saturated heterocyclic ring formed by R⁸ and R⁹ together with the nitrogen atom they are bound to is preferably selected from azetidin-1-yl carrying in the 3-position (relative to the 1-position of the nitrogen ring atom) 1 or 2 substituents R¹²; isoxazolidin-2-yl, piperidin-1-yl carrying in the 4-position (relative to the 1-position of the nitrogen ring atom) 1 or 2 substituents R¹²; and morpholin-1-yl, where R¹² is as defined above or, in particular, as defined below.

If two radicals R¹² bound to the same carbon ring atom together with this carbon atom form a ring, this is preferably a spiro-bound oxetan-3-yl ring; i.e. preferably the two radicals R¹² bound to the same carbon atom together form a group —CH₂—O—CH₂—.

Preferably, each R¹⁰ is independently selected from halogen and C₁-C₄-alkyl, preferably from F, Cl and CH₃, with the proviso that R¹⁰ is not halogen if it is bound to a carbon atom in α-position to a nitrogen ring atom; and is in particular CH₃.

Preferably, each R¹¹ is independently selected from halogen and C₁-C₄-alkyl, preferably from F, Cl and CH₃, with the proviso that R¹¹ is not halogen if it is bound to a carbon atom in α-position to a nitrogen ring atom; and is in particular CH₃;

or two non-geminal radicals R¹¹ form together a group —CH₂—.

In one embodiment, X¹ is N.

In another embodiment, X¹ is CH.

In one embodiment, X² is C—R¹.

In another embodiment, X² is N.

a is preferably 0 or 1, in particular 0.

b is preferably 0, 1 or 2, in particular 0.

The invention preferably relates to compounds of the formula I in which

-   R¹ (if present), R² and R³, independently of each other, are     selected from hydrogen, halogen, C₁-C₃-alkyl, fluorinated     C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy; -   R⁴ is selected from methoxy and ethoxy; -   R⁵ is hydrogen or methoxy; -   R⁶ is selected from cyano, fluorine and chlorine; -   R⁷ is hydrogen or fluorine; -   R⁸ is selected from hydrogen, C₁-C₄-alkyl, fluorinated C₁-C₄-alkyl,     C₃-C₆-cycloalkyl and fluorinated C₃-C₆-cycloalkyl; -   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated     C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy,     and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring     containing 1 or 2 heteroatoms or heteroatom groups selected from O,     N, S, NO, SO and SO₂ as ring members, where the heterocyclic ring     may carry 1, 2 or 3 substituents selected from halogen, hydroxyl,     cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and     C₁-C₄-haloalkoxy; or     -   R⁸ and R⁹, together with the nitrogen atom they are bound to,         form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,         where the heterocyclic ring may contain 1 or 2 further         heteroatoms or heteroatom groups selected from O, N, S, NO, SO         and SO₂ as ring members, and where the heterocyclic ring may         carry 1 or 2 substituents R¹² and/or 1 substituent R¹³; where in         case that the heterocyclic ring does not contain 1 or 2 further         heteroatoms or heteroatom groups as ring members, the         heterocyclic ring carries 1 or 2 substituents R¹² and optionally         1 substituent R¹³; -   each R¹² is independently selected from halogen, hydroxyl,     C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or     6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms     or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring     members, where the heterocyclic ring may carry 1, 2 or 3     substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or     -   two radicals R¹², together with the atom(s) they are bound to,         form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring         containing 1 or 2 heteroatoms or heteroatom groups selected from         O, N, S, NO, SO and SO₂ as ring members, where the heterocyclic         ring may carry 1, 2 or 3 substituents selected from halogen,         hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and         C₁-C₄-haloalkoxy; and -   R¹³ is selected halogen, hydroxyl, cyano, C₁-C₄-alkyl, fluorinated     C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated     C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, fluorinated     C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-,     4-, 5- or 6-membered saturated, partially unsaturated or maximally     unsaturated heterocyclic ring containing 1 or 2 heteroatoms or     heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring     members, where the heterocyclic ring may carry 1, 2 or 3     substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; -   each R¹⁰ is independently selected from halogen and C₁-C₄-alkyl or     two non-geminal radicals R¹⁰ form together a group —CH₂— or     —CH₂CH₂—; -   each R¹¹ is independently selected from halogen and C₁-C₄-alkyl or     two non-geminal radicals R¹¹ form together a group —CH₂— or     —CH₂CH₂—; -   a is 0, 1 or 2; -   b is 0, 1 or 2;     and the pharmaceutically acceptable salts thereof.

The invention more preferably relates to compounds of the formula I in which

-   R¹ (if present), R² and R³, independently of each other, are     selected from hydrogen, fluorine and methoxy; -   R⁴ is selected from methoxy and ethoxy; -   R⁵ is hydrogen or methoxy; -   R⁶ is selected from cyano, fluorine and chlorine; -   R⁷ is hydrogen or fluorine; -   R⁸ is selected from hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl; -   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated     C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy,     and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring     containing 1 oxygen atom as ring member; or     -   R⁸ and R⁹, together with the nitrogen atom they are bound to         form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,         where the heterocyclic ring contains 1 further oxygen atom as         ring member, and where the heterocyclic ring may carry 1 or 2         substituents R¹²; or form a 3-, 4-, 5- or 6-membered saturated         heterocyclic ring which carries 1 or 2 substituents R¹²; and -   each R¹² is independently selected from halogen, hydroxyl,     C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic     ring containing 1 oxygen atom as ring member; or     -   two radicals R¹² bound to the same carbon ring atom, together         with this carbon atom they are bound to, form a 3-, 4-, 5- or         6-membered saturated heterocyclic ring containing 1 oxygen atom         as ring member; -   each R¹ is independently selected from F, Cl and methyl or two     non-geminal radicals R¹⁰ form together a group —CH₂—; -   each R¹¹ is independently selected from F, Cl and methyl or two     non-geminal radicals R¹¹ form together a group —CH₂—; -   X¹ is N or CH; -   X² is C—R¹ or N; -   a is 0, 1 or 2, preferably 0 or 1; -   b is 0, 1 or 2, preferably 0 or 2;     and the pharmaceutically acceptable salts thereof.

The invention even more preferably relates to compounds of the formula I in which

-   R¹ (if present) is selected from hydrogen, fluorine and methoxy; -   R² is selected from hydrogen, fluorine and methoxy; -   R³ is selected from hydrogen and fluorine; -   R⁴ is selected from methoxy and ethoxy; -   R⁵ is hydrogen or methoxy; -   R⁶ is selected from cyano, fluorine and chlorine; -   R⁷ is hydrogen or fluorine; -   R⁸ is selected from hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl; -   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, and a     3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1     oxygen atom as ring member;     -   or     -   R⁸ and R⁹, together with the nitrogen atom they are bound to         form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,         where the heterocyclic ring contains 1 further oxygen atom as         ring member, and where the heterocyclic ring may carry 1 or 2         substituents R¹²; or form a 3-, 4-, 5- or 6-membered saturated         heterocyclic ring which carries 1 or 2 substituents R¹²; and -   each R¹² is independently selected from halogen, hydroxyl,     C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic     ring containing 1 oxygen atom as ring member; or     -   two radicals R¹² bound to the same carbon ring atom, together         with this carbon atom they are bound to, form a 3-, 4-, 5- or         6-membered saturated heterocyclic ring containing 1 oxygen atom         as ring member; -   X¹ is N or CH; -   X² is C—R¹ or N; -   a is 0; -   b is 0;     and the pharmaceutically acceptable salts thereof.

The invention even in particular relates to compounds of the formula I in which

-   R¹ (if present) is selected from hydrogen, fluorine and methoxy; -   R² is selected from hydrogen, fluorine and methoxy; -   R³ is selected from hydrogen and fluorine; -   R⁴ is selected from methoxy and ethoxy; -   R⁵ is hydrogen or methoxy; -   R⁶ is selected from cyano, fluorine and chlorine; -   R⁷ is hydrogen or fluorine; -   R⁸ is selected from hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl; -   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy,     oxetan-3-yl and tetrahydropyran-4-yl; or     -   R⁸ and R⁹, together with the nitrogen atom they are bound to         form a saturated heterocyclic ring selected from azetidin-1-yl         carrying in the 3-position (relative to the 1-position of the         nitrogen ring atom) 1 or 2 substituents R¹²; isoxazolidin-2-yl,         piperidin-1-yl carrying in the 4-position (relative to the         1-position of the nitrogen ring atom) 1 or 2 substituents R¹²;         and morpholin-1-yl; and each R¹² is independently selected from         halogen, hydroxyl, C₁-C₄-alkoxy, and oxetan-3-yl; or     -   two radicals R¹² bound to the same carbon ring atom together         form a group —CH₂—O—CH₂— (i.e. together with the carbon atom         they are bound to form a spiro-bound oxetan-3-yl ring); -   X¹ is N or CH; -   X² is C—R¹ or N; -   a is 0; -   b is 0;     and the pharmaceutically acceptable salts thereof.

Examples of preferred embodiment of the present invention are compounds of the formulae I.1 to I.40 and the N-oxides, stereoisomers and the pharmaceutically acceptable salts thereof, in which the radicals R¹, R², R³, R⁶, R⁷, R⁸ and R⁹ have one of the above general or preferred meanings. In particular, preferred compounds are the individual compounds compiled in the tables 1 to 28600 below. Moreover, the meanings mentioned below for the individual variables in the tables are per se, independently of the combination in which they are mentioned, a particularly preferred embodiment of the substituents in question.

Table 1

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 2

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 3

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 4

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 5

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 6

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 7

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 8

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 9

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 10

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 11

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 12

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 13

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 14

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 15

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 16

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 17

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 18

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 19

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 20

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 21

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 22

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 23

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 24

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 25

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 26

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 27

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 28

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 29

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 30

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 31

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 32

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 33

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 34

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 35

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 36

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 37

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 38

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 39

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 40

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 41

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 42

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 43

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 44

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 45

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 46

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 47

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 48

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 49

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 50

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 51

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 52

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 53

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 54

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 55

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 56

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 57

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 58

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 59

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 60

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 61

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 62

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 63

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 64

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 65

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 66

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 67

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 68

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 69

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 70

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 71

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 72

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 73

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 74

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 75

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 76

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 77

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 78

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 79

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 80

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 81

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 82

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 83

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 84

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 85

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 86

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 87

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 88

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 89

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 90

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 91

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 92

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 93

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 94

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 95

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 96

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 97

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 98

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 99

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 100

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 101

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 102

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 103

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 104

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 105

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 106

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 107

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 108

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 109

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 110

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 111

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 112

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 113

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 114

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 115

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 116

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 117

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 118

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 119

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 120

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 121

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 122

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 123

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 124

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 125

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 126

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 127

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 128

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 129

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 130

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 131

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 132

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 133

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 134

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 135

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 136

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 137

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 138

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 139

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 140

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 141

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 142

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 143

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 144

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 145

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 146

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 147

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 148

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 149

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 150

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 151

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 152

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 153

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 154

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 155

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 156

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 157

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 158

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 159

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 160

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 161

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 162

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 163

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 164

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 165

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 166

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 167

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 168

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 169

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 170

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 171

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 172

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 173

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 174

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 175

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 176

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 177

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 178

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 179

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 180

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 181

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 182

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 183

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 184

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 185

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 186

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 187

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 188

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 189

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 190

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 191

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 192

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 193

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 194

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 195

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 196

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 197

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 198

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 199

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 200

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 201

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 202

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 203

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 204

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 205

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 206

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 207

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 208

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 209

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 210

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 211

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 212

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 213

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 214

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 215

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 216

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 217

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 218

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 219

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 220

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 221

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 222

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 223

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 224

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 225

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 226

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 227

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 228

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 229

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 230

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 231

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 232

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 233

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 234

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 235

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 236

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 237

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 238

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 239

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 240

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 241

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 242

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 243

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 244

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 245

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 246

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 247

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 248

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 249

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 250

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 251

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 252

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 253

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 254

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 255

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 256

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 257

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 258

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 259

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 260

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 261

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 262

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 263

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 264

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 265

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 266

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 267

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 268

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 269

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 270

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 271

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 272

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 273

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 274

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 275

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 276

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 277

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 278

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 279

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 280

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 281

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 282

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 283

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 284

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 285

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 286

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 287

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 288

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 289

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 290

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 291

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 292

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 293

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 294

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 295

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 296

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 297

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 298

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 299

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 300

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 301

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 302

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 303

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 304

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 305

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 306

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 307

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 308

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 309

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 310

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 311

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 312

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 313

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 314

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 315

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 316

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 317

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 318

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 319

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 320

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 321

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 322

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 323

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 324

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 325

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 326

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 327

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 328

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 329

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 330

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 331

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 332

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 333

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 334

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 335

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 336

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 337

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 338

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 339

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 340

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 341

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 342

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 343

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 344

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 345

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 346

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 347

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 348

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 349

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 350

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 351

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 352

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 353

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 354

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 355

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 356

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 357

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 358

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 359

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 360

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 361

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 362

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 363

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 364

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 365

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 366

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 367

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 368

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 369

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 370

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 371

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 372

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 373

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 374

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 375

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 376

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 377

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 378

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 379

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 380

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 381

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 382

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 383

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 384

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 385

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 386

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 387

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 388

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 389

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 390

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 391

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 392

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 393

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 394

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 395

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 396

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 397

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 398

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 399

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 400

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 401

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 402

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 403

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 404

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 405

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 406

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 407

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 408

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 409

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 410

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 411

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 412

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 413

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 414

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 415

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 416

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 417

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 418

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 419

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 420

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 421

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 422

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 423

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 424

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 425

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 426

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 427

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 428

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 429

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 430

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 431

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 432

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 433

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 434

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 435

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 436

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 437

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 438

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 439

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 440

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 441

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 442

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 443

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 444

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 445

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 446

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 447

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 448

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 449

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 450

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 451

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 452

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 453

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 454

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 455

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 456

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 457

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 458

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 459

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 460

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 461

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 462

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 463

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 464

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 465

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 466

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 467

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 468

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 469

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 470

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 471

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 472

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 473

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 474

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 475

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 476

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 477

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 478

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 479

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 480

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 481

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 482

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 483

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 484

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 485

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 486

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 487

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 488

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 489

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 490

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 491

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 492

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 493

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 494

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 495

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 496

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 497

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 498

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 499

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 500

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 501

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 502

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 503

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 504

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 505

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 506

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 507

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 508

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 509

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 510

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 511

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 512

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 513

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 514

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 515

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 516

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 517

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 518

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 519

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 520

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 521

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 522

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 523

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 524

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 525

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 526

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 527

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 528

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 529

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 530

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 531

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 532

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 533

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 534

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 535

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 536

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 537

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 538

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 539

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 540

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 541

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 542

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 543

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 544

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 545

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 546

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 547

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 548

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 549

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 550

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 551

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 552

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 553

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 554

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 555

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 556

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 557

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 558

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 559

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 560

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 561

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 562

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 563

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 564

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 565

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 566

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 567

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 568

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 569

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 570

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 571

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 572

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 573

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 574

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 575

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 576

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 577

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 578

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 579

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 580

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 581

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 582

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 583

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 584

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 585

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 586

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 587

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 588

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 589

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 590

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 591

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 592

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 593

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 594

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 595

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 596

Compounds of the formula II in which R⁸ is cyclopentyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 597

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 598

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 599

Compounds of the formula II in which R⁸ is cyclopentyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 600

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 601

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is methoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 602

Compounds of the formula II in which R⁸ is cyclohexyl, R⁹ is ethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 603

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 604

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is isopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 605

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 606

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is sec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 607

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is isobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 608

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is tert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 609

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is fluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 610

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is difluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 611

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is trifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 612

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is 2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 613

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is 2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 614

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is 2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 615

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is pentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 616

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is methoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 617

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is ethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 618

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 619

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is isopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 620

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is methoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 621

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is ethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 622

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 623

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is isopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 624

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is methoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 625

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is ethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 626

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 627

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is isopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 628

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is methoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 629

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is ethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 630

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 631

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is isopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 632

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is methoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 633

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is ethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 634

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 635

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is isopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 636

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is methoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 637

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is ethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 638

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 639

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is isopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 640

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is oxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 641

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is oxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 642

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is tetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 643

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is tetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 644

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is tetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 645

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is tetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 646

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is tetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 647

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is thietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 648

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is thietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 649

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is 1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 650

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is 1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 651

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-fluoroaziridin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 652

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2,2-difluoroaziridin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 653

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-methoxyaziridin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 654

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-fluoroazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 655

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2,2-difluoroazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 656

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-fluoroazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 657

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3,3-difluoroazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 658

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-hydroxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 659

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-hydroxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 660

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-methoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 661

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-methoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 662

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-ethoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 663

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-ethoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 664

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-trifluoromethoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 665

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-trifluoromethoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 666

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-(oxetan-3-yl)-azetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 667

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-(oxetan-3-yl)-azetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 668

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) [1,3]oxazetidin-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 669

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) [1,3]diazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 670

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-oxa-6-aza-spiro[3.3]hept-6-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 671

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2,6-diaza-spiro[3.3]hept-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 672

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-fluoropyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 673

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2,2-difluoropyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 674

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-fluoropyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 675

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3,3-difluoropyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 676

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-hydroxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 677

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-hydroxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 678

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-methoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 679

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-methoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 680

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-ethoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 681

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-ethoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 682

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-trifluoromethoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 683

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-trifluoromethoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 684

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-(oxetan-3-yl)-pyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 685

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-(oxetan-3-yl)-pyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 686

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) tetrahydroisoxazolidin-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 687

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) tetrahydroxazolidin-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 688

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) tetrahydropyrazolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 689

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) tetrahydroimidazolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 690

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-fluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 691

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2,2-difluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 692

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-fluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 693

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3,3-difluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 694

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 4-fluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 695

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 4,4-difluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 696

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-hydroxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 697

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-hydroxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 698

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 4-hydroxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 699

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-methoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 700

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-methoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 701

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 4-methoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 702

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-ethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 703

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-ethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 704

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 4-ethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 705

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-trifluoromethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 706

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-trifluoromethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 707

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 4-trifluoromethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 708

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-(oxetan-3-yl)-piperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 709

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 3-(oxetan-3-yl)-piperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 710

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 4-(oxetan-3-yl)-piperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 711

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) morpholin-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 712

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) piperazin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 713

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2-oxa-7-aza-spiro[3.5]non-7-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 714

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2,7-diaza-spiro[3.5]non-7-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Table 715

Compounds of the formula I.1 in which R⁸ and R⁹, together with the nitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is) 2,7-diaza-spiro[3.5]non-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 716 to 1430

Compounds of the formula I.2, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 1431 to 2145

Compounds of the formula I.3, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 2146 to 2860

Compounds of the formula I.4, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 2861 to 3575

Compounds of the formula I.5, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 3576 to 4290

Compounds of the formula I.6, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 4291 to 5005

Compounds of the formula I.7, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 5006 to 5720

Compounds of the formula I.8, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 5721 to 6435

Compounds of the formula I.9, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 6436 to 7150

Compounds of the formula I.10, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 7151 to 7865

Compounds of the formula I.11, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 7866 to 8580

Compounds of the formula I.12, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 8581 to 9295

Compounds of the formula I.13, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 9296 to 10010

Compounds of the formula I.14, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 10011 to 10725

Compounds of the formula I.15, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 10726 to 11440

Compounds of the formula I.16, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 11441 to 12155

Compounds of the formula I.17, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 12156 to 12870

Compounds of the formula I.18, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 12871 to 13585

Compounds of the formula I.19, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 13586 to 14300

Compounds of the formula I.20, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table A

Tables 14301 to 15015

Compounds of the formula I.21, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 15016 to 15730

Compounds of the formula I.22, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 15731 to 16445

Compounds of the formula I.23, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 16646 to 17160

Compounds of the formula I.24, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 17161 to 17875

Compounds of the formula I.25, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 17876 to 18590

Compounds of the formula I.26, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 18591 to 19305

Compounds of the formula I.27, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 19306 to 20020

Compounds of the formula I.28, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 20021 to 20735

Compounds of the formula I.29, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 20736 to 21450

Compounds of the formula I.30, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 21451 to 22165

Compounds of the formula I.31, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 22166 to 22880

Compounds of the formula I.32, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 22881 to 23595

Compounds of the formula I.33, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 23596 to 24310

Compounds of the formula I.34, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 24311 to 25025

Compounds of the formula I.35, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 25026 to 25740

Compounds of the formula I.36, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 25741 to 26455

Compounds of the formula I.37, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 26456 to 27170

Compounds of the formula I.38, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 27171 to 27885

Compounds of the formula I.39, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

Tables 27886 to 28600

Compounds of the formula I.40, in which the combination of R⁸ and R⁹ is as defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row of Table B

TABLE A Example No. R¹ R² R³ R⁶ R⁷ A-1. H H H CN H A-2. F H H CN H A-3. CH₃ H H CN H A-4. OCH₃ H H CN H A-5. CH₂F H H CN H A-6. CHF₂ H H CN H A-7. CF₃ H H CN H A-8. OCH₂F H H CN H A-9. OCHF₂ H H CN H A-10. OCF₃ H H CN H A-11. H F H CN H A-12. H CH₃ H CN H A-13. H OCH₃ H CN H A-14. H CN H CN H A-15. H CH₂F H CN H A-16. H CHF₂ H CN H A-17. H CF₃ H CN H A-18. H OCH₂F H CN H A-19. H OCHF₂ H CN H A-20. H OCF₃ H CN H A-21. H H 3-F CN H A-22. H H 3-CH₃ CN H A-23. H H 3-OCH₃ CN H A-24. H H 5-F CN H A-25. H H 5-CH₃ CN H A-26. H H 5-OCH₃ CN H A-27. F F H CN H A-28. F CH₃ H CN H A-29. F OCH₃ H CN H A-30. F CN H CN H A-31. F CH₂F H CN H A-32. F CHF₂ H CN H A-33. F CF₃ H CN H A-34. F OCH₂F H CN H A-35. F OCHF₂ H CN H A-36. F OCF₃ H CN H A-37. F H 3-F CN H A-38. F H 3-CH₃ CN H A-39. F H 3-OCH₃ CN H A-40. F H 5-F CN H A-41. F H 5-CH₃ CN H A-42. F H 5-OCH₃ CN H A-43. CH₃ F H CN H A-44. CH₃ CH₃ H CN H A-45. CH₃ OCH₃ H CN H A-46. CH₃ CN H CN H A-47. CH₃ CH₂F H CN H A-48. CH₃ CHF₂ H CN H A-49. CH₃ CF₃ H CN H A-50. CH₃ OCH₂F H CN H A-51. CH₃ OCHF₂ H CN H A-52. CH₃ OCF₃ H CN H A-53. CH₃ H 3-F CN H A-54. CH₃ H 3-CH₃ CN H A-55. CH₃ H 3-OCH₃ CN H A-56. CH₃ H 5-F CN H A-57. CH₃ H 5-CH₃ CN H A-58. CH₃ H 5-OCH₃ CN H A-59. OCH₃ F H CN H A-60. OCH₃ CH₃ H CN H A-61. OCH₃ OCH₃ H CN H A-62. OCH₃ CN H CN H A-63. OCH₃ CH₂F H CN H A-64. OCH₃ CHF₂ H CN H A-65. OCH₃ CF₃ H CN H A-66. OCH₃ OCH₂F H CN H A-67. OCH₃ OCHF₂ H CN H A-68. OCH₃ OCF₃ H CN H A-69. OCH₃ H 3-F CN H A-70. OCH₃ H 3-CH₃ CN H A-71. OCH₃ H 3-OCH₃ CN H A-72. OCH₃ H 5-F CN H A-73. OCH₃ H 5-CH₃ CN H A-74. OCH₃ H 5-OCH₃ CN H A-75. H F 3-F CN H A-76. H F 3-CH₃ CN H A-77. H F 3-OCH₃ CN H A-78. H F 5-F CN H A-79. H F 5-CH₃ CN H A-80. H F 5-OCH₃ CN H A-81. H CH₃ 3-F CN H A-82. H CH₃ 3-CH₃ CN H A-83. H CH₃ 3-OCH₃ CN H A-84. H CH₃ 5-F CN H A-85. H CH₃ 5-CH₃ CN H A-86. H CH₃ 5-OCH₃ CN H A-87. H OCH₃ 3-F CN H A-88. H OCH₃ 3-CH₃ CN H A-89. H OCH₃ 3-OCH₃ CN H A-90. H OCH₃ 5-F CN H A-91. H OCH₃ 5-CH₃ CN H A-92. H OCH₃ 5-OCH₃ CN H A-93. H CN 3-F CN H A-94. H CN 3-CH₃ CN H A-95. H CN 3-OCH₃ CN H A-96. H CN 5-F CN H A-97. H CN 5-CH₃ CN H A-98. H CN 5-OCH₃ CN H A-99. H CH₂F 3-F CN H A-100. H CH₂F 3-CH₃ CN H A-101. H CH₂F 3-OCH₃ CN H A-102. H CH₂F 5-F CN H A-103. H CH₂F 5-CH₃ CN H A-104. H CH₂F 5-OCH₃ CN H A-105. H CHF₂ 3-F CN H A-106. H CHF₂ 3-CH₃ CN H A-107. H CHF₂ 3-OCH₃ CN H A-108. H CHF₂ 5-F CN H A-109. H CHF₂ 5-CH₃ CN H A-110. H CHF₂ 5-OCH₃ CN H A-111. H CF₃ 3-F CN H A-112. H CF₃ 3-CH₃ CN H A-113. H CF₃ 3-OCH₃ CN H A-114. H CF₃ 5-F CN H A-115. H CF₃ 5-CH₃ CN H A-116. H CF₃ 5-OCH₃ CN H A-117. H OCH₂F 3-F CN H A-118. H OCH₂F 3-CH₃ CN H A-119. H OCH₂F 3-OCH₃ CN H A-120. H OCH₂F 5-F CN H A-121. H OCH₂F 5-CH₃ CN H A-122. H OCH₂F 5-OCH₃ CN H A-123. H OCHF₂ 3-F CN H A-124. H OCHF₂ 3-CH₃ CN H A-125. H OCHF₂ 3-OCH₃ CN H A-126. H OCHF₂ 5-F CN H A-127. H OCHF₂ 5-CH₃ CN H A-128. H OCHF₂ 5-OCH₃ CN H A-129. H OCF₃ 3-F CN H A-130. H OCF₃ 3-CH₃ CN H A-131. H OCF₃ 3-OCH₃ CN H A-132. H OCF₃ 5-F CN H A-133. H OCF₃ 5-CH₃ CN H A-134. H OCF₃ 5-OCH₃ CN H A-135. F F 3-F CN H A-136. F F 3-CH₃ CN H A-137. F F 3-OCH₃ CN H A-138. F F 5-F CN H A-139. F F 5-CH₃ CN H A-140. F F 5-OCH₃ CN H A-141. F CH₃ 3-F CN H A-142. F CH₃ 3-CH₃ CN H A-143. F CH₃ 3-OCH₃ CN H A-144. F CH₃ 5-F CN H A-145. F CH₃ 5-CH₃ CN H A-146. F CH₃ 5-OCH₃ CN H A-147. F OCH₃ 3-F CN H A-148. F OCH₃ 3-CH₃ CN H A-149. F OCH₃ 3-OCH₃ CN H A-150. F OCH₃ 5-F CN H A-151. F OCH₃ 5-CH₃ CN H A-152. F OCH₃ 5-OCH₃ CN H A-153. F CN 3-F CN H A-154. F CN 3-CH₃ CN H A-155. F CN 3-OCH₃ CN H A-156. F CN 5-F CN H A-157. F CN 5-CH₃ CN H A-158. F CN 5-OCH₃ CN H A-159. F CH₂F 3-F CN H A-160. F CH₂F 3-CH₃ CN H A-161. F CH₂F 3-OCH₃ CN H A-162. F CH₂F 5-F CN H A-163. F CH₂F 5-CH₃ CN H A-164. F CH₂F 5-OCH₃ CN H A-165. F CHF₂ 3-F CN H A-166. F CHF₂ 3-CH₃ CN H A-167. F CHF₂ 3-OCH₃ CN H A-168. F CHF₂ 5-F CN H A-169. F CHF₂ 5-CH₃ CN H A-170. F CHF₂ 5-OCH₃ CN H A-171. F CF₃ 3-F CN H A-172. F CF₃ 3-CH₃ CN H A-173. F CF₃ 3-OCH₃ CN H A-174. F CF₃ 5-F CN H A-175. F CF₃ 5-CH₃ CN H A-176. F CF₃ 5-OCH₃ CN H A-177. F OCH₂F 3-F CN H A-178. F OCH₂F 3-CH₃ CN H A-179. F OCH₂F 3-OCH₃ CN H A-180. F OCH₂F 5-F CN H A-181. F OCH₂F 5-CH₃ CN H A-182. F OCH₂F 5-OCH₃ CN H A-183. F OCHF₂ 3-F CN H A-184. F OCHF₂ 3-CH₃ CN H A-185. F OCHF₂ 3-OCH₃ CN H A-186. F OCHF₂ 5-F CN H A-187. F OCHF₂ 5-CH₃ CN H A-188. F OCHF₂ 5-OCH₃ CN H A-189. F OCF₃ 3-F CN H A-190. F OCF₃ 3-CH₃ CN H A-191. F OCF₃ 3-OCH₃ CN H A-192. F OCF₃ 5-F CN H A-193. F OCF₃ 5-CH₃ CN H A-194. F OCF₃ 5-OCH₃ CN H A-195. CH₃ F 3-F CN H A-196. CH₃ F 3-CH₃ CN H A-197. CH₃ F 3-OCH₃ CN H A-198. CH₃ F 5-F CN H A-199. CH₃ F 5-CH₃ CN H A-200. CH₃ F 5-OCH₃ CN H A-201. CH₃ CH₃ 3-F CN H A-202. CH₃ CH₃ 3-CH₃ CN H A-203. CH₃ CH₃ 3-OCH₃ CN H A-204. CH₃ CH₃ 5-F CN H A-205. CH₃ CH₃ 5-CH₃ CN H A-206. CH₃ CH₃ 5-OCH₃ CN H A-207. CH₃ OCH₃ 3-F CN H A-208. CH₃ OCH₃ 3-CH₃ CN H A-209. CH₃ OCH₃ 3-OCH₃ CN H A-210. CH₃ OCH₃ 5-F CN H A-211. CH₃ OCH₃ 5-CH₃ CN H A-212. CH₃ OCH₃ 5-OCH₃ CN H A-213. CH₃ CN 3-F CN H A-214. CH₃ CN 3-CH₃ CN H A-215. CH₃ CN 3-OCH₃ CN H A-216. CH₃ CN 5-F CN H A-217. CH₃ CN 5-CH₃ CN H A-218. CH₃ CN 5-OCH₃ CN H A-219. CH₃ CH₂F 3-F CN H A-220. CH₃ CH₂F 3-CH₃ CN H A-221. CH₃ CH₂F 3-OCH₃ CN H A-222. CH₃ CH₂F 5-F CN H A-223. CH₃ CH₂F 5-CH₃ CN H A-224. CH₃ CH₂F 5-OCH₃ CN H A-225. CH₃ CHF₂ 3-F CN H A-226. CH₃ CHF₂ 3-CH₃ CN H A-227. CH₃ CHF₂ 3-OCH₃ CN H A-228. CH₃ CHF₂ 5-F CN H A-229. CH₃ CHF₂ 5-CH₃ CN H A-230. CH₃ CHF₂ 5-OCH₃ CN H A-231. CH₃ CF₃ 3-F CN H A-232. CH₃ CF₃ 3-CH₃ CN H A-233. CH₃ CF₃ 3-OCH₃ CN H A-234. CH₃ CF₃ 5-F CN H A-235. CH₃ CF₃ 5-CH₃ CN H A-236. CH₃ CF₃ 5-OCH₃ CN H A-237. CH₃ OCH₂F 3-F CN H A-238. CH₃ OCH₂F 3-CH₃ CN H A-239. CH₃ OCH₂F 3-OCH₃ CN H A-240. CH₃ OCH₂F 5-F CN H A-241. CH₃ OCH₂F 5-CH₃ CN H A-242. CH₃ OCH₂F 5-OCH₃ CN H A-243. CH₃ OCHF₂ 3-F CN H A-244. CH₃ OCHF₂ 3-CH₃ CN H A-245. CH₃ OCHF₂ 3-OCH₃ CN H A-246. CH₃ OCHF₂ 5-F CN H A-247. CH₃ OCHF₂ 5-CH₃ CN H A-248. CH₃ OCHF₂ 5-OCH₃ CN H A-249. CH₃ OCF₃ 3-F CN H A-250. CH₃ OCF₃ 3-CH₃ CN H A-251. CH₃ OCF₃ 3-OCH₃ CN H A-252. CH₃ OCF₃ 5-F CN H A-253. CH₃ OCF₃ 5-CH₃ CN H A-254. CH₃ OCF₃ 5-OCH₃ CN H A-255. OCH₃ F 3-F CN H A-256. OCH₃ F 3-CH₃ CN H A-257. OCH₃ F 3-OCH₃ CN H A-258. OCH₃ F 5-F CN H A-259. OCH₃ F 5-CH₃ CN H A-260. OCH₃ F 5-OCH₃ CN H A-261. OCH₃ CH₃ 3-F CN H A-262. OCH₃ CH₃ 3-CH₃ CN H A-263. OCH₃ CH₃ 3-OCH₃ CN H A-264. OCH₃ CH₃ 5-F CN H A-265. OCH₃ CH₃ 5-CH₃ CN H A-266. OCH₃ CH₃ 5-OCH₃ CN H A-267. OCH₃ OCH₃ 3-F CN H A-268. OCH₃ OCH₃ 3-CH₃ CN H A-269. OCH₃ OCH₃ 3-OCH₃ CN H A-270. OCH₃ OCH₃ 5-F CN H A-271. OCH₃ OCH₃ 5-CH₃ CN H A-272. OCH₃ OCH₃ 5-OCH₃ CN H A-273. OCH₃ CN 3-F CN H A-274. OCH₃ CN 3-CH₃ CN H A-275. OCH₃ CN 3-OCH₃ CN H A-276. OCH₃ CN 5-F CN H A-277. OCH₃ CN 5-CH₃ CN H A-278. OCH₃ CN 5-OCH₃ CN H A-279. OCH₃ CH₂F 3-F CN H A-280. OCH₃ CH₂F 3-CH₃ CN H A-281. OCH₃ CH₂F 3-OCH₃ CN H A-282. OCH₃ CH₂F 5-F CN H A-283. OCH₃ CH₂F 5-CH₃ CN H A-284. OCH₃ CH₂F 5-OCH₃ CN H A-285. OCH₃ CHF₂ 3-F CN H A-286. OCH₃ CHF₂ 3-CH₃ CN H A-287. OCH₃ CHF₂ 3-OCH₃ CN H A-288. OCH₃ CHF₂ 5-F CN H A-289. OCH₃ CHF₂ 5-CH₃ CN H A-290. OCH₃ CHF₂ 5-OCH₃ CN H A-291. OCH₃ CF₃ 3-F CN H A-292. OCH₃ CF₃ 3-CH₃ CN H A-293. OCH₃ CF₃ 3-OCH₃ CN H A-294. OCH₃ CF₃ 5-F CN H A-295. OCH₃ CF₃ 5-CH₃ CN H A-296. OCH₃ CF₃ 5-OCH₃ CN H A-297. OCH₃ OCH₂F 3-F CN H A-298. OCH₃ OCH₂F 3-CH₃ CN H A-299. OCH₃ OCH₂F 3-OCH₃ CN H A-300. OCH₃ OCH₂F 5-F CN H A-301. OCH₃ OCH₂F 5-CH₃ CN H A-302. OCH₃ OCH₂F 5-OCH₃ CN H A-303. OCH₃ OCHF₂ 3-F CN H A-304. OCH₃ OCHF₂ 3-CH₃ CN H A-305. OCH₃ OCHF₂ 3-OCH₃ CN H A-306. OCH₃ OCHF₂ 5-F CN H A-307. OCH₃ OCHF₂ 5-CH₃ CN H A-308. OCH₃ OCHF₂ 5-OCH₃ CN H A-309. OCH₃ OCF₃ 3-F CN H A-310. OCH₃ OCF₃ 3-CH₃ CN H A-311. OCH₃ OCF₃ 3-OCH₃ CN H A-312. OCH₃ OCF₃ 5-F CN H A-313. OCH₃ OCF₃ 5-CH₃ CN H A-314. OCH₃ OCF₃ 5-OCH₃ CN H A-315. CH₂F F 3-F CN H A-316. CH₂F F 3-CH₃ CN H A-317. CH₂F F 3-OCH₃ CN H A-318. CH₂F F 5-F CN H A-319. CH₂F F 5-CH₃ CN H A-320. CH₂F F 5-OCH₃ CN H A-321. CH₂F CH₃ 3-F CN H A-322. CH₂F CH₃ 3-CH₃ CN H A-323. CH₂F CH₃ 3-OCH₃ CN H A-324. CH₂F CH₃ 5-F CN H A-325. CH₂F CH₃ 5-CH₃ CN H A-326. CH₂F CH₃ 5-OCH₃ CN H A-327. CH₂F OCH₃ 3-F CN H A-328. CH₂F OCH₃ 3-CH₃ CN H A-329. CH₂F OCH₃ 3-OCH₃ CN H A-330. CH₂F OCH₃ 5-F CN H A-331. CH₂F OCH₃ 5-CH₃ CN H A-332. CH₂F OCH₃ 5-OCH₃ CN H A-333. CH₂F CN 3-F CN H A-334. CH₂F CN 3-CH₃ CN H A-335. CH₂F CN 3-OCH₃ CN H A-336. CH₂F CN 5-F CN H A-337. CH₂F CN 5-CH₃ CN H A-338. CH₂F CN 5-OCH₃ CN H A-339. CH₂F CH₂F 3-F CN H A-340. CH₂F CH₂F 3-CH₃ CN H A-341. CH₂F CH₂F 3-OCH₃ CN H A-342. CH₂F CH₂F 5-F CN H A-343. CH₂F CH₂F 5-CH₃ CN H A-344. CH₂F CH₂F 5-OCH₃ CN H A-345. CH₂F CHF₂ 3-F CN H A-346. CH₂F CHF₂ 3-CH₃ CN H A-347. CH₂F CHF₂ 3-OCH₃ CN H A-348. CH₂F CHF₂ 5-F CN H A-349. CH₂F CHF₂ 5-CH₃ CN H A-350. CH₂F CHF₂ 5-OCH₃ CN H A-351. CH₂F CF₃ 3-F CN H A-352. CH₂F CF₃ 3-CH₃ CN H A-353. CH₂F CF₃ 3-OCH₃ CN H A-354. CH₂F CF₃ 5-F CN H A-355. CH₂F CF₃ 5-CH₃ CN H A-356. CH₂F CF₃ 5-OCH₃ CN H A-357. CH₂F OCH₂F 3-F CN H A-358. CH₂F OCH₂F 3-CH₃ CN H A-359. CH₂F OCH₂F 3-OCH₃ CN H A-360. CH₂F OCH₂F 5-F CN H A-361. CH₂F OCH₂F 5-CH₃ CN H A-362. CH₂F OCH₂F 5-OCH₃ CN H A-363. CH₂F OCHF₂ 3-F CN H A-364. CH₂F OCHF₂ 3-CH₃ CN H A-365. CH₂F OCHF₂ 3-OCH₃ CN H A-366. CH₂F OCHF₂ 5-F CN H A-367. CH₂F OCHF₂ 5-CH₃ CN H A-368. CH₂F OCHF₂ 5-OCH₃ CN H A-369. CH₂F OCF₃ 3-F CN H A-370. CH₂F OCF₃ 3-CH₃ CN H A-371. CH₂F OCF₃ 3-OCH₃ CN H A-372. CH₂F OCF₃ 5-F CN H A-373. CH₂F OCF₃ 5-CH₃ CN H A-374. CH₂F OCF₃ 5-OCH₃ CN H A-375. CHF₂ F 3-F CN H A-376. CHF₂ F 3-CH₃ CN H A-377. CHF₂ F 3-OCH₃ CN H A-378. CHF₂ F 5-F CN H A-379. CHF₂ F 5-CH₃ CN H A-380. CHF₂ F 5-OCH₃ CN H A-381. CHF₂ CH₃ 3-F CN H A-382. CHF₂ CH₃ 3-CH₃ CN H A-383. CHF₂ CH₃ 3-OCH₃ CN H A-384. CHF₂ CH₃ 5-F CN H A-385. CHF₂ CH₃ 5-CH₃ CN H A-386. CHF₂ CH₃ 5-OCH₃ CN H A-387. CHF₂ OCH₃ 3-F CN H A-388. CHF₂ OCH₃ 3-CH₃ CN H A-389. CHF₂ OCH₃ 3-OCH₃ CN H A-390. CHF₂ OCH₃ 5-F CN H A-391. CHF₂ OCH₃ 5-CH₃ CN H A-392. CHF₂ OCH₃ 5-OCH₃ CN H A-393. CHF₂ CN 3-F CN H A-394. CHF₂ CN 3-CH₃ CN H A-395. CHF₂ CN 3-OCH₃ CN H A-396. CHF₂ CN 5-F CN H A-397. CHF₂ CN 5-CH₃ CN H A-398. CHF₂ CN 5-OCH₃ CN H A-399. CHF₂ CH₂F 3-F CN H A-400. CHF₂ CH₂F 3-CH₃ CN H A-401. CHF₂ CH₂F 3-OCH₃ CN H A-402. CHF₂ CH₂F 5-F CN H A-403. CHF₂ CH₂F 5-CH₃ CN H A-404. CHF₂ CH₂F 5-OCH₃ CN H A-405. CHF₂ CHF₂ 3-F CN H A-406. CHF₂ CHF₂ 3-CH₃ CN H A-407. CHF₂ CHF₂ 3-OCH₃ CN H A-408. CHF₂ CHF₂ 5-F CN H A-409. CHF₂ CHF₂ 5-CH₃ CN H A-410. CHF₂ CHF₂ 5-OCH₃ CN H A-411. CHF₂ CF₃ 3-F CN H A-412. CHF₂ CF₃ 3-CH₃ CN H A-413. CHF₂ CF₃ 3-OCH₃ CN H A-414. CHF₂ CF₃ 5-F CN H A-415. CHF₂ CF₃ 5-CH₃ CN H A-416. CHF₂ CF₃ 5-OCH₃ CN H A-417. CHF₂ OCH₂F 3-F CN H A-418. CHF₂ OCH₂F 3-CH₃ CN H A-419. CHF₂ OCH₂F 3-OCH₃ CN H A-420. CHF₂ OCH₂F 5-F CN H A-421. CHF₂ OCH₂F 5-CH₃ CN H A-422. CHF₂ OCH₂F 5-OCH₃ CN H A-423. CHF₂ OCHF₂ 3-F CN H A-424. CHF₂ OCHF₂ 3-CH₃ CN H A-425. CHF₂ OCHF₂ 3-OCH₃ CN H A-426. CHF₂ OCHF₂ 5-F CN H A-427. CHF₂ OCHF₂ 5-CH₃ CN H A-428. CHF₂ OCHF₂ 5-OCH₃ CN H A-429. CHF₂ OCF₃ 3-F CN H A-430. CHF₂ OCF₃ 3-CH₃ CN H A-431. CHF₂ OCF₃ 3-OCH₃ CN H A-432. CHF₂ OCF₃ 5-F CN H A-433. CHF₂ OCF₃ 5-CH₃ CN H A-434. CHF₂ OCF₃ 5-OCH₃ CN H A-435. CF₃ F 3-F CN H A-436. CF₃ F 3-CH₃ CN H A-437. CF₃ F 3-OCH₃ CN H A-438. CF₃ F 5-F CN H A-439. CF₃ F 5-CH₃ CN H A-440. CF₃ F 5-OCH₃ CN H A-441. CF₃ CH₃ 3-F CN H A-442. CF₃ CH₃ 3-CH₃ CN H A-443. CF₃ CH₃ 3-OCH₃ CN H A-444. CF₃ CH₃ 5-F CN H A-445. CF₃ CH₃ 5-CH₃ CN H A-446. CF₃ CH₃ 5-OCH₃ CN H A-447. CF₃ OCH₃ 3-F CN H A-448. CF₃ OCH₃ 3-CH₃ CN H A-449. CF₃ OCH₃ 3-OCH₃ CN H A-450. CF₃ OCH₃ 5-F CN H A-451. CF₃ OCH₃ 5-CH₃ CN H A-452. CF₃ OCH₃ 5-OCH₃ CN H A-453. CF₃ CN 3-F CN H A-454. CF₃ CN 3-CH₃ CN H A-455. CF₃ CN 3-OCH₃ CN H A-456. CF₃ CN 5-F CN H A-457. CF₃ CN 5-CH₃ CN H A-458. CF₃ CN 5-OCH₃ CN H A-459. CF₃ CH₂F 3-F CN H A-460. CF₃ CH₂F 3-CH₃ CN H A-461. CF₃ CH₂F 3-OCH₃ CN H A-462. CF₃ CH₂F 5-F CN H A-463. CF₃ CH₂F 5-CH₃ CN H A-464. CF₃ CH₂F 5-OCH₃ CN H A-465. CF₃ CHF₂ 3-F CN H A-466. CF₃ CHF₂ 3-CH₃ CN H A-467. CF₃ CHF₂ 3-OCH₃ CN H A-468. CF₃ CHF₂ 5-F CN H A-469. CF₃ CHF₂ 5-CH₃ CN H A-470. CF₃ CHF₂ 5-OCH₃ CN H A-471. CF₃ CF₃ 3-F CN H A-472. CF₃ CF₃ 3-CH₃ CN H A-473. CF₃ CF₃ 3-OCH₃ CN H A-474. CF₃ CF₃ 5-F CN H A-475. CF₃ CF₃ 5-CH₃ CN H A-476. CF₃ CF₃ 5-OCH₃ CN H A-477. CF₃ OCH₂F 3-F CN H A-478. CF₃ OCH₂F 3-CH₃ CN H A-479. CF₃ OCH₂F 3-OCH₃ CN H A-480. CF₃ OCH₂F 5-F CN H A-481. CF₃ OCH₂F 5-CH₃ CN H A-482. CF₃ OCH₂F 5-OCH₃ CN H A-483. CF₃ OCHF₂ 3-F CN H A-484. CF₃ OCHF₂ 3-CH₃ CN H A-485. CF₃ OCHF₂ 3-OCH₃ CN H A-486. CF₃ OCHF₂ 5-F CN H A-487. CF₃ OCHF₂ 5-CH₃ CN H A-488. CF₃ OCHF₂ 5-OCH₃ CN H A-489. CF₃ OCF₃ 3-F CN H A-490. CF₃ OCF₃ 3-CH₃ CN H A-491. CF₃ OCF₃ 3-OCH₃ CN H A-492. CF₃ OCF₃ 5-F CN H A-493. CF₃ OCF₃ 5-CH₃ CN H A-494. CF₃ OCF₃ 5-OCH₃ CN H A-495. OCH₂F F 3-F CN H A-496. OCH₂F F 3-CH₃ CN H A-497. OCH₂F F 3-OCH₃ CN H A-498. OCH₂F F 5-F CN H A-499. OCH₂F F 5-CH₃ CN H A-500. OCH₂F F 5-OCH₃ CN H A-501. OCH₂F CH₃ 3-F CN H A-502. OCH₂F CH₃ 3-CH₃ CN H A-503. OCH₂F CH₃ 3-OCH₃ CN H A-504. OCH₂F CH₃ 5-F CN H A-505. OCH₂F CH₃ 5-CH₃ CN H A-506. OCH₂F CH₃ 5-OCH₃ CN H A-507. OCH₂F OCH₃ 3-F CN H A-508. OCH₂F OCH₃ 3-CH₃ CN H A-509. OCH₂F OCH₃ 3-OCH₃ CN H A-510. OCH₂F OCH₃ 5-F CN H A-511. OCH₂F OCH₃ 5-CH₃ CN H A-512. OCH₂F OCH₃ 5-OCH₃ CN H A-513. OCH₂F CN 3-F CN H A-514. OCH₂F CN 3-CH₃ CN H A-515. OCH₂F CN 3-OCH₃ CN H A-516. OCH₂F CN 5-F CN H A-517. OCH₂F CN 5-CH₃ CN H A-518. OCH₂F CN 5-OCH₃ CN H A-519. OCH₂F CH₂F 3-F CN H A-520. OCH₂F CH₂F 3-CH₃ CN H A-521. OCH₂F CH₂F 3-OCH₃ CN H A-522. OCH₂F CH₂F 5-F CN H A-523. OCH₂F CH₂F 5-CH₃ CN H A-524. OCH₂F CH₂F 5-OCH₃ CN H A-525. OCH₂F CHF₂ 3-F CN H A-526. OCH₂F CHF₂ 3-CH₃ CN H A-527. OCH₂F CHF₂ 3-OCH₃ CN H A-528. OCH₂F CHF₂ 5-F CN H A-529. OCH₂F CHF₂ 5-CH₃ CN H A-530. OCH₂F CHF₂ 5-OCH₃ CN H A-531. OCH₂F CF₃ 3-F CN H A-532. OCH₂F CF₃ 3-CH₃ CN H A-533. OCH₂F CF₃ 3-OCH₃ CN H A-534. OCH₂F CF₃ 5-F CN H A-535. OCH₂F CF₃ 5-CH₃ CN H A-536. OCH₂F CF₃ 5-OCH₃ CN H A-537. OCH₂F OCH₂F 3-F CN H A-538. OCH₂F OCH₂F 3-CH₃ CN H A-539. OCH₂F OCH₂F 3-OCH₃ CN H A-540. OCH₂F OCH₂F 5-F CN H A-541. OCH₂F OCH₂F 5-CH₃ CN H A-542. OCH₂F OCH₂F 5-OCH₃ CN H A-543. OCH₂F OCHF₂ 3-F CN H A-544. OCH₂F OCHF₂ 3-CH₃ CN H A-545. OCH₂F OCHF₂ 3-OCH₃ CN H A-546. OCH₂F OCHF₂ 5-F CN H A-547. OCH₂F OCHF₂ 5-CH₃ CN H A-548. OCH₂F OCHF₂ 5-OCH₃ CN H A-549. OCH₂F OCF₃ 3-F CN H A-550. OCH₂F OCF₃ 3-CH₃ CN H A-551. OCH₂F OCF₃ 3-OCH₃ CN H A-552. OCH₂F OCF₃ 5-F CN H A-553. OCH₂F OCF₃ 5-CH₃ CN H A-554. OCH₂F OCF₃ 5-OCH₃ CN H A-555. OCHF₂ F 3-F CN H A-556. OCHF₂ F 3-CH₃ CN H A-557. OCHF₂ F 3-OCH₃ CN H A-558. OCHF₂ F 5-F CN H A-559. OCHF₂ F 5-CH₃ CN H A-560. OCHF₂ F 5-OCH₃ CN H A-561. OCHF₂ CH₃ 3-F CN H A-562. OCHF₂ CH₃ 3-CH₃ CN H A-563. OCHF₂ CH₃ 3-OCH₃ CN H A-564. OCHF₂ CH₃ 5-F CN H A-565. OCHF₂ CH₃ 5-CH₃ CN H A-566. OCHF₂ CH₃ 5-OCH₃ CN H A-567. OCHF₂ OCH₃ 3-F CN H A-568. OCHF₂ OCH₃ 3-CH₃ CN H A-569. OCHF₂ OCH₃ 3-OCH₃ CN H A-570. OCHF₂ OCH₃ 5-F CN H A-571. OCHF₂ OCH₃ 5-CH₃ CN H A-572. OCHF₂ OCH₃ 5-OCH₃ CN H A-573. OCHF₂ CN 3-F CN H A-574. OCHF₂ CN 3-CH₃ CN H A-575. OCHF₂ CN 3-OCH₃ CN H A-576. OCHF₂ CN 5-F CN H A-577. OCHF₂ CN 5-CH₃ CN H A-578. OCHF₂ CN 5-OCH₃ CN H A-579. OCHF₂ CH₂F 3-F CN H A-580. OCHF₂ CH₂F 3-CH₃ CN H A-581. OCHF₂ CH₂F 3-OCH₃ CN H A-582. OCHF₂ CH₂F 5-F CN H A-583. OCHF₂ CH₂F 5-CH₃ CN H A-584. OCHF₂ CH₂F 5-OCH₃ CN H A-585. OCHF₂ CHF₂ 3-F CN H A-586. OCHF₂ CHF₂ 3-CH₃ CN H A-587. OCHF₂ CHF₂ 3-OCH₃ CN H A-588. OCHF₂ CHF₂ 5-F CN H A-589. OCHF₂ CHF₂ 5-CH₃ CN H A-590. OCHF₂ CHF₂ 5-OCH₃ CN H A-591. OCHF₂ CF₃ 3-F CN H A-592. OCHF₂ CF₃ 3-CH₃ CN H A-593. OCHF₂ CF₃ 3-OCH₃ CN H A-594. OCHF₂ CF₃ 5-F CN H A-595. OCHF₂ CF₃ 5-CH₃ CN H A-596. OCHF₂ CF₃ 5-OCH₃ CN H A-597. OCHF₂ OCH₂F 3-F CN H A-598. OCHF₂ OCH₂F 3-CH₃ CN H A-599. OCHF₂ OCH₂F 3-OCH₃ CN H A-600. OCHF₂ OCH₂F 5-F CN H A-601. OCHF₂ OCH₂F 5-CH₃ CN H A-602. OCHF₂ OCH₂F 5-OCH₃ CN H A-603. OCHF₂ OCHF₂ 3-F CN H A-604. OCHF₂ OCHF₂ 3-CH₃ CN H A-605. OCHF₂ OCHF₂ 3-OCH₃ CN H A-606. OCHF₂ OCHF₂ 5-F CN H A-607. OCHF₂ OCHF₂ 5-CH₃ CN H A-608. OCHF₂ OCHF₂ 5-OCH₃ CN H A-609. OCHF₂ OCF₃ 3-F CN H A-610. OCHF₂ OCF₃ 3-CH₃ CN H A-611. OCHF₂ OCF₃ 3-OCH₃ CN H A-612. OCHF₂ OCF₃ 5-F CN H A-613. OCHF₂ OCF₃ 5-CH₃ CN H A-614. OCHF₂ OCF₃ 5-OCH₃ CN H A-615. OCF₃ F 3-F CN H A-616. OCF₃ F 3-CH₃ CN H A-617. OCF₃ F 3-OCH₃ CN H A-618. OCF₃ F 5-F CN H A-619. OCF₃ F 5-CH₃ CN H A-620. OCF₃ F 5-OCH₃ CN H A-621. OCF₃ CH₃ 3-F CN H A-622. OCF₃ CH₃ 3-CH₃ CN H A-623. OCF₃ CH₃ 3-OCH₃ CN H A-624. OCF₃ CH₃ 5-F CN H A-625. OCF₃ CH₃ 5-CH₃ CN H A-626. OCF₃ CH₃ 5-OCH₃ CN H A-627. OCF₃ OCH₃ 3-F CN H A-628. OCF₃ OCH₃ 3-CH₃ CN H A-629. OCF₃ OCH₃ 3-OCH₃ CN H A-630. OCF₃ OCH₃ 5-F CN H A-631. OCF₃ OCH₃ 5-CH₃ CN H A-632. OCF₃ OCH₃ 5-OCH₃ CN H A-633. OCF₃ CN 3-F CN H A-634. OCF₃ CN 3-CH₃ CN H A-635. OCF₃ CN 3-OCH₃ CN H A-636. OCF₃ CN 5-F CN H A-637. OCF₃ CN 5-CH₃ CN H A-638. OCF₃ CN 5-OCH₃ CN H A-639. OCF₃ CH₂F 3-F CN H A-640. OCF₃ CH₂F 3-CH₃ CN H A-641. OCF₃ CH₂F 3-OCH₃ CN H A-642. OCF₃ CH₂F 5-F CN H A-643. OCF₃ CH₂F 5-CH₃ CN H A-644. OCF₃ CH₂F 5-OCH₃ CN H A-645. OCF₃ CHF₂ 3-F CN H A-646. OCF₃ CHF₂ 3-CH₃ CN H A-647. OCF₃ CHF₂ 3-OCH₃ CN H A-648. OCF₃ CHF₂ 5-F CN H A-649. OCF₃ CHF₂ 5-CH₃ CN H A-650. OCF₃ CHF₂ 5-OCH₃ CN H A-651. OCF₃ CF₃ 3-F CN H A-652. OCF₃ CF₃ 3-CH₃ CN H A-653. OCF₃ CF₃ 3-OCH₃ CN H A-654. OCF₃ CF₃ 5-F CN H A-655. OCF₃ CF₃ 5-CH₃ CN H A-656. OCF₃ CF₃ 5-OCH₃ CN H A-657. OCF₃ OCH₂F 3-F CN H A-658. OCF₃ OCH₂F 3-CH₃ CN H A-659. OCF₃ OCH₂F 3-OCH₃ CN H A-660. OCF₃ OCH₂F 5-F CN H A-661. OCF₃ OCH₂F 5-CH₃ CN H A-662. OCF₃ OCH₂F 5-OCH₃ CN H A-663. OCF₃ OCHF₂ 3-F CN H A-664. OCF₃ OCHF₂ 3-CH₃ CN H A-665. OCF₃ OCHF₂ 3-OCH₃ CN H A-666. OCF₃ OCHF₂ 5-F CN H A-667. OCF₃ OCHF₂ 5-CH₃ CN H A-668. OCF₃ OCHF₂ 5-OCH₃ CN H A-669. OCF₃ OCF₃ 3-F CN H A-670. OCF₃ OCF₃ 3-CH₃ CN H A-671. OCF₃ OCF₃ 3-OCH₃ CN H A-672. OCF₃ OCF₃ 5-F CN H A-673. OCF₃ OCF₃ 5-CH₃ CN H A-674. OCF₃ OCF₃ 5-OCH₃ CN H A-675. H H H F H A-676. F H H F H A-677. CH₃ H H F H A-678. OCH₃ H H F H A-679. CH₂F H H F H A-680. CHF₂ H H F H A-681. CF₃ H H F H A-682. OCH₂F H H F H A-683. OCHF₂ H H F H A-684. OCF₃ H H F H A-685. H F H F H A-686. H CH₃ H F H A-687. H OCH₃ H F H A-688. H CN H F H A-689. H CH₂F H F H A-690. H CHF₂ H F H A-691. H CF₃ H F H A-692. H OCH₂F H F H A-693. H OCHF₂ H F H A-694. H OCF₃ H F H A-695. H H 3-F F H A-696. H H 3-CH₃ F H A-697. H H 3-OCH₃ F H A-698. H H 5-F F H A-699. H H 5-CH₃ F H A-700. H H 5-OCH₃ F H A-701. F F H F H A-702. F CH₃ H F H A-703. F OCH₃ H F H A-704. F CN H F H A-705. F CH₂F H F H A-706. F CHF₂ H F H A-707. F CF₃ H F H A-708. F OCH₂F H F H A-709. F OCHF₂ H F H A-710. F OCF₃ H F H A-711. F H 3-F F H A-712. F H 3-CH₃ F H A-713. F H 3-OCH₃ F H A-714. F H 5-F F H A-715. F H 5-CH₃ F H A-716. F H 5-OCH₃ F H A-717. CH₃ F H F H A-718. CH₃ CH₃ H F H A-719. CH₃ OCH₃ H F H A-720. CH₃ CN H F H A-721. CH₃ CH₂F H F H A-722. CH₃ CHF₂ H F H A-723. CH₃ CF₃ H F H A-724. CH₃ OCH₂F H F H A-725. CH₃ OCHF₂ H F H A-726. CH₃ OCF₃ H F H A-727. CH₃ H 3-F F H A-728. CH₃ H 3-CH₃ F H A-729. CH₃ H 3-OCH₃ F H A-730. CH₃ H 5-F F H A-731. CH₃ H 5-CH₃ F H A-732. CH₃ H 5-OCH₃ F H A-733. OCH₃ F H F H A-734. OCH₃ CH₃ H F H A-735. OCH₃ OCH₃ H F H A-736. OCH₃ CN H F H A-737. OCH₃ CH₂F H F H A-738. OCH₃ CHF₂ H F H A-739. OCH₃ CF₃ H F H A-740. OCH₃ OCH₂F H F H A-741. OCH₃ OCHF₂ H F H A-742. OCH₃ OCF₃ H F H A-743. OCH₃ H 3-F F H A-744. OCH₃ H 3-CH₃ F H A-745. OCH₃ H 3-OCH₃ F H A-746. OCH₃ H 5-F F H A-747. OCH₃ H 5-CH₃ F H A-748. OCH₃ H 5-OCH₃ F H A-749. H F 3-F F H A-750. H F 3-CH₃ F H A-751. H F 3-OCH₃ F H A-752. H F 5-F F H A-753. H F 5-CH₃ F H A-754. H F 5-OCH₃ F H A-755. H CH₃ 3-F F H A-756. H CH₃ 3-CH₃ F H A-757. H CH₃ 3-OCH₃ F H A-758. H CH₃ 5-F F H A-759. H CH₃ 5-CH₃ F H A-760. H CH₃ 5-OCH₃ F H A-761. H OCH₃ 3-F F H A-762. H OCH₃ 3-CH₃ F H A-763. H OCH₃ 3-OCH₃ F H A-764. H OCH₃ 5-F F H A-765. H OCH₃ 5-CH₃ F H A-766. H OCH₃ 5-OCH₃ F H A-767. H CN 3-F F H A-768. H CN 3-CH₃ F H A-769. H CN 3-OCH₃ F H A-770. H CN 5-F F H A-771. H CN 5-CH₃ F H A-772. H CN 5-OCH₃ F H A-773. H CH₂F 3-F F H A-774. H CH₂F 3-CH₃ F H A-775. H CH₂F 3-OCH₃ F H A-776. H CH₂F 5-F F H A-777. H CH₂F 5-CH₃ F H A-778. H CH₂F 5-OCH₃ F H A-779. H CHF₂ 3-F F H A-780. H CHF₂ 3-CH₃ F H A-781. H CHF₂ 3-OCH₃ F H A-782. H CHF₂ 5-F F H A-783. H CHF₂ 5-CH₃ F H A-784. H CHF₂ 5-OCH₃ F H A-785. H CF₃ 3-F F H A-786. H CF₃ 3-CH₃ F H A-787. H CF₃ 3-OCH₃ F H A-788. H CF₃ 5-F F H A-789. H CF₃ 5-CH₃ F H A-790. H CF₃ 5-OCH₃ F H A-791. H OCH₂F 3-F F H A-792. H OCH₂F 3-CH₃ F H A-793. H OCH₂F 3-OCH₃ F H A-794. H OCH₂F 5-F F H A-795. H OCH₂F 5-CH₃ F H A-796. H OCH₂F 5-OCH₃ F H A-797. H OCHF₂ 3-F F H A-798. H OCHF₂ 3-CH₃ F H A-799. H OCHF₂ 3-OCH₃ F H A-800. H OCHF₂ 5-F F H A-801. H OCHF₂ 5-CH₃ F H A-802. H OCHF₂ 5-OCH₃ F H A-803. H OCF₃ 3-F F H A-804. H OCF₃ 3-CH₃ F H A-805. H OCF₃ 3-OCH₃ F H A-806. H OCF₃ 5-F F H A-807. H OCF₃ 5-CH₃ F H A-808. H OCF₃ 5-OCH₃ F H A-809. F F 3-F F H A-810. F F 3-CH₃ F H A-811. F F 3-OCH₃ F H A-812. F F 5-F F H A-813. F F 5-CH₃ F H A-814. F F 5-OCH₃ F H A-815. F CH₃ 3-F F H A-816. F CH₃ 3-CH₃ F H A-817. F CH₃ 3-OCH₃ F H A-818. F CH₃ 5-F F H A-819. F CH₃ 5-CH₃ F H A-820. F CH₃ 5-OCH₃ F H A-821. F OCH₃ 3-F F H A-822. F OCH₃ 3-CH₃ F H A-823. F OCH₃ 3-OCH₃ F H A-824. F OCH₃ 5-F F H A-825. F OCH₃ 5-CH₃ F H A-826. F OCH₃ 5-OCH₃ F H A-827. F CN 3-F F H A-828. F CN 3-CH₃ F H A-829. F CN 3-OCH₃ F H A-830. F CN 5-F F H A-831. F CN 5-CH₃ F H A-832. F CN 5-OCH₃ F H A-833. F CH₂F 3-F F H A-834. F CH₂F 3-CH₃ F H A-835. F CH₂F 3-OCH₃ F H A-836. F CH₂F 5-F F H A-837. F CH₂F 5-CH₃ F H A-838. F CH₂F 5-OCH₃ F H A-839. F CHF₂ 3-F F H A-840. F CHF₂ 3-CH₃ F H A-841. F CHF₂ 3-OCH₃ F H A-842. F CHF₂ 5-F F H A-843. F CHF₂ 5-CH₃ F H A-844. F CHF₂ 5-OCH₃ F H A-845. F CF₃ 3-F F H A-846. F CF₃ 3-CH₃ F H A-847. F CF₃ 3-OCH₃ F H A-848. F CF₃ 5-F F H A-849. F CF₃ 5-CH₃ F H A-850. F CF₃ 5-OCH₃ F H A-851. F OCH₂F 3-F F H A-852. F OCH₂F 3-CH₃ F H A-853. F OCH₂F 3-OCH₃ F H A-854. F OCH₂F 5-F F H A-855. F OCH₂F 5-CH₃ F H A-856. F OCH₂F 5-OCH₃ F H A-857. F OCHF₂ 3-F F H A-858. F OCHF₂ 3-CH₃ F H A-859. F OCHF₂ 3-OCH₃ F H A-860. F OCHF₂ 5-F F H A-861. F OCHF₂ 5-CH₃ F H A-862. F OCHF₂ 5-OCH₃ F H A-863. F OCF₃ 3-F F H A-864. F OCF₃ 3-CH₃ F H A-865. F OCF₃ 3-OCH₃ F H A-866. F OCF₃ 5-F F H A-867. F OCF₃ 5-CH₃ F H A-868. F OCF₃ 5-OCH₃ F H A-869. CH₃ F 3-F F H A-870. CH₃ F 3-CH₃ F H A-871. CH₃ F 3-OCH₃ F H A-872. CH₃ F 5-F F H A-873. CH₃ F 5-CH₃ F H A-874. CH₃ F 5-OCH₃ F H A-875. CH₃ CH₃ 3-F F H A-876. CH₃ CH₃ 3-CH₃ F H A-877. CH₃ CH₃ 3-OCH₃ F H A-878. CH₃ CH₃ 5-F F H A-879. CH₃ CH₃ 5-CH₃ F H A-880. CH₃ CH₃ 5-OCH₃ F H A-881. CH₃ OCH₃ 3-F F H A-882. CH₃ OCH₃ 3-CH₃ F H A-883. CH₃ OCH₃ 3-OCH₃ F H A-884. CH₃ OCH₃ 5-F F H A-885. CH₃ OCH₃ 5-CH₃ F H A-886. CH₃ OCH₃ 5-OCH₃ F H A-887. CH₃ CN 3-F F H A-888. CH₃ CN 3-CH₃ F H A-889. CH₃ CN 3-OCH₃ F H A-890. CH₃ CN 5-F F H A-891. CH₃ CN 5-CH₃ F H A-892. CH₃ CN 5-OCH₃ F H A-893. CH₃ CH₂F 3-F F H A-894. CH₃ CH₂F 3-CH₃ F H A-895. CH₃ CH₂F 3-OCH₃ F H A-896. CH₃ CH₂F 5-F F H A-897. CH₃ CH₂F 5-CH₃ F H A-898. CH₃ CH₂F 5-OCH₃ F H A-899. CH₃ CHF₂ 3-F F H A-900. CH₃ CHF₂ 3-CH₃ F H A-901. CH₃ CHF₂ 3-OCH₃ F H A-902. CH₃ CHF₂ 5-F F H A-903. CH₃ CHF₂ 5-CH₃ F H A-904. CH₃ CHF₂ 5-OCH₃ F H A-905. CH₃ CF₃ 3-F F H A-906. CH₃ CF₃ 3-CH₃ F H A-907. CH₃ CF₃ 3-OCH₃ F H A-908. CH₃ CF₃ 5-F F H A-909. CH₃ CF₃ 5-CH₃ F H A-910. CH₃ CF₃ 5-OCH₃ F H A-911. CH₃ OCH₂F 3-F F H A-912. CH₃ OCH₂F 3-CH₃ F H A-913. CH₃ OCH₂F 3-OCH₃ F H A-914. CH₃ OCH₂F 5-F F H A-915. CH₃ OCH₂F 5-CH₃ F H A-916. CH₃ OCH₂F 5-OCH₃ F H A-917. CH₃ OCHF₂ 3-F F H A-918. CH₃ OCHF₂ 3-CH₃ F H A-919. CH₃ OCHF₂ 3-OCH₃ F H A-920. CH₃ OCHF₂ 5-F F H A-921. CH₃ OCHF₂ 5-CH₃ F H A-922. CH₃ OCHF₂ 5-OCH₃ F H A-923. CH₃ OCF₃ 3-F F H A-924. CH₃ OCF₃ 3-CH₃ F H A-925. CH₃ OCF₃ 3-OCH₃ F H A-926. CH₃ OCF₃ 5-F F H A-927. CH₃ OCF₃ 5-CH₃ F H A-928. CH₃ OCF₃ 5-OCH₃ F H A-929. OCH₃ F 3-F F H A-930. OCH₃ F 3-CH₃ F H A-931. OCH₃ F 3-OCH₃ F H A-932. OCH₃ F 5-F F H A-933. OCH₃ F 5-CH₃ F H A-934. OCH₃ F 5-OCH₃ F H A-935. OCH₃ CH₃ 3-F F H A-936. OCH₃ CH₃ 3-CH₃ F H A-937. OCH₃ CH₃ 3-OCH₃ F H A-938. OCH₃ CH₃ 5-F F H A-939. OCH₃ CH₃ 5-CH₃ F H A-940. OCH₃ CH₃ 5-OCH₃ F H A-941. OCH₃ OCH₃ 3-F F H A-942. OCH₃ OCH₃ 3-CH₃ F H A-943. OCH₃ OCH₃ 3-OCH₃ F H A-944. OCH₃ OCH₃ 5-F F H A-945. OCH₃ OCH₃ 5-CH₃ F H A-946. OCH₃ OCH₃ 5-OCH₃ F H A-947. OCH₃ CN 3-F F H A-948. OCH₃ CN 3-CH₃ F H A-949. OCH₃ CN 3-OCH₃ F H A-950. OCH₃ CN 5-F F H A-951. OCH₃ CN 5-CH₃ F H A-952. OCH₃ CN 5-OCH₃ F H A-953. OCH₃ CH₂F 3-F F H A-954. OCH₃ CH₂F 3-CH₃ F H A-955. OCH₃ CH₂F 3-OCH₃ F H A-956. OCH₃ CH₂F 5-F F H A-957. OCH₃ CH₂F 5-CH₃ F H A-958. OCH₃ CH₂F 5-OCH₃ F H A-959. OCH₃ CHF₂ 3-F F H A-960. OCH₃ CHF₂ 3-CH₃ F H A-961. OCH₃ CHF₂ 3-OCH₃ F H A-962. OCH₃ CHF₂ 5-F F H A-963. OCH₃ CHF₂ 5-CH₃ F H A-964. OCH₃ CHF₂ 5-OCH₃ F H A-965. OCH₃ CF₃ 3-F F H A-966. OCH₃ CF₃ 3-CH₃ F H A-967. OCH₃ CF₃ 3-OCH₃ F H A-968. OCH₃ CF₃ 5-F F H A-969. OCH₃ CF₃ 5-CH₃ F H A-970. OCH₃ CF₃ 5-OCH₃ F H A-971. OCH₃ OCH₂F 3-F F H A-972. OCH₃ OCH₂F 3-CH₃ F H A-973. OCH₃ OCH₂F 3-OCH₃ F H A-974. OCH₃ OCH₂F 5-F F H A-975. OCH₃ OCH₂F 5-CH₃ F H A-976. OCH₃ OCH₂F 5-OCH₃ F H A-977. OCH₃ OCHF₂ 3-F F H A-978. OCH₃ OCHF₂ 3-CH₃ F H A-979. OCH₃ OCHF₂ 3-OCH₃ F H A-980. OCH₃ OCHF₂ 5-F F H A-981. OCH₃ OCHF₂ 5-CH₃ F H A-982. OCH₃ OCHF₂ 5-OCH₃ F H A-983. OCH₃ OCF₃ 3-F F H A-984. OCH₃ OCF₃ 3-CH₃ F H A-985. OCH₃ OCF₃ 3-OCH₃ F H A-986. OCH₃ OCF₃ 5-F F H A-987. OCH₃ OCF₃ 5-CH₃ F H A-988. OCH₃ OCF₃ 5-OCH₃ F H A-989. CH₂F F 3-F F H A-990. CH₂F F 3-CH₃ F H A-991. CH₂F F 3-OCH₃ F H A-992. CH₂F F 5-F F H A-993. CH₂F F 5-CH₃ F H A-994. CH₂F F 5-OCH₃ F H A-995. CH₂F CH₃ 3-F F H A-996. CH₂F CH₃ 3-CH₃ F H A-997. CH₂F CH₃ 3-OCH₃ F H A-998. CH₂F CH₃ 5-F F H A-999. CH₂F CH₃ 5-CH₃ F H A-1000. CH₂F CH₃ 5-OCH₃ F H A-1001. CH₂F OCH₃ 3-F F H A-1002. CH₂F OCH₃ 3-CH₃ F H A-1003. CH₂F OCH₃ 3-OCH₃ F H A-1004. CH₂F OCH₃ 5-F F H A-1005. CH₂F OCH₃ 5-CH₃ F H A-1006. CH₂F OCH₃ 5-OCH₃ F H A-1007. CH₂F CN 3-F F H A-1008. CH₂F CN 3-CH₃ F H A-1009. CH₂F CN 3-OCH₃ F H A-1010. CH₂F CN 5-F F H A-1011. CH₂F CN 5-CH₃ F H A-1012. CH₂F CN 5-OCH₃ F H A-1013. CH₂F CH₂F 3-F F H A-1014. CH₂F CH₂F 3-CH₃ F H A-1015. CH₂F CH₂F 3-OCH₃ F H A-1016. CH₂F CH₂F 5-F F H A-1017. CH₂F CH₂F 5-CH₃ F H A-1018. CH₂F CH₂F 5-OCH₃ F H A-1019. CH₂F CHF₂ 3-F F H A-1020. CH₂F CHF₂ 3-CH₃ F H A-1021. CH₂F CHF₂ 3-OCH₃ F H A-1022. CH₂F CHF₂ 5-F F H A-1023. CH₂F CHF₂ 5-CH₃ F H A-1024. CH₂F CHF₂ 5-OCH₃ F H A-1025. CH₂F CF₃ 3-F F H A-1026. CH₂F CF₃ 3-CH₃ F H A-1027. CH₂F CF₃ 3-OCH₃ F H A-1028. CH₂F CF₃ 5-F F H A-1029. CH₂F CF₃ 5-CH₃ F H A-1030. CH₂F CF₃ 5-OCH₃ F H A-1031. CH₂F OCH₂F 3-F F H A-1032. CH₂F OCH₂F 3-CH₃ F H A-1033. CH₂F OCH₂F 3-OCH₃ F H A-1034. CH₂F OCH₂F 5-F F H A-1035. CH₂F OCH₂F 5-CH₃ F H A-1036. CH₂F OCH₂F 5-OCH₃ F H A-1037. CH₂F OCHF₂ 3-F F H A-1038. CH₂F OCHF₂ 3-CH₃ F H A-1039. CH₂F OCHF₂ 3-OCH₃ F H A-1040. CH₂F OCHF₂ 5-F F H A-1041. CH₂F OCHF₂ 5-CH₃ F H A-1042. CH₂F OCHF₂ 5-OCH₃ F H A-1043. CH₂F OCF₃ 3-F F H A-1044. CH₂F OCF₃ 3-CH₃ F H A-1045. CH₂F OCF₃ 3-OCH₃ F H A-1046. CH₂F OCF₃ 5-F F H A-1047. CH₂F OCF₃ 5-CH₃ F H A-1048. CH₂F OCF₃ 5-OCH₃ F H A-1049. CHF₂ F 3-F F H A-1050. CHF₂ F 3-CH₃ F H A-1051. CHF₂ F 3-OCH₃ F H A-1052. CHF₂ F 5-F F H A-1053. CHF₂ F 5-CH₃ F H A-1054. CHF₂ F 5-OCH₃ F H A-1055. CHF₂ CH₃ 3-F F H A-1056. CHF₂ CH₃ 3-CH₃ F H A-1057. CHF₂ CH₃ 3-OCH₃ F H A-1058. CHF₂ CH₃ 5-F F H A-1059. CHF₂ CH₃ 5-CH₃ F H A-1060. CHF₂ CH₃ 5-OCH₃ F H A-1061. CHF₂ OCH₃ 3-F F H A-1062. CHF₂ OCH₃ 3-CH₃ F H A-1063. CHF₂ OCH₃ 3-OCH₃ F H A-1064. CHF₂ OCH₃ 5-F F H A-1065. CHF₂ OCH₃ 5-CH₃ F H A-1066. CHF₂ OCH₃ 5-OCH₃ F H A-1067. CHF₂ CN 3-F F H A-1068. CHF₂ CN 3-CH₃ F H A-1069. CHF₂ CN 3-OCH₃ F H A-1070. CHF₂ CN 5-F F H A-1071. CHF₂ CN 5-CH₃ F H A-1072. CHF₂ CN 5-OCH₃ F H A-1073. CHF₂ CH₂F 3-F F H A-1074. CHF₂ CH₂F 3-CH₃ F H A-1075. CHF₂ CH₂F 3-OCH₃ F H A-1076. CHF₂ CH₂F 5-F F H A-1077. CHF₂ CH₂F 5-CH₃ F H A-1078. CHF₂ CH₂F 5-OCH₃ F H A-1079. CHF₂ CHF₂ 3-F F H A-1080. CHF₂ CHF₂ 3-CH₃ F H A-1081. CHF₂ CHF₂ 3-OCH₃ F H A-1082. CHF₂ CHF₂ 5-F F H A-1083. CHF₂ CHF₂ 5-CH₃ F H A-1084. CHF₂ CHF₂ 5-OCH₃ F H A-1085. CHF₂ CF₃ 3-F F H A-1086. CHF₂ CF₃ 3-CH₃ F H A-1087. CHF₂ CF₃ 3-OCH₃ F H A-1088. CHF₂ CF₃ 5-F F H A-1089. CHF₂ CF₃ 5-CH₃ F H A-1090. CHF₂ CF₃ 5-OCH₃ F H A-1091. CHF₂ OCH₂F 3-F F H A-1092. CHF₂ OCH₂F 3-CH₃ F H A-1093. CHF₂ OCH₂F 3-OCH₃ F H A-1094. CHF₂ OCH₂F 5-F F H A-1095. CHF₂ OCH₂F 5-CH₃ F H A-1096. CHF₂ OCH₂F 5-OCH₃ F H A-1097. CHF₂ OCHF₂ 3-F F H A-1098. CHF₂ OCHF₂ 3-CH₃ F H A-1099. CHF₂ OCHF₂ 3-OCH₃ F H A-1100. CHF₂ OCHF₂ 5-F F H A-1101. CHF₂ OCHF₂ 5-CH₃ F H A-1102. CHF₂ OCHF₂ 5-OCH₃ F H A-1103. CHF₂ OCF₃ 3-F F H A-1104. CHF₂ OCF₃ 3-CH₃ F H A-1105. CHF₂ OCF₃ 3-OCH₃ F H A-1106. CHF₂ OCF₃ 5-F F H A-1107. CHF₂ OCF₃ 5-CH₃ F H A-1108. CHF₂ OCF₃ 5-OCH₃ F H A-1109. CF₃ F 3-F F H A-1110. CF₃ F 3-CH₃ F H A-1111. CF₃ F 3-OCH₃ F H A-1112. CF₃ F 5-F F H A-1113. CF₃ F 5-CH₃ F H A-1114. CF₃ F 5-OCH₃ F H A-1115. CF₃ CH₃ 3-F F H A-1116. CF₃ CH₃ 3-CH₃ F H A-1117. CF₃ CH₃ 3-OCH₃ F H A-1118. CF₃ CH₃ 5-F F H A-1119. CF₃ CH₃ 5-CH₃ F H A-1120. CF₃ CH₃ 5-OCH₃ F H A-1121. CF₃ OCH₃ 3-F F H A-1122. CF₃ OCH₃ 3-CH₃ F H A-1123. CF₃ OCH₃ 3-OCH₃ F H A-1124. CF₃ OCH₃ 5-F F H A-1125. CF₃ OCH₃ 5-CH₃ F H A-1126. CF₃ OCH₃ 5-OCH₃ F H A-1127. CF₃ CN 3-F F H A-1128. CF₃ CN 3-CH₃ F H A-1129. CF₃ CN 3-OCH₃ F H A-1130. CF₃ CN 5-F F H A-1131. CF₃ CN 5-CH₃ F H A-1132. CF₃ CN 5-OCH₃ F H A-1133. CF₃ CH₂F 3-F F H A-1134. CF₃ CH₂F 3-CH₃ F H A-1135. CF₃ CH₂F 3-OCH₃ F H A-1136. CF₃ CH₂F 5-F F H A-1137. CF₃ CH₂F 5-CH₃ F H A-1138. CF₃ CH₂F 5-OCH₃ F H A-1139. CF₃ CHF₂ 3-F F H A-1140. CF₃ CHF₂ 3-CH₃ F H A-1141. CF₃ CHF₂ 3-OCH₃ F H A-1142. CF₃ CHF₂ 5-F F H A-1143. CF₃ CHF₂ 5-CH₃ F H A-1144. CF₃ CHF₂ 5-OCH₃ F H A-1145. CF₃ CF₃ 3-F F H A-1146. CF₃ CF₃ 3-CH₃ F H A-1147. CF₃ CF₃ 3-OCH₃ F H A-1148. CF₃ CF₃ 5-F F H A-1149. CF₃ CF₃ 5-CH₃ F H A-1150. CF₃ CF₃ 5-OCH₃ F H A-1151. CF₃ OCH₂F 3-F F H A-1152. CF₃ OCH₂F 3-CH₃ F H A-1153. CF₃ OCH₂F 3-OCH₃ F H A-1154. CF₃ OCH₂F 5-F F H A-1155. CF₃ OCH₂F 5-CH₃ F H A-1156. CF₃ OCH₂F 5-OCH₃ F H A-1157. CF₃ OCHF₂ 3-F F H A-1158. CF₃ OCHF₂ 3-CH₃ F H A-1159. CF₃ OCHF₂ 3-OCH₃ F H A-1160. CF₃ OCHF₂ 5-F F H A-1161. CF₃ OCHF₂ 5-CH₃ F H A-1162. CF₃ OCHF₂ 5-OCH₃ F H A-1163. CF₃ OCF₃ 3-F F H A-1164. CF₃ OCF₃ 3-CH₃ F H A-1165. CF₃ OCF₃ 3-OCH₃ F H A-1166. CF₃ OCF₃ 5-F F H A-1167. CF₃ OCF₃ 5-CH₃ F H A-1168. CF₃ OCF₃ 5-OCH₃ F H A-1169. OCH₂F F 3-F F H A-1170. OCH₂F F 3-CH₃ F H A-1171. OCH₂F F 3-OCH₃ F H A-1172. OCH₂F F 5-F F H A-1173. OCH₂F F 5-CH₃ F H A-1174. OCH₂F F 5-OCH₃ F H A-1175. OCH₂F CH₃ 3-F F H A-1176. OCH₂F CH₃ 3-CH₃ F H A-1177. OCH₂F CH₃ 3-OCH₃ F H A-1178. OCH₂F CH₃ 5-F F H A-1179. OCH₂F CH₃ 5-CH₃ F H A-1180. OCH₂F CH₃ 5-OCH₃ F H A-1181. OCH₂F OCH₃ 3-F F H A-1182. OCH₂F OCH₃ 3-CH₃ F H A-1183. OCH₂F OCH₃ 3-OCH₃ F H A-1184. OCH₂F OCH₃ 5-F F H A-1185. OCH₂F OCH₃ 5-CH₃ F H A-1186. OCH₂F OCH₃ 5-OCH₃ F H A-1187. OCH₂F CN 3-F F H A-1188. OCH₂F CN 3-CH₃ F H A-1189. OCH₂F CN 3-OCH₃ F H A-1190. OCH₂F CN 5-F F H A-1191. OCH₂F CN 5-CH₃ F H A-1192. OCH₂F CN 5-OCH₃ F H A-1193. OCH₂F CH₂F 3-F F H A-1194. OCH₂F CH₂F 3-CH₃ F H A-1195. OCH₂F CH₂F 3-OCH₃ F H A-1196. OCH₂F CH₂F 5-F F H A-1197. OCH₂F CH₂F 5-CH₃ F H A-1198. OCH₂F CH₂F 5-OCH₃ F H A-1199. OCH₂F CHF₂ 3-F F H A-1200. OCH₂F CHF₂ 3-CH₃ F H A-1201. OCH₂F CHF₂ 3-OCH₃ F H A-1202. OCH₂F CHF₂ 5-F F H A-1203. OCH₂F CHF₂ 5-CH₃ F H A-1204. OCH₂F CHF₂ 5-OCH₃ F H A-1205. OCH₂F CF₃ 3-F F H A-1206. OCH₂F CF₃ 3-CH₃ F H A-1207. OCH₂F CF₃ 3-OCH₃ F H A-1208. OCH₂F CF₃ 5-F F H A-1209. OCH₂F CF₃ 5-CH₃ F H A-1210. OCH₂F CF₃ 5-OCH₃ F H A-1211. OCH₂F OCH₂F 3-F F H A-1212. OCH₂F OCH₂F 3-CH₃ F H A-1213. OCH₂F OCH₂F 3-OCH₃ F H A-1214. OCH₂F OCH₂F 5-F F H A-1215. OCH₂F OCH₂F 5-CH₃ F H A-1216. OCH₂F OCH₂F 5-OCH₃ F H A-1217. OCH₂F OCHF₂ 3-F F H A-1218. OCH₂F OCHF₂ 3-CH₃ F H A-1219. OCH₂F OCHF₂ 3-OCH₃ F H A-1220. OCH₂F OCHF₂ 5-F F H A-1221. OCH₂F OCHF₂ 5-CH₃ F H A-1222. OCH₂F OCHF₂ 5-OCH₃ F H A-1223. OCH₂F OCF₃ 3-F F H A-1224. OCH₂F OCF₃ 3-CH₃ F H A-1225. OCH₂F OCF₃ 3-OCH₃ F H A-1226. OCH₂F OCF₃ 5-F F H A-1227. OCH₂F OCF₃ 5-CH₃ F H A-1228. OCH₂F OCF₃ 5-OCH₃ F H A-1229. OCHF₂ F 3-F F H A-1230. OCHF₂ F 3-CH₃ F H A-1231. OCHF₂ F 3-OCH₃ F H A-1232. OCHF₂ F 5-F F H A-1233. OCHF₂ F 5-CH₃ F H A-1234. OCHF₂ F 5-OCH₃ F H A-1235. OCHF₂ CH₃ 3-F F H A-1236. OCHF₂ CH₃ 3-CH₃ F H A-1237. OCHF₂ CH₃ 3-OCH₃ F H A-1238. OCHF₂ CH₃ 5-F F H A-1239. OCHF₂ CH₃ 5-CH₃ F H A-1240. OCHF₂ CH₃ 5-OCH₃ F H A-1241. OCHF₂ OCH₃ 3-F F H A-1242. OCHF₂ OCH₃ 3-CH₃ F H A-1243. OCHF₂ OCH₃ 3-OCH₃ F H A-1244. OCHF₂ OCH₃ 5-F F H A-1245. OCHF₂ OCH₃ 5-CH₃ F H A-1246. OCHF₂ OCH₃ 5-OCH₃ F H A-1247. OCHF₂ CN 3-F F H A-1248. OCHF₂ CN 3-CH₃ F H A-1249. OCHF₂ CN 3-OCH₃ F H A-1250. OCHF₂ CN 5-F F H A-1251. OCHF₂ CN 5-CH₃ F H A-1252. OCHF₂ CN 5-OCH₃ F H A-1253. OCHF₂ CH₂F 3-F F H A-1254. OCHF₂ CH₂F 3-CH₃ F H A-1255. OCHF₂ CH₂F 3-OCH₃ F H A-1256. OCHF₂ CH₂F 5-F F H A-1257. OCHF₂ CH₂F 5-CH₃ F H A-1258. OCHF₂ CH₂F 5-OCH₃ F H A-1259. OCHF₂ CHF₂ 3-F F H A-1260. OCHF₂ CHF₂ 3-CH₃ F H A-1261. OCHF₂ CHF₂ 3-OCH₃ F H A-1262. OCHF₂ CHF₂ 5-F F H A-1263. OCHF₂ CHF₂ 5-CH₃ F H A-1264. OCHF₂ CHF₂ 5-OCH₃ F H A-1265. OCHF₂ CF₃ 3-F F H A-1266. OCHF₂ CF₃ 3-CH₃ F H A-1267. OCHF₂ CF₃ 3-OCH₃ F H A-1268. OCHF₂ CF₃ 5-F F H A-1269. OCHF₂ CF₃ 5-CH₃ F H A-1270. OCHF₂ CF₃ 5-OCH₃ F H A-1271. OCHF₂ OCH₂F 3-F F H A-1272. OCHF₂ OCH₂F 3-CH₃ F H A-1273. OCHF₂ OCH₂F 3-OCH₃ F H A-1274. OCHF₂ OCH₂F 5-F F H A-1275. OCHF₂ OCH₂F 5-CH₃ F H A-1276. OCHF₂ OCH₂F 5-OCH₃ F H A-1277. OCHF₂ OCHF₂ 3-F F H A-1278. OCHF₂ OCHF₂ 3-CH₃ F H A-1279. OCHF₂ OCHF₂ 3-OCH₃ F H A-1280. OCHF₂ OCHF₂ 5-F F H A-1281. OCHF₂ OCHF₂ 5-CH₃ F H A-1282. OCHF₂ OCHF₂ 5-OCH₃ F H A-1283. OCHF₂ OCF₃ 3-F F H A-1284. OCHF₂ OCF₃ 3-CH₃ F H A-1285. OCHF₂ OCF₃ 3-OCH₃ F H A-1286. OCHF₂ OCF₃ 5-F F H A-1287. OCHF₂ OCF₃ 5-CH₃ F H A-1288. OCHF₂ OCF₃ 5-OCH₃ F H A-1289. OCF₃ F 3-F F H A-1290. OCF₃ F 3-CH₃ F H A-1291. OCF₃ F 3-OCH₃ F H A-1292. OCF₃ F 5-F F H A-1293. OCF₃ F 5-CH₃ F H A-1294. OCF₃ F 5-OCH₃ F H A-1295. OCF₃ CH₃ 3-F F H A-1296. OCF₃ CH₃ 3-CH₃ F H A-1297. OCF₃ CH₃ 3-OCH₃ F H A-1298. OCF₃ CH₃ 5-F F H A-1299. OCF₃ CH₃ 5-CH₃ F H A-1300. OCF₃ CH₃ 5-OCH₃ F H A-1301. OCF₃ OCH₃ 3-F F H A-1302. OCF₃ OCH₃ 3-CH₃ F H A-1303. OCF₃ OCH₃ 3-OCH₃ F H A-1304. OCF₃ OCH₃ 5-F F H A-1305. OCF₃ OCH₃ 5-CH₃ F H A-1306. OCF₃ OCH₃ 5-OCH₃ F H A-1307. OCF₃ CN 3-F F H A-1308. OCF₃ CN 3-CH₃ F H A-1309. OCF₃ CN 3-OCH₃ F H A-1310. OCF₃ CN 5-F F H A-1311. OCF₃ CN 5-CH₃ F H A-1312. OCF₃ CN 5-OCH₃ F H A-1313. OCF₃ CH₂F 3-F F H A-1314. OCF₃ CH₂F 3-CH₃ F H A-1315. OCF₃ CH₂F 3-OCH₃ F H A-1316. OCF₃ CH₂F 5-F F H A-1317. OCF₃ CH₂F 5-CH₃ F H A-1318. OCF₃ CH₂F 5-OCH₃ F H A-1319. OCF₃ CHF₂ 3-F F H A-1320. OCF₃ CHF₂ 3-CH₃ F H A-1321. OCF₃ CHF₂ 3-OCH₃ F H A-1322. OCF₃ CHF₂ 5-F F H A-1323. OCF₃ CHF₂ 5-CH₃ F H A-1324. OCF₃ CHF₂ 5-OCH₃ F H A-1325. OCF₃ CF₃ 3-F F H A-1326. OCF₃ CF₃ 3-CH₃ F H A-1327. OCF₃ CF₃ 3-OCH₃ F H A-1328. OCF₃ CF₃ 5-F F H A-1329. OCF₃ CF₃ 5-CH₃ F H A-1330. OCF₃ CF₃ 5-OCH₃ F H A-1331. OCF₃ OCH₂F 3-F F H A-1332. OCF₃ OCH₂F 3-CH₃ F H A-1333. OCF₃ OCH₂F 3-OCH₃ F H A-1334. OCF₃ OCH₂F 5-F F H A-1335. OCF₃ OCH₂F 5-CH₃ F H A-1336. OCF₃ OCH₂F 5-OCH₃ F H A-1337. OCF₃ OCHF₂ 3-F F H A-1338. OCF₃ OCHF₂ 3-CH₃ F H A-1339. OCF₃ OCHF₂ 3-OCH₃ F H A-1340. OCF₃ OCHF₂ 5-F F H A-1341. OCF₃ OCHF₂ 5-CH₃ F H A-1342. OCF₃ OCHF₂ 5-OCH₃ F H A-1343. OCF₃ OCF₃ 3-F F H A-1344. OCF₃ OCF₃ 3-CH₃ F H A-1345. OCF₃ OCF₃ 3-OCH₃ F H A-1346. OCF₃ OCF₃ 5-F F H A-1347. OCF₃ OCF₃ 5-CH₃ F H A-1348. OCF₃ OCF₃ 5-OCH₃ F H A-1349. H H H Cl H A-1350. F H H Cl H A-1351. CH₃ H H Cl H A-1352. OCH₃ H H Cl H A-1353. CH₂F H H Cl H A-1354. CHF₂ H H Cl H A-1355. CF₃ H H Cl H A-1356. OCH₂F H H Cl H A-1357. OCHF₂ H H Cl H A-1358. OCF₃ H H Cl H A-1359. H F H Cl H A-1360. H CH₃ H Cl H A-1361. H OCH₃ H Cl H A-1362. H CN H Cl H A-1363. H CH₂F H Cl H A-1364. H CHF₂ H Cl H A-1365. H CF₃ H Cl H A-1366. H OCH₂F H Cl H A-1367. H OCHF₂ H Cl H A-1368. H OCF₃ H Cl H A-1369. H H 3-F Cl H A-1370. H H 3-CH₃ Cl H A-1371. H H 3-OCH₃ Cl H A-1372. H H 5-F Cl H A-1373. H H 5-CH₃ Cl H A-1374. H H 5-OCH₃ Cl H A-1375. F F H Cl H A-1376. F CH₃ H Cl H A-1377. F OCH₃ H Cl H A-1378. F CN H Cl H A-1379. F CH₂F H Cl H A-1380. F CHF₂ H Cl H A-1381. F CF₃ H Cl H A-1382. F OCH₂F H Cl H A-1383. F OCHF₂ H Cl H A-1384. F OCF₃ H Cl H A-1385. F H 3-F Cl H A-1386. F H 3-CH₃ Cl H A-1387. F H 3-OCH₃ Cl H A-1388. F H 5-F Cl H A-1389. F H 5-CH₃ Cl H A-1390. F H 5-OCH₃ Cl H A-1391. CH₃ F H Cl H A-1392. CH₃ CH₃ H Cl H A-1393. CH₃ OCH₃ H Cl H A-1394. CH₃ CN H Cl H A-1395. CH₃ CH₂F H Cl H A-1396. CH₃ CHF₂ H Cl H A-1397. CH₃ CF₃ H Cl H A-1398. CH₃ OCH₂F H Cl H A-1399. CH₃ OCHF₂ H Cl H A-1400. CH₃ OCF₃ H Cl H A-1401. CH₃ H 3-F Cl H A-1402. CH₃ H 3-CH₃ Cl H A-1403. CH₃ H 3-OCH₃ Cl H A-1404. CH₃ H 5-F Cl H A-1405. CH₃ H 5-CH₃ Cl H A-1406. CH₃ H 5-OCH₃ Cl H A-1407. OCH₃ F H Cl H A-1408. OCH₃ CH₃ H Cl H A-1409. OCH₃ OCH₃ H Cl H A-1410. OCH₃ CN H Cl H A-1411. OCH₃ CH₂F H Cl H A-1412. OCH₃ CHF₂ H Cl H A-1413. OCH₃ CF₃ H Cl H A-1414. OCH₃ OCH₂F H Cl H A-1415. OCH₃ OCHF₂ H Cl H A-1416. OCH₃ OCF₃ H Cl H A-1417. OCH₃ H 3-F Cl H A-1418. OCH₃ H 3-CH₃ Cl H A-1419. OCH₃ H 3-OCH₃ Cl H A-1420. OCH₃ H 5-F Cl H A-1421. OCH₃ H 5-CH₃ Cl H A-1422. OCH₃ H 5-OCH₃ Cl H A-1423. H F 3-F Cl H A-1424. H F 3-CH₃ Cl H A-1425. H F 3-OCH₃ Cl H A-1426. H F 5-F Cl H A-1427. H F 5-CH₃ Cl H A-1428. H F 5-OCH₃ Cl H A-1429. H CH₃ 3-F Cl H A-1430. H CH₃ 3-CH₃ Cl H A-1431. H CH₃ 3-OCH₃ Cl H A-1432. H CH₃ 5-F Cl H A-1433. H CH₃ 5-CH₃ Cl H A-1434. H CH₃ 5-OCH₃ Cl H A-1435. H OCH₃ 3-F Cl H A-1436. H OCH₃ 3-CH₃ Cl H A-1437. H OCH₃ 3-OCH₃ Cl H A-1438. H OCH₃ 5-F Cl H A-1439. H OCH₃ 5-CH₃ Cl H A-1440. H OCH₃ 5-OCH₃ Cl H A-1441. H CN 3-F Cl H A-1442. H CN 3-CH₃ Cl H A-1443. H CN 3-OCH₃ Cl H A-1444. H CN 5-F Cl H A-1445. H CN 5-CH₃ Cl H A-1446. H CN 5-OCH₃ Cl H A-1447. H CH₂F 3-F Cl H A-1448. H CH₂F 3-CH₃ Cl H A-1449. H CH₂F 3-OCH₃ Cl H A-1450. H CH₂F 5-F Cl H A-1451. H CH₂F 5-CH₃ Cl H A-1452. H CH₂F 5-OCH₃ Cl H A-1453. H CHF₂ 3-F Cl H A-1454. H CHF₂ 3-CH₃ Cl H A-1455. H CHF₂ 3-OCH₃ Cl H A-1456. H CHF₂ 5-F Cl H A-1457. H CHF₂ 5-CH₃ Cl H A-1458. H CHF₂ 5-OCH₃ Cl H A-1459. H CF₃ 3-F Cl H A-1460. H CF₃ 3-CH₃ Cl H A-1461. H CF₃ 3-OCH₃ Cl H A-1462. H CF₃ 5-F Cl H A-1463. H CF₃ 5-CH₃ Cl H A-1464. H CF₃ 5-OCH₃ Cl H A-1465. H OCH₂F 3-F Cl H A-1466. H OCH₂F 3-CH₃ Cl H A-1467. H OCH₂F 3-OCH₃ Cl H A-1468. H OCH₂F 5-F Cl H A-1469. H OCH₂F 5-CH₃ Cl H A-1470. H OCH₂F 5-OCH₃ Cl H A-1471. H OCHF₂ 3-F Cl H A-1472. H OCHF₂ 3-CH₃ Cl H A-1473. H OCHF₂ 3-OCH₃ Cl H A-1474. H OCHF₂ 5-F Cl H A-1475. H OCHF₂ 5-CH₃ Cl H A-1476. H OCHF₂ 5-OCH₃ Cl H A-1477. H OCF₃ 3-F Cl H A-1478. H OCF₃ 3-CH₃ Cl H A-1479. H OCF₃ 3-OCH₃ Cl H A-1480. H OCF₃ 5-F Cl H A-1481. H OCF₃ 5-CH₃ Cl H A-1482. H OCF₃ 5-OCH₃ Cl H A-1483. F F 3-F Cl H A-1484. F F 3-CH₃ Cl H A-1485. F F 3-OCH₃ Cl H A-1486. F F 5-F Cl H A-1487. F F 5-CH₃ Cl H A-1488. F F 5-OCH₃ Cl H A-1489. F CH₃ 3-F Cl H A-1490. F CH₃ 3-CH₃ Cl H A-1491. F CH₃ 3-OCH₃ Cl H A-1492. F CH₃ 5-F Cl H A-1493. F CH₃ 5-CH₃ Cl H A-1494. F CH₃ 5-OCH₃ Cl H A-1495. F OCH₃ 3-F Cl H A-1496. F OCH₃ 3-CH₃ Cl H A-1497. F OCH₃ 3-OCH₃ Cl H A-1498. F OCH₃ 5-F Cl H A-1499. F OCH₃ 5-CH₃ Cl H A-1500. F OCH₃ 5-OCH₃ Cl H A-1501. F CN 3-F Cl H A-1502. F CN 3-CH₃ Cl H A-1503. F CN 3-OCH₃ Cl H A-1504. F CN 5-F Cl H A-1505. F CN 5-CH₃ Cl H A-1506. F CN 5-OCH₃ Cl H A-1507. F CH₂F 3-F Cl H A-1508. F CH₂F 3-CH₃ Cl H A-1509. F CH₂F 3-OCH₃ Cl H A-1510. F CH₂F 5-F Cl H A-1511. F CH₂F 5-CH₃ Cl H A-1512. F CH₂F 5-OCH₃ Cl H A-1513. F CHF₂ 3-F Cl H A-1514. F CHF₂ 3-CH₃ Cl H A-1515. F CHF₂ 3-OCH₃ Cl H A-1516. F CHF₂ 5-F Cl H A-1517. F CHF₂ 5-CH₃ Cl H A-1518. F CHF₂ 5-OCH₃ Cl H A-1519. F CF₃ 3-F Cl H A-1520. F CF₃ 3-CH₃ Cl H A-1521. F CF₃ 3-OCH₃ Cl H A-1522. F CF₃ 5-F Cl H A-1523. F CF₃ 5-CH₃ Cl H A-1524. F CF₃ 5-OCH₃ Cl H A-1525. F OCH₂F 3-F Cl H A-1526. F OCH₂F 3-CH₃ Cl H A-1527. F OCH₂F 3-OCH₃ Cl H A-1528. F OCH₂F 5-F Cl H A-1529. F OCH₂F 5-CH₃ Cl H A-1530. F OCH₂F 5-OCH₃ Cl H A-1531. F OCHF₂ 3-F Cl H A-1532. F OCHF₂ 3-CH₃ Cl H A-1533. F OCHF₂ 3-OCH₃ Cl H A-1534. F OCHF₂ 5-F Cl H A-1535. F OCHF₂ 5-CH₃ Cl H A-1536. F OCHF₂ 5-OCH₃ Cl H A-1537. F OCF₃ 3-F Cl H A-1538. F OCF₃ 3-CH₃ Cl H A-1539. F OCF₃ 3-OCH₃ Cl H A-1540. F OCF₃ 5-F Cl H A-1541. F OCF₃ 5-CH₃ Cl H A-1542. F OCF₃ 5-OCH₃ Cl H A-1543. CH₃ F 3-F Cl H A-1544. CH₃ F 3-CH₃ Cl H A-1545. CH₃ F 3-OCH₃ Cl H A-1546. CH₃ F 5-F Cl H A-1547. CH₃ F 5-CH₃ Cl H A-1548. CH₃ F 5-OCH₃ Cl H A-1549. CH₃ CH₃ 3-F Cl H A-1550. CH₃ CH₃ 3-CH₃ Cl H A-1551. CH₃ CH₃ 3-OCH₃ Cl H A-1552. CH₃ CH₃ 5-F Cl H A-1553. CH₃ CH₃ 5-CH₃ Cl H A-1554. CH₃ CH₃ 5-OCH₃ Cl H A-1555. CH₃ OCH₃ 3-F Cl H A-1556. CH₃ OCH₃ 3-CH₃ Cl H A-1557. CH₃ OCH₃ 3-OCH₃ Cl H A-1558. CH₃ OCH₃ 5-F Cl H A-1559. CH₃ OCH₃ 5-CH₃ Cl H A-1560. CH₃ OCH₃ 5-OCH₃ Cl H A-1561. CH₃ CN 3-F Cl H A-1562. CH₃ CN 3-CH₃ Cl H A-1563. CH₃ CN 3-OCH₃ Cl H A-1564. CH₃ CN 5-F Cl H A-1565. CH₃ CN 5-CH₃ Cl H A-1566. CH₃ CN 5-OCH₃ Cl H A-1567. CH₃ CH₂F 3-F Cl H A-1568. CH₃ CH₂F 3-CH₃ Cl H A-1569. CH₃ CH₂F 3-OCH₃ Cl H A-1570. CH₃ CH₂F 5-F Cl H A-1571. CH₃ CH₂F 5-CH₃ Cl H A-1572. CH₃ CH₂F 5-OCH₃ Cl H A-1573. CH₃ CHF₂ 3-F Cl H A-1574. CH₃ CHF₂ 3-CH₃ Cl H A-1575. CH₃ CHF₂ 3-OCH₃ Cl H A-1576. CH₃ CHF₂ 5-F Cl H A-1577. CH₃ CHF₂ 5-CH₃ Cl H A-1578. CH₃ CHF₂ 5-OCH₃ Cl H A-1579. CH₃ CF₃ 3-F Cl H A-1580. CH₃ CF₃ 3-CH₃ Cl H A-1581. CH₃ CF₃ 3-OCH₃ Cl H A-1582. CH₃ CF₃ 5-F Cl H A-1583. CH₃ CF₃ 5-CH₃ Cl H A-1584. CH₃ CF₃ 5-OCH₃ Cl H A-1585. CH₃ OCH₂F 3-F Cl H A-1586. CH₃ OCH₂F 3-CH₃ Cl H A-1587. CH₃ OCH₂F 3-OCH₃ Cl H A-1588. CH₃ OCH₂F 5-F Cl H A-1589. CH₃ OCH₂F 5-CH₃ Cl H A-1590. CH₃ OCH₂F 5-OCH₃ Cl H A-1591. CH₃ OCHF₂ 3-F Cl H A-1592. CH₃ OCHF₂ 3-CH₃ Cl H A-1593. CH₃ OCHF₂ 3-OCH₃ Cl H A-1594. CH₃ OCHF₂ 5-F Cl H A-1595. CH₃ OCHF₂ 5-CH₃ Cl H A-1596. CH₃ OCHF₂ 5-OCH₃ Cl H A-1597. CH₃ OCF₃ 3-F Cl H A-1598. CH₃ OCF₃ 3-CH₃ Cl H A-1599. CH₃ OCF₃ 3-OCH₃ Cl H A-1600. CH₃ OCF₃ 5-F Cl H A-1601. CH₃ OCF₃ 5-CH₃ Cl H A-1602. CH₃ OCF₃ 5-OCH₃ Cl H A-1603. OCH₃ F 3-F Cl H A-1604. OCH₃ F 3-CH₃ Cl H A-1605. OCH₃ F 3-OCH₃ Cl H A-1606. OCH₃ F 5-F Cl H A-1607. OCH₃ F 5-CH₃ Cl H A-1608. OCH₃ F 5-OCH₃ Cl H A-1609. OCH₃ CH₃ 3-F Cl H A-1610. OCH₃ CH₃ 3-CH₃ Cl H A-1611. OCH₃ CH₃ 3-OCH₃ Cl H A-1612. OCH₃ CH₃ 5-F Cl H A-1613. OCH₃ CH₃ 5-CH₃ Cl H A-1614. OCH₃ CH₃ 5-OCH₃ Cl H A-1615. OCH₃ OCH₃ 3-F Cl H A-1616. OCH₃ OCH₃ 3-CH₃ Cl H A-1617. OCH₃ OCH₃ 3-OCH₃ Cl H A-1618. OCH₃ OCH₃ 5-F Cl H A-1619. OCH₃ OCH₃ 5-CH₃ Cl H A-1620. OCH₃ OCH₃ 5-OCH₃ Cl H A-1621. OCH₃ CN 3-F Cl H A-1622. OCH₃ CN 3-CH₃ Cl H A-1623. OCH₃ CN 3-OCH₃ Cl H A-1624. OCH₃ CN 5-F Cl H A-1625. OCH₃ CN 5-CH₃ Cl H A-1626. OCH₃ CN 5-OCH₃ Cl H A-1627. OCH₃ CH₂F 3-F Cl H A-1628. OCH₃ CH₂F 3-CH₃ Cl H A-1629. OCH₃ CH₂F 3-OCH₃ Cl H A-1630. OCH₃ CH₂F 5-F Cl H A-1631. OCH₃ CH₂F 5-CH₃ Cl H A-1632. OCH₃ CH₂F 5-OCH₃ Cl H A-1633. OCH₃ CHF₂ 3-F Cl H A-1634. OCH₃ CHF₂ 3-CH₃ Cl H A-1635. OCH₃ CHF₂ 3-OCH₃ Cl H A-1636. OCH₃ CHF₂ 5-F Cl H A-1637. OCH₃ CHF₂ 5-CH₃ Cl H A-1638. OCH₃ CHF₂ 5-OCH₃ Cl H A-1639. OCH₃ CF₃ 3-F Cl H A-1640. OCH₃ CF₃ 3-CH₃ Cl H A-1641. OCH₃ CF₃ 3-OCH₃ Cl H A-1642. OCH₃ CF₃ 5-F Cl H A-1643. OCH₃ CF₃ 5-CH₃ Cl H A-1644. OCH₃ CF₃ 5-OCH₃ Cl H A-1645. OCH₃ OCH₂F 3-F Cl H A-1646. OCH₃ OCH₂F 3-CH₃ Cl H A-1647. OCH₃ OCH₂F 3-OCH₃ Cl H A-1648. OCH₃ OCH₂F 5-F Cl H A-1649. OCH₃ OCH₂F 5-CH₃ Cl H A-1650. OCH₃ OCH₂F 5-OCH₃ Cl H A-1651. OCH₃ OCHF₂ 3-F Cl H A-1652. OCH₃ OCHF₂ 3-CH₃ Cl H A-1653. OCH₃ OCHF₂ 3-OCH₃ Cl H A-1654. OCH₃ OCHF₂ 5-F Cl H A-1655. OCH₃ OCHF₂ 5-CH₃ Cl H A-1656. OCH₃ OCHF₂ 5-OCH₃ Cl H A-1657. OCH₃ OCF₃ 3-F Cl H A-1658. OCH₃ OCF₃ 3-CH₃ Cl H A-1659. OCH₃ OCF₃ 3-OCH₃ Cl H A-1660. OCH₃ OCF₃ 5-F Cl H A-1661. OCH₃ OCF₃ 5-CH₃ Cl H A-1662. OCH₃ OCF₃ 5-OCH₃ Cl H A-1663. CH₂F F 3-F Cl H A-1664. CH₂F F 3-CH₃ Cl H A-1665. CH₂F F 3-OCH₃ Cl H A-1666. CH₂F F 5-F Cl H A-1667. CH₂F F 5-CH₃ Cl H A-1668. CH₂F F 5-OCH₃ Cl H A-1669. CH₂F CH₃ 3-F Cl H A-1670. CH₂F CH₃ 3-CH₃ Cl H A-1671. CH₂F CH₃ 3-OCH₃ Cl H A-1672. CH₂F CH₃ 5-F Cl H A-1673. CH₂F CH₃ 5-CH₃ Cl H A-1674. CH₂F CH₃ 5-OCH₃ Cl H A-1675. CH₂F OCH₃ 3-F Cl H A-1676. CH₂F OCH₃ 3-CH₃ Cl H A-1677. CH₂F OCH₃ 3-OCH₃ Cl H A-1678. CH₂F OCH₃ 5-F Cl H A-1679. CH₂F OCH₃ 5-CH₃ Cl H A-1680. CH₂F OCH₃ 5-OCH₃ Cl H A-1681. CH₂F CN 3-F Cl H A-1682. CH₂F CN 3-CH₃ Cl H A-1683. CH₂F CN 3-OCH₃ Cl H A-1684. CH₂F CN 5-F Cl H A-1685. CH₂F CN 5-CH₃ Cl H A-1686. CH₂F CN 5-OCH₃ Cl H A-1687. CH₂F CH₂F 3-F Cl H A-1688. CH₂F CH₂F 3-CH₃ Cl H A-1689. CH₂F CH₂F 3-OCH₃ Cl H A-1690. CH₂F CH₂F 5-F Cl H A-1691. CH₂F CH₂F 5-CH₃ Cl H A-1692. CH₂F CH₂F 5-OCH₃ Cl H A-1693. CH₂F CHF₂ 3-F Cl H A-1694. CH₂F CHF₂ 3-CH₃ Cl H A-1695. CH₂F CHF₂ 3-OCH₃ Cl H A-1696. CH₂F CHF₂ 5-F Cl H A-1697. CH₂F CHF₂ 5-CH₃ Cl H A-1698. CH₂F CHF₂ 5-OCH₃ Cl H A-1699. CH₂F CF₃ 3-F Cl H A-1700. CH₂F CF₃ 3-CH₃ Cl H A-1701. CH₂F CF₃ 3-OCH₃ Cl H A-1702. CH₂F CF₃ 5-F Cl H A-1703. CH₂F CF₃ 5-CH₃ Cl H A-1704. CH₂F CF₃ 5-OCH₃ Cl H A-1705. CH₂F OCH₂F 3-F Cl H A-1706. CH₂F OCH₂F 3-CH₃ Cl H A-1707. CH₂F OCH₂F 3-OCH₃ Cl H A-1708. CH₂F OCH₂F 5-F Cl H A-1709. CH₂F OCH₂F 5-CH₃ Cl H A-1710. CH₂F OCH₂F 5-OCH₃ Cl H A-1711. CH₂F OCHF₂ 3-F Cl H A-1712. CH₂F OCHF₂ 3-CH₃ Cl H A-1713. CH₂F OCHF₂ 3-OCH₃ Cl H A-1714. CH₂F OCHF₂ 5-F Cl H A-1715. CH₂F OCHF₂ 5-CH₃ Cl H A-1716. CH₂F OCHF₂ 5-OCH₃ Cl H A-1717. CH₂F OCF₃ 3-F Cl H A-1718. CH₂F OCF₃ 3-CH₃ Cl H A-1719. CH₂F OCF₃ 3-OCH₃ Cl H A-1720. CH₂F OCF₃ 5-F Cl H A-1721. CH₂F OCF₃ 5-CH₃ Cl H A-1722. CH₂F OCF₃ 5-OCH₃ Cl H A-1723. CHF₂ F 3-F Cl H A-1724. CHF₂ F 3-CH₃ Cl H A-1725. CHF₂ F 3-OCH₃ Cl H A-1726. CHF₂ F 5-F Cl H A-1727. CHF₂ F 5-CH₃ Cl H A-1728. CHF₂ F 5-OCH₃ Cl H A-1729. CHF₂ CH₃ 3-F Cl H A-1730. CHF₂ CH₃ 3-CH₃ Cl H A-1731. CHF₂ CH₃ 3-OCH₃ Cl H A-1732. CHF₂ CH₃ 5-F Cl H A-1733. CHF₂ CH₃ 5-CH₃ Cl H A-1734. CHF₂ CH₃ 5-OCH₃ Cl H A-1735. CHF₂ OCH₃ 3-F Cl H A-1736. CHF₂ OCH₃ 3-CH₃ Cl H A-1737. CHF₂ OCH₃ 3-OCH₃ Cl H A-1738. CHF₂ OCH₃ 5-F Cl H A-1739. CHF₂ OCH₃ 5-CH₃ Cl H A-1740. CHF₂ OCH₃ 5-OCH₃ Cl H A-1741. CHF₂ CN 3-F Cl H A-1742. CHF₂ CN 3-CH₃ Cl H A-1743. CHF₂ CN 3-OCH₃ Cl H A-1744. CHF₂ CN 5-F Cl H A-1745. CHF₂ CN 5-CH₃ Cl H A-1746. CHF₂ CN 5-OCH₃ Cl H A-1747. CHF₂ CH₂F 3-F Cl H A-1748. CHF₂ CH₂F 3-CH₃ Cl H A-1749. CHF₂ CH₂F 3-OCH₃ Cl H A-1750. CHF₂ CH₂F 5-F Cl H A-1751. CHF₂ CH₂F 5-CH₃ Cl H A-1752. CHF₂ CH₂F 5-OCH₃ Cl H A-1753. CHF₂ CHF₂ 3-F Cl H A-1754. CHF₂ CHF₂ 3-CH₃ Cl H A-1755. CHF₂ CHF₂ 3-OCH₃ Cl H A-1756. CHF₂ CHF₂ 5-F Cl H A-1757. CHF₂ CHF₂ 5-CH₃ Cl H A-1758. CHF₂ CHF₂ 5-OCH₃ Cl H A-1759. CHF₂ CF₃ 3-F Cl H A-1760. CHF₂ CF₃ 3-CH₃ Cl H A-1761. CHF₂ CF₃ 3-OCH₃ Cl H A-1762. CHF₂ CF₃ 5-F Cl H A-1763. CHF₂ CF₃ 5-CH₃ Cl H A-1764. CHF₂ CF₃ 5-OCH₃ Cl H A-1765. CHF₂ OCH₂F 3-F Cl H A-1766. CHF₂ OCH₂F 3-CH₃ Cl H A-1767. CHF₂ OCH₂F 3-OCH₃ Cl H A-1768. CHF₂ OCH₂F 5-F Cl H A-1769. CHF₂ OCH₂F 5-CH₃ Cl H A-1770. CHF₂ OCH₂F 5-OCH₃ Cl H A-1771. CHF₂ OCHF₂ 3-F Cl H A-1772. CHF₂ OCHF₂ 3-CH₃ Cl H A-1773. CHF₂ OCHF₂ 3-OCH₃ Cl H A-1774. CHF₂ OCHF₂ 5-F Cl H A-1775. CHF₂ OCHF₂ 5-CH₃ Cl H A-1776. CHF₂ OCHF₂ 5-OCH₃ Cl H A-1777. CHF₂ OCF₃ 3-F Cl H A-1778. CHF₂ OCF₃ 3-CH₃ Cl H A-1779. CHF₂ OCF₃ 3-OCH₃ Cl H A-1780. CHF₂ OCF₃ 5-F Cl H A-1781. CHF₂ OCF₃ 5-CH₃ Cl H A-1782. CHF₂ OCF₃ 5-OCH₃ Cl H A-1783. CF₃ F 3-F Cl H A-1784. CF₃ F 3-CH₃ Cl H A-1785. CF₃ F 3-OCH₃ Cl H A-1786. CF₃ F 5-F Cl H A-1787. CF₃ F 5-CH₃ Cl H A-1788. CF₃ F 5-OCH₃ Cl H A-1789. CF₃ CH₃ 3-F Cl H A-1790. CF₃ CH₃ 3-CH₃ Cl H A-1791. CF₃ CH₃ 3-OCH₃ Cl H A-1792. CF₃ CH₃ 5-F Cl H A-1793. CF₃ CH₃ 5-CH₃ Cl H A-1794. CF₃ CH₃ 5-OCH₃ Cl H A-1795. CF₃ OCH₃ 3-F Cl H A-1796. CF₃ OCH₃ 3-CH₃ Cl H A-1797. CF₃ OCH₃ 3-OCH₃ Cl H A-1798. CF₃ OCH₃ 5-F Cl H A-1799. CF₃ OCH₃ 5-CH₃ Cl H A-1800. CF₃ OCH₃ 5-OCH₃ Cl H A-1801. CF₃ CN 3-F Cl H A-1802. CF₃ CN 3-CH₃ Cl H A-1803. CF₃ CN 3-OCH₃ Cl H A-1804. CF₃ CN 5-F Cl H A-1805. CF₃ CN 5-CH₃ Cl H A-1806. CF₃ CN 5-OCH₃ Cl H A-1807. CF₃ CH₂F 3-F Cl H A-1808. CF₃ CH₂F 3-CH₃ Cl H A-1809. CF₃ CH₂F 3-OCH₃ Cl H A-1810. CF₃ CH₂F 5-F Cl H A-1811. CF₃ CH₂F 5-CH₃ Cl H A-1812. CF₃ CH₂F 5-OCH₃ Cl H A-1813. CF₃ CHF₂ 3-F Cl H A-1814. CF₃ CHF₂ 3-CH₃ Cl H A-1815. CF₃ CHF₂ 3-OCH₃ Cl H A-1816. CF₃ CHF₂ 5-F Cl H A-1817. CF₃ CHF₂ 5-CH₃ Cl H A-1818. CF₃ CHF₂ 5-OCH₃ Cl H A-1819. CF₃ CF₃ 3-F Cl H A-1820. CF₃ CF₃ 3-CH₃ Cl H A-1821. CF₃ CF₃ 3-OCH₃ Cl H A-1822. CF₃ CF₃ 5-F Cl H A-1823. CF₃ CF₃ 5-CH₃ Cl H A-1824. CF₃ CF₃ 5-OCH₃ Cl H A-1825. CF₃ OCH₂F 3-F Cl H A-1826. CF₃ OCH₂F 3-CH₃ Cl H A-1827. CF₃ OCH₂F 3-OCH₃ Cl H A-1828. CF₃ OCH₂F 5-F Cl H A-1829. CF₃ OCH₂F 5-CH₃ Cl H A-1830. CF₃ OCH₂F 5-OCH₃ Cl H A-1831. CF₃ OCHF₂ 3-F Cl H A-1832. CF₃ OCHF₂ 3-CH₃ Cl H A-1833. CF₃ OCHF₂ 3-OCH₃ Cl H A-1834. CF₃ OCHF₂ 5-F Cl H A-1835. CF₃ OCHF₂ 5-CH₃ Cl H A-1836. CF₃ OCHF₂ 5-OCH₃ Cl H A-1837. CF₃ OCF₃ 3-F Cl H A-1838. CF₃ OCF₃ 3-CH₃ Cl H A-1839. CF₃ OCF₃ 3-OCH₃ Cl H A-1840. CF₃ OCF₃ 5-F Cl H A-1841. CF₃ OCF₃ 5-CH₃ Cl H A-1842. CF₃ OCF₃ 5-OCH₃ Cl H A-1843. OCH₂F F 3-F Cl H A-1844. OCH₂F F 3-CH₃ Cl H A-1845. OCH₂F F 3-OCH₃ Cl H A-1846. OCH₂F F 5-F Cl H A-1847. OCH₂F F 5-CH₃ Cl H A-1848. OCH₂F F 5-OCH₃ Cl H A-1849. OCH₂F CH₃ 3-F Cl H A-1850. OCH₂F CH₃ 3-CH₃ Cl H A-1851. OCH₂F CH₃ 3-OCH₃ Cl H A-1852. OCH₂F CH₃ 5-F Cl H A-1853. OCH₂F CH₃ 5-CH₃ Cl H A-1854. OCH₂F CH₃ 5-OCH₃ Cl H A-1855. OCH₂F OCH₃ 3-F Cl H A-1856. OCH₂F OCH₃ 3-CH₃ Cl H A-1857. OCH₂F OCH₃ 3-OCH₃ Cl H A-1858. OCH₂F OCH₃ 5-F Cl H A-1859. OCH₂F OCH₃ 5-CH₃ Cl H A-1860. OCH₂F OCH₃ 5-OCH₃ Cl H A-1861. OCH₂F CN 3-F Cl H A-1862. OCH₂F CN 3-CH₃ Cl H A-1863. OCH₂F CN 3-OCH₃ Cl H A-1864. OCH₂F CN 5-F Cl H A-1865. OCH₂F CN 5-CH₃ Cl H A-1866. OCH₂F CN 5-OCH₃ Cl H A-1867. OCH₂F CH₂F 3-F Cl H A-1868. OCH₂F CH₂F 3-CH₃ Cl H A-1869. OCH₂F CH₂F 3-OCH₃ Cl H A-1870. OCH₂F CH₂F 5-F Cl H A-1871. OCH₂F CH₂F 5-CH₃ Cl H A-1872. OCH₂F CH₂F 5-OCH₃ Cl H A-1873. OCH₂F CHF₂ 3-F Cl H A-1874. OCH₂F CHF₂ 3-CH₃ Cl H A-1875. OCH₂F CHF₂ 3-OCH₃ Cl H A-1876. OCH₂F CHF₂ 5-F Cl H A-1877. OCH₂F CHF₂ 5-CH₃ Cl H A-1878. OCH₂F CHF₂ 5-OCH₃ Cl H A-1879. OCH₂F CF₃ 3-F Cl H A-1880. OCH₂F CF₃ 3-CH₃ Cl H A-1881. OCH₂F CF₃ 3-OCH₃ Cl H A-1882. OCH₂F CF₃ 5-F Cl H A-1883. OCH₂F CF₃ 5-CH₃ Cl H A-1884. OCH₂F CF₃ 5-OCH₃ Cl H A-1885. OCH₂F OCH₂F 3-F Cl H A-1886. OCH₂F OCH₂F 3-CH₃ Cl H A-1887. OCH₂F OCH₂F 3-OCH₃ Cl H A-1888. OCH₂F OCH₂F 5-F Cl H A-1889. OCH₂F OCH₂F 5-CH₃ Cl H A-1890. OCH₂F OCH₂F 5-OCH₃ Cl H A-1891. OCH₂F OCHF₂ 3-F Cl H A-1892. OCH₂F OCHF₂ 3-CH₃ Cl H A-1893. OCH₂F OCHF₂ 3-OCH₃ Cl H A-1894. OCH₂F OCHF₂ 5-F Cl H A-1895. OCH₂F OCHF₂ 5-CH₃ Cl H A-1896. OCH₂F OCHF₂ 5-OCH₃ Cl H A-1897. OCH₂F OCF₃ 3-F Cl H A-1898. OCH₂F OCF₃ 3-CH₃ Cl H A-1899. OCH₂F OCF₃ 3-OCH₃ Cl H A-1900. OCH₂F OCF₃ 5-F Cl H A-1901. OCH₂F OCF₃ 5-CH₃ Cl H A-1902. OCH₂F OCF₃ 5-OCH₃ Cl H A-1903. OCHF₂ F 3-F Cl H A-1904. OCHF₂ F 3-CH₃ Cl H A-1905. OCHF₂ F 3-OCH₃ Cl H A-1906. OCHF₂ F 5-F Cl H A-1907. OCHF₂ F 5-CH₃ Cl H A-1908. OCHF₂ F 5-OCH₃ Cl H A-1909. OCHF₂ CH₃ 3-F Cl H A-1910. OCHF₂ CH₃ 3-CH₃ Cl H A-1911. OCHF₂ CH₃ 3-OCH₃ Cl H A-1912. OCHF₂ CH₃ 5-F Cl H A-1913. OCHF₂ CH₃ 5-CH₃ Cl H A-1914. OCHF₂ CH₃ 5-OCH₃ Cl H A-1915. OCHF₂ OCH₃ 3-F Cl H A-1916. OCHF₂ OCH₃ 3-CH₃ Cl H A-1917. OCHF₂ OCH₃ 3-OCH₃ Cl H A-1918. OCHF₂ OCH₃ 5-F Cl H A-1919. OCHF₂ OCH₃ 5-CH₃ Cl H A-1920. OCHF₂ OCH₃ 5-OCH₃ Cl H A-1921. OCHF₂ CN 3-F Cl H A-1922. OCHF₂ CN 3-CH₃ Cl H A-1923. OCHF₂ CN 3-OCH₃ Cl H A-1924. OCHF₂ CN 5-F Cl H A-1925. OCHF₂ CN 5-CH₃ Cl H A-1926. OCHF₂ CN 5-OCH₃ Cl H A-1927. OCHF₂ CH₂F 3-F Cl H A-1928. OCHF₂ CH₂F 3-CH₃ Cl H A-1929. OCHF₂ CH₂F 3-OCH₃ Cl H A-1930. OCHF₂ CH₂F 5-F Cl H A-1931. OCHF₂ CH₂F 5-CH₃ Cl H A-1932. OCHF₂ CH₂F 5-OCH₃ Cl H A-1933. OCHF₂ CHF₂ 3-F Cl H A-1934. OCHF₂ CHF₂ 3-CH₃ Cl H A-1935. OCHF₂ CHF₂ 3-OCH₃ Cl H A-1936. OCHF₂ CHF₂ 5-F Cl H A-1937. OCHF₂ CHF₂ 5-CH₃ Cl H A-1938. OCHF₂ CHF₂ 5-OCH₃ Cl H A-1939. OCHF₂ CF₃ 3-F Cl H A-1940. OCHF₂ CF₃ 3-CH₃ Cl H A-1941. OCHF₂ CF₃ 3-OCH₃ Cl H A-1942. OCHF₂ CF₃ 5-F Cl H A-1943. OCHF₂ CF₃ 5-CH₃ Cl H A-1944. OCHF₂ CF₃ 5-OCH₃ Cl H A-1945. OCHF₂ OCH₂F 3-F Cl H A-1946. OCHF₂ OCH₂F 3-CH₃ Cl H A-1947. OCHF₂ OCH₂F 3-OCH₃ Cl H A-1948. OCHF₂ OCH₂F 5-F Cl H A-1949. OCHF₂ OCH₂F 5-CH₃ Cl H A-1950. OCHF₂ OCH₂F 5-OCH₃ Cl H A-1951. OCHF₂ OCHF₂ 3-F Cl H A-1952. OCHF₂ OCHF₂ 3-CH₃ Cl H A-1953. OCHF₂ OCHF₂ 3-OCH₃ Cl H A-1954. OCHF₂ OCHF₂ 5-F Cl H A-1955. OCHF₂ OCHF₂ 5-CH₃ Cl H A-1956. OCHF₂ OCHF₂ 5-OCH₃ Cl H A-1957. OCHF₂ OCF₃ 3-F Cl H A-1958. OCHF₂ OCF₃ 3-CH₃ Cl H A-1959. OCHF₂ OCF₃ 3-OCH₃ Cl H A-1960. OCHF₂ OCF₃ 5-F Cl H A-1961. OCHF₂ OCF₃ 5-CH₃ Cl H A-1962. OCHF₂ OCF₃ 5-OCH₃ Cl H A-1963. OCF₃ F 3-F Cl H A-1964. OCF₃ F 3-CH₃ Cl H A-1965. OCF₃ F 3-OCH₃ Cl H A-1966. OCF₃ F 5-F Cl H A-1967. OCF₃ F 5-CH₃ Cl H A-1968. OCF₃ F 5-OCH₃ Cl H A-1969. OCF₃ CH₃ 3-F Cl H A-1970. OCF₃ CH₃ 3-CH₃ Cl H A-1971. OCF₃ CH₃ 3-OCH₃ Cl H A-1972. OCF₃ CH₃ 5-F Cl H A-1973. OCF₃ CH₃ 5-CH₃ Cl H A-1974. OCF₃ CH₃ 5-OCH₃ Cl H A-1975. OCF₃ OCH₃ 3-F Cl H A-1976. OCF₃ OCH₃ 3-CH₃ Cl H A-1977. OCF₃ OCH₃ 3-OCH₃ Cl H A-1978. OCF₃ OCH₃ 5-F Cl H A-1979. OCF₃ OCH₃ 5-CH₃ Cl H A-1980. OCF₃ OCH₃ 5-OCH₃ Cl H A-1981. OCF₃ CN 3-F Cl H A-1982. OCF₃ CN 3-CH₃ Cl H A-1983. OCF₃ CN 3-OCH₃ Cl H A-1984. OCF₃ CN 5-F Cl H A-1985. OCF₃ CN 5-CH₃ Cl H A-1986. OCF₃ CN 5-OCH₃ Cl H A-1987. OCF₃ CH₂F 3-F Cl H A-1988. OCF₃ CH₂F 3-CH₃ Cl H A-1989. OCF₃ CH₂F 3-OCH₃ Cl H A-1990. OCF₃ CH₂F 5-F Cl H A-1991. OCF₃ CH₂F 5-CH₃ Cl H A-1992. OCF₃ CH₂F 5-OCH₃ Cl H A-1993. OCF₃ CHF₂ 3-F Cl H A-1994. OCF₃ CHF₂ 3-CH₃ Cl H A-1995. OCF₃ CHF₂ 3-OCH₃ Cl H A-1996. OCF₃ CHF₂ 5-F Cl H A-1997. OCF₃ CHF₂ 5-CH₃ Cl H A-1998. OCF₃ CHF₂ 5-OCH₃ Cl H A-1999. OCF₃ CF₃ 3-F Cl H A-2000. OCF₃ CF₃ 3-CH₃ Cl H A-2001. OCF₃ CF₃ 3-OCH₃ Cl H A-2002. OCF₃ CF₃ 5-F Cl H A-2003. OCF₃ CF₃ 5-CH₃ Cl H A-2004. OCF₃ CF₃ 5-OCH₃ Cl H A-2005. OCF₃ OCH₂F 3-F Cl H A-2006. OCF₃ OCH₂F 3-CH₃ Cl H A-2007. OCF₃ OCH₂F 3-OCH₃ Cl H A-2008. OCF₃ OCH₂F 5-F Cl H A-2009. OCF₃ OCH₂F 5-CH₃ Cl H A-2010. OCF₃ OCH₂F 5-OCH₃ Cl H A-2011. OCF₃ OCHF₂ 3-F Cl H A-2012. OCF₃ OCHF₂ 3-CH₃ Cl H A-2013. OCF₃ OCHF₂ 3-OCH₃ Cl H A-2014. OCF₃ OCHF₂ 5-F Cl H A-2015. OCF₃ OCHF₂ 5-CH₃ Cl H A-2016. OCF₃ OCHF₂ 5-OCH₃ Cl H A-2017. OCF₃ OCF₃ 3-F Cl H A-2018. OCF₃ OCF₃ 3-CH₃ Cl H A-2019. OCF₃ OCF₃ 3-OCH₃ Cl H A-2020. OCF₃ OCF₃ 5-F Cl H A-2021. OCF₃ OCF₃ 5-CH₃ Cl H A-2022. OCF₃ OCF₃ 5-OCH₃ Cl H A-2023. H H H CN F A-2024. F H H CN F A-2025. CH₃ H H CN F A-2026. OCH₃ H H CN F A-2027. CH₂F H H CN F A-2028. CHF₂ H H CN F A-2029. CF₃ H H CN F A-2030. OCH₂F H H CN F A-2031. OCHF₂ H H CN F A-2032. OCF₃ H H CN F A-2033. H F H CN F A-2034. H CH₃ H CN F A-2035. H OCH₃ H CN F A-2036. H CN H CN F A-2037. H CH₂F H CN F A-2038. H CHF₂ H CN F A-2039. H CF₃ H CN F A-2040. H OCH₂F H CN F A-2041. H OCHF₂ H CN F A-2042. H OCF₃ H CN F A-2043. H H 3-F CN F A-2044. H H 3-CH₃ CN F A-2045. H H 3-OCH₃ CN F A-2046. H H 5-F CN F A-2047. H H 5-CH₃ CN F A-2048. H H 5-OCH₃ CN F A-2049. F F H CN F A-2050. F CH₃ H CN F A-2051. F OCH₃ H CN F A-2052. F CN H CN F A-2053. F CH₂F H CN F A-2054. F CHF₂ H CN F A-2055. F CF₃ H CN F A-2056. F OCH₂F H CN F A-2057. F OCHF₂ H CN F A-2058. F OCF₃ H CN F A-2059. F H 3-F CN F A-2060. F H 3-CH₃ CN F A-2061. F H 3-OCH₃ CN F A-2062. F H 5-F CN F A-2063. F H 5-CH₃ CN F A-2064. F H 5-OCH₃ CN F A-2065. CH₃ F H CN F A-2066. CH₃ CH₃ H CN F A-2067. CH₃ OCH₃ H CN F A-2068. CH₃ CN H CN F A-2069. CH₃ CH₂F H CN F A-2070. CH₃ CHF₂ H CN F A-2071. CH₃ CF₃ H CN F A-2072. CH₃ OCH₂F H CN F A-2073. CH₃ OCHF₂ H CN F A-2074. CH₃ OCF₃ H CN F A-2075. CH₃ H 3-F CN F A-2076. CH₃ H 3-CH₃ CN F A-2077. CH₃ H 3-OCH₃ CN F A-2078. CH₃ H 5-F CN F A-2079. CH₃ H 5-CH₃ CN F A-2080. CH₃ H 5-OCH₃ CN F A-2081. OCH₃ F H CN F A-2082. OCH₃ CH₃ H CN F A-2083. OCH₃ OCH₃ H CN F A-2084. OCH₃ CN H CN F A-2085. OCH₃ CH₂F H CN F A-2086. OCH₃ CHF₂ H CN F A-2087. OCH₃ CF₃ H CN F A-2088. OCH₃ OCH₂F H CN F A-2089. OCH₃ OCHF₂ H CN F A-2090. OCH₃ OCF₃ H CN F A-2091. OCH₃ H 3-F CN F A-2092. OCH₃ H 3-CH₃ CN F A-2093. OCH₃ H 3-OCH₃ CN F A-2094. OCH₃ H 5-F CN F A-2095. OCH₃ H 5-CH₃ CN F A-2096. OCH₃ H 5-OCH₃ CN F A-2097. H F 3-F CN F A-2098. H F 3-CH₃ CN F A-2099. H F 3-OCH₃ CN F A-2100. H F 5-F CN F A-2101. H F 5-CH₃ CN F A-2102. H F 5-OCH₃ CN F A-2103. H CH₃ 3-F CN F A-2104. H CH₃ 3-CH₃ CN F A-2105. H CH₃ 3-OCH₃ CN F A-2106. H CH₃ 5-F CN F A-2107. H CH₃ 5-CH₃ CN F A-2108. H CH₃ 5-OCH₃ CN F A-2109. H OCH₃ 3-F CN F A-2110. H OCH₃ 3-CH₃ CN F A-2111. H OCH₃ 3-OCH₃ CN F A-2112. H OCH₃ 5-F CN F A-2113. H OCH₃ 5-CH₃ CN F A-2114. H OCH₃ 5-OCH₃ CN F A-2115. H CN 3-F CN F A-2116. H CN 3-CH₃ CN F A-2117. H CN 3-OCH₃ CN F A-2118. H CN 5-F CN F A-2119. H CN 5-CH₃ CN F A-2120. H CN 5-OCH₃ CN F A-2121. H CH₂F 3-F CN F A-2122. H CH₂F 3-CH₃ CN F A-2123. H CH₂F 3-OCH₃ CN F A-2124. H CH₂F 5-F CN F A-2125. H CH₂F 5-CH₃ CN F A-2126. H CH₂F 5-OCH₃ CN F A-2127. H CHF₂ 3-F CN F A-2128. H CHF₂ 3-CH₃ CN F A-2129. H CHF₂ 3-OCH₃ CN F A-2130. H CHF₂ 5-F CN F A-2131. H CHF₂ 5-CH₃ CN F A-2132. H CHF₂ 5-OCH₃ CN F A-2133. H CF₃ 3-F CN F A-2134. H CF₃ 3-CH₃ CN F A-2135. H CF₃ 3-OCH₃ CN F A-2136. H CF₃ 5-F CN F A-2137. H CF₃ 5-CH₃ CN F A-2138. H CF₃ 5-OCH₃ CN F A-2139. H OCH₂F 3-F CN F A-2140. H OCH₂F 3-CH₃ CN F A-2141. H OCH₂F 3-OCH₃ CN F A-2142. H OCH₂F 5-F CN F A-2143. H OCH₂F 5-CH₃ CN F A-2144. H OCH₂F 5-OCH₃ CN F A-2145. H OCHF₂ 3-F CN F A-2146. H OCHF₂ 3-CH₃ CN F A-2147. H OCHF₂ 3-OCH₃ CN F A-2148. H OCHF₂ 5-F CN F A-2149. H OCHF₂ 5-CH₃ CN F A-2150. H OCHF₂ 5-OCH₃ CN F A-2151. H OCF₃ 3-F CN F A-2152. H OCF₃ 3-CH₃ CN F A-2153. H OCF₃ 3-OCH₃ CN F A-2154. H OCF₃ 5-F CN F A-2155. H OCF₃ 5-CH₃ CN F A-2156. H OCF₃ 5-OCH₃ CN F A-2157. F F 3-F CN F A-2158. F F 3-CH₃ CN F A-2159. F F 3-OCH₃ CN F A-2160. F F 5-F CN F A-2161. F F 5-CH₃ CN F A-2162. F F 5-OCH₃ CN F A-2163. F CH₃ 3-F CN F A-2164. F CH₃ 3-CH₃ CN F A-2165. F CH₃ 3-OCH₃ CN F A-2166. F CH₃ 5-F CN F A-2167. F CH₃ 5-CH₃ CN F A-2168. F CH₃ 5-OCH₃ CN F A-2169. F OCH₃ 3-F CN F A-2170. F OCH₃ 3-CH₃ CN F A-2171. F OCH₃ 3-OCH₃ CN F A-2172. F OCH₃ 5-F CN F A-2173. F OCH₃ 5-CH₃ CN F A-2174. F OCH₃ 5-OCH₃ CN F A-2175. F CN 3-F CN F A-2176. F CN 3-CH₃ CN F A-2177. F CN 3-OCH₃ CN F A-2178. F CN 5-F CN F A-2179. F CN 5-CH₃ CN F A-2180. F CN 5-OCH₃ CN F A-2181. F CH₂F 3-F CN F A-2182. F CH₂F 3-CH₃ CN F A-2183. F CH₂F 3-OCH₃ CN F A-2184. F CH₂F 5-F CN F A-2185. F CH₂F 5-CH₃ CN F A-2186. F CH₂F 5-OCH₃ CN F A-2187. F CHF₂ 3-F CN F A-2188. F CHF₂ 3-CH₃ CN F A-2189. F CHF₂ 3-OCH₃ CN F A-2190. F CHF₂ 5-F CN F A-2191. F CHF₂ 5-CH₃ CN F A-2192. F CHF₂ 5-OCH₃ CN F A-2193. F CF₃ 3-F CN F A-2194. F CF₃ 3-CH₃ CN F A-2195. F CF₃ 3-OCH₃ CN F A-2196. F CF₃ 5-F CN F A-2197. F CF₃ 5-CH₃ CN F A-2198. F CF₃ 5-OCH₃ CN F A-2199. F OCH₂F 3-F CN F A-2200. F OCH₂F 3-CH₃ CN F A-2201. F OCH₂F 3-OCH₃ CN F A-2202. F OCH₂F 5-F CN F A-2203. F OCH₂F 5-CH₃ CN F A-2204. F OCH₂F 5-OCH₃ CN F A-2205. F OCHF₂ 3-F CN F A-2206. F OCHF₂ 3-CH₃ CN F A-2207. F OCHF₂ 3-OCH₃ CN F A-2208. F OCHF₂ 5-F CN F A-2209. F OCHF₂ 5-CH₃ CN F A-2210. F OCHF₂ 5-OCH₃ CN F A-2211. F OCF₃ 3-F CN F A-2212. F OCF₃ 3-CH₃ CN F A-2213. F OCF₃ 3-OCH₃ CN F A-2214. F OCF₃ 5-F CN F A-2215. F OCF₃ 5-CH₃ CN F A-2216. F OCF₃ 5-OCH₃ CN F A-2217. CH₃ F 3-F CN F A-2218. CH₃ F 3-CH₃ CN F A-2219. CH₃ F 3-OCH₃ CN F A-2220. CH₃ F 5-F CN F A-2221. CH₃ F 5-CH₃ CN F A-2222. CH₃ F 5-OCH₃ CN F A-2223. CH₃ CH₃ 3-F CN F A-2224. CH₃ CH₃ 3-CH₃ CN F A-2225. CH₃ CH₃ 3-OCH₃ CN F A-2226. CH₃ CH₃ 5-F CN F A-2227. CH₃ CH₃ 5-CH₃ CN F A-2228. CH₃ CH₃ 5-OCH₃ CN F A-2229. CH₃ OCH₃ 3-F CN F A-2230. CH₃ OCH₃ 3-CH₃ CN F A-2231. CH₃ OCH₃ 3-OCH₃ CN F A-2232. CH₃ OCH₃ 5-F CN F A-2233. CH₃ OCH₃ 5-CH₃ CN F A-2234. CH₃ OCH₃ 5-OCH₃ CN F A-2235. CH₃ CN 3-F CN F A-2236. CH₃ CN 3-CH₃ CN F A-2237. CH₃ CN 3-OCH₃ CN F A-2238. CH₃ CN 5-F CN F A-2239. CH₃ CN 5-CH₃ CN F A-2240. CH₃ CN 5-OCH₃ CN F A-2241. CH₃ CH₂F 3-F CN F A-2242. CH₃ CH₂F 3-CH₃ CN F A-2243. CH₃ CH₂F 3-OCH₃ CN F A-2244. CH₃ CH₂F 5-F CN F A-2245. CH₃ CH₂F 5-CH₃ CN F A-2246. CH₃ CH₂F 5-OCH₃ CN F A-2247. CH₃ CHF₂ 3-F CN F A-2248. CH₃ CHF₂ 3-CH₃ CN F A-2249. CH₃ CHF₂ 3-OCH₃ CN F A-2250. CH₃ CHF₂ 5-F CN F A-2251. CH₃ CHF₂ 5-CH₃ CN F A-2252. CH₃ CHF₂ 5-OCH₃ CN F A-2253. CH₃ CF₃ 3-F CN F A-2254. CH₃ CF₃ 3-CH₃ CN F A-2255. CH₃ CF₃ 3-OCH₃ CN F A-2256. CH₃ CF₃ 5-F CN F A-2257. CH₃ CF₃ 5-CH₃ CN F A-2258. CH₃ CF₃ 5-OCH₃ CN F A-2259. CH₃ OCH₂F 3-F CN F A-2260. CH₃ OCH₂F 3-CH₃ CN F A-2261. CH₃ OCH₂F 3-OCH₃ CN F A-2262. CH₃ OCH₂F 5-F CN F A-2263. CH₃ OCH₂F 5-CH₃ CN F A-2264. CH₃ OCH₂F 5-OCH₃ CN F A-2265. CH₃ OCHF₂ 3-F CN F A-2266. CH₃ OCHF₂ 3-CH₃ CN F A-2267. CH₃ OCHF₂ 3-OCH₃ CN F A-2268. CH₃ OCHF₂ 5-F CN F A-2269. CH₃ OCHF₂ 5-CH₃ CN F A-2270. CH₃ OCHF₂ 5-OCH₃ CN F A-2271. CH₃ OCF₃ 3-F CN F A-2272. CH₃ OCF₃ 3-CH₃ CN F A-2273. CH₃ OCF₃ 3-OCH₃ CN F A-2274. CH₃ OCF₃ 5-F CN F A-2275. CH₃ OCF₃ 5-CH₃ CN F A-2276. CH₃ OCF₃ 5-OCH₃ CN F A-2277. OCH₃ F 3-F CN F A-2278. OCH₃ F 3-CH₃ CN F A-2279. OCH₃ F 3-OCH₃ CN F A-2280. OCH₃ F 5-F CN F A-2281. OCH₃ F 5-CH₃ CN F A-2282. OCH₃ F 5-OCH₃ CN F A-2283. OCH₃ CH₃ 3-F CN F A-2284. OCH₃ CH₃ 3-CH₃ CN F A-2285. OCH₃ CH₃ 3-OCH₃ CN F A-2286. OCH₃ CH₃ 5-F CN F A-2287. OCH₃ CH₃ 5-CH₃ CN F A-2288. OCH₃ CH₃ 5-OCH₃ CN F A-2289. OCH₃ OCH₃ 3-F CN F A-2290. OCH₃ OCH₃ 3-CH₃ CN F A-2291. OCH₃ OCH₃ 3-OCH₃ CN F A-2292. OCH₃ OCH₃ 5-F CN F A-2293. OCH₃ OCH₃ 5-CH₃ CN F A-2294. OCH₃ OCH₃ 5-OCH₃ CN F A-2295. OCH₃ CN 3-F CN F A-2296. OCH₃ CN 3-CH₃ CN F A-2297. OCH₃ CN 3-OCH₃ CN F A-2298. OCH₃ CN 5-F CN F A-2299. OCH₃ CN 5-CH₃ CN F A-2300. OCH₃ CN 5-OCH₃ CN F A-2301. OCH₃ CH₂F 3-F CN F A-2302. OCH₃ CH₂F 3-CH₃ CN F A-2303. OCH₃ CH₂F 3-OCH₃ CN F A-2304. OCH₃ CH₂F 5-F CN F A-2305. OCH₃ CH₂F 5-CH₃ CN F A-2306. OCH₃ CH₂F 5-OCH₃ CN F A-2307. OCH₃ CHF₂ 3-F CN F A-2308. OCH₃ CHF₂ 3-CH₃ CN F A-2309. OCH₃ CHF₂ 3-OCH₃ CN F A-2310. OCH₃ CHF₂ 5-F CN F A-2311. OCH₃ CHF₂ 5-CH₃ CN F A-2312. OCH₃ CHF₂ 5-OCH₃ CN F A-2313. OCH₃ CF₃ 3-F CN F A-2314. OCH₃ CF₃ 3-CH₃ CN F A-2315. OCH₃ CF₃ 3-OCH₃ CN F A-2316. OCH₃ CF₃ 5-F CN F A-2317. OCH₃ CF₃ 5-CH₃ CN F A-2318. OCH₃ CF₃ 5-OCH₃ CN F A-2319. OCH₃ OCH₂F 3-F CN F A-2320. OCH₃ OCH₂F 3-CH₃ CN F A-2321. OCH₃ OCH₂F 3-OCH₃ CN F A-2322. OCH₃ OCH₂F 5-F CN F A-2323. OCH₃ OCH₂F 5-CH₃ CN F A-2324. OCH₃ OCH₂F 5-OCH₃ CN F A-2325. OCH₃ OCHF₂ 3-F CN F A-2326. OCH₃ OCHF₂ 3-CH₃ CN F A-2327. OCH₃ OCHF₂ 3-OCH₃ CN F A-2328. OCH₃ OCHF₂ 5-F CN F A-2329. OCH₃ OCHF₂ 5-CH₃ CN F A-2330. OCH₃ OCHF₂ 5-OCH₃ CN F A-2331. OCH₃ OCF₃ 3-F CN F A-2332. OCH₃ OCF₃ 3-CH₃ CN F A-2333. OCH₃ OCF₃ 3-OCH₃ CN F A-2334. OCH₃ OCF₃ 5-F CN F A-2335. OCH₃ OCF₃ 5-CH₃ CN F A-2336. OCH₃ OCF₃ 5-OCH₃ CN F A-2337. CH₂F F 3-F CN F A-2338. CH₂F F 3-CH₃ CN F A-2339. CH₂F F 3-OCH₃ CN F A-2340. CH₂F F 5-F CN F A-2341. CH₂F F 5-CH₃ CN F A-2342. CH₂F F 5-OCH₃ CN F A-2343. CH₂F CH₃ 3-F CN F A-2344. CH₂F CH₃ 3-CH₃ CN F A-2345. CH₂F CH₃ 3-OCH₃ CN F A-2346. CH₂F CH₃ 5-F CN F A-2347. CH₂F CH₃ 5-CH₃ CN F A-2348. CH₂F CH₃ 5-OCH₃ CN F A-2349. CH₂F OCH₃ 3-F CN F A-2350. CH₂F OCH₃ 3-CH₃ CN F A-2351. CH₂F OCH₃ 3-OCH₃ CN F A-2352. CH₂F OCH₃ 5-F CN F A-2353. CH₂F OCH₃ 5-CH₃ CN F A-2354. CH₂F OCH₃ 5-OCH₃ CN F A-2355. CH₂F CN 3-F CN F A-2356. CH₂F CN 3-CH₃ CN F A-2357. CH₂F CN 3-OCH₃ CN F A-2358. CH₂F CN 5-F CN F A-2359. CH₂F CN 5-CH₃ CN F A-2360. CH₂F CN 5-OCH₃ CN F A-2361. CH₂F CH₂F 3-F CN F A-2362. CH₂F CH₂F 3-CH₃ CN F A-2363. CH₂F CH₂F 3-OCH₃ CN F A-2364. CH₂F CH₂F 5-F CN F A-2365. CH₂F CH₂F 5-CH₃ CN F A-2366. CH₂F CH₂F 5-OCH₃ CN F A-2367. CH₂F CHF₂ 3-F CN F A-2368. CH₂F CHF₂ 3-CH₃ CN F A-2369. CH₂F CHF₂ 3-OCH₃ CN F A-2370. CH₂F CHF₂ 5-F CN F A-2371. CH₂F CHF₂ 5-CH₃ CN F A-2372. CH₂F CHF₂ 5-OCH₃ CN F A-2373. CH₂F CF₃ 3-F CN F A-2374. CH₂F CF₃ 3-CH₃ CN F A-2375. CH₂F CF₃ 3-OCH₃ CN F A-2376. CH₂F CF₃ 5-F CN F A-2377. CH₂F CF₃ 5-CH₃ CN F A-2378. CH₂F CF₃ 5-OCH₃ CN F A-2379. CH₂F OCH₂F 3-F CN F A-2380. CH₂F OCH₂F 3-CH₃ CN F A-2381. CH₂F OCH₂F 3-OCH₃ CN F A-2382. CH₂F OCH₂F 5-F CN F A-2383. CH₂F OCH₂F 5-CH₃ CN F A-2384. CH₂F OCH₂F 5-OCH₃ CN F A-2385. CH₂F OCHF₂ 3-F CN F A-2386. CH₂F OCHF₂ 3-CH₃ CN F A-2387. CH₂F OCHF₂ 3-OCH₃ CN F A-2388. CH₂F OCHF₂ 5-F CN F A-2389. CH₂F OCHF₂ 5-CH₃ CN F A-2390. CH₂F OCHF₂ 5-OCH₃ CN F A-2391. CH₂F OCF₃ 3-F CN F A-2392. CH₂F OCF₃ 3-CH₃ CN F A-2393. CH₂F OCF₃ 3-OCH₃ CN F A-2394. CH₂F OCF₃ 5-F CN F A-2395. CH₂F OCF₃ 5-CH₃ CN F A-2396. CH₂F OCF₃ 5-OCH₃ CN F A-2397. CHF₂ F 3-F CN F A-2398. CHF₂ F 3-CH₃ CN F A-2399. CHF₂ F 3-OCH₃ CN F A-2400. CHF₂ F 5-F CN F A-2401. CHF₂ F 5-CH₃ CN F A-2402. CHF₂ F 5-OCH₃ CN F A-2403. CHF₂ CH₃ 3-F CN F A-2404. CHF₂ CH₃ 3-CH₃ CN F A-2405. CHF₂ CH₃ 3-OCH₃ CN F A-2406. CHF₂ CH₃ 5-F CN F A-2407. CHF₂ CH₃ 5-CH₃ CN F A-2408. CHF₂ CH₃ 5-OCH₃ CN F A-2409. CHF₂ OCH₃ 3-F CN F A-2410. CHF₂ OCH₃ 3-CH₃ CN F A-2411. CHF₂ OCH₃ 3-OCH₃ CN F A-2412. CHF₂ OCH₃ 5-F CN F A-2413. CHF₂ OCH₃ 5-CH₃ CN F A-2414. CHF₂ OCH₃ 5-OCH₃ CN F A-2415. CHF₂ CN 3-F CN F A-2416. CHF₂ CN 3-CH₃ CN F A-2417. CHF₂ CN 3-OCH₃ CN F A-2418. CHF₂ CN 5-F CN F A-2419. CHF₂ CN 5-CH₃ CN F A-2420. CHF₂ CN 5-OCH₃ CN F A-2421. CHF₂ CH₂F 3-F CN F A-2422. CHF₂ CH₂F 3-CH₃ CN F A-2423. CHF₂ CH₂F 3-OCH₃ CN F A-2424. CHF₂ CH₂F 5-F CN F A-2425. CHF₂ CH₂F 5-CH₃ CN F A-2426. CHF₂ CH₂F 5-OCH₃ CN F A-2427. CHF₂ CHF₂ 3-F CN F A-2428. CHF₂ CHF₂ 3-CH₃ CN F A-2429. CHF₂ CHF₂ 3-OCH₃ CN F A-2430. CHF₂ CHF₂ 5-F CN F A-2431. CHF₂ CHF₂ 5-CH₃ CN F A-2432. CHF₂ CHF₂ 5-OCH₃ CN F A-2433. CHF₂ CF₃ 3-F CN F A-2434. CHF₂ CF₃ 3-CH₃ CN F A-2435. CHF₂ CF₃ 3-OCH₃ CN F A-2436. CHF₂ CF₃ 5-F CN F A-2437. CHF₂ CF₃ 5-CH₃ CN F A-2438. CHF₂ CF₃ 5-OCH₃ CN F A-2439. CHF₂ OCH₂F 3-F CN F A-2440. CHF₂ OCH₂F 3-CH₃ CN F A-2441. CHF₂ OCH₂F 3-OCH₃ CN F A-2442. CHF₂ OCH₂F 5-F CN F A-2443. CHF₂ OCH₂F 5-CH₃ CN F A-2444. CHF₂ OCH₂F 5-OCH₃ CN F A-2445. CHF₂ OCHF₂ 3-F CN F A-2446. CHF₂ OCHF₂ 3-CH₃ CN F A-2447. CHF₂ OCHF₂ 3-OCH₃ CN F A-2448. CHF₂ OCHF₂ 5-F CN F A-2449. CHF₂ OCHF₂ 5-CH₃ CN F A-2450. CHF₂ OCHF₂ 5-OCH₃ CN F A-2451. CHF₂ OCF₃ 3-F CN F A-2452. CHF₂ OCF₃ 3-CH₃ CN F A-2453. CHF₂ OCF₃ 3-OCH₃ CN F A-2454. CHF₂ OCF₃ 5-F CN F A-2455. CHF₂ OCF₃ 5-CH₃ CN F A-2456. CHF₂ OCF₃ 5-OCH₃ CN F A-2457. CF₃ F 3-F CN F A-2458. CF₃ F 3-CH₃ CN F A-2459. CF₃ F 3-OCH₃ CN F A-2460. CF₃ F 5-F CN F A-2461. CF₃ F 5-CH₃ CN F A-2462. CF₃ F 5-OCH₃ CN F A-2463. CF₃ CH₃ 3-F CN F A-2464. CF₃ CH₃ 3-CH₃ CN F A-2465. CF₃ CH₃ 3-OCH₃ CN F A-2466. CF₃ CH₃ 5-F CN F A-2467. CF₃ CH₃ 5-CH₃ CN F A-2468. CF₃ CH₃ 5-OCH₃ CN F A-2469. CF₃ OCH₃ 3-F CN F A-2470. CF₃ OCH₃ 3-CH₃ CN F A-2471. CF₃ OCH₃ 3-OCH₃ CN F A-2472. CF₃ OCH₃ 5-F CN F A-2473. CF₃ OCH₃ 5-CH₃ CN F A-2474. CF₃ OCH₃ 5-OCH₃ CN F A-2475. CF₃ CN 3-F CN F A-2476. CF₃ CN 3-CH₃ CN F A-2477. CF₃ CN 3-OCH₃ CN F A-2478. CF₃ CN 5-F CN F A-2479. CF₃ CN 5-CH₃ CN F A-2480. CF₃ CN 5-OCH₃ CN F A-2481. CF₃ CH₂F 3-F CN F A-2482. CF₃ CH₂F 3-CH₃ CN F A-2483. CF₃ CH₂F 3-OCH₃ CN F A-2484. CF₃ CH₂F 5-F CN F A-2485. CF₃ CH₂F 5-CH₃ CN F A-2486. CF₃ CH₂F 5-OCH₃ CN F A-2487. CF₃ CHF₂ 3-F CN F A-2488. CF₃ CHF₂ 3-CH₃ CN F A-2489. CF₃ CHF₂ 3-OCH₃ CN F A-2490. CF₃ CHF₂ 5-F CN F A-2491. CF₃ CHF₂ 5-CH₃ CN F A-2492. CF₃ CHF₂ 5-OCH₃ CN F A-2493. CF₃ CF₃ 3-F CN F A-2494. CF₃ CF₃ 3-CH₃ CN F A-2495. CF₃ CF₃ 3-OCH₃ CN F A-2496. CF₃ CF₃ 5-F CN F A-2497. CF₃ CF₃ 5-CH₃ CN F A-2498. CF₃ CF₃ 5-OCH₃ CN F A-2499. CF₃ OCH₂F 3-F CN F A-2500. CF₃ OCH₂F 3-CH₃ CN F A-2501. CF₃ OCH₂F 3-OCH₃ CN F A-2502. CF₃ OCH₂F 5-F CN F A-2503. CF₃ OCH₂F 5-CH₃ CN F A-2504. CF₃ OCH₂F 5-OCH₃ CN F A-2505. CF₃ OCHF₂ 3-F CN F A-2506. CF₃ OCHF₂ 3-CH₃ CN F A-2507. CF₃ OCHF₂ 3-OCH₃ CN F A-2508. CF₃ OCHF₂ 5-F CN F A-2509. CF₃ OCHF₂ 5-CH₃ CN F A-2510. CF₃ OCHF₂ 5-OCH₃ CN F A-2511. CF₃ OCF₃ 3-F CN F A-2512. CF₃ OCF₃ 3-CH₃ CN F A-2513. CF₃ OCF₃ 3-OCH₃ CN F A-2514. CF₃ OCF₃ 5-F CN F A-2515. CF₃ OCF₃ 5-CH₃ CN F A-2516. CF₃ OCF₃ 5-OCH₃ CN F A-2517. OCH₂F F 3-F CN F A-2518. OCH₂F F 3-CH₃ CN F A-2519. OCH₂F F 3-OCH₃ CN F A-2520. OCH₂F F 5-F CN F A-2521. OCH₂F F 5-CH₃ CN F A-2522. OCH₂F F 5-OCH₃ CN F A-2523. OCH₂F CH₃ 3-F CN F A-2524. OCH₂F CH₃ 3-CH₃ CN F A-2525. OCH₂F CH₃ 3-OCH₃ CN F A-2526. OCH₂F CH₃ 5-F CN F A-2527. OCH₂F CH₃ 5-CH₃ CN F A-2528. OCH₂F CH₃ 5-OCH₃ CN F A-2529. OCH₂F OCH₃ 3-F CN F A-2530. OCH₂F OCH₃ 3-CH₃ CN F A-2531. OCH₂F OCH₃ 3-OCH₃ CN F A-2532. OCH₂F OCH₃ 5-F CN F A-2533. OCH₂F OCH₃ 5-CH₃ CN F A-2534. OCH₂F OCH₃ 5-OCH₃ CN F A-2535. OCH₂F CN 3-F CN F A-2536. OCH₂F CN 3-CH₃ CN F A-2537. OCH₂F CN 3-OCH₃ CN F A-2538. OCH₂F CN 5-F CN F A-2539. OCH₂F CN 5-CH₃ CN F A-2540. OCH₂F CN 5-OCH₃ CN F A-2541. OCH₂F CH₂F 3-F CN F A-2542. OCH₂F CH₂F 3-CH₃ CN F A-2543. OCH₂F CH₂F 3-OCH₃ CN F A-2544. OCH₂F CH₂F 5-F CN F A-2545. OCH₂F CH₂F 5-CH₃ CN F A-2546. OCH₂F CH₂F 5-OCH₃ CN F A-2547. OCH₂F CHF₂ 3-F CN F A-2548. OCH₂F CHF₂ 3-CH₃ CN F A-2549. OCH₂F CHF₂ 3-OCH₃ CN F A-2550. OCH₂F CHF₂ 5-F CN F A-2551. OCH₂F CHF₂ 5-CH₃ CN F A-2552. OCH₂F CHF₂ 5-OCH₃ CN F A-2553. OCH₂F CF₃ 3-F CN F A-2554. OCH₂F CF₃ 3-CH₃ CN F A-2555. OCH₂F CF₃ 3-OCH₃ CN F A-2556. OCH₂F CF₃ 5-F CN F A-2557. OCH₂F CF₃ 5-CH₃ CN F A-2558. OCH₂F CF₃ 5-OCH₃ CN F A-2559. OCH₂F OCH₂F 3-F CN F A-2560. OCH₂F OCH₂F 3-CH₃ CN F A-2561. OCH₂F OCH₂F 3-OCH₃ CN F A-2562. OCH₂F OCH₂F 5-F CN F A-2563. OCH₂F OCH₂F 5-CH₃ CN F A-2564. OCH₂F OCH₂F 5-OCH₃ CN F A-2565. OCH₂F OCHF₂ 3-F CN F A-2566. OCH₂F OCHF₂ 3-CH₃ CN F A-2567. OCH₂F OCHF₂ 3-OCH₃ CN F A-2568. OCH₂F OCHF₂ 5-F CN F A-2569. OCH₂F OCHF₂ 5-CH₃ CN F A-2570. OCH₂F OCHF₂ 5-OCH₃ CN F A-2571. OCH₂F OCF₃ 3-F CN F A-2572. OCH₂F OCF₃ 3-CH₃ CN F A-2573. OCH₂F OCF₃ 3-OCH₃ CN F A-2574. OCH₂F OCF₃ 5-F CN F A-2575. OCH₂F OCF₃ 5-CH₃ CN F A-2576. OCH₂F OCF₃ 5-OCH₃ CN F A-2577. OCHF₂ F 3-F CN F A-2578. OCHF₂ F 3-CH₃ CN F A-2579. OCHF₂ F 3-OCH₃ CN F A-2580. OCHF₂ F 5-F CN F A-2581. OCHF₂ F 5-CH₃ CN F A-2582. OCHF₂ F 5-OCH₃ CN F A-2583. OCHF₂ CH₃ 3-F CN F A-2584. OCHF₂ CH₃ 3-CH₃ CN F A-2585. OCHF₂ CH₃ 3-OCH₃ CN F A-2586. OCHF₂ CH₃ 5-F CN F A-2587. OCHF₂ CH₃ 5-CH₃ CN F A-2588. OCHF₂ CH₃ 5-OCH₃ CN F A-2589. OCHF₂ OCH₃ 3-F CN F A-2590. OCHF₂ OCH₃ 3-CH₃ CN F A-2591. OCHF₂ OCH₃ 3-OCH₃ CN F A-2592. OCHF₂ OCH₃ 5-F CN F A-2593. OCHF₂ OCH₃ 5-CH₃ CN F A-2594. OCHF₂ OCH₃ 5-OCH₃ CN F A-2595. OCHF₂ CN 3-F CN F A-2596. OCHF₂ CN 3-CH₃ CN F A-2597. OCHF₂ CN 3-OCH₃ CN F A-2598. OCHF₂ CN 5-F CN F A-2599. OCHF₂ CN 5-CH₃ CN F A-2600. OCHF₂ CN 5-OCH₃ CN F A-2601. OCHF₂ CH₂F 3-F CN F A-2602. OCHF₂ CH₂F 3-CH₃ CN F A-2603. OCHF₂ CH₂F 3-OCH₃ CN F A-2604. OCHF₂ CH₂F 5-F CN F A-2605. OCHF₂ CH₂F 5-CH₃ CN F A-2606. OCHF₂ CH₂F 5-OCH₃ CN F A-2607. OCHF₂ CHF₂ 3-F CN F A-2608. OCHF₂ CHF₂ 3-CH₃ CN F A-2609. OCHF₂ CHF₂ 3-OCH₃ CN F A-2610. OCHF₂ CHF₂ 5-F CN F A-2611. OCHF₂ CHF₂ 5-CH₃ CN F A-2612. OCHF₂ CHF₂ 5-OCH₃ CN F A-2613. OCHF₂ CF₃ 3-F CN F A-2614. OCHF₂ CF₃ 3-CH₃ CN F A-2615. OCHF₂ CF₃ 3-OCH₃ CN F A-2616. OCHF₂ CF₃ 5-F CN F A-2617. OCHF₂ CF₃ 5-CH₃ CN F A-2618. OCHF₂ CF₃ 5-OCH₃ CN F A-2619. OCHF₂ OCH₂F 3-F CN F A-2620. OCHF₂ OCH₂F 3-CH₃ CN F A-2621. OCHF₂ OCH₂F 3-OCH₃ CN F A-2622. OCHF₂ OCH₂F 5-F CN F A-2623. OCHF₂ OCH₂F 5-CH₃ CN F A-2624. OCHF₂ OCH₂F 5-OCH₃ CN F A-2625. OCHF₂ OCHF₂ 3-F CN F A-2626. OCHF₂ OCHF₂ 3-CH₃ CN F A-2627. OCHF₂ OCHF₂ 3-OCH₃ CN F A-2628. OCHF₂ OCHF₂ 5-F CN F A-2629. OCHF₂ OCHF₂ 5-CH₃ CN F A-2630. OCHF₂ OCHF₂ 5-OCH₃ CN F A-2631. OCHF₂ OCF₃ 3-F CN F A-2632. OCHF₂ OCF₃ 3-CH₃ CN F A-2633. OCHF₂ OCF₃ 3-OCH₃ CN F A-2634. OCHF₂ OCF₃ 5-F CN F A-2635. OCHF₂ OCF₃ 5-CH₃ CN F A-2636. OCHF₂ OCF₃ 5-OCH₃ CN F A-2637. OCF₃ F 3-F CN F A-2638. OCF₃ F 3-CH₃ CN F A-2639. OCF₃ F 3-OCH₃ CN F A-2640. OCF₃ F 5-F CN F A-2641. OCF₃ F 5-CH₃ CN F A-2642. OCF₃ F 5-OCH₃ CN F A-2643. OCF₃ CH₃ 3-F CN F A-2644. OCF₃ CH₃ 3-CH₃ CN F A-2645. OCF₃ CH₃ 3-OCH₃ CN F A-2646. OCF₃ CH₃ 5-F CN F A-2647. OCF₃ CH₃ 5-CH₃ CN F A-2648. OCF₃ CH₃ 5-OCH₃ CN F A-2649. OCF₃ OCH₃ 3-F CN F A-2650. OCF₃ OCH₃ 3-CH₃ CN F A-2651. OCF₃ OCH₃ 3-OCH₃ CN F A-2652. OCF₃ OCH₃ 5-F CN F A-2653. OCF₃ OCH₃ 5-CH₃ CN F A-2654. OCF₃ OCH₃ 5-OCH₃ CN F A-2655. OCF₃ CN 3-F CN F A-2656. OCF₃ CN 3-CH₃ CN F A-2657. OCF₃ CN 3-OCH₃ CN F A-2658. OCF₃ CN 5-F CN F A-2659. OCF₃ CN 5-CH₃ CN F A-2660. OCF₃ CN 5-OCH₃ CN F A-2661. OCF₃ CH₂F 3-F CN F A-2662. OCF₃ CH₂F 3-CH₃ CN F A-2663. OCF₃ CH₂F 3-OCH₃ CN F A-2664. OCF₃ CH₂F 5-F CN F A-2665. OCF₃ CH₂F 5-CH₃ CN F A-2666. OCF₃ CH₂F 5-OCH₃ CN F A-2667. OCF₃ CHF₂ 3-F CN F A-2668. OCF₃ CHF₂ 3-CH₃ CN F A-2669. OCF₃ CHF₂ 3-OCH₃ CN F A-2670. OCF₃ CHF₂ 5-F CN F A-2671. OCF₃ CHF₂ 5-CH₃ CN F A-2672. OCF₃ CHF₂ 5-OCH₃ CN F A-2673. OCF₃ CF₃ 3-F CN F A-2674. OCF₃ CF₃ 3-CH₃ CN F A-2675. OCF₃ CF₃ 3-OCH₃ CN F A-2676. OCF₃ CF₃ 5-F CN F A-2677. OCF₃ CF₃ 5-CH₃ CN F A-2678. OCF₃ CF₃ 5-OCH₃ CN F A-2679. OCF₃ OCH₂F 3-F CN F A-2680. OCF₃ OCH₂F 3-CH₃ CN F A-2681. OCF₃ OCH₂F 3-OCH₃ CN F A-2682. OCF₃ OCH₂F 5-F CN F A-2683. OCF₃ OCH₂F 5-CH₃ CN F A-2684. OCF₃ OCH₂F 5-OCH₃ CN F A-2685. OCF₃ OCHF₂ 3-F CN F A-2686. OCF₃ OCHF₂ 3-CH₃ CN F A-2687. OCF₃ OCHF₂ 3-OCH₃ CN F A-2688. OCF₃ OCHF₂ 5-F CN F A-2689. OCF₃ OCHF₂ 5-CH₃ CN F A-2690. OCF₃ OCHF₂ 5-OCH₃ CN F A-2691. OCF₃ OCF₃ 3-F CN F A-2692. OCF₃ OCF₃ 3-CH₃ CN F A-2693. OCF₃ OCF₃ 3-OCH₃ CN F A-2694. OCF₃ OCF₃ 5-F CN F A-2695. OCF₃ OCF₃ 5-CH₃ CN F A-2696. OCF₃ OCF₃ 5-OCH₃ CN F A-2697. H H H F F A-2698. F H H F F A-2699. CH₃ H H F F A-2700. OCH₃ H H F F A-2701. CH₂F H H F F A-2702. CHF₂ H H F F A-2703. CF₃ H H F F A-2704. OCH₂F H H F F A-2705. OCHF₂ H H F F A-2706. OCF₃ H H F F A-2707. H F H F F A-2708. H CH₃ H F F A-2709. H OCH₃ H F F A-2710. H CN H F F A-2711. H CH₂F H F F A-2712. H CHF₂ H F F A-2713. H CF₃ H F F A-2714. H OCH₂F H F F A-2715. H OCHF₂ H F F A-2716. H OCF₃ H F F A-2717. H H 3-F F F A-2718. H H 3-CH₃ F F A-2719. H H 3-OCH₃ F F A-2720. H H 5-F F F A-2721. H H 5-CH₃ F F A-2722. H H 5-OCH₃ F F A-2723. F F H F F A-2724. F CH₃ H F F A-2725. F OCH₃ H F F A-2726. F CN H F F A-2727. F CH₂F H F F A-2728. F CHF₂ H F F A-2729. F CF₃ H F F A-2730. F OCH₂F H F F A-2731. F OCHF₂ H F F A-2732. F OCF₃ H F F A-2733. F H 3-F F F A-2734. F H 3-CH₃ F F A-2735. F H 3-OCH₃ F F A-2736. F H 5-F F F A-2737. F H 5-CH₃ F F A-2738. F H 5-OCH₃ F F A-2739. CH₃ F H F F A-2740. CH₃ CH₃ H F F A-2741. CH₃ OCH₃ H F F A-2742. CH₃ CN H F F A-2743. CH₃ CH₂F H F F A-2744. CH₃ CHF₂ H F F A-2745. CH₃ CF₃ H F F A-2746. CH₃ OCH₂F H F F A-2747. CH₃ OCHF₂ H F F A-2748. CH₃ OCF₃ H F F A-2749. CH₃ H 3-F F F A-2750. CH₃ H 3-CH₃ F F A-2751. CH₃ H 3-OCH₃ F F A-2752. CH₃ H 5-F F F A-2753. CH₃ H 5-CH₃ F F A-2754. CH₃ H 5-OCH₃ F F A-2755. OCH₃ F H F F A-2756. OCH₃ CH₃ H F F A-2757. OCH₃ OCH₃ H F F A-2758. OCH₃ CN H F F A-2759. OCH₃ CH₂F H F F A-2760. OCH₃ CHF₂ H F F A-2761. OCH₃ CF₃ H F F A-2762. OCH₃ OCH₂F H F F A-2763. OCH₃ OCHF₂ H F F A-2764. OCH₃ OCF₃ H F F A-2765. OCH₃ H 3-F F F A-2766. OCH₃ H 3-CH₃ F F A-2767. OCH₃ H 3-OCH₃ F F A-2768. OCH₃ H 5-F F F A-2769. OCH₃ H 5-CH₃ F F A-2770. OCH₃ H 5-OCH₃ F F A-2771. H F 3-F F F A-2772. H F 3-CH₃ F F A-2773. H F 3-OCH₃ F F A-2774. H F 5-F F F A-2775. H F 5-CH₃ F F A-2776. H F 5-OCH₃ F F A-2777. H CH₃ 3-F F F A-2778. H CH₃ 3-CH₃ F F A-2779. H CH₃ 3-OCH₃ F F A-2780. H CH₃ 5-F F F A-2781. H CH₃ 5-CH₃ F F A-2782. H CH₃ 5-OCH₃ F F A-2783. H OCH₃ 3-F F F A-2784. H OCH₃ 3-CH₃ F F A-2785. H OCH₃ 3-OCH₃ F F A-2786. H OCH₃ 5-F F F A-2787. H OCH₃ 5-CH₃ F F A-2788. H OCH₃ 5-OCH₃ F F A-2789. H CN 3-F F F A-2790. H CN 3-CH₃ F F A-2791. H CN 3-OCH₃ F F A-2792. H CN 5-F F F A-2793. H CN 5-CH₃ F F A-2794. H CN 5-OCH₃ F F A-2795. H CH₂F 3-F F F A-2796. H CH₂F 3-CH₃ F F A-2797. H CH₂F 3-OCH₃ F F A-2798. H CH₂F 5-F F F A-2799. H CH₂F 5-CH₃ F F A-2800. H CH₂F 5-OCH₃ F F A-2801. H CHF₂ 3-F F F A-2802. H CHF₂ 3-CH₃ F F A-2803. H CHF₂ 3-OCH₃ F F A-2804. H CHF₂ 5-F F F A-2805. H CHF₂ 5-CH₃ F F A-2806. H CHF₂ 5-OCH₃ F F A-2807. H CF₃ 3-F F F A-2808. H CF₃ 3-CH₃ F F A-2809. H CF₃ 3-OCH₃ F F A-2810. H CF₃ 5-F F F A-2811. H CF₃ 5-CH₃ F F A-2812. H CF₃ 5-OCH₃ F F A-2813. H OCH₂F 3-F F F A-2814. H OCH₂F 3-CH₃ F F A-2815. H OCH₂F 3-OCH₃ F F A-2816. H OCH₂F 5-F F F A-2817. H OCH₂F 5-CH₃ F F A-2818. H OCH₂F 5-OCH₃ F F A-2819. H OCHF₂ 3-F F F A-2820. H OCHF₂ 3-CH₃ F F A-2821. H OCHF₂ 3-OCH₃ F F A-2822. H OCHF₂ 5-F F F A-2823. H OCHF₂ 5-CH₃ F F A-2824. H OCHF₂ 5-OCH₃ F F A-2825. H OCF₃ 3-F F F A-2826. H OCF₃ 3-CH₃ F F A-2827. H OCF₃ 3-OCH₃ F F A-2828. H OCF₃ 5-F F F A-2829. H OCF₃ 5-CH₃ F F A-2830. H OCF₃ 5-OCH₃ F F A-2831. F F 3-F F F A-2832. F F 3-CH₃ F F A-2833. F F 3-OCH₃ F F A-2834. F F 5-F F F A-2835. F F 5-CH₃ F F A-2836. F F 5-OCH₃ F F A-2837. F CH₃ 3-F F F A-2838. F CH₃ 3-CH₃ F F A-2839. F CH₃ 3-OCH₃ F F A-2840. F CH₃ 5-F F F A-2841. F CH₃ 5-CH₃ F F A-2842. F CH₃ 5-OCH₃ F F A-2843. F OCH₃ 3-F F F A-2844. F OCH₃ 3-CH₃ F F A-2845. F OCH₃ 3-OCH₃ F F A-2846. F OCH₃ 5-F F F A-2847. F OCH₃ 5-CH₃ F F A-2848. F OCH₃ 5-OCH₃ F F A-2849. F CN 3-F F F A-2850. F CN 3-CH₃ F F A-2851. F CN 3-OCH₃ F F A-2852. F CN 5-F F F A-2853. F CN 5-CH₃ F F A-2854. F CN 5-OCH₃ F F A-2855. F CH₂F 3-F F F A-2856. F CH₂F 3-CH₃ F F A-2857. F CH₂F 3-OCH₃ F F A-2858. F CH₂F 5-F F F A-2859. F CH₂F 5-CH₃ F F A-2860. F CH₂F 5-OCH₃ F F A-2861. F CHF₂ 3-F F F A-2862. F CHF₂ 3-CH₃ F F A-2863. F CHF₂ 3-OCH₃ F F A-2864. F CHF₂ 5-F F F A-2865. F CHF₂ 5-CH₃ F F A-2866. F CHF₂ 5-OCH₃ F F A-2867. F CF₃ 3-F F F A-2868. F CF₃ 3-CH₃ F F A-2869. F CF₃ 3-OCH₃ F F A-2870. F CF₃ 5-F F F A-2871. F CF₃ 5-CH₃ F F A-2872. F CF₃ 5-OCH₃ F F A-2873. F OCH₂F 3-F F F A-2874. F OCH₂F 3-CH₃ F F A-2875. F OCH₂F 3-OCH₃ F F A-2876. F OCH₂F 5-F F F A-2877. F OCH₂F 5-CH₃ F F A-2878. F OCH₂F 5-OCH₃ F F A-2879. F OCHF₂ 3-F F F A-2880. F OCHF₂ 3-CH₃ F F A-2881. F OCHF₂ 3-OCH₃ F F A-2882. F OCHF₂ 5-F F F A-2883. F OCHF₂ 5-CH₃ F F A-2884. F OCHF₂ 5-OCH₃ F F A-2885. F OCF₃ 3-F F F A-2886. F OCF₃ 3-CH₃ F F A-2887. F OCF₃ 3-OCH₃ F F A-2888. F OCF₃ 5-F F F A-2889. F OCF₃ 5-CH₃ F F A-2890. F OCF₃ 5-OCH₃ F F A-2891. CH₃ F 3-F F F A-2892. CH₃ F 3-CH₃ F F A-2893. CH₃ F 3-OCH₃ F F A-2894. CH₃ F 5-F F F A-2895. CH₃ F 5-CH₃ F F A-2896. CH₃ F 5-OCH₃ F F A-2897. CH₃ CH₃ 3-F F F A-2898. CH₃ CH₃ 3-CH₃ F F A-2899. CH₃ CH₃ 3-OCH₃ F F A-2900. CH₃ CH₃ 5-F F F A-2901. CH₃ CH₃ 5-CH₃ F F A-2902. CH₃ CH₃ 5-OCH₃ F F A-2903. CH₃ OCH₃ 3-F F F A-2904. CH₃ OCH₃ 3-CH₃ F F A-2905. CH₃ OCH₃ 3-OCH₃ F F A-2906. CH₃ OCH₃ 5-F F F A-2907. CH₃ OCH₃ 5-CH₃ F F A-2908. CH₃ OCH₃ 5-OCH₃ F F A-2909. CH₃ CN 3-F F F A-2910. CH₃ CN 3-CH₃ F F A-2911. CH₃ CN 3-OCH₃ F F A-2912. CH₃ CN 5-F F F A-2913. CH₃ CN 5-CH₃ F F A-2914. CH₃ CN 5-OCH₃ F F A-2915. CH₃ CH₂F 3-F F F A-2916. CH₃ CH₂F 3-CH₃ F F A-2917. CH₃ CH₂F 3-OCH₃ F F A-2918. CH₃ CH₂F 5-F F F A-2919. CH₃ CH₂F 5-CH₃ F F A-2920. CH₃ CH₂F 5-OCH₃ F F A-2921. CH₃ CHF₂ 3-F F F A-2922. CH₃ CHF₂ 3-CH₃ F F A-2923. CH₃ CHF₂ 3-OCH₃ F F A-2924. CH₃ CHF₂ 5-F F F A-2925. CH₃ CHF₂ 5-CH₃ F F A-2926. CH₃ CHF₂ 5-OCH₃ F F A-2927. CH₃ CF₃ 3-F F F A-2928. CH₃ CF₃ 3-CH₃ F F A-2929. CH₃ CF₃ 3-OCH₃ F F A-2930. CH₃ CF₃ 5-F F F A-2931. CH₃ CF₃ 5-CH₃ F F A-2932. CH₃ CF₃ 5-OCH₃ F F A-2933. CH₃ OCH₂F 3-F F F A-2934. CH₃ OCH₂F 3-CH₃ F F A-2935. CH₃ OCH₂F 3-OCH₃ F F A-2936. CH₃ OCH₂F 5-F F F A-2937. CH₃ OCH₂F 5-CH₃ F F A-2938. CH₃ OCH₂F 5-OCH₃ F F A-2939. CH₃ OCHF₂ 3-F F F A-2940. CH₃ OCHF₂ 3-CH₃ F F A-2941. CH₃ OCHF₂ 3-OCH₃ F F A-2942. CH₃ OCHF₂ 5-F F F A-2943. CH₃ OCHF₂ 5-CH₃ F F A-2944. CH₃ OCHF₂ 5-OCH₃ F F A-2945. CH₃ OCF₃ 3-F F F A-2946. CH₃ OCF₃ 3-CH₃ F F A-2947. CH₃ OCF₃ 3-OCH₃ F F A-2948. CH₃ OCF₃ 5-F F F A-2949. CH₃ OCF₃ 5-CH₃ F F A-2950. CH₃ OCF₃ 5-OCH₃ F F A-2951. OCH₃ F 3-F F F A-2952. OCH₃ F 3-CH₃ F F A-2953. OCH₃ F 3-OCH₃ F F A-2954. OCH₃ F 5-F F F A-2955. OCH₃ F 5-CH₃ F F A-2956. OCH₃ F 5-OCH₃ F F A-2957. OCH₃ CH₃ 3-F F F A-2958. OCH₃ CH₃ 3-CH₃ F F A-2959. OCH₃ CH₃ 3-OCH₃ F F A-2960. OCH₃ CH₃ 5-F F F A-2961. OCH₃ CH₃ 5-CH₃ F F A-2962. OCH₃ CH₃ 5-OCH₃ F F A-2963. OCH₃ OCH₃ 3-F F F A-2964. OCH₃ OCH₃ 3-CH₃ F F A-2965. OCH₃ OCH₃ 3-OCH₃ F F A-2966. OCH₃ OCH₃ 5-F F F A-2967. OCH₃ OCH₃ 5-CH₃ F F A-2968. OCH₃ OCH₃ 5-OCH₃ F F A-2969. OCH₃ CN 3-F F F A-2970. OCH₃ CN 3-CH₃ F F A-2971. OCH₃ CN 3-OCH₃ F F A-2972. OCH₃ CN 5-F F F A-2973. OCH₃ CN 5-CH₃ F F A-2974. OCH₃ CN 5-OCH₃ F F A-2975. OCH₃ CH₂F 3-F F F A-2976. OCH₃ CH₂F 3-CH₃ F F A-2977. OCH₃ CH₂F 3-OCH₃ F F A-2978. OCH₃ CH₂F 5-F F F A-2979. OCH₃ CH₂F 5-CH₃ F F A-2980. OCH₃ CH₂F 5-OCH₃ F F A-2981. OCH₃ CHF₂ 3-F F F A-2982. OCH₃ CHF₂ 3-CH₃ F F A-2983. OCH₃ CHF₂ 3-OCH₃ F F A-2984. OCH₃ CHF₂ 5-F F F A-2985. OCH₃ CHF₂ 5-CH₃ F F A-2986. OCH₃ CHF₂ 5-OCH₃ F F A-2987. OCH₃ CF₃ 3-F F F A-2988. OCH₃ CF₃ 3-CH₃ F F A-2989. OCH₃ CF₃ 3-OCH₃ F F A-2990. OCH₃ CF₃ 5-F F F A-2991. OCH₃ CF₃ 5-CH₃ F F A-2992. OCH₃ CF₃ 5-OCH₃ F F A-2993. OCH₃ OCH₂F 3-F F F A-2994. OCH₃ OCH₂F 3-CH₃ F F A-2995. OCH₃ OCH₂F 3-OCH₃ F F A-2996. OCH₃ OCH₂F 5-F F F A-2997. OCH₃ OCH₂F 5-CH₃ F F A-2998. OCH₃ OCH₂F 5-OCH₃ F F A-2999. OCH₃ OCHF₂ 3-F F F A-3000. OCH₃ OCHF₂ 3-CH₃ F F A-3001. OCH₃ OCHF₂ 3-OCH₃ F F A-3002. OCH₃ OCHF₂ 5-F F F A-3003. OCH₃ OCHF₂ 5-CH₃ F F A-3004. OCH₃ OCHF₂ 5-OCH₃ F F A-3005. OCH₃ OCF₃ 3-F F F A-3006. OCH₃ OCF₃ 3-CH₃ F F A-3007. OCH₃ OCF₃ 3-OCH₃ F F A-3008. OCH₃ OCF₃ 5-F F F A-3009. OCH₃ OCF₃ 5-CH₃ F F A-3010. OCH₃ OCF₃ 5-OCH₃ F F A-3011. CH₂F F 3-F F F A-3012. CH₂F F 3-CH₃ F F A-3013. CH₂F F 3-OCH₃ F F A-3014. CH₂F F 5-F F F A-3015. CH₂F F 5-CH₃ F F A-3016. CH₂F F 5-OCH₃ F F A-3017. CH₂F CH₃ 3-F F F A-3018. CH₂F CH₃ 3-CH₃ F F A-3019. CH₂F CH₃ 3-OCH₃ F F A-3020. CH₂F CH₃ 5-F F F A-3021. CH₂F CH₃ 5-CH₃ F F A-3022. CH₂F CH₃ 5-OCH₃ F F A-3023. CH₂F OCH₃ 3-F F F A-3024. CH₂F OCH₃ 3-CH₃ F F A-3025. CH₂F OCH₃ 3-OCH₃ F F A-3026. CH₂F OCH₃ 5-F F F A-3027. CH₂F OCH₃ 5-CH₃ F F A-3028. CH₂F OCH₃ 5-OCH₃ F F A-3029. CH₂F CN 3-F F F A-3030. CH₂F CN 3-CH₃ F F A-3031. CH₂F CN 3-OCH₃ F F A-3032. CH₂F CN 5-F F F A-3033. CH₂F CN 5-CH₃ F F A-3034. CH₂F CN 5-OCH₃ F F A-3035. CH₂F CH₂F 3-F F F A-3036. CH₂F CH₂F 3-CH₃ F F A-3037. CH₂F CH₂F 3-OCH₃ F F A-3038. CH₂F CH₂F 5-F F F A-3039. CH₂F CH₂F 5-CH₃ F F A-3040. CH₂F CH₂F 5-OCH₃ F F A-3041. CH₂F CHF₂ 3-F F F A-3042. CH₂F CHF₂ 3-CH₃ F F A-3043. CH₂F CHF₂ 3-OCH₃ F F A-3044. CH₂F CHF₂ 5-F F F A-3045. CH₂F CHF₂ 5-CH₃ F F A-3046. CH₂F CHF₂ 5-OCH₃ F F A-3047. CH₂F CF₃ 3-F F F A-3048. CH₂F CF₃ 3-CH₃ F F A-3049. CH₂F CF₃ 3-OCH₃ F F A-3050. CH₂F CF₃ 5-F F F A-3051. CH₂F CF₃ 5-CH₃ F F A-3052. CH₂F CF₃ 5-OCH₃ F F A-3053. CH₂F OCH₂F 3-F F F A-3054. CH₂F OCH₂F 3-CH₃ F F A-3055. CH₂F OCH₂F 3-OCH₃ F F A-3056. CH₂F OCH₂F 5-F F F A-3057. CH₂F OCH₂F 5-CH₃ F F A-3058. CH₂F OCH₂F 5-OCH₃ F F A-3059. CH₂F OCHF₂ 3-F F F A-3060. CH₂F OCHF₂ 3-CH₃ F F A-3061. CH₂F OCHF₂ 3-OCH₃ F F A-3062. CH₂F OCHF₂ 5-F F F A-3063. CH₂F OCHF₂ 5-CH₃ F F A-3064. CH₂F OCHF₂ 5-OCH₃ F F A-3065. CH₂F OCF₃ 3-F F F A-3066. CH₂F OCF₃ 3-CH₃ F F A-3067. CH₂F OCF₃ 3-OCH₃ F F A-3068. CH₂F OCF₃ 5-F F F A-3069. CH₂F OCF₃ 5-CH₃ F F A-3070. CH₂F OCF₃ 5-OCH₃ F F A-3071. CHF₂ F 3-F F F A-3072. CHF₂ F 3-CH₃ F F A-3073. CHF₂ F 3-OCH₃ F F A-3074. CHF₂ F 5-F F F A-3075. CHF₂ F 5-CH₃ F F A-3076. CHF₂ F 5-OCH₃ F F A-3077. CHF₂ CH₃ 3-F F F A-3078. CHF₂ CH₃ 3-CH₃ F F A-3079. CHF₂ CH₃ 3-OCH₃ F F A-3080. CHF₂ CH₃ 5-F F F A-3081. CHF₂ CH₃ 5-CH₃ F F A-3082. CHF₂ CH₃ 5-OCH₃ F F A-3083. CHF₂ OCH₃ 3-F F F A-3084. CHF₂ OCH₃ 3-CH₃ F F A-3085. CHF₂ OCH₃ 3-OCH₃ F F A-3086. CHF₂ OCH₃ 5-F F F A-3087. CHF₂ OCH₃ 5-CH₃ F F A-3088. CHF₂ OCH₃ 5-OCH₃ F F A-3089. CHF₂ CN 3-F F F A-3090. CHF₂ CN 3-CH₃ F F A-3091. CHF₂ CN 3-OCH₃ F F A-3092. CHF₂ CN 5-F F F A-3093. CHF₂ CN 5-CH₃ F F A-3094. CHF₂ CN 5-OCH₃ F F A-3095. CHF₂ CH₂F 3-F F F A-3096. CHF₂ CH₂F 3-CH₃ F F A-3097. CHF₂ CH₂F 3-OCH₃ F F A-3098. CHF₂ CH₂F 5-F F F A-3099. CHF₂ CH₂F 5-CH₃ F F A-3100. CHF₂ CH₂F 5-OCH₃ F F A-3101. CHF₂ CHF₂ 3-F F F A-3102. CHF₂ CHF₂ 3-CH₃ F F A-3103. CHF₂ CHF₂ 3-OCH₃ F F A-3104. CHF₂ CHF₂ 5-F F F A-3105. CHF₂ CHF₂ 5-CH₃ F F A-3106. CHF₂ CHF₂ 5-OCH₃ F F A-3107. CHF₂ CF₃ 3-F F F A-3108. CHF₂ CF₃ 3-CH₃ F F A-3109. CHF₂ CF₃ 3-OCH₃ F F A-3110. CHF₂ CF₃ 5-F F F A-3111. CHF₂ CF₃ 5-CH₃ F F A-3112. CHF₂ CF₃ 5-OCH₃ F F A-3113. CHF₂ OCH₂F 3-F F F A-3114. CHF₂ OCH₂F 3-CH₃ F F A-3115. CHF₂ OCH₂F 3-OCH₃ F F A-3116. CHF₂ OCH₂F 5-F F F A-3117. CHF₂ OCH₂F 5-CH₃ F F A-3118. CHF₂ OCH₂F 5-OCH₃ F F A-3119. CHF₂ OCHF₂ 3-F F F A-3120. CHF₂ OCHF₂ 3-CH₃ F F A-3121. CHF₂ OCHF₂ 3-OCH₃ F F A-3122. CHF₂ OCHF₂ 5-F F F A-3123. CHF₂ OCHF₂ 5-CH₃ F F A-3124. CHF₂ OCHF₂ 5-OCH₃ F F A-3125. CHF₂ OCF₃ 3-F F F A-3126. CHF₂ OCF₃ 3-CH₃ F F A-3127. CHF₂ OCF₃ 3-OCH₃ F F A-3128. CHF₂ OCF₃ 5-F F F A-3129. CHF₂ OCF₃ 5-CH₃ F F A-3130. CHF₂ OCF₃ 5-OCH₃ F F A-3131. CF₃ F 3-F F F A-3132. CF₃ F 3-CH₃ F F A-3133. CF₃ F 3-OCH₃ F F A-3134. CF₃ F 5-F F F A-3135. CF₃ F 5-CH₃ F F A-3136. CF₃ F 5-OCH₃ F F A-3137. CF₃ CH₃ 3-F F F A-3138. CF₃ CH₃ 3-CH₃ F F A-3139. CF₃ CH₃ 3-OCH₃ F F A-3140. CF₃ CH₃ 5-F F F A-3141. CF₃ CH₃ 5-CH₃ F F A-3142. CF₃ CH₃ 5-OCH₃ F F A-3143. CF₃ OCH₃ 3-F F F A-3144. CF₃ OCH₃ 3-CH₃ F F A-3145. CF₃ OCH₃ 3-OCH₃ F F A-3146. CF₃ OCH₃ 5-F F F A-3147. CF₃ OCH₃ 5-CH₃ F F A-3148. CF₃ OCH₃ 5-OCH₃ F F A-3149. CF₃ CN 3-F F F A-3150. CF₃ CN 3-CH₃ F F A-3151. CF₃ CN 3-OCH₃ F F A-3152. CF₃ CN 5-F F F A-3153. CF₃ CN 5-CH₃ F F A-3154. CF₃ CN 5-OCH₃ F F A-3155. CF₃ CH₂F 3-F F F A-3156. CF₃ CH₂F 3-CH₃ F F A-3157. CF₃ CH₂F 3-OCH₃ F F A-3158. CF₃ CH₂F 5-F F F A-3159. CF₃ CH₂F 5-CH₃ F F A-3160. CF₃ CH₂F 5-OCH₃ F F A-3161. CF₃ CHF₂ 3-F F F A-3162. CF₃ CHF₂ 3-CH₃ F F A-3163. CF₃ CHF₂ 3-OCH₃ F F A-3164. CF₃ CHF₂ 5-F F F A-3165. CF₃ CHF₂ 5-CH₃ F F A-3166. CF₃ CHF₂ 5-OCH₃ F F A-3167. CF₃ CF₃ 3-F F F A-3168. CF₃ CF₃ 3-CH₃ F F A-3169. CF₃ CF₃ 3-OCH₃ F F A-3170. CF₃ CF₃ 5-F F F A-3171. CF₃ CF₃ 5-CH₃ F F A-3172. CF₃ CF₃ 5-OCH₃ F F A-3173. CF₃ OCH₂F 3-F F F A-3174. CF₃ OCH₂F 3-CH₃ F F A-3175. CF₃ OCH₂F 3-OCH₃ F F A-3176. CF₃ OCH₂F 5-F F F A-3177. CF₃ OCH₂F 5-CH₃ F F A-3178. CF₃ OCH₂F 5-OCH₃ F F A-3179. CF₃ OCHF₂ 3-F F F A-3180. CF₃ OCHF₂ 3-CH₃ F F A-3181. CF₃ OCHF₂ 3-OCH₃ F F A-3182. CF₃ OCHF₂ 5-F F F A-3183. CF₃ OCHF₂ 5-CH₃ F F A-3184. CF₃ OCHF₂ 5-OCH₃ F F A-3185. CF₃ OCF₃ 3-F F F A-3186. CF₃ OCF₃ 3-CH₃ F F A-3187. CF₃ OCF₃ 3-OCH₃ F F A-3188. CF₃ OCF₃ 5-F F F A-3189. CF₃ OCF₃ 5-CH₃ F F A-3190. CF₃ OCF₃ 5-OCH₃ F F A-3191. OCH₂F F 3-F F F A-3192. OCH₂F F 3-CH₃ F F A-3193. OCH₂F F 3-OCH₃ F F A-3194. OCH₂F F 5-F F F A-3195. OCH₂F F 5-CH₃ F F A-3196. OCH₂F F 5-OCH₃ F F A-3197. OCH₂F CH₃ 3-F F F A-3198. OCH₂F CH₃ 3-CH₃ F F A-3199. OCH₂F CH₃ 3-OCH₃ F F A-3200. OCH₂F CH₃ 5-F F F A-3201. OCH₂F CH₃ 5-CH₃ F F A-3202. OCH₂F CH₃ 5-OCH₃ F F A-3203. OCH₂F OCH₃ 3-F F F A-3204. OCH₂F OCH₃ 3-CH₃ F F A-3205. OCH₂F OCH₃ 3-OCH₃ F F A-3206. OCH₂F OCH₃ 5-F F F A-3207. OCH₂F OCH₃ 5-CH₃ F F A-3208. OCH₂F OCH₃ 5-OCH₃ F F A-3209. OCH₂F CN 3-F F F A-3210. OCH₂F CN 3-CH₃ F F A-3211. OCH₂F CN 3-OCH₃ F F A-3212. OCH₂F CN 5-F F F A-3213. OCH₂F CN 5-CH₃ F F A-3214. OCH₂F CN 5-OCH₃ F F A-3215. OCH₂F CH₂F 3-F F F A-3216. OCH₂F CH₂F 3-CH₃ F F A-3217. OCH₂F CH₂F 3-OCH₃ F F A-3218. OCH₂F CH₂F 5-F F F A-3219. OCH₂F CH₂F 5-CH₃ F F A-3220. OCH₂F CH₂F 5-OCH₃ F F A-3221. OCH₂F CHF₂ 3-F F F A-3222. OCH₂F CHF₂ 3-CH₃ F F A-3223. OCH₂F CHF₂ 3-OCH₃ F F A-3224. OCH₂F CHF₂ 5-F F F A-3225. OCH₂F CHF₂ 5-CH₃ F F A-3226. OCH₂F CHF₂ 5-OCH₃ F F A-3227. OCH₂F CF₃ 3-F F F A-3228. OCH₂F CF₃ 3-CH₃ F F A-3229. OCH₂F CF₃ 3-OCH₃ F F A-3230. OCH₂F CF₃ 5-F F F A-3231. OCH₂F CF₃ 5-CH₃ F F A-3232. OCH₂F CF₃ 5-OCH₃ F F A-3233. OCH₂F OCH₂F 3-F F F A-3234. OCH₂F OCH₂F 3-CH₃ F F A-3235. OCH₂F OCH₂F 3-OCH₃ F F A-3236. OCH₂F OCH₂F 5-F F F A-3237. OCH₂F OCH₂F 5-CH₃ F F A-3238. OCH₂F OCH₂F 5-OCH₃ F F A-3239. OCH₂F OCHF₂ 3-F F F A-3240. OCH₂F OCHF₂ 3-CH₃ F F A-3241. OCH₂F OCHF₂ 3-OCH₃ F F A-3242. OCH₂F OCHF₂ 5-F F F A-3243. OCH₂F OCHF₂ 5-CH₃ F F A-3244. OCH₂F OCHF₂ 5-OCH₃ F F A-3245. OCH₂F OCF₃ 3-F F F A-3246. OCH₂F OCF₃ 3-CH₃ F F A-3247. OCH₂F OCF₃ 3-OCH₃ F F A-3248. OCH₂F OCF₃ 5-F F F A-3249. OCH₂F OCF₃ 5-CH₃ F F A-3250. OCH₂F OCF₃ 5-OCH₃ F F A-3251. OCHF₂ F 3-F F F A-3252. OCHF₂ F 3-CH₃ F F A-3253. OCHF₂ F 3-OCH₃ F F A-3254. OCHF₂ F 5-F F F A-3255. OCHF₂ F 5-CH₃ F F A-3256. OCHF₂ F 5-OCH₃ F F A-3257. OCHF₂ CH₃ 3-F F F A-3258. OCHF₂ CH₃ 3-CH₃ F F A-3259. OCHF₂ CH₃ 3-OCH₃ F F A-3260. OCHF₂ CH₃ 5-F F F A-3261. OCHF₂ CH₃ 5-CH₃ F F A-3262. OCHF₂ CH₃ 5-OCH₃ F F A-3263. OCHF₂ OCH₃ 3-F F F A-3264. OCHF₂ OCH₃ 3-CH₃ F F A-3265. OCHF₂ OCH₃ 3-OCH₃ F F A-3266. OCHF₂ OCH₃ 5-F F F A-3267. OCHF₂ OCH₃ 5-CH₃ F F A-3268. OCHF₂ OCH₃ 5-OCH₃ F F A-3269. OCHF₂ CN 3-F F F A-3270. OCHF₂ CN 3-CH₃ F F A-3271. OCHF₂ CN 3-OCH₃ F F A-3272. OCHF₂ CN 5-F F F A-3273. OCHF₂ CN 5-CH₃ F F A-3274. OCHF₂ CN 5-OCH₃ F F A-3275. OCHF₂ CH₂F 3-F F F A-3276. OCHF₂ CH₂F 3-CH₃ F F A-3277. OCHF₂ CH₂F 3-OCH₃ F F A-3278. OCHF₂ CH₂F 5-F F F A-3279. OCHF₂ CH₂F 5-CH₃ F F A-3280. OCHF₂ CH₂F 5-OCH₃ F F A-3281. OCHF₂ CHF₂ 3-F F F A-3282. OCHF₂ CHF₂ 3-CH₃ F F A-3283. OCHF₂ CHF₂ 3-OCH₃ F F A-3284. OCHF₂ CHF₂ 5-F F F A-3285. OCHF₂ CHF₂ 5-CH₃ F F A-3286. OCHF₂ CHF₂ 5-OCH₃ F F A-3287. OCHF₂ CF₃ 3-F F F A-3288. OCHF₂ CF₃ 3-CH₃ F F A-3289. OCHF₂ CF₃ 3-OCH₃ F F A-3290. OCHF₂ CF₃ 5-F F F A-3291. OCHF₂ CF₃ 5-CH₃ F F A-3292. OCHF₂ CF₃ 5-OCH₃ F F A-3293. OCHF₂ OCH₂F 3-F F F A-3294. OCHF₂ OCH₂F 3-CH₃ F F A-3295. OCHF₂ OCH₂F 3-OCH₃ F F A-3296. OCHF₂ OCH₂F 5-F F F A-3297. OCHF₂ OCH₂F 5-CH₃ F F A-3298. OCHF₂ OCH₂F 5-OCH₃ F F A-3299. OCHF₂ OCHF₂ 3-F F F A-3300. OCHF₂ OCHF₂ 3-CH₃ F F A-3301. OCHF₂ OCHF₂ 3-OCH₃ F F A-3302. OCHF₂ OCHF₂ 5-F F F A-3303. OCHF₂ OCHF₂ 5-CH₃ F F A-3304. OCHF₂ OCHF₂ 5-OCH₃ F F A-3305. OCHF₂ OCF₃ 3-F F F A-3306. OCHF₂ OCF₃ 3-CH₃ F F A-3307. OCHF₂ OCF₃ 3-OCH₃ F F A-3308. OCHF₂ OCF₃ 5-F F F A-3309. OCHF₂ OCF₃ 5-CH₃ F F A-3310. OCHF₂ OCF₃ 5-OCH₃ F F A-3311. OCF₃ F 3-F F F A-3312. OCF₃ F 3-CH₃ F F A-3313. OCF₃ F 3-OCH₃ F F A-3314. OCF₃ F 5-F F F A-3315. OCF₃ F 5-CH₃ F F A-3316. OCF₃ F 5-OCH₃ F F A-3317. OCF₃ CH₃ 3-F F F A-3318. OCF₃ CH₃ 3-CH₃ F F A-3319. OCF₃ CH₃ 3-OCH₃ F F A-3320. OCF₃ CH₃ 5-F F F A-3321. OCF₃ CH₃ 5-CH₃ F F A-3322. OCF₃ CH₃ 5-OCH₃ F F A-3323. OCF₃ OCH₃ 3-F F F A-3324. OCF₃ OCH₃ 3-CH₃ F F A-3325. OCF₃ OCH₃ 3-OCH₃ F F A-3326. OCF₃ OCH₃ 5-F F F A-3327. OCF₃ OCH₃ 5-CH₃ F F A-3328. OCF₃ OCH₃ 5-OCH₃ F F A-3329. OCF₃ CN 3-F F F A-3330. OCF₃ CN 3-CH₃ F F A-3331. OCF₃ CN 3-OCH₃ F F A-3332. OCF₃ CN 5-F F F A-3333. OCF₃ CN 5-CH₃ F F A-3334. OCF₃ CN 5-OCH₃ F F A-3335. OCF₃ CH₂F 3-F F F A-3336. OCF₃ CH₂F 3-CH₃ F F A-3337. OCF₃ CH₂F 3-OCH₃ F F A-3338. OCF₃ CH₂F 5-F F F A-3339. OCF₃ CH₂F 5-CH₃ F F A-3340. OCF₃ CH₂F 5-OCH₃ F F A-3341. OCF₃ CHF₂ 3-F F F A-3342. OCF₃ CHF₂ 3-CH₃ F F A-3343. OCF₃ CHF₂ 3-OCH₃ F F A-3344. OCF₃ CHF₂ 5-F F F A-3345. OCF₃ CHF₂ 5-CH₃ F F A-3346. OCF₃ CHF₂ 5-OCH₃ F F A-3347. OCF₃ CF₃ 3-F F F A-3348. OCF₃ CF₃ 3-CH₃ F F A-3349. OCF₃ CF₃ 3-OCH₃ F F A-3350. OCF₃ CF₃ 5-F F F A-3351. OCF₃ CF₃ 5-CH₃ F F A-3352. OCF₃ CF₃ 5-OCH₃ F F A-3353. OCF₃ OCH₂F 3-F F F A-3354. OCF₃ OCH₂F 3-CH₃ F F A-3355. OCF₃ OCH₂F 3-OCH₃ F F A-3356. OCF₃ OCH₂F 5-F F F A-3357. OCF₃ OCH₂F 5-CH₃ F F A-3358. OCF₃ OCH₂F 5-OCH₃ F F A-3359. OCF₃ OCHF₂ 3-F F F A-3360. OCF₃ OCHF₂ 3-CH₃ F F A-3361. OCF₃ OCHF₂ 3-OCH₃ F F A-3362. OCF₃ OCHF₂ 5-F F F A-3363. OCF₃ OCHF₂ 5-CH₃ F F A-3364. OCF₃ OCHF₂ 5-OCH₃ F F A-3365. OCF₃ OCF₃ 3-F F F A-3366. OCF₃ OCF₃ 3-CH₃ F F A-3367. OCF₃ OCF₃ 3-OCH₃ F F A-3368. OCF₃ OCF₃ 5-F F F A-3369. OCF₃ OCF₃ 5-CH₃ F F A-3370. OCF₃ OCF₃ 5-OCH₃ F F A-3371. H H H Cl F A-3372. F H H Cl F A-3373. CH₃ H H Cl F A-3374. OCH₃ H H Cl F A-3375. CH₂F H H Cl F A-3376. CHF₂ H H Cl F A-3377. CF₃ H H Cl F A-3378. OCH₂F H H Cl F A-3379. OCHF₂ H H Cl F A-3380. OCF₃ H H Cl F A-3381. H F H Cl F A-3382. H CH₃ H Cl F A-3383. H OCH₃ H Cl F A-3384. H CN H Cl F A-3385. H CH₂F H Cl F A-3386. H CHF₂ H Cl F A-3387. H CF₃ H Cl F A-3388. H OCH₂F H Cl F A-3389. H OCHF₂ H Cl F A-3390. H OCF₃ H Cl F A-3391. H H 3-F Cl F A-3392. H H 3-CH₃ Cl F A-3393. H H 3-OCH₃ Cl F A-3394. H H 5-F Cl F A-3395. H H 5-CH₃ Cl F A-3396. H H 5-OCH₃ Cl F A-3397. F F H Cl F A-3398. F CH₃ H Cl F A-3399. F OCH₃ H Cl F A-3400. F CN H Cl F A-3401. F CH₂F H Cl F A-3402. F CHF₂ H Cl F A-3403. F CF₃ H Cl F A-3404. F OCH₂F H Cl F A-3405. F OCHF₂ H Cl F A-3406. F OCF₃ H Cl F A-3407. F H 3-F Cl F A-3408. F H 3-CH₃ Cl F A-3409. F H 3-OCH₃ Cl F A-3410. F H 5-F Cl F A-3411. F H 5-CH₃ Cl F A-3412. F H 5-OCH₃ Cl F A-3413. CH₃ F H Cl F A-3414. CH₃ CH₃ H Cl F A-3415. CH₃ OCH₃ H Cl F A-3416. CH₃ CN H Cl F A-3417. CH₃ CH₂F H Cl F A-3418. CH₃ CHF₂ H Cl F A-3419. CH₃ CF₃ H Cl F A-3420. CH₃ OCH₂F H Cl F A-3421. CH₃ OCHF₂ H Cl F A-3422. CH₃ OCF₃ H Cl F A-3423. CH₃ H 3-F Cl F A-3424. CH₃ H 3-CH₃ Cl F A-3425. CH₃ H 3-OCH₃ Cl F A-3426. CH₃ H 5-F Cl F A-3427. CH₃ H 5-CH₃ Cl F A-3428. CH₃ H 5-OCH₃ Cl F A-3429. OCH₃ F H Cl F A-3430. OCH₃ CH₃ H Cl F A-3431. OCH₃ OCH₃ H Cl F A-3432. OCH₃ CN H Cl F A-3433. OCH₃ CH₂F H Cl F A-3434. OCH₃ CHF₂ H Cl F A-3435. OCH₃ CF₃ H Cl F A-3436. OCH₃ OCH₂F H Cl F A-3437. OCH₃ OCHF₂ H Cl F A-3438. OCH₃ OCF₃ H Cl F A-3439. OCH₃ H 3-F Cl F A-3440. OCH₃ H 3-CH₃ Cl F A-3441. OCH₃ H 3-OCH₃ Cl F A-3442. OCH₃ H 5-F Cl F A-3443. OCH₃ H 5-CH₃ Cl F A-3444. OCH₃ H 5-OCH₃ Cl F A-3445. H F 3-F Cl F A-3446. H F 3-CH₃ Cl F A-3447. H F 3-OCH₃ Cl F A-3448. H F 5-F Cl F A-3449. H F 5-CH₃ Cl F A-3450. H F 5-OCH₃ Cl F A-3451. H CH₃ 3-F Cl F A-3452. H CH₃ 3-CH₃ Cl F A-3453. H CH₃ 3-OCH₃ Cl F A-3454. H CH₃ 5-F Cl F A-3455. H CH₃ 5-CH₃ Cl F A-3456. H CH₃ 5-OCH₃ Cl F A-3457. H OCH₃ 3-F Cl F A-3458. H OCH₃ 3-CH₃ Cl F A-3459. H OCH₃ 3-OCH₃ Cl F A-3460. H OCH₃ 5-F Cl F A-3461. H OCH₃ 5-CH₃ Cl F A-3462. H OCH₃ 5-OCH₃ Cl F A-3463. H CN 3-F Cl F A-3464. H CN 3-CH₃ Cl F A-3465. H CN 3-OCH₃ Cl F A-3466. H CN 5-F Cl F A-3467. H CN 5-CH₃ Cl F A-3468. H CN 5-OCH₃ Cl F A-3469. H CH₂F 3-F Cl F A-3470. H CH₂F 3-CH₃ Cl F A-3471. H CH₂F 3-OCH₃ Cl F A-3472. H CH₂F 5-F Cl F A-3473. H CH₂F 5-CH₃ Cl F A-3474. H CH₂F 5-OCH₃ Cl F A-3475. H CHF₂ 3-F Cl F A-3476. H CHF₂ 3-CH₃ Cl F A-3477. H CHF₂ 3-OCH₃ Cl F A-3478. H CHF₂ 5-F Cl F A-3479. H CHF₂ 5-CH₃ Cl F A-3480. H CHF₂ 5-OCH₃ Cl F A-3481. H CF₃ 3-F Cl F A-3482. H CF₃ 3-CH₃ Cl F A-3483. H CF₃ 3-OCH₃ Cl F A-3484. H CF₃ 5-F Cl F A-3485. H CF₃ 5-CH₃ Cl F A-3486. H CF₃ 5-OCH₃ Cl F A-3487. H OCH₂F 3-F Cl F A-3488. H OCH₂F 3-CH₃ Cl F A-3489. H OCH₂F 3-OCH₃ Cl F A-3490. H OCH₂F 5-F Cl F A-3491. H OCH₂F 5-CH₃ Cl F A-3492. H OCH₂F 5-OCH₃ Cl F A-3493. H OCHF₂ 3-F Cl F A-3494. H OCHF₂ 3-CH₃ Cl F A-3495. H OCHF₂ 3-OCH₃ Cl F A-3496. H OCHF₂ 5-F Cl F A-3497. H OCHF₂ 5-CH₃ Cl F A-3498. H OCHF₂ 5-OCH₃ Cl F A-3499. H OCF₃ 3-F Cl F A-3500. H OCF₃ 3-CH₃ Cl F A-3501. H OCF₃ 3-OCH₃ Cl F A-3502. H OCF₃ 5-F Cl F A-3503. H OCF₃ 5-CH₃ Cl F A-3504. H OCF₃ 5-OCH₃ Cl F A-3505. F F 3-F Cl F A-3506. F F 3-CH₃ Cl F A-3507. F F 3-OCH₃ Cl F A-3508. F F 5-F Cl F A-3509. F F 5-CH₃ Cl F A-3510. F F 5-OCH₃ Cl F A-3511. F CH₃ 3-F Cl F A-3512. F CH₃ 3-CH₃ Cl F A-3513. F CH₃ 3-OCH₃ Cl F A-3514. F CH₃ 5-F Cl F A-3515. F CH₃ 5-CH₃ Cl F A-3516. F CH₃ 5-OCH₃ Cl F A-3517. F OCH₃ 3-F Cl F A-3518. F OCH₃ 3-CH₃ Cl F A-3519. F OCH₃ 3-OCH₃ Cl F A-3520. F OCH₃ 5-F Cl F A-3521. F OCH₃ 5-CH₃ Cl F A-3522. F OCH₃ 5-OCH₃ Cl F A-3523. F CN 3-F Cl F A-3524. F CN 3-CH₃ Cl F A-3525. F CN 3-OCH₃ Cl F A-3526. F CN 5-F Cl F A-3527. F CN 5-CH₃ Cl F A-3528. F CN 5-OCH₃ Cl F A-3529. F CH₂F 3-F Cl F A-3530. F CH₂F 3-CH₃ Cl F A-3531. F CH₂F 3-OCH₃ Cl F A-3532. F CH₂F 5-F Cl F A-3533. F CH₂F 5-CH₃ Cl F A-3534. F CH₂F 5-OCH₃ Cl F A-3535. F CHF₂ 3-F Cl F A-3536. F CHF₂ 3-CH₃ Cl F A-3537. F CHF₂ 3-OCH₃ Cl F A-3538. F CHF₂ 5-F Cl F A-3539. F CHF₂ 5-CH₃ Cl F A-3540. F CHF₂ 5-OCH₃ Cl F A-3541. F CF₃ 3-F Cl F A-3542. F CF₃ 3-CH₃ Cl F A-3543. F CF₃ 3-OCH₃ Cl F A-3544. F CF₃ 5-F Cl F A-3545. F CF₃ 5-CH₃ Cl F A-3546. F CF₃ 5-OCH₃ Cl F A-3547. F OCH₂F 3-F Cl F A-3548. F OCH₂F 3-CH₃ Cl F A-3549. F OCH₂F 3-OCH₃ Cl F A-3550. F OCH₂F 5-F Cl F A-3551. F OCH₂F 5-CH₃ Cl F A-3552. F OCH₂F 5-OCH₃ Cl F A-3553. F OCHF₂ 3-F Cl F A-3554. F OCHF₂ 3-CH₃ Cl F A-3555. F OCHF₂ 3-OCH₃ Cl F A-3556. F OCHF₂ 5-F Cl F A-3557. F OCHF₂ 5-CH₃ Cl F A-3558. F OCHF₂ 5-OCH₃ Cl F A-3559. F OCF₃ 3-F Cl F A-3560. F OCF₃ 3-CH₃ Cl F A-3561. F OCF₃ 3-OCH₃ Cl F A-3562. F OCF₃ 5-F Cl F A-3563. F OCF₃ 5-CH₃ Cl F A-3564. F OCF₃ 5-OCH₃ Cl F A-3565. CH₃ F 3-F Cl F A-3566. CH₃ F 3-CH₃ Cl F A-3567. CH₃ F 3-OCH₃ Cl F A-3568. CH₃ F 5-F Cl F A-3569. CH₃ F 5-CH₃ Cl F A-3570. CH₃ F 5-OCH₃ Cl F A-3571. CH₃ CH₃ 3-F Cl F A-3572. CH₃ CH₃ 3-CH₃ Cl F A-3573. CH₃ CH₃ 3-OCH₃ Cl F A-3574. CH₃ CH₃ 5-F Cl F A-3575. CH₃ CH₃ 5-CH₃ Cl F A-3576. CH₃ CH₃ 5-OCH₃ Cl F A-3577. CH₃ OCH₃ 3-F Cl F A-3578. CH₃ OCH₃ 3-CH₃ Cl F A-3579. CH₃ OCH₃ 3-OCH₃ Cl F A-3580. CH₃ OCH₃ 5-F Cl F A-3581. CH₃ OCH₃ 5-CH₃ Cl F A-3582. CH₃ OCH₃ 5-OCH₃ Cl F A-3583. CH₃ CN 3-F Cl F A-3584. CH₃ CN 3-CH₃ Cl F A-3585. CH₃ CN 3-OCH₃ Cl F A-3586. CH₃ CN 5-F Cl F A-3587. CH₃ CN 5-CH₃ Cl F A-3588. CH₃ CN 5-OCH₃ Cl F A-3589. CH₃ CH₂F 3-F Cl F A-3590. CH₃ CH₂F 3-CH₃ Cl F A-3591. CH₃ CH₂F 3-OCH₃ Cl F A-3592. CH₃ CH₂F 5-F Cl F A-3593. CH₃ CH₂F 5-CH₃ Cl F A-3594. CH₃ CH₂F 5-OCH₃ Cl F A-3595. CH₃ CHF₂ 3-F Cl F A-3596. CH₃ CHF₂ 3-CH₃ Cl F A-3597. CH₃ CHF₂ 3-OCH₃ Cl F A-3598. CH₃ CHF₂ 5-F Cl F A-3599. CH₃ CHF₂ 5-CH₃ Cl F A-3600. CH₃ CHF₂ 5-OCH₃ Cl F A-3601. CH₃ CF₃ 3-F Cl F A-3602. CH₃ CF₃ 3-CH₃ Cl F A-3603. CH₃ CF₃ 3-OCH₃ Cl F A-3604. CH₃ CF₃ 5-F Cl F A-3605. CH₃ CF₃ 5-CH₃ Cl F A-3606. CH₃ CF₃ 5-OCH₃ Cl F A-3607. CH₃ OCH₂F 3-F Cl F A-3608. CH₃ OCH₂F 3-CH₃ Cl F A-3609. CH₃ OCH₂F 3-OCH₃ Cl F A-3610. CH₃ OCH₂F 5-F Cl F A-3611. CH₃ OCH₂F 5-CH₃ Cl F A-3612. CH₃ OCH₂F 5-OCH₃ Cl F A-3613. CH₃ OCHF₂ 3-F Cl F A-3614. CH₃ OCHF₂ 3-CH₃ Cl F A-3615. CH₃ OCHF₂ 3-OCH₃ Cl F A-3616. CH₃ OCHF₂ 5-F Cl F A-3617. CH₃ OCHF₂ 5-CH₃ Cl F A-3618. CH₃ OCHF₂ 5-OCH₃ Cl F A-3619. CH₃ OCF₃ 3-F Cl F A-3620. CH₃ OCF₃ 3-CH₃ Cl F A-3621. CH₃ OCF₃ 3-OCH₃ Cl F A-3622. CH₃ OCF₃ 5-F Cl F A-3623. CH₃ OCF₃ 5-CH₃ Cl F A-3624. CH₃ OCF₃ 5-OCH₃ Cl F A-3625. OCH₃ F 3-F Cl F A-3626. OCH₃ F 3-CH₃ Cl F A-3627. OCH₃ F 3-OCH₃ Cl F A-3628. OCH₃ F 5-F Cl F A-3629. OCH₃ F 5-CH₃ Cl F A-3630. OCH₃ F 5-OCH₃ Cl F A-3631. OCH₃ CH₃ 3-F Cl F A-3632. OCH₃ CH₃ 3-CH₃ Cl F A-3633. OCH₃ CH₃ 3-OCH₃ Cl F A-3634. OCH₃ CH₃ 5-F Cl F A-3635. OCH₃ CH₃ 5-CH₃ Cl F A-3636. OCH₃ CH₃ 5-OCH₃ Cl F A-3637. OCH₃ OCH₃ 3-F Cl F A-3638. OCH₃ OCH₃ 3-CH₃ Cl F A-3639. OCH₃ OCH₃ 3-OCH₃ Cl F A-3640. OCH₃ OCH₃ 5-F Cl F A-3641. OCH₃ OCH₃ 5-CH₃ Cl F A-3642. OCH₃ OCH₃ 5-OCH₃ Cl F A-3643. OCH₃ CN 3-F Cl F A-3644. OCH₃ CN 3-CH₃ Cl F A-3645. OCH₃ CN 3-OCH₃ Cl F A-3646. OCH₃ CN 5-F Cl F A-3647. OCH₃ CN 5-CH₃ Cl F A-3648. OCH₃ CN 5-OCH₃ Cl F A-3649. OCH₃ CH₂F 3-F Cl F A-3650. OCH₃ CH₂F 3-CH₃ Cl F A-3651. OCH₃ CH₂F 3-OCH₃ Cl F A-3652. OCH₃ CH₂F 5-F Cl F A-3653. OCH₃ CH₂F 5-CH₃ Cl F A-3654. OCH₃ CH₂F 5-OCH₃ Cl F A-3655. OCH₃ CHF₂ 3-F Cl F A-3656. OCH₃ CHF₂ 3-CH₃ Cl F A-3657. OCH₃ CHF₂ 3-OCH₃ Cl F A-3658. OCH₃ CHF₂ 5-F Cl F A-3659. OCH₃ CHF₂ 5-CH₃ Cl F A-3660. OCH₃ CHF₂ 5-OCH₃ Cl F A-3661. OCH₃ CF₃ 3-F Cl F A-3662. OCH₃ CF₃ 3-CH₃ Cl F A-3663. OCH₃ CF₃ 3-OCH₃ Cl F A-3664. OCH₃ CF₃ 5-F Cl F A-3665. OCH₃ CF₃ 5-CH₃ Cl F A-3666. OCH₃ CF₃ 5-OCH₃ Cl F A-3667. OCH₃ OCH₂F 3-F Cl F A-3668. OCH₃ OCH₂F 3-CH₃ Cl F A-3669. OCH₃ OCH₂F 3-OCH₃ Cl F A-3670. OCH₃ OCH₂F 5-F Cl F A-3671. OCH₃ OCH₂F 5-CH₃ Cl F A-3672. OCH₃ OCH₂F 5-OCH₃ Cl F A-3673. OCH₃ OCHF₂ 3-F Cl F A-3674. OCH₃ OCHF₂ 3-CH₃ Cl F A-3675. OCH₃ OCHF₂ 3-OCH₃ Cl F A-3676. OCH₃ OCHF₂ 5-F Cl F A-3677. OCH₃ OCHF₂ 5-CH₃ Cl F A-3678. OCH₃ OCHF₂ 5-OCH₃ Cl F A-3679. OCH₃ OCF₃ 3-F Cl F A-3680. OCH₃ OCF₃ 3-CH₃ Cl F A-3681. OCH₃ OCF₃ 3-OCH₃ Cl F A-3682. OCH₃ OCF₃ 5-F Cl F A-3683. OCH₃ OCF₃ 5-CH₃ Cl F A-3684. OCH₃ OCF₃ 5-OCH₃ Cl F A-3685. CH₂F F 3-F Cl F A-3686. CH₂F F 3-CH₃ Cl F A-3687. CH₂F F 3-OCH₃ Cl F A-3688. CH₂F F 5-F Cl F A-3689. CH₂F F 5-CH₃ Cl F A-3690. CH₂F F 5-OCH₃ Cl F A-3691. CH₂F CH₃ 3-F Cl F A-3692. CH₂F CH₃ 3-CH₃ Cl F A-3693. CH₂F CH₃ 3-OCH₃ Cl F A-3694. CH₂F CH₃ 5-F Cl F A-3695. CH₂F CH₃ 5-CH₃ Cl F A-3696. CH₂F CH₃ 5-OCH₃ Cl F A-3697. CH₂F OCH₃ 3-F Cl F A-3698. CH₂F OCH₃ 3-CH₃ Cl F A-3699. CH₂F OCH₃ 3-OCH₃ Cl F A-3700. CH₂F OCH₃ 5-F Cl F A-3701. CH₂F OCH₃ 5-CH₃ Cl F A-3702. CH₂F OCH₃ 5-OCH₃ Cl F A-3703. CH₂F CN 3-F Cl F A-3704. CH₂F CN 3-CH₃ Cl F A-3705. CH₂F CN 3-OCH₃ Cl F A-3706. CH₂F CN 5-F Cl F A-3707. CH₂F CN 5-CH₃ Cl F A-3708. CH₂F CN 5-OCH₃ Cl F A-3709. CH₂F CH₂F 3-F Cl F A-3710. CH₂F CH₂F 3-CH₃ Cl F A-3711. CH₂F CH₂F 3-OCH₃ Cl F A-3712. CH₂F CH₂F 5-F Cl F A-3713. CH₂F CH₂F 5-CH₃ Cl F A-3714. CH₂F CH₂F 5-OCH₃ Cl F A-3715. CH₂F CHF₂ 3-F Cl F A-3716. CH₂F CHF₂ 3-CH₃ Cl F A-3717. CH₂F CHF₂ 3-OCH₃ Cl F A-3718. CH₂F CHF₂ 5-F Cl F A-3719. CH₂F CHF₂ 5-CH₃ Cl F A-3720. CH₂F CHF₂ 5-OCH₃ Cl F A-3721. CH₂F CF₃ 3-F Cl F A-3722. CH₂F CF₃ 3-CH₃ Cl F A-3723. CH₂F CF₃ 3-OCH₃ Cl F A-3724. CH₂F CF₃ 5-F Cl F A-3725. CH₂F CF₃ 5-CH₃ Cl F A-3726. CH₂F CF₃ 5-OCH₃ Cl F A-3727. CH₂F OCH₂F 3-F Cl F A-3728. CH₂F OCH₂F 3-CH₃ Cl F A-3729. CH₂F OCH₂F 3-OCH₃ Cl F A-3730. CH₂F OCH₂F 5-F Cl F A-3731. CH₂F OCH₂F 5-CH₃ Cl F A-3732. CH₂F OCH₂F 5-OCH₃ Cl F A-3733. CH₂F OCHF₂ 3-F Cl F A-3734. CH₂F OCHF₂ 3-CH₃ Cl F A-3735. CH₂F OCHF₂ 3-OCH₃ Cl F A-3736. CH₂F OCHF₂ 5-F Cl F A-3737. CH₂F OCHF₂ 5-CH₃ Cl F A-3738. CH₂F OCHF₂ 5-OCH₃ Cl F A-3739. CH₂F OCF₃ 3-F Cl F A-3740. CH₂F OCF₃ 3-CH₃ Cl F A-3741. CH₂F OCF₃ 3-OCH₃ Cl F A-3742. CH₂F OCF₃ 5-F Cl F A-3743. CH₂F OCF₃ 5-CH₃ Cl F A-3744. CH₂F OCF₃ 5-OCH₃ Cl F A-3745. CHF₂ F 3-F Cl F A-3746. CHF₂ F 3-CH₃ Cl F A-3747. CHF₂ F 3-OCH₃ Cl F A-3748. CHF₂ F 5-F Cl F A-3749. CHF₂ F 5-CH₃ Cl F A-3750. CHF₂ F 5-OCH₃ Cl F A-3751. CHF₂ CH₃ 3-F Cl F A-3752. CHF₂ CH₃ 3-CH₃ Cl F A-3753. CHF₂ CH₃ 3-OCH₃ Cl F A-3754. CHF₂ CH₃ 5-F Cl F A-3755. CHF₂ CH₃ 5-CH₃ Cl F A-3756. CHF₂ CH₃ 5-OCH₃ Cl F A-3757. CHF₂ OCH₃ 3-F Cl F A-3758. CHF₂ OCH₃ 3-CH₃ Cl F A-3759. CHF₂ OCH₃ 3-OCH₃ Cl F A-3760. CHF₂ OCH₃ 5-F Cl F A-3761. CHF₂ OCH₃ 5-CH₃ Cl F A-3762. CHF₂ OCH₃ 5-OCH₃ Cl F A-3763. CHF₂ CN 3-F Cl F A-3764. CHF₂ CN 3-CH₃ Cl F A-3765. CHF₂ CN 3-OCH₃ Cl F A-3766. CHF₂ CN 5-F Cl F A-3767. CHF₂ CN 5-CH₃ Cl F A-3768. CHF₂ CN 5-OCH₃ Cl F A-3769. CHF₂ CH₂F 3-F Cl F A-3770. CHF₂ CH₂F 3-CH₃ Cl F A-3771. CHF₂ CH₂F 3-OCH₃ Cl F A-3772. CHF₂ CH₂F 5-F Cl F A-3773. CHF₂ CH₂F 5-CH₃ Cl F A-3774. CHF₂ CH₂F 5-OCH₃ Cl F A-3775. CHF₂ CHF₂ 3-F Cl F A-3776. CHF₂ CHF₂ 3-CH₃ Cl F A-3777. CHF₂ CHF₂ 3-OCH₃ Cl F A-3778. CHF₂ CHF₂ 5-F Cl F A-3779. CHF₂ CHF₂ 5-CH₃ Cl F A-3780. CHF₂ CHF₂ 5-OCH₃ Cl F A-3781. CHF₂ CF₃ 3-F Cl F A-3782. CHF₂ CF₃ 3-CH₃ Cl F A-3783. CHF₂ CF₃ 3-OCH₃ Cl F A-3784. CHF₂ CF₃ 5-F Cl F A-3785. CHF₂ CF₃ 5-CH₃ Cl F A-3786. CHF₂ CF₃ 5-OCH₃ Cl F A-3787. CHF₂ OCH₂F 3-F Cl F A-3788. CHF₂ OCH₂F 3-CH₃ Cl F A-3789. CHF₂ OCH₂F 3-OCH₃ Cl F A-3790. CHF₂ OCH₂F 5-F Cl F A-3791. CHF₂ OCH₂F 5-CH₃ Cl F A-3792. CHF₂ OCH₂F 5-OCH₃ Cl F A-3793. CHF₂ OCHF₂ 3-F Cl F A-3794. CHF₂ OCHF₂ 3-CH₃ Cl F A-3795. CHF₂ OCHF₂ 3-OCH₃ Cl F A-3796. CHF₂ OCHF₂ 5-F Cl F A-3797. CHF₂ OCHF₂ 5-CH₃ Cl F A-3798. CHF₂ OCHF₂ 5-OCH₃ Cl F A-3799. CHF₂ OCF₃ 3-F Cl F A-3800. CHF₂ OCF₃ 3-CH₃ Cl F A-3801. CHF₂ OCF₃ 3-OCH₃ Cl F A-3802. CHF₂ OCF₃ 5-F Cl F A-3803. CHF₂ OCF₃ 5-CH₃ Cl F A-3804. CHF₂ OCF₃ 5-OCH₃ Cl F A-3805. CF₃ F 3-F Cl F A-3806. CF₃ F 3-CH₃ Cl F A-3807. CF₃ F 3-OCH₃ Cl F A-3808. CF₃ F 5-F Cl F A-3809. CF₃ F 5-CH₃ Cl F A-3810. CF₃ F 5-OCH₃ Cl F A-3811. CF₃ CH₃ 3-F Cl F A-3812. CF₃ CH₃ 3-CH₃ Cl F A-3813. CF₃ CH₃ 3-OCH₃ Cl F A-3814. CF₃ CH₃ 5-F Cl F A-3815. CF₃ CH₃ 5-CH₃ Cl F A-3816. CF₃ CH₃ 5-OCH₃ Cl F A-3817. CF₃ OCH₃ 3-F Cl F A-3818. CF₃ OCH₃ 3-CH₃ Cl F A-3819. CF₃ OCH₃ 3-OCH₃ Cl F A-3820. CF₃ OCH₃ 5-F Cl F A-3821. CF₃ OCH₃ 5-CH₃ Cl F A-3822. CF₃ OCH₃ 5-OCH₃ Cl F A-3823. CF₃ CN 3-F Cl F A-3824. CF₃ CN 3-CH₃ Cl F A-3825. CF₃ CN 3-OCH₃ Cl F A-3826. CF₃ CN 5-F Cl F A-3827. CF₃ CN 5-CH₃ Cl F A-3828. CF₃ CN 5-OCH₃ Cl F A-3829. CF₃ CH₂F 3-F Cl F A-3830. CF₃ CH₂F 3-CH₃ Cl F A-3831. CF₃ CH₂F 3-OCH₃ Cl F A-3832. CF₃ CH₂F 5-F Cl F A-3833. CF₃ CH₂F 5-CH₃ Cl F A-3834. CF₃ CH₂F 5-OCH₃ Cl F A-3835. CF₃ CHF₂ 3-F Cl F A-3836. CF₃ CHF₂ 3-CH₃ Cl F A-3837. CF₃ CHF₂ 3-OCH₃ Cl F A-3838. CF₃ CHF₂ 5-F Cl F A-3839. CF₃ CHF₂ 5-CH₃ Cl F A-3840. CF₃ CHF₂ 5-OCH₃ Cl F A-3841. CF₃ CF₃ 3-F Cl F A-3842. CF₃ CF₃ 3-CH₃ Cl F A-3843. CF₃ CF₃ 3-OCH₃ Cl F A-3844. CF₃ CF₃ 5-F Cl F A-3845. CF₃ CF₃ 5-CH₃ Cl F A-3846. CF₃ CF₃ 5-OCH₃ Cl F A-3847. CF₃ OCH₂F 3-F Cl F A-3848. CF₃ OCH₂F 3-CH₃ Cl F A-3849. CF₃ OCH₂F 3-OCH₃ Cl F A-3850. CF₃ OCH₂F 5-F Cl F A-3851. CF₃ OCH₂F 5-CH₃ Cl F A-3852. CF₃ OCH₂F 5-OCH₃ Cl F A-3853. CF₃ OCHF₂ 3-F Cl F A-3854. CF₃ OCHF₂ 3-CH₃ Cl F A-3855. CF₃ OCHF₂ 3-OCH₃ Cl F A-3856. CF₃ OCHF₂ 5-F Cl F A-3857. CF₃ OCHF₂ 5-CH₃ Cl F A-3858. CF₃ OCHF₂ 5-OCH₃ Cl F A-3859. CF₃ OCF₃ 3-F Cl F A-3860. CF₃ OCF₃ 3-CH₃ Cl F A-3861. CF₃ OCF₃ 3-OCH₃ Cl F A-3862. CF₃ OCF₃ 5-F Cl F A-3863. CF₃ OCF₃ 5-CH₃ Cl F A-3864. CF₃ OCF₃ 5-OCH₃ Cl F A-3865. OCH₂F F 3-F Cl F A-3866. OCH₂F F 3-CH₃ Cl F A-3867. OCH₂F F 3-OCH₃ Cl F A-3868. OCH₂F F 5-F Cl F A-3869. OCH₂F F 5-CH₃ Cl F A-3870. OCH₂F F 5-OCH₃ Cl F A-3871. OCH₂F CH₃ 3-F Cl F A-3872. OCH₂F CH₃ 3-CH₃ Cl F A-3873. OCH₂F CH₃ 3-OCH₃ Cl F A-3874. OCH₂F CH₃ 5-F Cl F A-3875. OCH₂F CH₃ 5-CH₃ Cl F A-3876. OCH₂F CH₃ 5-OCH₃ Cl F A-3877. OCH₂F OCH₃ 3-F Cl F A-3878. OCH₂F OCH₃ 3-CH₃ Cl F A-3879. OCH₂F OCH₃ 3-OCH₃ Cl F A-3880. OCH₂F OCH₃ 5-F Cl F A-3881. OCH₂F OCH₃ 5-CH₃ Cl F A-3882. OCH₂F OCH₃ 5-OCH₃ Cl F A-3883. OCH₂F CN 3-F Cl F A-3884. OCH₂F CN 3-CH₃ Cl F A-3885. OCH₂F CN 3-OCH₃ Cl F A-3886. OCH₂F CN 5-F Cl F A-3887. OCH₂F CN 5-CH₃ Cl F A-3888. OCH₂F CN 5-OCH₃ Cl F A-3889. OCH₂F CH₂F 3-F Cl F A-3890. OCH₂F CH₂F 3-CH₃ Cl F A-3891. OCH₂F CH₂F 3-OCH₃ Cl F A-3892. OCH₂F CH₂F 5-F Cl F A-3893. OCH₂F CH₂F 5-CH₃ Cl F A-3894. OCH₂F CH₂F 5-OCH₃ Cl F A-3895. OCH₂F CHF₂ 3-F Cl F A-3896. OCH₂F CHF₂ 3-CH₃ Cl F A-3897. OCH₂F CHF₂ 3-OCH₃ Cl F A-3898. OCH₂F CHF₂ 5-F Cl F A-3899. OCH₂F CHF₂ 5-CH₃ Cl F A-3900. OCH₂F CHF₂ 5-OCH₃ Cl F A-3901. OCH₂F CF₃ 3-F Cl F A-3902. OCH₂F CF₃ 3-CH₃ Cl F A-3903. OCH₂F CF₃ 3-OCH₃ Cl F A-3904. OCH₂F CF₃ 5-F Cl F A-3905. OCH₂F CF₃ 5-CH₃ Cl F A-3906. OCH₂F CF₃ 5-OCH₃ Cl F A-3907. OCH₂F OCH₂F 3-F Cl F A-3908. OCH₂F OCH₂F 3-CH₃ Cl F A-3909. OCH₂F OCH₂F 3-OCH₃ Cl F A-3910. OCH₂F OCH₂F 5-F Cl F A-3911. OCH₂F OCH₂F 5-CH₃ Cl F A-3912. OCH₂F OCH₂F 5-OCH₃ Cl F A-3913. OCH₂F OCHF₂ 3-F Cl F A-3914. OCH₂F OCHF₂ 3-CH₃ Cl F A-3915. OCH₂F OCHF₂ 3-OCH₃ Cl F A-3916. OCH₂F OCHF₂ 5-F Cl F A-3917. OCH₂F OCHF₂ 5-CH₃ Cl F A-3918. OCH₂F OCHF₂ 5-OCH₃ Cl F A-3919. OCH₂F OCF₃ 3-F Cl F A-3920. OCH₂F OCF₃ 3-CH₃ Cl F A-3921. OCH₂F OCF₃ 3-OCH₃ Cl F A-3922. OCH₂F OCF₃ 5-F Cl F A-3923. OCH₂F OCF₃ 5-CH₃ Cl F A-3924. OCH₂F OCF₃ 5-OCH₃ Cl F A-3925. OCHF₂ F 3-F Cl F A-3926. OCHF₂ F 3-CH₃ Cl F A-3927. OCHF₂ F 3-OCH₃ Cl F A-3928. OCHF₂ F 5-F Cl F A-3929. OCHF₂ F 5-CH₃ Cl F A-3930. OCHF₂ F 5-OCH₃ Cl F A-3931. OCHF₂ CH₃ 3-F Cl F A-3932. OCHF₂ CH₃ 3-CH₃ Cl F A-3933. OCHF₂ CH₃ 3-OCH₃ Cl F A-3934. OCHF₂ CH₃ 5-F Cl F A-3935. OCHF₂ CH₃ 5-CH₃ Cl F A-3936. OCHF₂ CH₃ 5-OCH₃ Cl F A-3937. OCHF₂ OCH₃ 3-F Cl F A-3938. OCHF₂ OCH₃ 3-CH₃ Cl F A-3939. OCHF₂ OCH₃ 3-OCH₃ Cl F A-3940. OCHF₂ OCH₃ 5-F Cl F A-3941. OCHF₂ OCH₃ 5-CH₃ Cl F A-3942. OCHF₂ OCH₃ 5-OCH₃ Cl F A-3943. OCHF₂ CN 3-F Cl F A-3944. OCHF₂ CN 3-CH₃ Cl F A-3945. OCHF₂ CN 3-OCH₃ Cl F A-3946. OCHF₂ CN 5-F Cl F A-3947. OCHF₂ CN 5-CH₃ Cl F A-3948. OCHF₂ CN 5-OCH₃ Cl F A-3949. OCHF₂ CH₂F 3-F Cl F A-3950. OCHF₂ CH₂F 3-CH₃ Cl F A-3951. OCHF₂ CH₂F 3-OCH₃ Cl F A-3952. OCHF₂ CH₂F 5-F Cl F A-3953. OCHF₂ CH₂F 5-CH₃ Cl F A-3954. OCHF₂ CH₂F 5-OCH₃ Cl F A-3955. OCHF₂ CHF₂ 3-F Cl F A-3956. OCHF₂ CHF₂ 3-CH₃ Cl F A-3957. OCHF₂ CHF₂ 3-OCH₃ Cl F A-3958. OCHF₂ CHF₂ 5-F Cl F A-3959. OCHF₂ CHF₂ 5-CH₃ Cl F A-3960. OCHF₂ CHF₂ 5-OCH₃ Cl F A-3961. OCHF₂ CF₃ 3-F Cl F A-3962. OCHF₂ CF₃ 3-CH₃ Cl F A-3963. OCHF₂ CF₃ 3-OCH₃ Cl F A-3964. OCHF₂ CF₃ 5-F Cl F A-3965. OCHF₂ CF₃ 5-CH₃ Cl F A-3966. OCHF₂ CF₃ 5-OCH₃ Cl F A-3967. OCHF₂ OCH₂F 3-F Cl F A-3968. OCHF₂ OCH₂F 3-CH₃ Cl F A-3969. OCHF₂ OCH₂F 3-OCH₃ Cl F A-3970. OCHF₂ OCH₂F 5-F Cl F A-3971. OCHF₂ OCH₂F 5-CH₃ Cl F A-3972. OCHF₂ OCH₂F 5-OCH₃ Cl F A-3973. OCHF₂ OCHF₂ 3-F Cl F A-3974. OCHF₂ OCHF₂ 3-CH₃ Cl F A-3975. OCHF₂ OCHF₂ 3-OCH₃ Cl F A-3976. OCHF₂ OCHF₂ 5-F Cl F A-3977. OCHF₂ OCHF₂ 5-CH₃ Cl F A-3978. OCHF₂ OCHF₂ 5-OCH₃ Cl F A-3979. OCHF₂ OCF₃ 3-F Cl F A-3980. OCHF₂ OCF₃ 3-CH₃ Cl F A-3981. OCHF₂ OCF₃ 3-OCH₃ Cl F A-3982. OCHF₂ OCF₃ 5-F Cl F A-3983. OCHF₂ OCF₃ 5-CH₃ Cl F A-3984. OCHF₂ OCF₃ 5-OCH₃ Cl F A-3985. OCF₃ F 3-F Cl F A-3986. OCF₃ F 3-CH₃ Cl F A-3987. OCF₃ F 3-OCH₃ Cl F A-3988. OCF₃ F 5-F Cl F A-3989. OCF₃ F 5-CH₃ Cl F A-3990. OCF₃ F 5-OCH₃ Cl F A-3991. OCF₃ CH₃ 3-F Cl F A-3992. OCF₃ CH₃ 3-CH₃ Cl F A-3993. OCF₃ CH₃ 3-OCH₃ Cl F A-3994. OCF₃ CH₃ 5-F Cl F A-3995. OCF₃ CH₃ 5-CH₃ Cl F A-3996. OCF₃ CH₃ 5-OCH₃ Cl F A-3997. OCF₃ OCH₃ 3-F Cl F A-3998. OCF₃ OCH₃ 3-CH₃ Cl F A-3999. OCF₃ OCH₃ 3-OCH₃ Cl F A-4000. OCF₃ OCH₃ 5-F Cl F A-4001. OCF₃ OCH₃ 5-CH₃ Cl F A-4002. OCF₃ OCH₃ 5-OCH₃ Cl F A-4003. OCF₃ CN 3-F Cl F A-4004. OCF₃ CN 3-CH₃ Cl F A-4005. OCF₃ CN 3-OCH₃ Cl F A-4006. OCF₃ CN 5-F Cl F A-4007. OCF₃ CN 5-CH₃ Cl F A-4008. OCF₃ CN 5-OCH₃ Cl F A-4009. OCF₃ CH₂F 3-F Cl F A-4010. OCF₃ CH₂F 3-CH₃ Cl F A-4011. OCF₃ CH₂F 3-OCH₃ Cl F A-4012. OCF₃ CH₂F 5-F Cl F A-4013. OCF₃ CH₂F 5-CH₃ Cl F A-4014. OCF₃ CH₂F 5-OCH₃ Cl F A-4015. OCF₃ CHF₂ 3-F Cl F A-4016. OCF₃ CHF₂ 3-CH₃ Cl F A-4017. OCF₃ CHF₂ 3-OCH₃ Cl F A-4018. OCF₃ CHF₂ 5-F Cl F A-4019. OCF₃ CHF₂ 5-CH₃ Cl F A-4020. OCF₃ CHF₂ 5-OCH₃ Cl F A-4021. OCF₃ CF₃ 3-F Cl F A-4022. OCF₃ CF₃ 3-CH₃ Cl F A-4023. OCF₃ CF₃ 3-OCH₃ Cl F A-4024. OCF₃ CF₃ 5-F Cl F A-4025. OCF₃ CF₃ 5-CH₃ Cl F A-4026. OCF₃ CF₃ 5-OCH₃ Cl F A-4027. OCF₃ OCH₂F 3-F Cl F A-4028. OCF₃ OCH₂F 3-CH₃ Cl F A-4029. OCF₃ OCH₂F 3-OCH₃ Cl F A-4030. OCF₃ OCH₂F 5-F Cl F A-4031. OCF₃ OCH₂F 5-CH₃ Cl F A-4032. OCF₃ OCH₂F 5-OCH₃ Cl F A-4033. OCF₃ OCHF₂ 3-F Cl F A-4034. OCF₃ OCHF₂ 3-CH₃ Cl F A-4035. OCF₃ OCHF₂ 3-OCH₃ Cl F A-4036. OCF₃ OCHF₂ 5-F Cl F A-4037. OCF₃ OCHF₂ 5-CH₃ Cl F A-4038. OCF₃ OCHF₂ 5-OCH₃ Cl F A-4039. OCF₃ OCF₃ 3-F Cl F A-4040. OCF₃ OCF₃ 3-CH₃ Cl F A-4041. OCF₃ OCF₃ 3-OCH₃ Cl F A-4042. OCF₃ OCF₃ 5-F Cl F A-4043. OCF₃ OCF₃ 5-CH₃ Cl F A-4044. OCF₃ OCF₃ 5-OCH₃ Cl F

TABLE B Example No. R² R³ R⁶ R⁷ B-1. H H CN H B-2. F H CN H B-3. CH₃ H CN H B-4. OCH₃ H CN H B-5. CN H CN H B-6. CH₂F H CN H B-7. CHF₂ H CN H B-8. CF₃ H CN H B-9. OCH₂F H CN H B-10. OCHF₂ H CN H B-11. OCF₃ H CN H B-12. H 3-F CN H B-13. H 3-CH₃ CN H B-14. H 3-OCH₃ CN H B-15. H 5-F CN H B-16. H 5-CH₃ CN H B-17. H 5-OCH₃ CN H B-18. H 6-F CN H B-19. H 6-CH₃ CN H B-20. H 6-OCH₃ CN H B-21. F 3-F CN H B-22. F 3-CH₃ CN H B-23. F 3-OCH₃ CN H B-24. F 5-F CN H B-25. F 5-CH₃ CN H B-26. F 5-OCH₃ CN H B-27. F 6-F CN H B-28. F 6-CH₃ CN H B-29. F 6-OCH₃ CN H B-30. CH₃ 3-F CN H B-31. CH₃ 3-CH₃ CN H B-32. CH₃ 3-OCH₃ CN H B-33. CH₃ 5-F CN H B-34. CH₃ 5-CH₃ CN H B-35. CH₃ 5-OCH₃ CN H B-36. CH₃ 6-F CN H B-37. CH₃ 6-CH₃ CN H B-38. CH₃ 6-OCH₃ CN H B-39. OCH₃ 3-F CN H B-40. OCH₃ 3-CH₃ CN H B-41. OCH₃ 3-OCH₃ CN H B-42. OCH₃ 5-F CN H B-43. OCH₃ 5-CH₃ CN H B-44. OCH₃ 5-OCH₃ CN H B-45. OCH₃ 6-F CN H B-46. OCH₃ 6-CH₃ CN H B-47. OCH₃ 6-OCH₃ CN H B-48. CN 3-F CN H B-49. CN 3-CH₃ CN H B-50. CN 3-OCH₃ CN H B-51. CN 5-F CN H B-52. CN 5-CH₃ CN H B-53. CN 5-OCH₃ CN H B-54. CN 6-F CN H B-55. CN 6-CH₃ CN H B-56. CN 6-OCH₃ CN H B-57. CH₂F 3-F CN H B-58. CH₂F 3-CH₃ CN H B-59. CH₂F 3-OCH₃ CN H B-60. CH₂F 5-F CN H B-61. CH₂F 5-CH₃ CN H B-62. CH₂F 5-OCH₃ CN H B-63. CH₂F 6-F CN H B-64. CH₂F 6-CH₃ CN H B-65. CH₂F 6-OCH₃ CN H B-66. CHF₂ 3-F CN H B-67. CHF₂ 3-CH₃ CN H B-68. CHF₂ 3-OCH₃ CN H B-69. CHF₂ 5-F CN H B-70. CHF₂ 5-CH₃ CN H B-71. CHF₂ 5-OCH₃ CN H B-72. CHF₂ 6-F CN H B-73. CHF₂ 6-CH₃ CN H B-74. CHF₂ 6-OCH₃ CN H B-75. CF₃ 3-F CN H B-76. CF₃ 3-CH₃ CN H B-77. CF₃ 3-OCH₃ CN H B-78. CF₃ 5-F CN H B-79. CF₃ 5-CH₃ CN H B-80. CF₃ 5-OCH₃ CN H B-81. CF₃ 6-F CN H B-82. CF₃ 6-CH₃ CN H B-83. CF₃ 6-OCH₃ CN H B-84. OCH₂F 3-F CN H B-85. OCH₂F 3-CH₃ CN H B-86. OCH₂F 3-OCH₃ CN H B-87. OCH₂F 5-F CN H B-88. OCH₂F 5-CH₃ CN H B-89. OCH₂F 5-OCH₃ CN H B-90. OCH₂F 6-F CN H B-91. OCH₂F 6-CH₃ CN H B-92. OCH₂F 6-OCH₃ CN H B-93. OCHF₂ 3-F CN H B-94. OCHF₂ 3-CH₃ CN H B-95. OCHF₂ 3-OCH₃ CN H B-96. OCHF₂ 5-F CN H B-97. OCHF₂ 5-CH₃ CN H B-98. OCHF₂ 5-OCH₃ CN H B-99. OCHF₂ 6-F CN H B-100. OCHF₂ 6-CH₃ CN H B-101. OCHF₂ 6-OCH₃ CN H B-102. OCF₃ 3-F CN H B-103. OCF₃ 3-CH₃ CN H B-104. OCF₃ 3-OCH₃ CN H B-105. OCF₃ 5-F CN H B-106. OCF₃ 5-CH₃ CN H B-107. OCF₃ 5-OCH₃ CN H B-108. OCF₃ 6-F CN H B-109. OCF₃ 6-CH₃ CN H B-110. OCF₃ 6-OCH₃ CN H B-111. H H F H B-112. F H F H B-113. CH₃ H F H B-114. OCH₃ H F H B-115. CN H F H B-116. CH₂F H F H B-117. CHF₂ H F H B-118. CF₃ H F H B-119. OCH₂F H F H B-120. OCHF₂ H F H B-121. OCF₃ H F H B-122. H 3-F F H B-123. H 3-CH₃ F H B-124. H 3-OCH₃ F H B-125. H 5-F F H B-126. H 5-CH₃ F H B-127. H 5-OCH₃ F H B-128. H 6-F F H B-129. H 6-CH₃ F H B-130. H 6-OCH₃ F H B-131. F 3-F F H B-132. F 3-CH₃ F H B-133. F 3-OCH₃ F H B-134. F 5-F F H B-135. F 5-CH₃ F H B-136. F 5-OCH₃ F H B-137. F 6-F F H B-138. F 6-CH₃ F H B-139. F 6-OCH₃ F H B-140. CH₃ 3-F F H B-141. CH₃ 3-CH₃ F H B-142. CH₃ 3-OCH₃ F H B-143. CH₃ 5-F F H B-144. CH₃ 5-CH₃ F H B-145. CH₃ 5-OCH₃ F H B-146. CH₃ 6-F F H B-147. CH₃ 6-CH₃ F H B-148. CH₃ 6-OCH₃ F H B-149. OCH₃ 3-F F H B-150. OCH₃ 3-CH₃ F H B-151. OCH₃ 3-OCH₃ F H B-152. OCH₃ 5-F F H B-153. OCH₃ 5-CH₃ F H B-154. OCH₃ 5-OCH₃ F H B-155. OCH₃ 6-F F H B-156. OCH₃ 6-CH₃ F H B-157. OCH₃ 6-OCH₃ F H B-158. CN 3-F F H B-159. CN 3-CH₃ F H B-160. CN 3-OCH₃ F H B-161. CN 5-F F H B-162. CN 5-CH₃ F H B-163. CN 5-OCH₃ F H B-164. CN 6-F F H B-165. CN 6-CH₃ F H B-166. CN 6-OCH₃ F H B-167. CH₂F 3-F F H B-168. CH₂F 3-CH₃ F H B-169. CH₂F 3-OCH₃ F H B-170. CH₂F 5-F F H B-171. CH₂F 5-CH₃ F H B-172. CH₂F 5-OCH₃ F H B-173. CH₂F 6-F F H B-174. CH₂F 6-CH₃ F H B-175. CH₂F 6-OCH₃ F H B-176. CHF₂ 3-F F H B-177. CHF₂ 3-CH₃ F H B-178. CHF₂ 3-OCH₃ F H B-179. CHF₂ 5-F F H B-180. CHF₂ 5-CH₃ F H B-181. CHF₂ 5-OCH₃ F H B-182. CHF₂ 6-F F H B-183. CHF₂ 6-CH₃ F H B-184. CHF₂ 6-OCH₃ F H B-185. CF₃ 3-F F H B-186. CF₃ 3-CH₃ F H B-187. CF₃ 3-OCH₃ F H B-188. CF₃ 5-F F H B-189. CF₃ 5-CH₃ F H B-190. CF₃ 5-OCH₃ F H B-191. CF₃ 6-F F H B-192. CF₃ 6-CH₃ F H B-193. CF₃ 6-OCH₃ F H B-194. OCH₂F 3-F F H B-195. OCH₂F 3-CH₃ F H B-196. OCH₂F 3-OCH₃ F H B-197. OCH₂F 5-F F H B-198. OCH₂F 5-CH₃ F H B-199. OCH₂F 5-OCH₃ F H B-200. OCH₂F 6-F F H B-201. OCH₂F 6-CH₃ F H B-202. OCH₂F 6-OCH₃ F H B-203. OCHF₂ 3-F F H B-204. OCHF₂ 3-CH₃ F H B-205. OCHF₂ 3-OCH₃ F H B-206. OCHF₂ 5-F F H B-207. OCHF₂ 5-CH₃ F H B-208. OCHF₂ 5-OCH₃ F H B-209. OCHF₂ 6-F F H B-210. OCHF₂ 6-CH₃ F H B-211. OCHF₂ 6-OCH₃ F H B-212. OCF₃ 3-F F H B-213. OCF₃ 3-CH₃ F H B-214. OCF₃ 3-OCH₃ F H B-215. OCF₃ 5-F F H B-216. OCF₃ 5-CH₃ F H B-217. OCF₃ 5-OCH₃ F H B-218. OCF₃ 6-F F H B-219. OCF₃ 6-CH₃ F H B-220. OCF₃ 6-OCH₃ F H B-221. H H Cl H B-222. F H Cl H B-223. CH₃ H Cl H B-224. OCH₃ H Cl H B-225. CN H Cl H B-226. CH₂F H Cl H B-227. CHF₂ H Cl H B-228. CF₃ H Cl H B-229. OCH₂F H Cl H B-230. OCHF₂ H Cl H B-231. OCF₃ H Cl H B-232. H 3-F Cl H B-233. H 3-CH₃ Cl H B-234. H 3-OCH₃ Cl H B-235. H 5-F Cl H B-236. H 5-CH₃ Cl H B-237. H 5-OCH₃ Cl H B-238. H 6-F Cl H B-239. H 6-CH₃ Cl H B-240. H 6-OCH₃ Cl H B-241. F 3-F Cl H B-242. F 3-CH₃ Cl H B-243. F 3-OCH₃ Cl H B-244. F 5-F Cl H B-245. F 5-CH₃ Cl H B-246. F 5-OCH₃ Cl H B-247. F 6-F Cl H B-248. F 6-CH₃ Cl H B-249. F 6-OCH₃ Cl H B-250. CH₃ 3-F Cl H B-251. CH₃ 3-CH₃ Cl H B-252. CH₃ 3-OCH₃ Cl H B-253. CH₃ 5-F Cl H B-254. CH₃ 5-CH₃ Cl H B-255. CH₃ 5-OCH₃ Cl H B-256. CH₃ 6-F Cl H B-257. CH₃ 6-CH₃ Cl H B-258. CH₃ 6-OCH₃ Cl H B-259. OCH₃ 3-F Cl H B-260. OCH₃ 3-CH₃ Cl H B-261. OCH₃ 3-OCH₃ Cl H B-262. OCH₃ 5-F Cl H B-263. OCH₃ 5-CH₃ Cl H B-264. OCH₃ 5-OCH₃ Cl H B-265. OCH₃ 6-F Cl H B-266. OCH₃ 6-CH₃ Cl H B-267. OCH₃ 6-OCH₃ Cl H B-268. CN 3-F Cl H B-269. CN 3-CH₃ Cl H B-270. CN 3-OCH₃ Cl H B-271. CN 5-F Cl H B-272. CN 5-CH₃ Cl H B-273. CN 5-OCH₃ Cl H B-274. CN 6-F Cl H B-275. CN 6-CH₃ Cl H B-276. CN 6-OCH₃ Cl H B-277. CH₂F 3-F Cl H B-278. CH₂F 3-CH₃ Cl H B-279. CH₂F 3-OCH₃ Cl H B-280. CH₂F 5-F Cl H B-281. CH₂F 5-CH₃ Cl H B-282. CH₂F 5-OCH₃ Cl H B-283. CH₂F 6-F Cl H B-284. CH₂F 6-CH₃ Cl H B-285. CH₂F 6-OCH₃ Cl H B-286. CHF₂ 3-F Cl H B-287. CHF₂ 3-CH₃ Cl H B-288. CHF₂ 3-OCH₃ Cl H B-289. CHF₂ 5-F Cl H B-290. CHF₂ 5-CH₃ Cl H B-291. CHF₂ 5-OCH₃ Cl H B-292. CHF₂ 6-F Cl H B-293. CHF₂ 6-CH₃ Cl H B-294. CHF₂ 6-OCH₃ Cl H B-295. CF₃ 3-F Cl H B-296. CF₃ 3-CH₃ Cl H B-297. CF₃ 3-OCH₃ Cl H B-298. CF₃ 5-F Cl H B-299. CF₃ 5-CH₃ Cl H B-300. CF₃ 5-OCH₃ Cl H B-301. CF₃ 6-F Cl H B-302. CF₃ 6-CH₃ Cl H B-303. CF₃ 6-OCH₃ Cl H B-304. OCH₂F 3-F Cl H B-305. OCH₂F 3-CH₃ Cl H B-306. OCH₂F 3-OCH₃ Cl H B-307. OCH₂F 5-F Cl H B-308. OCH₂F 5-CH₃ Cl H B-309. OCH₂F 5-OCH₃ Cl H B-310. OCH₂F 6-F Cl H B-311. OCH₂F 6-CH₃ Cl H B-312. OCH₂F 6-OCH₃ Cl H B-313. OCHF₂ 3-F Cl H B-314. OCHF₂ 3-CH₃ Cl H B-315. OCHF₂ 3-OCH₃ Cl H B-316. OCHF₂ 5-F Cl H B-317. OCHF₂ 5-CH₃ Cl H B-318. OCHF₂ 5-OCH₃ Cl H B-319. OCHF₂ 6-F Cl H B-320. OCHF₂ 6-CH₃ Cl H B-321. OCHF₂ 6-OCH₃ Cl H B-322. OCF₃ 3-F Cl H B-323. OCF₃ 3-CH₃ Cl H B-324. OCF₃ 3-OCH₃ Cl H B-325. OCF₃ 5-F Cl H B-326. OCF₃ 5-CH₃ Cl H B-327. OCF₃ 5-OCH₃ Cl H B-328. OCF₃ 6-F Cl H B-329. OCF₃ 6-CH₃ Cl H B-330. OCF₃ 6-OCH₃ Cl H B-331. H H CN F B-332. F H CN F B-333. CH₃ H CN F B-334. OCH₃ H CN F B-335. CN H CN F B-336. CH₂F H CN F B-337. CHF₂ H CN F B-338. CF₃ H CN F B-339. OCH₂F H CN F B-340. OCHF₂ H CN F B-341. OCF₃ H CN F B-342. H 3-F CN F B-343. H 3-CH₃ CN F B-344. H 3-OCH₃ CN F B-345. H 5-F CN F B-346. H 5-CH₃ CN F B-347. H 5-OCH₃ CN F B-348. H 6-F CN F B-349. H 6-CH₃ CN F B-350. H 6-OCH₃ CN F B-351. F 3-F CN F B-352. F 3-CH₃ CN F B-353. F 3-OCH₃ CN F B-354. F 5-F CN F B-355. F 5-CH₃ CN F B-356. F 5-OCH₃ CN F B-357. F 6-F CN F B-358. F 6-CH₃ CN F B-359. F 6-OCH₃ CN F B-360. CH₃ 3-F CN F B-361. CH₃ 3-CH₃ CN F B-362. CH₃ 3-OCH₃ CN F B-363. CH₃ 5-F CN F B-364. CH₃ 5-CH₃ CN F B-365. CH₃ 5-OCH₃ CN F B-366. CH₃ 6-F CN F B-367. CH₃ 6-CH₃ CN F B-368. CH₃ 6-OCH₃ CN F B-369. OCH₃ 3-F CN F B-370. OCH₃ 3-CH₃ CN F B-371. OCH₃ 3-OCH₃ CN F B-372. OCH₃ 5-F CN F B-373. OCH₃ 5-CH₃ CN F B-374. OCH₃ 5-OCH₃ CN F B-375. OCH₃ 6-F CN F B-376. OCH₃ 6-CH₃ CN F B-377. OCH₃ 6-OCH₃ CN F B-378. CN 3-F CN F B-379. CN 3-CH₃ CN F B-380. CN 3-OCH₃ CN F B-381. CN 5-F CN F B-382. CN 5-CH₃ CN F B-383. CN 5-OCH₃ CN F B-384. CN 6-F CN F B-385. CN 6-CH₃ CN F B-386. CN 6-OCH₃ CN F B-387. CH₂F 3-F CN F B-388. CH₂F 3-CH₃ CN F B-389. CH₂F 3-OCH₃ CN F B-390. CH₂F 5-F CN F B-391. CH₂F 5-CH₃ CN F B-392. CH₂F 5-OCH₃ CN F B-393. CH₂F 6-F CN F B-394. CH₂F 6-CH₃ CN F B-395. CH₂F 6-OCH₃ CN F B-396. CHF₂ 3-F CN F B-397. CHF₂ 3-CH₃ CN F B-398. CHF₂ 3-OCH₃ CN F B-399. CHF₂ 5-F CN F B-400. CHF₂ 5-CH₃ CN F B-401. CHF₂ 5-OCH₃ CN F B-402. CHF₂ 6-F CN F B-403. CHF₂ 6-CH₃ CN F B-404. CHF₂ 6-OCH₃ CN F B-405. CF₃ 3-F CN F B-406. CF₃ 3-CH₃ CN F B-407. CF₃ 3-OCH₃ CN F B-408. CF₃ 5-F CN F B-409. CF₃ 5-CH₃ CN F B-410. CF₃ 5-OCH₃ CN F B-411. CF₃ 6-F CN F B-412. CF₃ 6-CH₃ CN F B-413. CF₃ 6-OCH₃ CN F B-414. OCH₂F 3-F CN F B-415. OCH₂F 3-CH₃ CN F B-416. OCH₂F 3-OCH₃ CN F B-417. OCH₂F 5-F CN F B-418. OCH₂F 5-CH₃ CN F B-419. OCH₂F 5-OCH₃ CN F B-420. OCH₂F 6-F CN F B-421. OCH₂F 6-CH₃ CN F B-422. OCH₂F 6-OCH₃ CN F B-423. OCHF₂ 3-F CN F B-424. OCHF₂ 3-CH₃ CN F B-425. OCHF₂ 3-OCH₃ CN F B-426. OCHF₂ 5-F CN F B-427. OCHF₂ 5-CH₃ CN F B-428. OCHF₂ 5-OCH₃ CN F B-429. OCHF₂ 6-F CN F B-430. OCHF₂ 6-CH₃ CN F B-431. OCHF₂ 6-OCH₃ CN F B-432. OCF₃ 3-F CN F B-433. OCF₃ 3-CH₃ CN F B-434. OCF₃ 3-OCH₃ CN F B-435. OCF₃ 5-F CN F B-436. OCF₃ 5-CH₃ CN F B-437. OCF₃ 5-OCH₃ CN F B-438. OCF₃ 6-F CN F B-439. OCF₃ 6-CH₃ CN F B-440. OCF₃ 6-OCH₃ CN F B-441. H H F F B-442. F H F F B-443. CH₃ H F F B-444. OCH₃ H F F B-445. CN H F F B-446. CH₂F H F F B-447. CHF₂ H F F B-448. CF₃ H F F B-449. OCH₂F H F F B-450. OCHF₂ H F F B-451. OCF₃ H F F B-452. H 3-F F F B-453. H 3-CH₃ F F B-454. H 3-OCH₃ F F B-455. H 5-F F F B-456. H 5-CH₃ F F B-457. H 5-OCH₃ F F B-458. H 6-F F F B-459. H 6-CH₃ F F B-460. H 6-OCH₃ F F B-461. F 3-F F F B-462. F 3-CH₃ F F B-463. F 3-OCH₃ F F B-464. F 5-F F F B-465. F 5-CH₃ F F B-466. F 5-OCH₃ F F B-467. F 6-F F F B-468. F 6-CH₃ F F B-469. F 6-OCH₃ F F B-470. CH₃ 3-F F F B-471. CH₃ 3-CH₃ F F B-472. CH₃ 3-OCH₃ F F B-473. CH₃ 5-F F F B-474. CH₃ 5-CH₃ F F B-475. CH₃ 5-OCH₃ F F B-476. CH₃ 6-F F F B-477. CH₃ 6-CH₃ F F B-478. CH₃ 6-OCH₃ F F B-479. OCH₃ 3-F F F B-480. OCH₃ 3-CH₃ F F B-481. OCH₃ 3-OCH₃ F F B-482. OCH₃ 5-F F F B-483. OCH₃ 5-CH₃ F F B-484. OCH₃ 5-OCH₃ F F B-485. OCH₃ 6-F F F B-486. OCH₃ 6-CH₃ F F B-487. OCH₃ 6-OCH₃ F F B-488. CN 3-F F F B-489. CN 3-CH₃ F F B-490. CN 3-OCH₃ F F B-491. CN 5-F F F B-492. CN 5-CH₃ F F B-493. CN 5-OCH₃ F F B-494. CN 6-F F F B-495. CN 6-CH₃ F F B-496. CN 6-OCH₃ F F B-497. CH₂F 3-F F F B-498. CH₂F 3-CH₃ F F B-499. CH₂F 3-OCH₃ F F B-500. CH₂F 5-F F F B-501. CH₂F 5-CH₃ F F B-502. CH₂F 5-OCH₃ F F B-503. CH₂F 6-F F F B-504. CH₂F 6-CH₃ F F B-505. CH₂F 6-OCH₃ F F B-506. CHF₂ 3-F F F B-507. CHF₂ 3-CH₃ F F B-508. CHF₂ 3-OCH₃ F F B-509. CHF₂ 5-F F F B-510. CHF₂ 5-CH₃ F F B-511. CHF₂ 5-OCH₃ F F B-512. CHF₂ 6-F F F B-513. CHF₂ 6-CH₃ F F B-514. CHF₂ 6-OCH₃ F F B-515. CF₃ 3-F F F B-516. CF₃ 3-CH₃ F F B-517. CF₃ 3-OCH₃ F F B-518. CF₃ 5-F F F B-519. CF₃ 5-CH₃ F F B-520. CF₃ 5-OCH₃ F F B-521. CF₃ 6-F F F B-522. CF₃ 6-CH₃ F F B-523. CF₃ 6-OCH₃ F F B-524. OCH₂F 3-F F F B-525. OCH₂F 3-CH₃ F F B-526. OCH₂F 3-OCH₃ F F B-527. OCH₂F 5-F F F B-528. OCH₂F 5-CH₃ F F B-529. OCH₂F 5-OCH₃ F F B-530. OCH₂F 6-F F F B-531. OCH₂F 6-CH₃ F F B-532. OCH₂F 6-OCH₃ F F B-533. OCHF₂ 3-F F F B-534. OCHF₂ 3-CH₃ F F B-535. OCHF₂ 3-OCH₃ F F B-536. OCHF₂ 5-F F F B-537. OCHF₂ 5-CH₃ F F B-538. OCHF₂ 5-OCH₃ F F B-539. OCHF₂ 6-F F F B-540. OCHF₂ 6-CH₃ F F B-541. OCHF₂ 6-OCH₃ F F B-542. OCF₃ 3-F F F B-543. OCF₃ 3-CH₃ F F B-544. OCF₃ 3-OCH₃ F F B-545. OCF₃ 5-F F F B-546. OCF₃ 5-CH₃ F F B-547. OCF₃ 5-OCH₃ F F B-548. OCF₃ 6-F F F B-549. OCF₃ 6-CH₃ F F B-550. OCF₃ 6-OCH₃ F F B-551. H H Cl F B-552. F H Cl F B-553. CH₃ H Cl F B-554. OCH₃ H Cl F B-555. CN H Cl F B-556. CH₂F H Cl F B-557. CHF₂ H Cl F B-558. CF₃ H Cl F B-559. OCH₂F H Cl F B-560. OCHF₂ H Cl F B-561. OCF₃ H Cl F B-562. H 3-F Cl F B-563. H 3-CH₃ Cl F B-564. H 3-OCH₃ Cl F B-565. H 5-F Cl F B-566. H 5-CH₃ Cl F B-567. H 5-OCH₃ Cl F B-568. H 6-F Cl F B-569. H 6-CH₃ Cl F B-570. H 6-OCH₃ Cl F B-571. F 3-F Cl F B-572. F 3-CH₃ Cl F B-573. F 3-OCH₃ Cl F B-574. F 5-F Cl F B-575. F 5-CH₃ Cl F B-576. F 5-OCH₃ Cl F B-577. F 6-F Cl F B-578. F 6-CH₃ Cl F B-579. F 6-OCH₃ Cl F B-580. CH₃ 3-F Cl F B-581. CH₃ 3-CH₃ Cl F B-582. CH₃ 3-OCH₃ Cl F B-583. CH₃ 5-F Cl F B-584. CH₃ 5-CH₃ Cl F B-585. CH₃ 5-OCH₃ Cl F B-586. CH₃ 6-F Cl F B-587. CH₃ 6-CH₃ Cl F B-588. CH₃ 6-OCH₃ Cl F B-589. OCH₃ 3-F Cl F B-590. OCH₃ 3-CH₃ Cl F B-591. OCH₃ 3-OCH₃ Cl F B-592. OCH₃ 5-F Cl F B-593. OCH₃ 5-CH₃ Cl F B-594. OCH₃ 5-OCH₃ Cl F B-595. OCH₃ 6-F Cl F B-596. OCH₃ 6-CH₃ Cl F B-597. OCH₃ 6-OCH₃ Cl F B-598. CN 3-F Cl F B-599. CN 3-CH₃ Cl F B-600. CN 3-OCH₃ Cl F B-601. CN 5-F Cl F B-602. CN 5-CH₃ Cl F B-603. CN 5-OCH₃ Cl F B-604. CN 6-F Cl F B-605. CN 6-CH₃ Cl F B-606. CN 6-OCH₃ Cl F B-607. CH₂F 3-F Cl F B-608. CH₂F 3-CH₃ Cl F B-609. CH₂F 3-OCH₃ Cl F B-610. CH₂F 5-F Cl F B-611. CH₂F 5-CH₃ Cl F B-612. CH₂F 5-OCH₃ Cl F B-613. CH₂F 6-F Cl F B-614. CH₂F 6-CH₃ Cl F B-615. CH₂F 6-OCH₃ Cl F B-616. CHF₂ 3-F Cl F B-617. CHF₂ 3-CH₃ Cl F B-618. CHF₂ 3-OCH₃ Cl F B-619. CHF₂ 5-F Cl F B-620. CHF₂ 5-CH₃ Cl F B-621. CHF₂ 5-OCH₃ Cl F B-622. CHF₂ 6-F Cl F B-623. CHF₂ 6-CH₃ Cl F B-624. CHF₂ 6-OCH₃ Cl F B-625. CF₃ 3-F Cl F B-626. CF₃ 3-CH₃ Cl F B-627. CF₃ 3-OCH₃ Cl F B-628. CF₃ 5-F Cl F B-629. CF₃ 5-CH₃ Cl F B-630. CF₃ 5-OCH₃ Cl F B-631. CF₃ 6-F Cl F B-632. CF₃ 6-CH₃ Cl F B-633. CF₃ 6-OCH₃ Cl F B-634. OCH₂F 3-F Cl F B-635. OCH₂F 3-CH₃ Cl F B-636. OCH₂F 3-OCH₃ Cl F B-637. OCH₂F 5-F Cl F B-638. OCH₂F 5-CH₃ Cl F B-639. OCH₂F 5-OCH₃ Cl F B-640. OCH₂F 6-F Cl F B-641. OCH₂F 6-CH₃ Cl F B-642. OCH₂F 6-OCH₃ Cl F B-643. OCHF₂ 3-F Cl F B-644. OCHF₂ 3-CH₃ Cl F B-645. OCHF₂ 3-OCH₃ Cl F B-646. OCHF₂ 5-F Cl F B-647. OCHF₂ 5-CH₃ Cl F B-648. OCHF₂ 5-OCH₃ Cl F B-649. OCHF₂ 6-F Cl F B-650. OCHF₂ 6-CH₃ Cl F B-651. OCHF₂ 6-OCH₃ Cl F B-652. OCF₃ 3-F Cl F B-653. OCF₃ 3-CH₃ Cl F B-654. OCF₃ 3-OCH₃ Cl F B-655. OCF₃ 5-F Cl F B-656. OCF₃ 5-CH₃ Cl F B-657. OCF₃ 5-OCH₃ Cl F B-658. OCF₃ 6-F Cl F B-659. OCF₃ 6-CH₃ Cl F B-660. OCF₃ 6-OCH₃ Cl F

The positions (e.g. 3-/5-/6-) of R³ are relative to the 2- and 4-positions of radicals R¹ and R² and to the 1-position of the attachment point of the ring to the SO₂ group.

The preferred compounds among the compounds I.1 to I.40 mentioned above are those of the formulae I.1, I.6, I.11, I.16, I.21, I.26, I.31 and I.36, and especially compounds of the formulae I.1, I.6, I.16 and I.21. Particularly preferred are compounds of the formulae I.1 and I.6.

In a specific embodiment, the compounds I are selected from the compounds specified in the examples, either as a free base or in form of a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof or as their racemate or any other mixture of their steroisomers.

The compounds I of the invention have a center of chirality in position 3 of the 2-oxindole ring. The compounds of the invention may therefore be in the form of a 1:1 mixture of enantiomers (racemate) or of a nonracemic mixture of enantiomers in which one of the two enantiomers, either the enantiomer which rotates the plane of vibration of linearly polarized light to the left (i.e. minus rotation) (hereinafter (−) enantiomer) or the enantiomer which rotates the plane of vibration of linearly polarized light to the right (i.e. plus rotation) (hereinafter (+) enantiomer), is enriched, or of substantially enantiopure compounds, that is to say of substantially enantiopure (−) enantiomer or (+) enantiomer. Since the compounds of the invention have a single center of asymmetry and no axis/plane of chirality, a nonracemic mixture can also be defined as a mixture of enantiomers in which either the R or the S enantiomer predominates. Substantially enantiopure compounds can accordingly also be defined as substantially enantiopure R enantiomer or substantially enantiopure S enantiomer.

“Substantially enantiopure compounds” means in the context of the present invention those compounds having an enantiomeric excess (ee; % ee=(R−S)/(R+S)×100 or (S−R)/(S+R)×100) of at least 80% ee, preferably at least 85% ee, more preferably at least 90% ee, even more preferably at least 95% ee and in particular at least 98% ee.

In one embodiment of the invention, the compounds of the invention are in the form of substantially enantiopure compounds. Particularly preferred compounds have an enantiomeric excess of at least 85% ee, more preferably of at least 90% ee, even more preferably of at least 95% ee and in particular of at least 98% ee.

The invention thus relates both to the pure enantiomers and to mixtures thereof, e.g. mixtures in which one enantiomer is present in enriched form, but also to the racemates. The invention also relates to the pharmaceutically acceptable salts of the pure enantiomers of compounds I, and the mixtures of enantiomers in the form of the pharmaceutically acceptable salts of compounds I.

Preferred embodiments of the invention are compounds of the formula I as detailed above which are characterized in that they are in optically active form, and the enantiomer of the relevant compound of the formula I is the S-enantiomner, in the form of a free base, or a pharmaceutically acceptable salt thereof.

Particularly preference is given to compounds of the general formula I and their pharmaceutically acceptable salts as detailed above in which the corresponding S-enantiomer is present in an optical purity (enantiomeric excess, ee) of more than 50% ee, particularly preferably of at least 80% ee, more preferably of at least 90% ee and even more preferably of at least 95% ee and in particular of at least 98% ee.

Likewise preferred embodiments of the invention are compounds of the general formula I as detailed above which are characterized in that they are in optically inactive form, i.e. in the form of the racemate, or in the form of a pharmaceutically acceptable salt of the racemate.

Examples of synthetic routes for preparing the oxindole derivatives of the invention are described below.

The compounds of the invention can be prepared by using methods described in WO 2005/030755, WO 2006/005609 and the other references mentioned in the outset for synthesizing analogous compounds, and the preparation is outlined by way of example in the below synthesis schemes. The variables in these synthetic schemes have the same meanings as in formula I.

As shown in scheme 1, 3-hydroxy-1,3-dihydroindol-2-ones IV can be obtained by addition of metallated heterocycles III onto the 3-keto group of the isatins II. The metallated heterocycles, such as, for example, the corresponding Grignard (Mg) or organyllithium compound III (M=MgX or Li; X═I or Br), can be obtained in any conventional way from halogen or hydrocarbon compounds by reaction with Mg or lithium-organic compounds. Exemplary methods are described in Houben-Weyl, Methoden der Organischen Chemie, vol. 13, 1-2, chapter on Mg and Li compounds. The isatins II are either commercially available or were prepared in analogy to methods described in the literature (Advances in Heterocyclic Chemistry, A. R. Katritzky and A. J. Boulton, Academic Press, New York, 1975, 18, 2-58; J. Brazil. Chem. Soc. 12, 273-324, 2001).

The 3-hydroxyoxindoles IV can be converted into the compounds V which have a leaving group LG′ in position 3, where the leaving group LG′ is a conventional leaving group such as, for example, chlorine or bromide. The intermediate V with for example LG′=Cl can be prepared by treating the alcohol IV with thionyl chloride in the pres-presence of a base such as, for example, pyridine, in a suitable solvent such as, for example, dichloromethane. The compounds V can subsequently be reacted with amines, such as, for example, ammonia, in a substitution reaction to give the amines VI.

In the first variant amines VI are converted into the sulfonylated product VIII by treatment with sulfonyl chlorides VII after deprotonation with a strong base such as, for example, potassium tert-butoxide or sodium hydride in DMF. Sulfonyl chlorides VII employed can either be purchased or be prepared by known processes (for example J. Med. Chem. 40, 1149 (1997)). Compounds VIII are then reacted with carbonic acid halide, such as phenyl chloroformate, in the presence of a base such as, for example, pyridine, to give the corresponding carbamate IX (LG=leaving group; in case of using phenyl chloroformate, LG=phenoxy).

As shown in scheme 2, intermediate IX can then be reacted with an appropriate amine X to give directly the compounds of the general formula I; this conversion can be done at room temperature or elevated temperature and with the addition of auxiliary bases such as, for example, triethylamine or diisopropylethylamine.

In a second variant compounds of the general formula I are prepared from intermediates IX in a two-step sequence: intermediate IX can be reacted with an appropriate azetidine-3-one XII or 1-(3-azetidinyl)-4-piperidinone XIII employing the same method and conditions as described above to give the corresponding oxo compounds XIV or XV. Reductive amination of compounds XIV or XV with the appropriate amines XVI or XVII then gives the compounds of the general formula I. The latter reaction is carried out in the presence of a suitable reduction agent, e.g. boron-based reduction agent, typically a boronic ester, such as sodium triacetoxyhydroborate, or cyanoborohydride; where appropriate a Lewis acid such as e.g. zinc chloride or titanium isopropoxide is added to the reaction. General examples for reductive amination are described in the literature, e.g. Comprehensive Organic Transformations 2^(nd) ed, R. Larock, Wiley VCH, 835-846.

As shown in scheme 3, in a third variant amines VI are first reacted with a carboonic acid halide, such as phenyl chloroformate, in the presence of a base such as, for example, pyridine, to give the corresponding carbamate XVIII (LG=leaving group; in case of using phenyl chloroformate, LG=phenoxy), and then reacted further with an appropriate amine at room temperature or elevated temperature and with the addition of auxiliary bases such as, for example, pyridine, triethylamine or diisopropylethylamine. to give intermediate XIX. Sulfonylation of compounds XIX by treatment with sulfonyl chlorides VII after deprotonation with a strong base such as, for example, potassium tert-butoxide or sodium hydride in DMF, then gives the compounds of the general formula I.

If not indicated otherwise, the above-described reactions are generally carried out in a solvent at temperatures between room temperature and the boiling temperature of the solvent employed. Alternatively, the activation energy which is required for the reaction can be introduced into the reaction mixture using microwaves, something which has proved to be of value, in particular, in the case of the reactions catalyzed by transition metals (with regard to reactions using microwaves, see Tetrahedron 2001, 57, p. 9199 ff. p. 9225 ff. and also, in a general manner, “Microwaves in Organic Synthesis”, André Loupy (Ed.), Wiley-VCH 2002.

The acid addition salts of compounds I are prepared in a customary manner by mixing the free base with a corresponding acid, where appropriate in solution in an organic solvent, for example a lower alcohol, such as methanol, ethanol or propanol, an ether, such as methyl tert-butyl ether or diisopropyl ether, a ketone, such as acetone or methyl ethyl ketone, or an ester, such as ethyl acetate.

Routine experimentations, including appropriate manipulation of the reaction conditions, reagents and sequence of the synthetic route, protection of any chemical functionality that may not be compatible with the reaction conditions, and deprotection at a suitable point in the reaction sequence of the preparation methods are within routine techniques.

Suitable protecting groups and the methods for protecting and deprotecting different substituents using such suitable protecting groups are well known to those skilled in the art; examples of which may be found in T. Greene and P. Wuts, Protective Groups in Organic Synthesis (3rd ed.), John Wiley & Sons, NY (1999), which is incorporated herein by reference in its entirety. Synthesis of the compounds of the invention may be accomplished by methods analogous to those described in the synthetic scheme described hereinabove and in specific examples.

Starting materials, if not commercially available, may be prepared by procedures selected from standard organic chemical techniques, techniques that are analogous to the synthesis of known, structurally similar compounds, or techniques that are analogous to the above described schemes or the procedures described in the synthetic examples section.

When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the procedures described herein using an optically active starting material (prepared, for example, by asymmetric induction of a suitable reaction step), or by resolution of a mixture of the stereoisomers of the compound or intermediates using a standard procedure (such as chromatographic separation, recrystallization or enzymatic resolution).

Similarly, when a pure geometric isomer of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure geometric isomer as a starting material, or by resolution of a mixture of the geometric isomers of the compound or intermediates using a standard procedure such as chromatographic separation.

The present invention moreover relates to compounds of formula I as defined above, wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope (e.g., hydrogen by deuterium, ¹²C by ¹³C, ¹⁴N by ¹⁵N, ¹⁶O by ¹⁸O) and preferably wherein at least one hydrogen atom has been replaced by a deuterium atom.

Of course, the compounds according to the invention contain more of the respective isotope than this naturally occurs and thus is anyway present in the compounds I.

Stable isotopes (e.g., deuterium, ¹³C, ¹⁵N, ¹⁸O) are nonradioactive isotopes which contain one additional neutron than the normally abundant isotope of the respective atom. Deuterated compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the non deuterated parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. Labelled Comp. Radiopharmaceut., 36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol., 77, 79-88 (1999).

Incorporation of a heavy atom, particularly substitution of deuterium for hydrogen, can give rise to an isotope effect that could alter the pharmacokinetics of the drug.

Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These changes may influence the fate of the drug at different steps along its passage through the body. Absorption, distribution, metabolism or excretion can be changed. Absorption and distribution are processes that depend primarily on the molecular size and the lipophilicity of the substance. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction.

Drug metabolism can give rise to large isotopic effect if the breaking of a chemical bond to a deuterium atom is the rate limiting step in the process. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. In any reaction in which the breaking of this bond is the rate limiting step, the reaction will proceed slower for the molecule with the heavy isotope due to “kinetic isotope effect”. A reaction involving breaking a C-D bond can be up to 700 percent slower than a similar reaction involving breaking a C—H bond. If the C-D bond is not involved in any of the steps leading to the metabolite, there may not be any effect to alter the behavior of the drug. If a deuterium is placed at a site involved in the metabolism of a drug, an isotope effect will be observed only if breaking of the C-D bond is the rate limiting step. There is evidence to suggest that whenever cleavage of an aliphatic C—H bond occurs, usually by oxidation catalyzed by a mixed-function oxidase, replacement of the hydrogen by deuterium will lead to observable isotope effect. It is also important to understand that the incorporation of deuterium at the site of metabolism slows its rate to the point where another metabolite produced by attack at a carbon atom not substituted by deuterium becomes the major pathway a process called “metabolic switching”.

Deuterium tracers, such as deuterium-labeled drugs and doses, in some cases repeatedly, of thousands of milligrams of deuterated water, are also used in healthy humans of all ages, including neonates and pregnant women, without reported incident (e.g. Pons G and Rey E, Pediatrics 1999 104: 633; Coward W A et al., Lancet 1979 7: 13; Schwarcz H P, Control. Clin. Trials 1984 5(4 Suppl): 573; Rodewald L E et al., J. Pediatr. 1989 114: 885; Butte N F et al. Br. J. Nutr. 1991 65: 3; MacLennan A H et al. Am. J. Obstet Gynecol. 1981 139: 948). Thus, it is clear that any deuterium released, for instance, during the metabolism of compounds of this invention poses no health risk.

The weight percentage of hydrogen in a mammal (approximately 9%) and natural abundance of deuterium (approximately 0.015%) indicates that a 70 kg human normally contains nearly a gram of deuterium. Furthermore, replacement of up to about 15% of normal hydrogen with deuterium has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201: 357). Higher deuterium concentrations, usually in excess of 20%, can be toxic in animals. However, acute replacement of as high as 15%-23% of the hydrogen in humans' fluids with deuterium was found not to cause toxicity (Blagojevic N et al. in “Dosimetry & Treatment Planning for Neutron Capture Therapy”, Zamenhof R, Solares G and Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp. 125-134; Diabetes Metab. 23: 251 (1997)).

Increasing the amount of deuterium present in a compound above its natural abundance is called enrichment or deuterium-enrichment. Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %.

The hydrogens present on a particular organic compound have different capacities for exchange with deuterium. Certain hydrogen atoms are easily exchangeable under physiological conditions and, if replaced by deuterium atoms, it is expected that they will readily exchange for protons after administration to a patient. Certain hydrogen atoms may be exchanged for deuterium atoms by the action of a deuteric acid such as D₂SO₄/D₂O. Alternatively, deuterium atoms may be incorporated in various combinations during the synthesis of compounds of the invention. Certain hydrogen atoms are not easily exchangeable for deuterium atoms. However, deuterium atoms at the remaining positions may be incorporated by the use of deuterated starting materials or intermediates during the construction of compounds of the invention.

Deuterated and deuterium-enriched compounds of the invention can be prepared by using known methods described in the literature. Such methods can be carried out utilizing corresponding deuterated and optionally, other isotope-containing reagents and/or intermediates to synthesize the compounds delineated herein, or invoking standard synthetic protocols known in the art for introducing isotopic atoms to a chemical structure. Relevant procedures and intermediates are disclosed, for instance in Lizondo, J et al., Drugs Fut, 21(11), 1116 (1996); Brickner, S J et al., J Med Chem, 39(3), 673 (1996); Mallesham, B et al., Org Lett, 5(7), 963 (2003); PCT publications WO1997010223, WO2005099353, WO1995007271, WO2006008754; U.S. Pat. Nos. 7,538,189; 7,534,814; 7,531,685; 7,528,131; 7,521,421; 7,514,068; 7,511,013; and US Patent Application Publication Nos. 20090137457; 20090131485; 20090131363; 20090118238; 20090111840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416; 20090082471, the methods are hereby incorporated by reference.

A further aspect of the present invention relates to a pharmaceutical composition comprising at least one compound of the general formula I and/or an N-oxide, a stereoisomer or a pharmaceutically acceptable salt thereof as detailed above, and a pharmaceutically acceptable carrier; or comprising at least one compound I wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope, preferably wherein at least one hydrogen atom has been replaced by a deuterium atom, in combination with at least one pharmaceutically acceptable carrier and/or auxiliary substance. Suitable carriers depend inter alia on the dosage form of the composition and are known in principle to the skilled worker. Some suitable carriers are described hereinafter.

The present invention furthermore relates to a compound I as defined above or an N-oxide, a stereoisomer or a pharmaceutically acceptable salt thereof for use as a medicament. The present invention also relates to a compound I as defined above or an N-oxide, a stereoisomer or a pharmaceutically acceptable salt thereof for the treatment of vasopressin-related diseases, especially of disorders which respond to the modulation of the vasopressin receptor and in particular of the V1b receptor.

A further aspect of the present invention relates to the use of compounds of the formula I and/or of an N-oxide, a stereoisomer or of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of vasopressin-related diseases, especially of disorders which respond to the modulation of the vasopressin receptor and in particular of the V1b receptor.

Vasopressin-related diseases are those in which the progress of the disease is at least partly dependent on vasopressin, i.e. diseases which show an elevated vasopressin level which may contribute directly or indirectly to the pathological condition. In other words, vasopressin-related diseases are those which can be influenced by modulating the vasopressin receptor, for example by administration of a vasopressin receptor ligand (agonist, antagonist, partial antagonist/agonist, inverse agonist etc.).

In a preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from diabetes, insulin resistance, nocturnal enuresis, incontinence and diseases in which impairments of blood clotting occur, and/or for delaying micturition. The term “diabetes” means all types of diabetes, especially diabetes mellitus (including type I and especially type II), diabetes renalis and in particular diabetes insipidus. The types of diabetes are preferably diabetes mellitus of type II (with insulin resistance) or diabetes insipidus.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemias of the heart, impairments of the renal system, edemas, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, impairments of the gastrointestinal tract, gastritic vasospasm, hepatocirrhosis, gastric and intestinal ulcers, emesis, emesis occurring during chemotherapy, and travel sickness.

The compounds of the invention of the formula I or their N-oxides, stereoisomers or pharmaceutically acceptable salts or the pharmaceutical composition of the invention can also be used for the treatment of various vasopressin-related complaints which have central nervous causes or alterations in the HPA axis (hypothalamic pituitary adrenal axis), for example for affective disorders such as depressive disorders and anxiety disorders. Depressive disorders include for example dysthymic disorders, major depression, seasonal depression, treatment-resistant depression disorders, bipolar disorders, or childhood onset mood disorders. Anxiety disorders include for example phobias, post-traumatic stress disorders, general anxiety disorders, panic disorders, drug withdrawal-induced anxiety disorders, and obsessive-compulsive disorders.

Vasopressin-related complaints which have central nervous causes or alterations in the HPA axis are further cognitive disorders such as Alzheimer's disease, MCI (Mild Cognitive Impairment) and CIAS (Cognitive Impairment Associated with Schizophrenia).

The compounds of the invention of the formula I and their N-oxides, a stereoisomers or pharmaceutically acceptable salts or the pharmaceutical composition of the invention can likewise be employed for the treatment of anxiety disorders and stress-dependent anxiety disorders, such as, for example, generalized anxiety disorders, phobias, post-traumatic anxiety disorders, panic anxiety disorders, obsessive-compulsive anxiety disorders, acute stress-dependent anxiety disorders, drug withdrawal-induced anxiety disorders and social phobia.

The compounds of the invention of the formula I and their N-oxides, stereoisomers or pharmaceutically acceptable salts or the pharmaceutical composition of the invention can likewise be employed for the treatment and/or prophylaxis of social impairment, such as autism or social impairment related with schizophrenia.

The compounds of the invention of the formula I and their N-oxides, stereoisomers or pharmaceutically acceptable salts or the pharmaceutical composition of the invention can likewise be employed for the treatment and/or prophylaxis of increased aggression in conditions such as Alzheimer's disease and schizophrenia.

The compounds of the invention can furthermore also be employed for the treatment of memory impairments, Alzheimer's disease, psychoses, psychotic disorders, sleep disorders and/or Cushing's syndrome, and all stress-dependent diseases.

Accordingly, a further preferred embodiment of the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of affective disorders.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of anxiety disorders and/or stress-dependent anxiety disorders.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of memory impairments and/or Alzheimer's disease.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of psychoses and/or psychotic disorders.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of Cushing's syndrome or other stress-dependent diseases.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of sleep disorders.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of depressive disorders. In the case of depressive disorders, specific mention is to be made of childhood onset mood disorders, i.e. depressive moods having their onset in childhood, but also of major depression, seasonal depression, bipolar disorders and dysthymic disorders, and especially of major depression and seasonal depression as well as of the depressive phases of bipolar disorders. The invention also relates to compounds of the formula I or N-oxides, stereoisomers or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of treatment-resistant depression disorders and for the use in an add-on therapy of depressive disorders.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of vasomotor symptoms and/or thermoregulatory dysfunctions such as, for example, the hot flush symptom.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of drug or pharmaceutical dependencies and/or dependencies mediated by other factors, for the treatment of drug-use disorders, for the treatment and/or prophylaxis of stress caused by withdrawal of one or more factors mediating the dependence and/or for the treatment and/or prophylaxis of stress-induced relapses into drug or pharmaceutical dependencies and/or dependencies mediated by other factors. To be more precise, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of substance-related and addictive disorders such as substance use disorder, substance-induced disorder, alcohol use disorder, alcohol intoxication, alcohol withdrawal, unspecified alcohol-related disorder, caffeine intoxication, caffeine withdrawal, unspecified caffeine disorder, cannabis use disorder, cannabis withdrawal, unspecified cannabis-related disorder, phencyclidine use disorder, other hallucinogen use disorders, phencyclidine intoxication, other hallucinogen disorders, hallucinogen persisting perception disorder, unspecified phencyclidine disorder, inhalant use disorder, inhalant intoxication, opioid use disorder, opioid withdrawal, sedative, hypnotic or anxiolytic use disorder, sedative, hypnotic or anxiolytic withdrawal, stimu-stimulant use disorder, stimulant intoxication, stimulant withdrawal, tobacco use disorder, tobacco withdrawal, unspecified tobacco-related disorder, other (or unknown) substance use disorders, other (or unknown) substance intoxication, other (or unknown) substance withdrawal, other (or unknown) substance related disorder and gambling disorder; as well as to compounds of the invention of the formula I or of an N-oxide, a stereoisomer or of pharmaceutically acceptable salts thereof for the treatment and/or prophylaxis of the above-listed diseases.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of schizophrenia and/or psychosis.

In a further preferred embodiment, the present invention relates to the use of compounds of the invention of the formula I or of an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of pain, e.g. acute or chronic pain, preferably chronic pain, especially neuropathic pain. Chronic pain may be a complex regional pain syndrome, pain arising from peripheral neuropathies, post-operative pain, chronic fatigue syndrome pain, tension-type headache, pain arising from mechanical nerve injury and severe pain associated with diseases such as cancer, metabolic disease, neurotropic viral disease, neurotoxicity, inflammation, multiple sclerosis or any pain arising as a consequence of or associated with stress or depressive illness.

A further aspect of the invention relates to a compound I or pharmaceutically acceptable salts thereof for use as a medicament, and to a compound I or an N-oxide, a stereoisomer or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of the above-defined diseases.

A further aspect of the invention relates to a method for the treatment and/or prophylaxis of vasopressin-related diseases, in which an effective amount of at least one compound of the invention of the formula I or of an N-oxide, a stereoisomer or of at least one pharmaceutically acceptable salt thereof or of a pharmaceutical composition of the invention is administered to a patient.

Concerning the definition of vasopressin-related diseases, reference is made to the above statements.

In a preferred embodiment of the invention, the method of the invention serves for the treatment and/or prophylaxis of disorders selected from diabetes, insulin resistance, nocturnal enuresis, incontinence and diseases in which impairments of blood clotting occur, and/or for delaying micturition. Concerning the definition of diabetes, reference is made to the above statements.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of disorders selected from hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemias of the heart, impairments of the renal system, edemas, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, impairments of the gastrointestinal tract, gastritic vasospasm, hepatocirrhosis, gastric and intestinal ulcers, emesis, emesis occurring during chemotherapy, and travel sickness.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of affective disorders.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of anxiety disorders and/or stress-dependent anxiety disorders.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of memory impairments and/or Alzheimer's disease.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of psychoses and/or psychotic disorders.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of Cushing's syndrome.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of sleep disorders in a patient.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of depressive disorders. In the case of depressive disorders, specific mention is to be made of major depression, seasonal depression, bipolar disorders, dysthymic disorders and childhood onset mood disorders, i.e. depressive moods having their onset in childhood, and especially of major depression and seasonal depression as well as of the depressive phases of bipolar disorders. The method of the invention also serves for the treatment of treatment-resistant depression disorders and as an add-on therapy of depressive disorders.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of vasomotor symptoms and/or thermoregulatory dysfunctions, such as, for example, the hot flush symptom.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of drug or pharmaceutical dependencies and/or dependencies mediated by other factors, for the treatment of drug-use disorders, for the treatment and/or prophylaxis of stress caused by withdrawal of one or more factors mediating the dependence, and/or for the treatment and/or prophylaxis of stress-induced relapses into drug or pharmaceutical dependencies and/or dependencies mediated by other factors.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of schizophrenia and/or psychosis.

In a further preferred embodiment, the method of the invention serves for the treatment and/or prophylaxis of pain, e.g. acute or chronic pain, preferably chronic pain, especially neuropathic pain.

The patient to be treated prophylactically or therapeutically with the method of the invention is preferably a mammal, for example a human or a nonhuman mammal or a nonhuman transgenic mammal. Specifically it is a human.

The compounds of the general formula I and their pharmaceutically acceptable salts as detailed above can be prepared by a skilled worker with knowledge of the technical teaching of the invention in implementing and/or in analogous implementation of process steps known per se.

The compounds I and/or their pharmaceutically acceptable salts, N-oxides and their stereoisomers are distinguished by having a selectivity for the vasopressin V1b receptor subtype vis-à-vis at least one of the closely related vasopressin/oxytocin receptor subtypes (for example vasopressin V1a, vasopressin V2 and/or oxytocin).

Alternatively, or preferably in addition, the compounds I and/or their pharmaceutically acceptable salts, N-oxides and a stereoisomers are distinguished by having an improved metabolic stability.

The metabolic stability of a compound can be measured for example by incubating a solution of this compound with liver microsomes from particular species (for example rat, dog or human) and determining the half-life of the compound under these conditions (R S Obach, Curr Opin Drug Discov Devel. 2001, 4, 36-44). It is possible in this connection to conclude from an observed longer half-life that the metabolic stability of the compound is improved. The stability in the presence of human liver microsomes is of particular interest because it makes it possible to predict the metabolic degradation of the compound in the human liver. Compounds with increased metabolic stability (measured in the liver microsome test) are therefore probably also degraded more slowly in the liver. The slower metabolic degradation in the liver may lead to higher and/or longer-lasting concentrations (active levels) of the compound in the body, so that the elimination half-life of the compounds of the invention is increased. Increased and/or longer-lasting active levels may lead to a better activity of the compound in the treatment or prophylaxis of various vasopressin-related diseases. In addition, an improved metabolic stability may lead to an increased bioavailability after oral administration, because the compound is subject, after absorption in the intestine, to less metabolic degradation in the liver (so-called first pass effect). An increased oral bioavailability may, owing to an increased concentration (active level) of the compound, lead to a better activity of the compound after oral administration.

The compounds of the invention are effective after administration by various routes. Possible examples are intravenous, intramuscular, subcutaneous, topical, intratracheal, intranasal, transdermal, vaginal, rectal, sublingual, buccal or oral administration, and administration is frequently intravenous, intramuscular or, in particular, oral.

The present invention also relates to pharmaceutical compositions which comprise an effective dose of a compound I of the invention and/or an N-oxide, a stereoisomer and/or a pharmaceutically acceptable salt thereof and suitable pharmaceutical carriers (drug carriers).

These drug carriers are chosen according to the pharmaceutical form and the desired mode of administration and are known in principle to the skilled worker.

The compounds of the invention of the formula I, their N-oxides, steroisomers or optionally suitable salts of these compounds can be used to produce pharmaceutical compositions for oral, sublingual, buccal, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal, vaginal or rectal administration, and be administered to animals or humans in uniform administration forms, mixed with conventional pharmaceutical carriers, for the prophylaxis or treatment of the above disorders or diseases.

The suitable administration forms (dose units) include forms for oral administration such as tablets, gelatin capsules, powders, granules and solutions or suspensions for oral intake, forms for sublingual, buccal, intratracheal or intranasal administration, aerosols, implants, forms of subcutaneous, intramuscular or intravenous administration and forms of rectal administration.

The compounds of the invention can be used in creams, ointments or lotions for topical administration.

In order to achieve the desired prophylactic or therapeutic effect, the dose of the active ingredient can vary between 0.01 and 50 mg per kg of body weight and per day.

Each unit dose may comprise from 0.05 to 5000 mg, preferably 1 to 1000 mg, of the active ingredient in combination with a pharmaceutical carrier. This unit dose can be administered once to 5 times a day, so that a daily dose of from 0.5 to 25 000 mg, preferably 1 to 5000 mg, is administered.

If a solid composition is prepared in the form of tablets, the active ingredient is mixed with a solid pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, silicon dioxide or the like.

The tablets can be coated with sucrose, a cellulose derivative or another suitable substance or be treated otherwise in order to display a sustained or delayed activity and to release a predetermined amount of the active ingredient continuously.

A preparation in the form of gelatin capsules is obtained by mixing the active ingredient with an extender and including the resulting mixture in soft or hard gelatin capsules.

A preparation in the form of a syrup or elixir or for administration in the form of drops may contain active ingredients together with a sweetener, which is preferably calorie-free, methylparaben or propylparaben as antiseptics, a flavoring and a suitable coloring substance.

Water-dispersible powders or granules may comprise the active ingredients mixed with dispersants, wetting agents or suspending agents, such as polyvinylpyrrolidones, and sweeteners or masking flavors.

Rectal or vaginal administration is achieved by using suppositories which are prepared with binders which melt at rectal temperature, for example cocoa butter or polyethylene glycols. Parenteral administration is effected by using aqueous suspensions, isotonic saline solutions or sterile and injectable solutions which comprise pharmacologically acceptable dispersants and/or wetting agents, for example propylene glycol or polyethylene glycol.

The active ingredient may also be formulated as microcapsules or centrosomes, if suitable with one or more carriers or additives.

The compositions of the invention may, in addition to the compounds of the invention, comprise other active ingredients which may be beneficial for the treatment of the disorders or diseases indicated above.

The present invention thus further relates to pharmaceutical compositions in which a plurality of active ingredients are present together, where at least one of these is a compound I of the invention, or salt thereof.

The invention is explained in more detail below by means of examples, but the examples are not to be understood to be restrictive.

The compounds of the invention can be prepared by various synthetic routes. The methods mentioned, as described accordingly in synthesis schemes 1, 2 and 3, are explained in greater detail merely by way of example using the given examples without being exclusively restricted to synthesis route 1, 2 or 3 or analogous methods.

EXPERIMENTAL SECTION Abbreviations Used Et₃N: Triethylamine THF: Tetrahydrofuran DMF: N,N-Dimethylformamide

DMSO: Dimethyl sulfoxide TFA: Trifluoroacetic acid RT room temperature p: pseudo (for example pt pseudo triplet) b: broad (for example bs broad singlet) s: singlet d: doublet t: triplet m: multiplet dd: doublet of doublets dt: doublet of triplets tt: triplet of triplets

I. Preparation of the Starting Compounds 1.) (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

To a solution of (S)-phenyl (5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)carbamate (425 mg, 0,691 mmol) and azetidin-3-one hydrochloride (80 mg, 0,744 mmol) in DMF (6 ml) Et3N (1 ml, 7.17 mmol) was added and the mixture stirred over night at room temperature. Subsequently 40 ml of water and 10 ml NaHCO₃-solution were added and the mixture extracted twice with ethyl acetate. The combined organic layers were washed 3× with brine, dried over MgSO₄, filtered off and evaporated to give 430 mg of a yellow solid.

Flash chromatography (silica gel/gradient from 0 to 5% methanol in dichloromethane) yielded 330 mg of the title compound as white solid.

ESI-MS [M+H⁺]=592.2

2.) (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

To a solution of (S)-phenyl (5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)carbamate (1 g, 1,665 mmol) and azetidin-3-one hydrochloride (220 mg, 2,046 mmol) in 10 ml of DMF Et₃N (1.5 ml, 10.76 mmol) was added and the mixture stirred over night at room temperature. 70 ml of water and 10 ml of 10% NaHCO₃-solution were added, the mixture extracted twice with ethyl acetate, the combined organic layers washed twice with brine, dried over MgSO₄, filtered and concentrated to leave 1.3 g of the crude product as yellow oil. Flash chromatography (silica gel/gradient from 0 to 5% methanol in dichloromethane) yielded 610 mg of the title compound as an off-white solid.

ESI-MS [M+H⁺]=578.1

3.) (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-oxopiperidin-1-yl)azetidine-1-carboxamide

To a solution of (S)-phenyl (5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)carbamate (1.3 g, 2,009 mmol) and 1-(3-azetidinyl)-4-piperidinone (0.37 g, 2,399 mmol) in DMF (9 ml) Et₃N (2 ml, 14.35 mmol) was added and the mixture stirred over night at room temperature. Water (80 ml) was added, stirring continued for 30 min, the precipitated solid filtered off, subsequently washed with water and n-pentane, and dried under vacuum to give 705 mg of a solid. The aqueous layers were re-extracted twice with ethyl acetate, the combined organic layers washed with brine, dried over MgSO₄, filtered and evaporated to leave 360 mg of yellow oil. Flash chromatography (silica gel/gradient from 0 to 5% methanol in dichloromethane) of the combined crude product yielded 500 mg of the title compound as white solid.

ESI-MS [M+H⁺]=675.2.

Following the procedures as described for intermediates 1 and 2 and using the appropriate starting material were prepared:

4.) (S)—N-(1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

ESI-MS [M+H⁺]=603.1.

5.) (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

ESI-MS [M+H⁺]=610.1.

6.) (S)—N-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

ESI-MS [M+H⁺]=602.1.

7.) (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-oxopiperidin-1-yl)azetidine-1-carboxamide

ESI-MS [M+H⁺]=661.2.

8.) (S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

a) To a solution of (S)-3-amino-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile (9 g, 30.6 mmol) in dichloromethane (150 ml) at 5° C. were added subsequently pyridine (20 ml) and then dropwise phenyl chloroformate (4.5 ml, 35.8 mmol), and stirring was continued for 1.5 hr. Dichloromethane (220 ml) and water (60 ml) were added, the mixture was stirred for 20 min, the organic layer washed subsequently with water and brine, dried over MgSO₄, filtered and concentrated to give 18.7 g of a brown oil. Flash chromatography of the crude product (silica gel/gradient from 0 to 30% methanol in dichloromethane) yielded 12.1 g of the title compound as amorphous solid; ESI-MS [M+H⁺]=415.0.

b) To a solution of (S)-phenyl (5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)carbamate (2.6 g, 5.65 mmol) and 4-(1-(azetidin-3-yl)piperidin-4-yl)morpholine×3TFA (3.3 g, 5.82 mmol) in acetonitrile (80 ml) at 5° C. Et₃N (5.5 ml, 39.5 mmol) was added and then stirred over night at room temperature. The mixture then was concentrated, treated with 100 ml of ice water, digested 3× with dichloromethane, the combined organic layers washed with brine, dried over MgSO₄, filtered and evaporated to give 3.0 g of a yellow oil. Flash chromatography of the crude product (silica gel/gradient from 0 to 50% methanol in dichloromethane) yielded 1.2 g of the title compound as amorphous solid; ESI-MS [M+H+]=546.2.

9.) (S)—N—(C-cyano-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

Synthesis according to procedure as described for intermediate 8.

ESI-MS [M+H⁺]=532.2.

10.) (S)-Phenyl (5-Cyano-3-(2,5-dimethoxyphenyl)-1-((2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)carbamate

To a solution of (S)-3-amino-3-(2,5-dimethoxyphenyl)-2-oxoindoline-5-carbonitrile (425 mg, 1,374 mmol) DMF (10 ml) at 5° C. first sodium hydride (60%: 77 mg, 1,924 mmol) and after stirring for 20 min 2,4-dimethoxybenzenesulfonyl chloride (358 mg, 1,511 mmol) was added, and stirring continued for 30 min. Then 40 ml of water and 10 ml of 10% NaHCO₃-solution were added, extracted twice with ethyl acetate, the combined organic layers washed with brine, dried over MgSO₄, filtered and evaporated to give 730 mg of a yellow solid.

The crude product was dissolved in dichloromethane (20 ml), pyridine (0,834 ml, 10.32 mmol) and phenyl chloroformate (0,194 ml, 1,547 mmol) were added at 5° C. and stirred 1 for h at 5° C. The mixture was diluted with 120 ml of water, the organic layer washed 3× with water, dried over MgSO₄, filtered and evaporated to leave 966 mg of a yellow solid, which was treated with 50 ml of methyl-tert-butylether/diisopropylether 1:5 to give 630 mg of the title compound as white solid.

ESI-MS [M+H+]=630.0

11) N-Methyl-N-(oxetan-3-yl)piperidin-4-amine×2TFA

To a solution of 1-Boc-4-methylaminopiperidine (500 mg, 2,333 mmol) in THF (10 ml) 3-oxetanone (235 mg, 3.27 mmol) was added and the mixture stirred over night at room temperature. Then subsequently sodium cyanoborohydride (176 mg, 2.80 mmol) and acetic acid (0.27 ml, 4.72 mmol) were added and stirring continued for 3 days at room temperature. The mixture was concentrated under vacuum, the obtained residue diluted with 20 ml of and and 10 ml of 10% NaHCO₃-solution, extracted 2× with dichloromethane, the combined organic layers dried over MgSO₄, filtered off and evaporated to leave 700 mg of the crude product. Flash chromatography (silica gel/gradient from 0 to 10% methanol in dichloromethane) gave 230 mg of a clear oil, which was treated with TFA (2 ml, 26.0 mmol) for 1 hr. The mixture was concentrated, diluted with 20 ml of methyl-tert-butylether, the precipitate filtered off, washed with 10 ml of methyl-tert-butyl ether and dried to yield 340 mg of the title compound as white solid;

ESI-MS [M+H+]=171.2.

12) N-Ethyl-N-(oxetan-3-yl)piperidin-4-amine×2TFA

To a solution of 1-Boc-4-piperidinone (0.6 g, 3.01 mmol) and N-ethyloxetan-3-amine (0.38 g, 3.76 mmol) in methanol (5 ml) were added zinc chloride (1,231 g, 9.03 mmol), and then after 10 min stirring sodium cyanoborohydride (0,473 g, 7.53 mmol), and the mixture stirred over night at room temperature. For work-up 2 ml of 10% NaHCO₃-solution were added, the mixture concentrated, diluted with 80 ml of water, extracted 3× with ethyl acetate, the combined organic layers washed twice with brine, dried over MgSO₄, filtered and evaporated to give 730 mg of a clear oil. The Boc-protected amine was treated with 2 ml of TFA for 1 hr, concentrated, and the obtained residue digested with 20 ml methyl-tert-butylether. Filtering off the precipitate, washing and drying gave 690 mg of the title compound as white solid.

ESI-MS [M+H⁺]=185.2.

13) N-Cyclopropyl-N-(oxetan-3-yl)piperidin-4-amine×2TFA

To a solution of 1-tert-butoxycarbonyl-4-(cyclopropylamino)piperidine (2 g, 8.32 mmol) and 3-oxetanone (0,840 g, 11.65 mmol) in methanol (25 ml) subsequently zinc chloride (2,155 g, 15.81 mmol)—and after stirring for 10 min—sodium cyanoborohydride (0,994 g, 15.81 mmol) were added and the mixture was stirred over night. 20 ml of a 10% NaHCO₃-solution were added to the reaction mixture and concentrated under vacuum. After addition of 60 ml of water, 10 ml of 10% NaHCO₃-solution and 30 ml of dichloromethane the formed solid was filtered off, washed with 10 ml of water and 10 ml of dichloromethane, the aqueous layer digested again with dichloromethane, and the combined organic layers then washed with water, dried over MgSO₄, filtered and evaporated to leave 2.29 g of a yellow oil. Hash chromatography (silica gel/gradient from 0 to 15% methanol in dichloromethane) yielded 1.57 g of a clear oil, which was dissolved in dichloromethane (1 ml) and treated with TFA (4 ml) for 15 min. The mixture was concentrated, 40 ml of methyl-tert-butylether added and stirred for 2 hr. The precipitate was filtered off, washed and dried to give 1.9 g of the title compound as white solid.

ESI-MS [M+H⁺]=197.2

14) 1-(Azetidin-3-yl)-N-methyl-N-(oxetan-3-yl)piperidin-4-amine×3TFA

a. To a solution of 1-Boc-4-methylaminopiperidine (5.5 g, 25.7 mmol) and 3-oxetanone (3 g, 41.6 mmol) in methanol (50 ml) and THF (40 ml) subsequently were added zinc chloride—and after stirring for 10 min—sodium cyanoborohydride (2.3 g, 36.6 mmol), and the mixture stirred over night at room temperature. The mixture was concentrated, 30 ml of 10% NaHCO₃-solution, 100 ml of water and 70 ml of dichloromethane added, filtered, and the aqueous layer digested with dichloromethane. The combined organic layers were washed with brine, dried over MgSO₄, filtered and evaporated to leave 6.78 g of a pale yellow oil. The crude product was treated with TFA (15 ml) in dichloromethane (40 ml) at 5° C. over night, the mixture concentrated, diluted with 150 ml of methyl-tert-butylether, stirred for 2 hr, the precipitated solid was filtered off, washed again with 50 ml methyl-tert-butylether and dried to give 9.63 g of the amine 2TFA salt as white solid.

c. Reductive amination tert-butyl 3-oxoazetidine-1-carboxylate (3 g, 17.52 mmol) with N-methyl-N-(oxetan-3-yl)piperidin-4-amine×2TFA (8 g, 20.09 mmol) following the procedure as described for step a and followed by BOC-cleavage using TFA gave 19.5 g of a yellow oil, which was treated with 150 ml of methyl-tert-butylether for 2 hr, the precipitated solid filtered off, washed and dried to give 8.5 g of the title compound as white solid.

ESI-MS [M+H+]=171.2

15) 4-(1-(Azetidin-3-yl)piperidin-4-yl)morpholine×3TFA

Reductive amination of 1-Boc-azetidinone (5 g, 29.2 mmol) and 4-(piperidin-4-yl)-morpholine (5.97 g, 35.0 mmol) as described for intermediate 13 and subsequent cleavage of Boc yielded 12.1 g of the title compound as white solid.

ESI-MS [M+H+]=226.2

II. Preparation of the Compounds of the Formula I

Enantiomers of the compounds I were prepared by using enantiomerically pure starting compounds.

Example 1 (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide (400 mg, 0,676 mmol) and 4-(piperidin-4-yl)-morpholine (400 mg, 2.35 mmol) were stirred in THF (15 ml) over night at room temperature. Sodium cyanoborohydride (70 mg, 1,114 mmol) and acetic acid (250 μl, 4.37 mmol) were added and the mixture was stirred for 2 hr. Subsequently 40 ml of water and 10 ml of a 10% NaHCO₃-solution were added, extracted twice with ethyl acetate, the combined organic layers washed with brine, dried over MgSO₄, filtered off and evaporated to give 620 mg as white solid. Flash chromatography of the crude product (silica gel/gradient from 0 to 10% methanol in dichloromethane) yielded 336 mg of the title compound as white solid.

ESI-MS [M+H⁺]=746.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.88 (dd, 1H), 7.83 (m, 3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.65 (d, 1H), 4.08 (q, 2H), 3.86 (s, 3H), 3.79 (m broad, 2H), 3.65-3.50 (m, 6H), 3.46 (s, 3H), 2.95 (m, 1H), 2.71 (m, 2H), 2.39 (m, 4H), 2.08 (m, 1H), 1.71 (4H), 1.34 (m, 2H), 0.95 (t, 3H).

Example 2 (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

To a solution of (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide (250 mg, 0,423 mmol) and N-methyl-N-(oxetan-3-yl)piperidin-4-amine TFA-salt (200 mg, 0,502 mmol) in methanol (5 ml) zinc chloride (115 mg, 0,844 mmol) was added and stirred for 10 min. Sodium cyanoborohydride (55 mg, 0,875 mmol) was added and the mixture stirred over night. Then 2 ml of 10% NaHCO₃-solution were added, the mixture was concentrated under vacuum, 60 ml of water and 20 ml of dichloromethane were added, and the solid was filtered off and washed with 10 ml of water and 10 ml of dichloromethane. The aqueous layer was separated and extracted with dichloromethane, and the combined organic layers were washed with water, dried over MgSO₄, filtered and concentrated to give 350 mg of a clear oil. Flash chromatography of the crude product (silica gel/gradient from 0 to 10% methanol in dichloromethane) afforded 123 mg of the title compound as white solid.

ESI-MS [M+H⁺]=746.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.88 (dd, 1H), 7.83 (m, 3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.46 (m, 4H), 4.07 (q, 2H), 3.85 (s, 3H), 3.78 (m broad, 3H), 3.55 (m broad, 2H), 3.46 (s, 3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.20 (m, 1H), 2.08 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H), 0.95 (t, 3H).

Example 3 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

To a solution of (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide (80 mg, 0,139 mmol) and 4-(piperidin-4-yl)-morpholine (50 mg, 0,294 mmol) in ethanol (5 ml) and THF (5 ml) titanium isopropoxide (2000, 0,672 mmol) was added, the mixture then stirred over night at room temperature and then for 50 min. at 60° C. The mixture was then cooled to 25° C., sodium cyanoborohydride (25 mg, 0,398 mmol) was added and stirring continued for 30 min. For work-up 2 ml of water and 2 ml of 10% NaHCO₃-solution were added, the mixture concentrated under vacuum, the obtained residue di-diluted with 20 ml of water and 20 ml dichloromethane, filtered over celite, washed with 20 ml of dichloromethane, the organic layer separated and dried over MgSO₄, to leave 80 mg of a yellow solid. Flash chromatography of the crude product (silica gel/gradient from 0 to 10% methanol in dichloromethane) afforded 17.7 mg of the title compound as white solid.

ESI-MS [M+H⁺]=732.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.91 (d, 1H), 7.86 (d, 1H), 7.80 (dd, 1H), 7.78 (dd, 1H), 7.70 (m, 1H), 7.64 (s broad, 1H), 7.06 (dd, 1H), 6.72 (dd, 1H), 6.68 (dd, 1H), 3.87 (s, 3H), 3.70 (s, 3H), 3.65-3.55 (m, 6H), 3.51 (s, 3H), 2.96 (m, 1H), 2.74 (m, 2H), 2.55-2.40 (m, overlapped with DMSO), 2.1 (m, 1H), 1.75 (m, 4H), 1.37 (m, 2H).

Example 4 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

To a solution of (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide (225 mg, 0,390 mmol) and N-methyl-N-(oxetan-3-yl)piperidin-4-amine TFA-salt (220 mg, 0,552 mmol) in methanol (3 ml) and THF (6 ml) zinc chloride (200 mg, 1,468 mmol) was added and the mixture stirred for 10 min. The sodium cyanoborohydride (100 mg, 1,591 mmol) was added and stirring continued over night at room temperature. Then 6 ml of 10% NaHCO₃-solution were added, concentrated under under vacuum, 50 ml of water and 20 ml of ethyl acetate, the aqueous layer extracted again with ethyl acetate, and the combined organic layers washed twice with brine, dried over MgSO₄, filtered and evaporated to leave 235 mg of a yellow solid. Flash chromatography of the crude product (silica gel/gradient from 0 to 10% methanol in dichloromethane) afforded 108 mg of the title compound as white solid.

ESI-MS [M+H⁺]=732.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.90 (d, 1H), 7.82 (d, 1H), 7.81 (dd, 1H), 7.79 (dd, 1H), 7.70 (m, 1H), 7.58 (s broad, 1H), 7.06 (dd, 1H), 6.72 (dd, 1H), 6.68 (dd, 1H), 4.46 (m, 4H), 3.86 (s, 3H), 3.80-3.70 (m broad, 3H), 3.65 (s, 3H), 3.60-3.52 (m broad, 2H), 3.50 (s, 3H), 2.92 (m, 1H), 2.71 (d, 2H), 2.19 (m, 2H), 2.19 (m, 1H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H).

The following compounds were obtained according to the procedures described for examples 1-4 using the appropriate starting materials.

Example 5 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(ethyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is ethyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=760.6.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.88 (d, 1H), 7.86-7.80 (m, 3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.47 (dt, 4H), 4.15-3.99 (m, 3H), 3.86 (s, 1H), 3.77 (m broad, 1H), 3.54 (m broad, 1H), 3.46 (s, 3H), 2.93 (m, 1H), 2.70 (t, 2H), 2.58 (m, 2H), 2.37 (m, 1H), 1.68 (m, 2H), 1.51 (m, 2H), 1.29 (m, 2H), 0.94 (dt, 6H).

Example 6 (S)-3-(4-(2-Oxa-7-Azaspiro[3.5]nonan-7-yl)piperidin-1-yl)-N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form 2-oxa-7-aza-spiro[3.5]non-7-yl)

ESI-MS [M+H+]=786.30.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.88 (d, 1H), 7.84-7.80 (m, 3H), 7.66 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.24 (s, 4H), 4.09 (q, 2H), 3.86 (s, 3H), 3.80 and 3.62 (each m broad, 2H), 3.46 (s, 3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.40-2.30 (m, 4H), 2.15 (m, 1H), 1.85-1.65 (m, 8H), 1.38 (m, 2H), 0.95 (t, 3H).

Example 7 N-[(3S)-5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-ethoxy-3-pyridyl)-2-oxoindolin-3-yl]-3-[4-[cyclopropyl(oxetan-3-yl)amino]-1-piperidyl]azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is cyclopropyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=772.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.89 (d, 1H), 7.83 (dd, 3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.71 (dd, 1H), 6.66 (d, 1H), 4.67 (m, 2H), 4.43 (m, 2H), 4.18 (m, 1H), 4.09 (q, 2H), 3.86 (s, 3H), 3.73 (m boad, 2H), 3.60 (m broad, 2H), 3.46 (s, 3H), 2.93 (m, 1H), 2.72 (t, 2H), 2.48 (m, overlapped with DMSO), 1.94 (m, 1H), 1.67 (m, 2H), 1.56 (m, 2H), 1.45 (m, 2H), 0.95 (t, 3H), 0.50 (m, 2H), 0.30 (m, 2H).

Example 8 (S)—N-(1-((2,4-Dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is F, R⁷ is F, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

ESI-MS [M+H+]=757.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.89 (d, 1H), 7.74 (dd, 1H), 7.62 (dd, 1H), 7.48 (s, 1H), 7.34 (m, 1H), 7.02 (dd, 1H), 6.70 (dd, 1H), 6.67 (d, 1H), 4.11 (q, 2H), 3.86 (s, 3H), 3.80-3.70 (m broad, 2H), 3.67-3.52 (m, 6H), 3.50 (s, 3H), 2.94 (m, 1H), 2.70 (m, 2H), 2.42 (m, 4H), 2.08 (m, 1H), 1.71 (m, 4H), 1.35 (m, 2H), 1.01 (t, 3H).

Example 9

(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide (compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is F, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

ESI-MS [M+H+]=764.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.89 (s, 1H), 7.88 (s, 1H), 7.71 (d, 1H), 7.68 (d, 1H), 7.56 (s, 1H), 7.07 (dd, 1H), 6.71 (dd, 1H), 6.67 (d, 1H), 4.10 (q, 2H), 3.86 (s, 3H), 3.84-3.70 (m broad, 2H), 3.68-3.53 (m, 6H), 3.52 (s, 3H), 2.94 (m, 1H), 2.71 (m, 2H), 2.42 (m, 4H), 2.08 (m, 1H), 1.72 (m, 4H), 1.34 (m, 2H), 0.99 (t, 3H).

Example 10 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is F, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=764.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.88 (m, 1H), 7.69 (dd, 1H), 7.56 (s, 1H), 7.07 (dd, 1H), 6.71 (dd, 1H), 6.67 (d, 1H), 4.53-4.38 (m, 4H), 4.09 (q, 2H), 3.84 (m broad, 2H), 3.58 (m broad, 2H), 3.51 (s, 3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.19 (m, 1H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H), 0.99 (t, 3H).

Example 11 N-[(3S)-1-[(2,4-Dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxo-2,3-dihydro-1H-indol-3-yl]-3-{4-[methyl(oxetan-3-yl)amino]piperidin-1-yl}azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is F, R⁷ is F, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=757.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.89 (d, 1H), 7.73 (dd, 1H), 7.62 (dd, 1H), 7.48 (s, 1H), 7.34 (m, 1H), 7.02 (dd, 1H), 6.71 (dd 1H), 6.67 (d, 1H), 4.46 (m, 4H), 4.10 (q, 2H), 3.85 (s, 3H), 3.75 (m broad, 3H), 3.55 (m broad, 2H), 3.50 (s, 3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.19 (m, 1H), 2.11 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H), 1.01 (t, 3H).

Example 12 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(cyclopropyl (oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is cyclopropyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=758.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.90 (d, 1H), 7.86 (d, 1H), 7.81 (m, 2H), 7.70 (d, 1H), 7.59 (s, 1H), 7.06 (dd, 1H), 6.72 (dd, 1H), 6.68 (d, 1H), 4.67 (m 2H), 4.43 (m 2H), 4.18 (1H), 3.87 s, 3H), 3.77 (m broad, 2H), 3.65 (s, 3H), 3.58 (m broad, 2H), 3.52 (s, 3H), 2.94 (m, 1H), 2.71 (m, 2H), 2.61 (m, 2H), 2.39 (m, 1H), 1.68 (m, 2H), 1.52 (m, 2H), 1.29 (m, 2H), 0.93 (t, 3H).

Example 13 (S)—N-(5-Chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is Cl, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

ESI-MS [M+H+]=756.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.12 (dd, 1H), 7.88 (d, 1H), 7.69 (dd, 1H), 7.66 (d, 1H), 7.49 (s, 1H), 7.38 (dd, 1H), 7.33 (d, 1H), 7.01 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.11 (q, 2H), 3.86 (s, 3H), 3.79 (m broad, 2H), 3.68-3.50 (m, 6H), 3.47 (s, 3H), 2.95 (m, 1H), 2.73 (m, 2H), 2.09 (m, 1H), 1.72 (m, 4H), 1.35 (m, 2H), 1.0 (t, 3H).

Example 14 (S)—N-(5-Chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is Cl, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=756.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.12 (dd, 1H), 7.88 (d, 1H), 7.69 (d, 1H), 7.66 (d, 1H), 7.49 (s, 1H), 7.38 (dd, 1H), 7.33 (d, 1H), 7.01 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.45 (m, 4H), 4.11 (q, 2H), 3.88 (s, 3H), 3.80 (m broad, 2H), 3.57 (m broad, 3H), 3.46 (s, 3H), 2.92 (m, 1H), 2.71 (m, 2H), 2.20 (m, 1H), 2.08 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H), 1.00 (t, 3H).

Example 15 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-((2-methoxyethyl)(methyl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl and R⁹ is 2-methoxyethyl)

To a solution of (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-oxopiperidin-1-yl)azetidine-1-carboxamide (60 mg, 0,089 mmol) and N-(2-methoxyethyl)methylamine (10 mg, 0,112 mmol) in a 1:1 mixture of methanol and THF (3 ml) first zinc chloride (20 mg, 0,147 mmol), and after stirring for 10 min, sodium cyanoborohydride (15 mg, 0,239 mmol) was added and stirring continued over night. For work-up 5 ml of 10% NaHCO3-solution were added, the mixture concentrated, diluted with 50 ml of water and 20 ml of ethyl acetate, separated and the aqueous layer re-extracted with ethyl acetate. The combined organic layers then were washed with brine, dried over MgSO4, filtered and evaporated to leave 70 mg of a white solid. Flash chromatography of the crude product (silica gel/gradient from 0 to 10% methanol in dichloromethane) yielded 45 mg of the title compound as white solid.

ESI-MS [M+H+]=748.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.09 (q, 2H), 3.86 (s, 3H), 3.77 (m broad, 2H), 3.58 (m broad, 2H), 3.46 (s, 3H), 3.22 (s, 3H), 2.94 (m, 1H), 2.72 (m, 2H), 2.52 (m overlapped with DMSO), 2.28 (m, 1H), 2.17 (s, 3H), 1.70 (m, 2H), 1.63 (m, 2H), 1.38 (m, 2H), 0.95 (t, 3H).

Example 16 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methoxy(methyl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is methoxy)

ESI-MS [M+H+]=720.3

Example 17 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(isoxazolidin-2-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form isoxazolidin-2-yl)

ESI-MS [M+H+]=732.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.89 (d, 1H), 7.83 (m, 3H), 7.67 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.09 (q, 2H), 3.86 (s, 3H), 3.76 (m, 3H), 3.62 (m, 3H), 3.47 (s, 3H), 3.03 (m, 1H), 2.96 (m, 1H), 2.65 (m, 2H), 2.55 (m, 1H), 2.36 (m, 1H), 2.13 (m, 2H), 2.13 (m, 1H), 1.92 (m, 1H), 1.77 (m, 2H), 1.64 (m, 1H), 1.35 (m, 2H), 0.94 (t, 3H).

Example 18 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-(oxetan-3-yl)azetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form 3-(oxetan-3-yl)-azetidin-1-yl)

ESI-MS [M+H+]=772.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.88 (d, 1H), 7.84 (m, 3H), 7.66 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.63 (dd, 2H), 4.27 (dd, 2H), 4.09 (q, 2H), 3.86 (s, 3H), 3.72 (m broad, 2H), 3.53 (m broad, 2H), 3.46 (s, 3H), 3.22 (m, 2H), 3.11 (m, 1H), 2.95 (m, 1H), 2.76 (m, 2H), 2.62 (m, 1H), 2.53 (m overlapped with DMSO), 1.96 (m, 1H), 1.79 (m, 2H), 1.57 (m, 2H), 1.10 (m, 2H), 0.95 (t, 3H).

Example 19 (S)-3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-yl)piperidin-1-yl)-N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form 2-oxa-6-aza-spiro[3.3]hept-6-yl)

ESI-MS [M+H+]=758.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66 (s, 1H), 7.53 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.65 (d, 1H), 4.57 (s, 4H), 4.08 (q, 2H), 3.85 (s, 3H), 3.78 (m broad, 2H), 3.58 (m broad, 2H), 3.46 (s, 3H), 3.19 (s, 3H), 2.94 (m, 1H), 2.54 (overlapped with DMSO), 1.86 (m, 1H), 1.75 (m, 2H), 1.54 (m, 2H), 1.09 (m, 2H), 0.94 (t, 3H).

Example 20 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(oxetan-3-ylamino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is hydrogen, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=718.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.91 (d, 1H), 7.86 (d, 1H), 7.82 (d, 1H), 7.80 (dd, 1H), 7.70 (d, 1H), 7.57 (s, 1H), 7.06 (dd, 1H), 6.71 (dd, 1H), 6.68 (d, 1H), 4.60 (m, 2H), 4.28 (m, 2H), 3.91 (m, 1H), 3.85 (s, 3H), 3.75 (m broad, 2H), 3.65 (s, 3H), 3.59 (m broad, 3H), 3.53 (s, 3H), 2.93 (m, 1H), 2.61 (m, 2H), 2.30 (m, 1H), 1.72 (m, 2H), 1.60 (m, 2H), 1.17 (m, 2H).

Example 21 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is tetrahydropyran-4-yl)

ESI-MS [M+H+]=760.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.91 (d, 1H), 7.86 (d, 1H), 7.82 (d, 1H), 7.80 (m, 2H), 7.70 (d, 1H), 7.58 (s, 1H), 7.06 (dd, 1H), 6.72 (dd, 1H), 6.68 (d, 1H), 3.85 (s, 3H), 3.80 (m, 3H), 3.75 (m, 2H), 3.65 (s, 3H), 3.60 (m, 2H), 3.51 (s, 3H), 3.27 (m, 2H), 2.93 (m, 1H), 2.74-2.64 (m, 3H), 1.72 (m, 2H), 1.58 (m, 4H), 1.43 (m, 4H).

Example 22 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(oxetan-3-yl(propyl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is propyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=760.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.89 (d, 1H), 7.73 (dd, 1H), 7.62 (dd, 1H), 7.48 (s, 1H), 7.34 (m, 1H), 7.02 (dd, 1H), 6.70 (dd, 1H), 6.67 (d, 1H), 4.46 (m, 4H), 4.11 (q, 2H), 3.86 (s, 3H), 3.78 (m broad, 2H), 3.57 (m broad, 2H), 3.50 (s, 3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.54 (m, overlapped with DMSO), 2.19 (m, 1H), 2.08 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H), 1.01 (t, 3H).

Example 23 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(ethyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is ethyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=746.3

¹H NMR (600 MHz, DMSO) δ 8.15 (dd, 1H), 7.90 (d, 1H), 7.86 (d, 1H), 7.80 (m, 2H), 7.69 (d, 1H), 7.58 (s, 1H), 7.06 (dd, 1H), 6.72 (dd, 1H), 6.68 (d, 1H), 4.47 (dt, 4H), 4.04 (m, 1H), 3.87 (s, 3H), 3.85 (m broad, 2H), 3.65 (m, 3H), 3.56 (m broad, 2H), 3.53 (s, 3H), 2.94 (m, 1H), 2.71 (m, 2H), 2.60 (m, 2H), 2.39 (m, 1H), 1.68 (m, 2H), 1.52 (m, 2H), 1.29 (m, 2H), 0.93 (t, 3H).

Example 24 (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is 5-F (relative to the 2- and 4-positions of R¹ and R²), R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

a. To a solution of (S)-3-amino-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile (1.0 g, 3.40 mmol) in DMF (12 ml) at 5° C. sodium hydride (55%: 0.22 g, 5.04 mmol) was added. After stirring for 20 min 5-fluoro-2,4-dimethoxybenzene-1-sulfonyl chloride (1.0 g, 3.93 mmol) was added and stirring continued for 1 hr at 5° C. After completion of the reaction 30 ml of water were added dropwise, the mixture digested 3× with dichloromethane, the combined organic layers washed with brine, dried over MgSO₄, filtered and concentrated to leave a brown oil, which was purified by flash chromatography (silica gel/gradient from 0 to 15% methanol in dichloromethane) to yield 1.5 g; ESI-MS [M+H+]=513.2.

b. To a solution of (S)-3-amino-3-(2-ethoxypyridin-3-yl)-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-2-oxoindoline-5-carbonitrile (1.5 g, 2.63 mmol) in dichloromethane (50 ml) at 5° C. were added dropwise pyridine (2.3 ml, 28.4 mmol) and phenylchloroformate (0.8 ml, 6.37 mmol), and the mixture stirred over night at room temperature. The mixture was diluted with dichloromethane, digested twice with water, the organic layer washed subsequently with 10% NaHCO3-solution and brine, dried over MgSO4, filtered and concentrated to give 2.1 g of a yellow oil, which was further purified by flash chromatography (silica gel/gradient from 0 to 15% methanol in dichloromethane) to give 0.7 g of a yellow amorphous solid; ESI-MS [M+H+]=633.9.

c. To a solution of (S)-phenyl (5-cyano-3-(2-ethoxypyridin-3-yl)-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)carbamate (80 mg, 0,126 mmol) and 4-(1-(azetidin-3-yl)piperidin-4-yl)morpholine×3TFA (70 mg, 0,123 mmol) in DMF (3 ml) at 5° C. Et3N (120 μl, 0,861 mmol) was added and then stirred for 4 h at room temperature. The mixture was concentrated, diluted with dichloromethane, washed with water and brine, dried over MgSO₄, filtered and evaporated to leave 210 mg of a brown oil. Flash chromatography (silica gel/gradient from 0 to 20% methanol in dichloromethane) yielded 52 mg of the title compound as white solid.

ESI-MS [M+H+]=764.3.

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.89 (d, 1H), 7.74 (dd, 1H), 7.62 (dd, 1H), 7.48 (s, 1H), 7.34 (m, 1H), 7.02 (dd, 1H), 6.70 (dd, 1H), 6.67 (d, 1H), 4.11 (q, 2H), 3.86 (s, 3H), 3.75 (m broad, 2H), 3.70-3.55 (m, 6H), 3.50 (s, 3H), 2.94 (m, 1H), 2.71 (m, 2H), 2.42 (m, 4H), 2.08 (m, 1H), 1.71 (m, 4H), 1.34 (m, 2H), 1.01 (t, 3H).

Example 25 (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((4-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is H, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

Prepared according to the procedure described for EXAMPLE 25:

ESI-MS [M+H+]=716.3.

Example 26 (S)—N-(5-Cyano-1-((2,4-difluorophenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I. 1, wherein R¹ is F, R² is F, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

To a solution of (S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide (200 mg, 0,367 mmol) in THF (3 ml) at 5° C. potassium tert-butoxide (60 mg, 0,535 mmol) and after 30 min 2,4-diflurobenzenesulfonylchloride (90 mg, 0,423 mmol) were added, and the mixture stirred over night at room temperature. The mixture was diluted with 20 ml of water, digested 3× with dichloromethane, and the combined organic layers washed with brine, dried over MgSO4, filtered and concentrated to give 300 mg of a clear oil. Flash chromatography (silica gel/gradient from 0 to 20% methanol in dichloromethane) yielded 115 mg of the title compound as white solid.

ESI-MS [M+H+]=716.3.

¹H NMR (600 MHz, DMSO) δ 8.30 (dd, 1H), 8.10 (m, 2H), 7.88 (m, 2H), 7.57 (s, 2H), 7.50 (m, 1H), 7.34 (m, 1H), 7.12 (dd, 1H), 4.09 (q, 2H), 3.80-3.50 (m, 7H), 2.93 (m, 1H), 2.71 (m, 2H), 2.39 (m, 4H), 2.08 (m, 1H), 1.71 (m, 4H), 1.4 (m, 2H), 0.98 (t, 3H).

The following compounds were prepared according to the procedure as described for EXAMPLE 27

Example 27 (S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-1-((2-fluoro-4-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is F, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

ESI-MS [M+H+]=734.3.

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 8.01 (dd, 1H), 7.94 (t, 1H), 7.85 (m, 2H), 7.61 (s, 1H), 7.58 (s, 1H), 7.10 (dd, 1H), 7.05 (dd, 1H), 6.98 (dd, 1H), 4.05 (m, 2H), 3.86 (s, 3H), 3.75 (m broad, 2H), 3.60-3.50 (m, 5H), 2.93 (m, 1H), 2.71 (m, 2H), 2.39 (m, 4H), 2.09 (m, 1H), 1.72 (m, 4H), 1.35 (m, 2H), 0.93 (t, 3H).

Example 28 (S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-1-((4-fluoro-2-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is F, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

ESI-MS [M+H+]=734.3.

1H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 8.01 (dd, 1H), 7.94 (dd, 1H), 7.86 (m, 2H), 7.64 (s, 1H), 7.56 (s, 1H), 7.15 (dd, 1H), 7.09 (dd, 1H), 6.98 (td, 1H), 4.10 (m, 2H), 3.74 (m broad, 2H), 3.62-3.50 (m, 6H), 3.49 (s, 3H), 2.94 (m, 1H), 2.71 (m, 2H), 2.39 (m, 4H), 2.08 (m, 1H), 1.71 (m, 4H), 1.34 (m, 2H), 0.98 (t, 3H).

Example 29 (S)—N-(5-Cyano-1-((2-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is H, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=702.2.

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.98 (d, 1H), 7.87 (d, 1H), 7.82 (m, 2H), 7.71 (m, 2H), 7.69 (s, 1H), 7.24 (d, 1H), 7.16 (m, 1H), 7.06 (m, 1H), 4.44 (m, 4H), 3.84 (q, 2H), 3.75 (m broad, 2H), 3.63 (s, 3H), 3.54 (s, 3H, overlapped with m broad, 2H), 2.92 (m, 1H), 2.69 (m, 2H), 2.19 (m, 1H), 1.66 (m, 2H), 1.49 (m, 2H), 1.37 (m, 2H).

Example 30 (S)—N-(5-Cyano-1-((4-fluoro-2-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is F, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=720.2.

¹H NMR (600 MHz, DMSO) δ 8.16 (dd, 1H), 8.04 (dd, 1H), 7.91 (dd, 1H), 7.87 (d, 1H), 7.83 (dd, 1H), 7.69 (d, 1H), 7.60 (s, 3H), 7.17 (dd, 1H), 7.10 (dd, 1H), 7.00 (td, 1H), 4.45 (m, 4H), 3.83-3.50 (m broad, 5H) overlapped with 3.65 (s, 3H), 2.92 (m, 1H), 2.71 (m, 2H), 2.19 (m, 1H), 1.66 (m, 2H), 1.50 (m, 2H), 1.36 (m, 2H).

Example 31 (S)—N-(5-Cyano-1-((4-fluorophenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is H, R² is F, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=690.2.

¹H NMR (600 MHz, DMSO) δ 8.16 (m, 3H), 8.05 (dd, 1H), 7.88 (d, 1H), 7.83 (dd, 1H), 7.65 (d, 2H), 7.53 (m, 2H), 7.13 (dd, 1H), 4.45 (m, 4H), 3.92-3.47 (m, 5H), 3.42 (s, 3H), 2.93 (m, 1H), 2.72 (m, 2H), 2.20 (m, 1H), 2.06 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H).

Example 32 (S)—N-(5-Cyano-1-((2-fluoro-4-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is F, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=720.3.

¹H NMR (600 MHz, DMSO) δ 8.16 (dd, 1H), 8.0 (m, 1H), 7.98 (m, 1H), 7.85 (m, 2H), 7.67 (s, 1H), 7.62 (s, 1H), 7.11 (m 2H), 7.0 (dd, 1H), 4.46 (m, 4H), 3.87 (s, 3H), 3.79-3.60 (m, 5H), 3.57 (s, 3H), 2.92 (m, 1H), 2.71 (m, 2H), 2.20 (m, 1H), 2.10 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H).

Example 33 (S)—N-(5-Cyano-1-((2,4-difluorophenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is F, R² is F, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=708.2.

¹H NMR (600 MHz, DMSO) δ 8.17 (dd, 1H), 8.14 (m, 1H), 8.06 (dd, 1H), 7.86 (m, 2H), 7.68 (s, 1H), 7.65 (s, 1H), 7.60 (m, 1H), 7.37 (m, 1H), 7.14 (dd, 1H), 4.46 (m, 4H), 3.90-3.55 (m, 5H), overlapped with 3.60 (s, 3H), 2.932 (m, 1H), 2.70 (m, 2H), 2.19 (m, 1H), 2.19 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.35 (m, 2H).

Example 34 (S)—N-(5-Cyano-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is 5-F (relative to the 2- and 4-positions of R¹ and R²), R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=750.3.

¹H NMR (600 MHz, DMSO) δ 8.16 (dd, 1H), 7.87 (m, 2H), 7.82 (dd, 1H), 7.75 (dd, 1H), 7.70 (d, 1H), 7.62 (s, 1H), 7.09 (dd, 1H), 6.92 (d, 1H), 4.46 (m, 4H), 3.96 (s, 3H), 3.85 (m broad, 2H), 3.66 and 3.58 (each s, 3H) overlapped with 3.70-3.50 (m, 3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.20 (m, 1H), 2.15 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H).

Example 35 (S)—N-(5-cyano-1-((4-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is H, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=702.3.

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 8.00 (dd, 1H), 7.85 (d, 1H), 7.82 (dd, 1H), 7.63 (m, 2H), 7.18 (m, 2H), 7.10 (dd, 1H), 4.45 (m, 4H), 3.86 (s, 3H), 3.75-3.65 (m, 3H), 3.59 (m broad, 2H), 2.93 (m, 1H), 2.72 (m, 2H), 2.20 (m, 1H), 2.09 (s, 3H), 1.68 (m, 2H), 1.52 (m, 2H), 1.37 (m, 2H).

Example 36 (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((5-methoxypyridin-2-yl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide×TFA

(compound of formula I.21, wherein R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

ESI-MS [M+H+]=717.3.

Example 37 (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((2-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is H, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

ESI-MS [M+H+]=716.3

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 7.97 (dd, 1H), 7.85 (m, 3H), 7.71 (m, 1H), 7.67 (s, 1H), 7.56 (s, 1H), 7.20 (d, 1H), 7.14 (m, 1H), 7.06 (dd, 1H), 4.08 (q, 2H), 3.81 (m broad, 2H), 3.75-3.50 (m, 5H), 3.49 (s, 1H), 2.93 (m, 1H), 2.70 (m, 2H), 2.40 (m, 4H), 2.08 (m, 1H), 1.71 (m, 4H), 1.34 (m, 2H), 0.94 (t, 3H).

Example 38 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(isopropyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is isopropyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=760.3

¹H NMR (600 MHz, DMSO) δ 8.15 (dd, 1H), 7.91 (d, 1H), 7.86 (d, 1H), 7.81 (m, 2H), 7.69 (d, 1H), 7.58 (s, 1H), 7.06 (dd, 1H), 6.72 (dd, 1H), 6.68 (d, 1H), 4.47 (m, 4H), 4.23 (m, 1H), 3.87 (s, 4H), 3.75 (m broad, 2H), 3.65 (s, 3H), 3.58 (m broad, 2H) 3.53 (s, 3H), 3.03 (m, 1H), 2.93 (m, 1H), 2.71 (m, 2H), 2.59 (m, 1H), 1.74 (m, 2H), 1.42 (m, 4H), 0.94 (d, 3H), 0.93 (d, 3H).

Example 39 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3,3-difluoroazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form 3,3-difluoroazetidin-1-yl)

ESI-MS [M+H+]=752.3

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.88 (d, 1H), 7.86-7.80 (m, 3H), 7.66 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.09 (q, 2H), 3.86 (s, 4H), 3.78 (m broad, 2H), 3.66-3.53 (m, 6H), 3.52 (s, 3H), 2.98 (m, 1H), 2.57 (m, 2H), 2.16 (d, 1H), 1.83 (d, 2H), 1.62 (d, 2H), 1.19 (m, 2H), 0.95 (t, 3H).

Example 40 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4,4-difluoro-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form 4,4-difluoropiperidin-1-yl)

ESI-MS [M+H+]=780.3

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.09 (q, 2H), 3.86 (s, 3H), 3.73 (m broad, 2H), 3.58 (m broad, 2H), 3.46 (s, 3H), 2.95 (m, 1H), 2.73 (m, 2H), 2.55 (m, 4H), 2.32 (m, 1H), 1.90 (m, 4H), 1.68 (m, 4H), 1.42 (m, 2H), 0.95 (t, 3H).

Example 41 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-methoxyazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form 3-methoxyazetidin-1-yl)

ESI-MS [M+H+]=746.3

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.07 (q, 2H), 3.89 (m, 1H), 3.86 (s, 3H), 3.76 (m broad, 2H), 3.58 (m broad, 2H), 3.46 (s, 3H), 3.42 (m, 2H), 3.13 (s, 3H), 2.95 (m, 1H), 2.69 (m, 2H), 2.51 (m, overlapped with DMSO, 2H), 1.94 (m, 1H), 1.79 (m, 2H), 1.59 (d, 2H), 1.14 (m, 2H), 0.95 (t, 3H).

Example 42 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-methoxy-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form 4-methoxypiperidin-1-yl)

ESI-MS [M+H+]=774.3

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.09 (q, 2H), 3.86 (s, 3H), 3.76 (m broad, 2H), 3.58 (m broad, 2H), 3.46 (s, 3H), 3.20 (s, 3H), 3.10 (m, 1H), 2.93 (m, 1H), 2.70 (m, 4H), 2.17 (m, 3H), 1.80 (m, 2H), 1.68 (m, 4H), 1.37 (m, 4H), 0.95 (t, 3H).

Example 43 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-hydroxyazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form 3-hydroxyazetidin-1-yl)

ESI-MS [M+H+]=732.3

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.87 (d, J=11.1 Hz, 1H), 7.83 (m, 3H), 7.66 (s, 1H), 7.53 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 5.23 (d, 1H), 4.09 (q, 2H), 3.86 (s, 3H), 3.76 (m broad, 2H), 3.58 (m broad, 2H), 3.45 (s, 3H), 3.41 (m, 3H), 2.95 (m, 1H), 2.60 (m, 2H), 2.52 (m overlapped with DMSO), 1.91 (m, 1H), 1.78 (s, 2H), 1.58 (m, 2H), 1.11 (m, 2H), 0.95 (t, 3H).

Example 44 (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-hydroxy-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form 4-hydroxypiperidin-1-yl)

ESI-MS [M+H+]=760.3

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.51 (d, 1H), 4.08 (q, 2H), 3.86 (s, 3H), 3.73 (m broad, 2H), 3.54 (m broad, 2H), 3.46 (s, 3H), 3.40 (m, overlapped with DMSO), 2.93 (m, 1H), 2.71 (m, 4H), 2.14 (m, 3H), 1.67 (m, 6H), 1.33 (m, 4H), 0.95 (t, 3H).

Example 45 (S)—N-(5-Cyano-3-(2,5-dimethoxyphenyl)-1-((2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.16, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to, form morpholin-4-yl)

ESI-MS [M+H+]=761.2

¹H NMR (600 MHz, DMSO) δ 7.90 (d, 1H), 7.84 (d, 1H), 7.77 (dd, 1H), 7.69 (d, 1H), 7.48 (s, 1H), 7.07 (d, 1H), 6.95-6.86 (m, 2H), 6.70 (dd, 1H), 6.66 (d, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.70-3.55 (m, 11H), 3.50 (s, 3H), 2.90 (m, 1H), 2.70 (m, 2H), 2.40 (m, 4H), 2.07 (m, 1H), 1.70 (m, 4H), 1.35 (m, 2H).

Example 46 (S)—N-(5-Cyano-3-(2,5-dimethoxyphenyl)-1-((2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.16, wherein R¹ is methoxy, R² is methoxy, R³ is H, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=761.3

¹H NMR (600 MHz, DMSO) δ 7.90 (d, 1H), 7.84 (d, 1H), 7.77 (dd, 1H), 7.68 (d, 1H), 7.48 (s, 1H), 7.07 (d, 1H), 6.96-6.87 (m, 2H), 6.69 (m, 1H), 6.66 (d, 1H), 4.53-4.41 (m, 4H), 3.90-3.81 (m, 5H), 3.74 (s, 3H), 3.64-3.56 (m, 3H), 3.53 (s, 3H), 3.49 (s, 3H), 2.91 (m, 1H), 2.70 (m, 2H), 2.19 (m, 1H), 2.08 (s, 3H), 1.66 (m, 2H), 1.50 (m, 2H), 1.35 (m, 2H).

III. Determination of the Biological Activity 1. Vasopressin V1b Receptor Binding Assay: Substances:

The test substances were dissolved in a concentration of 5 mM in 100% DMSO and further diluted to 5×10⁻⁴M to 5×10⁻⁹ M. These serial DMSO predilutions were diluted 1:10 with assay buffer. The substance concentration was further diluted 1:5 in the assay mixture resulting in 2% DMSO in the mixture. All dilutions were performed in a Biomek NX automation workstation (Beckman)

Membrane Preparation:

CHO-K1 cells with stably expressed human vasopressin V1b receptor (clone 3H2) were harvested and homogenized in 50 mM Tris-HCl and in the presence of protease inhibitors (Roche complete Mini #1836170) using a Polytron homogenizer at intermediate setting for 2×10 seconds, and subsequently centrifuged at 40 000×g for 1 h. The membrane pellet was again homogenized and centrifuged as described and subsequently taken up in 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen in liquid nitrogen at −190° C.

Binding Assay:

The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).

The incubation buffer was: 50 mM Tris, 10 mM MgCl₂, 0.1% BSA, pH 7.4.

In the assay mixture (2000), membranes (26 μg protein in incubation buffer) from CHO-K1 cells with stably expressed human V1b receptors (cell line hV1b_3H2_CHO) were incubated with 1.5 nM ³H-AVP (8-Arg-vasopressin, PerkinElmer, NET 800) in incubation buffer (50 mM Tris, 10 mM MgCl₂, 0.1% BSA, pH 7.4) (total binding) or additionally with increasing concentrations of test substance (displacement experiment). The nonspecific binding was determined with 1 μM AVP (Fluka 94836). All determinations were carried out as duplicate determinations. After incubation (60 minutes at room temperature), the free radioligand was filtered off by vacuum filtration (Tomtec Mach III) through Wathman GF/B glass fiber filter plates (UniFilter, PerkinElmer 6005177). The liquid scintillation measurement took place in a Microbeta TriLux 12 (Wallac).

Analysis:

The binding parameters were calculated by nonlinear regression in SAS. The algorithms of the program operate in analogy to the LIGAND analysis program (Munson P T and Rodbard D, Analytical Biochem. 107, 220-239 (1980)). The Kd of ³H-AVP for the recombinant human V1b receptors is 0.4 nM and was used to determine the Ki.

2. Vasopressin V1a Receptor Binding Assay: Substances:

The test substances were dissolved in a concentration of 5 mM M in DMSO. Further dilution of these DMSO solutions took place as described for V1b.

Membrane Preparation:

CHO-K1 cells with stably expressed human vasopressin V1a receptor (clone 5) were harvested and homogenized in 50 mM Tris-HCl and in the presence of protease inhibitors (Roche complete Mini #1836170) using a Polytron homogenizer at intermediate setting for 2×10 seconds, and subsequently centrifuged at 40 000×g for 1 h. The membrane pellet was again homogenized in a High-Pressure-Homogenizer, Polytec 50K at 1500 PSI (Heinemann, Germany) and subsequently taken up in 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen in liquid nitrogen at −190° C.

Binding Assay:

The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).

The incubation buffer was: 50 mM Tris, 10 mM MgCl₂, 0.1% BSA, pH 7.4.

In the assay mixture (200 μl), membranes (40 μg protein in incubation buffer) from CHO-K1 cells with stably expressed human V1a receptors (cell line hV1a_5_CHO) were incubated with 0.04 nM ¹²⁵I-AVP (8-Arg-vasopressin, PerkinElmer NEX 128) in incubation buffer (50 mM Tris, 10 mM MgCl₂, 0.1% BSA, pH 7.4) (total binding) or additionally with increasing concentrations of test substance (displacement experiment). The nonspecific binding was determined with 1 μM AVP (Fluka 94836). Duplicate determinations were carried out.

After incubation (60 minutes at room temperature), the samples were processed as described for V1b.

Analysis:

The binding parameters were calculated by nonlinear regression in SAS. The algorithms of the program operate in analogy to the LIGAND analysis program (Munson P J and Rodbard D, Analytical Biochem. 107, 220-239 (1980)). The Kd of ¹²⁵I-AVP for the recombinant hV1a receptors was determined in saturation experiments. A Kd of 1.33 nM was used to determine the Ki.

3. Oxytocin Receptor Binding Assay Substances:

The substances were dissolved in a concentration of 5 mM in DMSO and diluted further as described for V1b.

Membrane Preparation:

Confluent HEK-293 cells with transiently expressing recombinant human oxytocin receptors were harvested and centrifuged at 750×g at room temperature for 5 minutes. The pellet was taken up in ice-cold lysis buffer (50 mM Tris-HCl, 10% glycerol, pH 7.4 and Roche complete protease inhibitor) and thereby subjected to an osmotic shock at 4° C. for 20 minutes. Lysed cells were then centrifuged at 750×g at 4° C. for 20 minutes, the pellet was taken up in incubation buffer (50 mM Tris, 10 mM MgCl₂, 0.1% BSA, pH 7.4), and aliquots corresponding to 10⁷ cells/ml were prepared. The aliquots were frozen at −80° C. until use.

Binding Assay:

On the day of the experiment, the cell lysate was thawed, homogenized, and diluted with incubation buffer (50 mM Tris, 10 mM MgCl₂, 0.1% BSA, pH 7.4) to the desired concentration. The reaction mixture of 0.200 ml was composed of cell lysate corresponding to 5×10⁴ cells (HEK-293 cells expressing transiently human OT receptors) and 1 nM 3H-oxytocin (PerkinElmer NET858) in the presence of test substance (displacement experiment) or incubation buffer only (total binding). The nonspecific binding was determined in the presence of 1 μM oxytocin (Bachem AG, H2510). Determinations were carried out in duplicates. After 60 minutes incubation at room temperature, bound and free radioligand were separated by filtration under vacuum on GF/B UniFilter plates (Perkin Elmer #6005177) pre-incubated with 0.3% PEI. The bound radioactivity was determined by liquid scintillation measurement in a Microbeta (Perkin Elmer) plate counter.

Analysis:

The binding parameters were calculated by nonlinear regression analysis (SAS) in analogy to the LIGAND program of Munson and Rodbard (Analytical Biochem 1980; 107: 220-239). The Kd of ³H-oxytocin for the recombinant hOT receptors was 7.6 nM and was used to calculate the Ki from competition binding experiments.

4. Determination of the Microsomal Half-Life:

The metabolic stability of the compounds of the invention was determined in the following assay.

The test substances were incubated in a concentration of 0.5 μM as follows: 0.5 μM test substance are preincubated together with liver microsomes from different species (from rat, human or other species) (0.25 mg of microsomal protein/ml) in 0.05 M potassium phosphate buffer of pH 7.4 in microtiter plates at 37° C. for 5 min. The reaction is started by adding NADPH (1 mg/mL). After 0, 5, 10, 15, 20 and 30 min, 50 μl aliquots are removed, and the reaction is immediately stopped and cooled with the same volume of acetonitrile. The samples are frozen until analyzed. The remaining concentration of undegraded test substance is determined by MSMS. The half-life (T½) is determined from the gradient of the signal of test substance/unit time plot, it being possible to calculate the half-life of the test substance, assuming first order kinetics, from the decrease in the concentration of the compound with time. The microsomal clearance (mCl) is calculated from mCl=ln 2/T½/(content of microsomal protein in mg/ml)×1000 [ml/min/mg] (modified from references: Di, The Society for Biomoleculur Screening, 2003, 453-462; Obach, D M D, 1999 vol 27. N 11, 1350-1359).

5. Methods for In Vitro Determination of the Cytochrome P450 (CYP) Inhibition Luminescent Substrates for 2C9 and 3A4:

0.4 mg/ml human liver microsomes are preincubated with the test substances to be investigated (0-20 μM), the CYP-specific substrates, in 0.05 M potassium phosphate buffer of pH 7.4 at 37° C. for 10 min. The Cyp-specific substrate for CYP 2C9 is lucifer-luciferin H, and for CYP 3A4 is luciferin BE. The reaction is started by adding NADPH. After incubation at RT for 30 min, the luciferin detection reagent is added, and the resulting luminescence signal is measured (modified from reference: Promega, Technical Bulletin P450-GLO™ Assays).

Midazolam CYP 3A4 Time-Dependent Inhibition

The assay consists of 2 parts. Firstly, the test substance is preincubated with the liver microsomes (with NADPH=preincubation, then addition of the substrate; in the second part the substrate and the test substance are added simultaneously=coincubation.

Preincubation:

0.05 mg/ml microsomal protein (human liver microsomes) are preincubated with 0-10 μM (or 50 μM) test substance in 50 mM potassium phosphate buffer for 5 min. The reaction is started with NADPH. After 30 min 4 μM midazolam (final concentration) are added, and incubation is continued for 10 min. 75 μl of the reaction solution are removed after 10 min, and stopped with 150 μl of acetonitrile solution.

Coincubation:

0.05 mg/ml microsomal protein (human liver microsomes) are preincubated with 4 μm midazolam (final concentration) and 0-10 μM (or 50 0\4) test substance in 50 mM potassium phosphate buffer for 5 min. The reaction is started with NADPH. 75 μl of the reaction solution are removed after 10 min and stopped with 150 μl of acetonitrile solution. The samples are frozen until the MSMS analysis (modified from references: Obdach, Journal of Pharmacology & Experimental Therapeutics, Vol 316, 1, 336-348, 2006; Walsky, Drug Metabolism and Disposition Vol 32, 6, 647-660, 2004).

6. Method for Determining the Solubility in Water (in Mg/Ml)

The solubility in water of the compounds of the invention can be determined for example by the so-called shake flask method (as specified in ASTM International: E 1148-02, Standard test methods for measurement of aqueous solubility, Book of Standards Volume 11.05.). This entails an excess of the solid compound being put into a buffer solution with a particular pH (for example phosphate buffer of pH 7.4), and the resulting mixture being shaken or stirred until equilibrium has been set up (typically 24 or 48 hours, sometimes even up to 7 days). The undissolved solid is then removed by filtration or centrifugation, and the concentration of the dissolved compound is determined by UV spectroscopy or high pressure liquid chromatography (HPLC) by means of an appropriate calibration plot.

7. Results

The results of the receptor binding investigations are expressed as receptor binding constants [K_(i)(V1b)] or selectivities [K_(i)(V1a)/K_(i)(V1b)]. The results of the investigation of the metabolic stability are indicated as microsomal clearance (mCl).

The compounds of the invention show very high affinities for the V1b receptor in these assays (maximally 100 nM, or maximally 10 nM, frequently <1 nM). The compounds also show high selectivities vis-à-vis the V1a receptor and a good metabolic stability, measured as microsomal clearance.

The results are listed in table C. The numbers of the compounds refer to the synthesis examples.

TABLE C Example K_(i)(h-V1b)* [nM] K_(i)(h-V1a)/Ki(h-V1b) 1 +++ +++ 2 +++ +++ 3 +++ +++ 4 ++ +++ 5 ++ +++ 6 ++ +++ 8 +++ ++ 9 +++ ++ 10 +++ +++ 11 ++ ++ 13 +++ +++ 14 +++ ++ 15 ++ +++ 17 + +++ 18 +++ +++ 19 +++ +++ 20 ++ + 21 +++ + 23 ++ ++ 24 ++ +++ 25 +++ ++ 26 ++ +++ 27 +++ +++ 28 ++ +++ 29 ++ + 30 ++ + 31 ++ + 32 ++ + 33 + + 35 ++ ++ 36 ++ + 37 ++ +++ 38 + + 39 + +++ 40 +++ +++ 41 ++ +++ 42 ++ +++ 43 ++ +++ 44 +++ +++ 45 +++ + 46 +++ ++ * h = human Key: K_(i)(h-V1b) K_(i)(h-V1a)/K_(i)(h-V1b) + >10-100 nM 10-<25 ++ 1-10 nM 25-75 +++ <1 nM >75 

1. A compound of formula I

wherein X¹ is N or CH; X² is C—R¹ or N; R¹ and R², independently of each other, are selected from hydrogen, halogen, cyano, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-hydroxyalkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy; R³ is selected from hydrogen, halogen, cyano, hydroxyl, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-hydroxyalkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy; R⁴ is selected from C₁-C₃-alkoxy; R⁵ is selected from hydrogen and C₁-C₃-alkoxy; R⁶ is selected from cyano and halogen; R⁷ is selected from hydrogen, halogen and cyano; R⁸ is selected from hydrogen, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₃-C₇-halocycloalkyl and phenyl which may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, phenoxy, wherein the phenyl moiety may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or R⁸ and R⁹, together with the nitrogen atom they are bound to, form a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring, wherein the heterocyclic ring may contain 1 or 2 further heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, and wherein the heterocyclic ring may carry 1 or 2 substituents R¹² and/or 1 or 2 substituents R^(D); wherein in case that the heterocyclic ring does not contain 1 or 2 further heteroatoms or heteroatom groups as ring members, the heterocyclic ring carries 1 or 2 substituents R¹² and optionally 1 or 2 substituents R^(D); R¹⁰ and R¹¹, independently of each other and independently of each occurrence, are selected from halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy, with the proviso that R¹⁰ and R¹¹ are not halogen, C₁-C₄-alkoxy or C₁-C₄-haloalkoxy if they are bound to a carbon atom in α-position to a nitrogen ring atom; or two non-geminal radicals R¹⁰ form together a group —(CH₂)_(n)—, wherein n is 1, 2, 3 or 4, wherein 1 or 2 hydrogen atoms in this group may be replaced a methyl group; or two non-geminal radicals R¹¹ form together a group —(CH₂)_(n)—, wherein n is 1, 2, 3 or 4, wherein 1 or 2 hydrogen atoms in this group may be replaced a methyl group; each R¹² is independently selected from halogen, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, phenoxy, benzyloxy, wherein the phenyl moiety in the two last-mentioned radicals may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or two radicals R¹², together with the atom(s) they are bound to, form a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; each R¹³ is independently selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₃-C₇-halocycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, C₁-C₄-alkylcarbonyl, C₁-C₄-haloalkylcarbonyl, phenyl, phenoxy and a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the phenyl moieties or the heterocyclic ring may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; a is 0, 1 or 2; and b is 0, 1, 2, 3 or 4; or a N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof; and the above compound, wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope.
 2. The compound of claim 1, wherein at least one hydrogen atom has been replaced by a deuterium atom.
 3. The compound of claim 1, wherein X² is C—R¹ and R¹, R² and R³, independently of each other, are selected from the group consisting of hydrogen, halogen, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy.
 4. The compound of claim 3, wherein R¹, R² and R³, independently of each other, are selected from the group consisting of hydrogen, fluorine and methoxy.
 5. The compound of claim 4, wherein R¹ is selected from hydrogen, fluorine and methoxy.
 6. The compound of claim 4, wherein R² is selected from the group consisting of hydrogen, fluorine and methoxy.
 7. The compound of claim 4, wherein R³ is hydrogen or fluorine.
 8. The compound of claim 1, wherein X² is N and R² and R³, independently of each other, are selected from the group consisting of hydrogen, halogen, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy.
 9. The compound of claim 8, wherein R² is selected from the group consisting of hydrogen, fluorine and methoxy.
 10. The compound of claim 8, wherein R³ is selected from the group consisting of hydrogen, fluorine and methoxy.
 11. The compound of claim 1, wherein R⁴ is selected from the group consisting of methoxy and ethoxy.
 12. The compound of claim 1, wherein R⁵ is hydrogen or methoxy.
 13. The compound of claim 1, wherein R⁶ is selected from the group consisting of cyano, fluorine and chlorine.
 14. The compound of claim 1, wherein R⁷ is hydrogen or fluorine.
 15. The compound of claim 1, wherein R⁸ is selected from the group consisting of hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₃-C₆-cycloalkyl and C₃-C₆-halocycloalkyl; R⁹ is selected from the group consisting of C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₆-cycloalkoxy, C₃-C₆-halocycloalkoxy, and a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or R⁸ and R⁹, together with the nitrogen atom they are bound to, form a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring, wherein the heterocyclic ring may contain 1 or 2 further heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, and wherein the heterocyclic ring may carry 1 or 2 substituents R¹² and/or 1 substituent R¹³; wherein in case that the heterocyclic ring does not contain 1 or 2 further heteroatoms or heteroatom groups as ring members, the heterocyclic ring carries 1 or 2 substituents R¹² and optionally 1 substituent R¹³; each R¹² is independently selected from the group consisting of halogen, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₆-cycloalkoxy, C₃-C₆-halocycloalkoxy, and a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or two radicals R¹², together with the atom(s) they are bound to, form a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and R¹³ is selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₃-C₆-halocycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, C₁-C₄-alkylcarbonyl, C₁-C₄-haloalkylcarbonyl, phenyl, phenoxy and a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the phenyl moieties or the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy.
 16. The compound of claim 15, wherein R⁸ is selected from the group consisting of hydrogen, C₁-C₄-alkyl, fluorinated C₁-C₄-alkyl, C₃-C₆-cycloalkyl and fluorinated C₃-C₆-cycloalkyl; R⁹ is selected from the group consisting of C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or R⁸ and R⁹, together with the nitrogen atom they are bound to, form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring, wherein the heterocyclic ring may contain 1 or 2 further heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, and wherein the heterocyclic ring may carry 1 or 2 substituents R¹² and/or 1 substituent R¹³; wherein in case that the heterocyclic ring does not contain 1 or 2 further heteroatoms or heteroatom groups as ring members, the heterocyclic ring carries 1 or 2 substituents R¹² and optionally 1 substituent R¹³; each R¹² is independently selected from the group consisting of halogen, hydroxyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from halogen, hydroxyl, cyano, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or two radicals R¹², together with the atom(s) they are bound to, form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and R¹³ is selected from the group consisting of halogen, hydroxyl, cyano, fluorinated C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, fluorinated C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy.
 17. The compound of claim 16, wherein R⁸ is selected from the group consisting of hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl; R⁹ is selected from the group consisting of C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 oxygen atom as ring member; or R⁸ and R⁹, together with the nitrogen atom they are bound to form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring, wherein the heterocyclic ring contains 1 further oxygen atom as ring member, and wherein the heterocyclic ring may carry 1 or 2 substituents R¹²; or form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring which carries 1 or 2 substituents R¹²; and each R¹² is independently selected from the group consisting of halogen, hydroxyl, C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 oxygen atom as ring member; or two radicals R¹² bound to the same carbon ring atom, together with this carbon atom they are bound to, form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 oxygen atom as ring member.
 18. The compound of claim 17, wherein the saturated heterocyclic ring formed by R⁸ and R⁹ together with the nitrogen atom they are bound to is selected from the group consisting of azetidin-1-yl carrying in the 3-position (relative to the 1-position of the nitrogen ring atom) 1 or 2 substituents R¹²; isoxazolidin-2-yl, piperidin-1-yl carrying in the 4-position (relative to the 1-position of the nitrogen ring atom) 1 or 2 substituents R¹²; and morpholin 1-yl.
 19. The compound of claim 17, wherein two radicals R¹² bound to the same carbon ring atom together form a group —CH₂—O—CH₂— (i.e. together with the carbon atom they are bound to form a spiro-bound oxetan-3-yl ring).
 20. The compound of claim 1, wherein each R¹⁰ is independently selected from the group consisting of halogen and C₁-C₄-alkyl, with the proviso that R¹⁰ is not halogen if it is bound to a carbon atom in α-position to a nitrogen ring atom.
 21. The compound of claim 1, wherein each R¹¹ is independently selected from the group consisting of halogen and C₁-C₄-alkyl, with the proviso that R¹¹ is not halogen if it is bound to a carbon atom in α-position to a nitrogen ring atom; or two non-geminal radicals R¹¹ form together a group —CH₂—.
 22. The compound of claim 1, wherein X¹ is N.
 23. The compound of claim 1, wherein X¹ is CH.
 24. The compound of claim 1, wherein X² is C—R¹.
 25. The compound of claim 1, wherein X² is N.
 26. The compound of claim 1, wherein a is 0 or
 1. 27. The compound of claim 1, wherein b is 0, 1 or
 2. 28. A compound selected from the group consisting of (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(ethyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)-3-(4-(2-Oxa-7-Azaspiro[3.5]nonan-7-yl)piperidin-1-yl)-N-(5-cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)azetidine-1-carboxamide; N-[(3 S)-5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-ethoxy-3-pyridyl)-2-oxoindolin-3-yl]-3 [4-[cyclopropyl(oxetan-3-yl)amino]-1-piperidyl]azetidine-1-carboxamide; (S)—N-(1-((2,4-Dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; N-[(3 S)-1-[(2,4-Dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxo-2,3-dihydro-1H-indol-3-yl]-3-{4-[methyl(oxetan-3-yl)amino]piperidin-1-yl}azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(cyclopropyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Chloro-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(2-methoxyethyl)(methyl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methoxy(methyl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(isoxazolidin-2-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-(oxetan-3-yl)azetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)-3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-yl)piperidin-1-yl)-N-(5-cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(oxetan-3-ylamino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(oxetan-3-yl(propyl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(ethyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-(2,4-difluorophenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-1-(2-fluoro-4-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-1-((4-fluoro-2-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((4-fluoro-2-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((4-fluorophenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2-fluoro-4-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-difluorophenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-cyano-1-((4-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((5-methoxypyridin-2-yl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((2-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(isopropyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3,3-difluoroazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4,4-difluoro-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-methoxyazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-methoxy-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-hydroxyazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-hydroxy-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2,5-dimethoxyphenyl)-1-(2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; and (S)—N-(5-Cyano-3-(2,5-dimethoxyphenyl)-1-((2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; or a N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof; and the above compound, wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope.
 29. A pharmaceutical composition comprising a compound of claim 1 or an N-oxide, a stereoisomer, or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.
 30. (canceled)
 31. (canceled)
 32. (canceled)
 33. (canceled)
 34. (canceled)
 35. A method for the treatment and/or prophylaxis of vasopressin-related diseases, comprising administering an effective amount of a compound of claim 1 or an N-oxide, stereoisomer or pharmaceutically acceptable salt thereof to a subject in need thereof.
 36. The method of claim 35, wherein the vasopressin-related diseases is selected from the group consisting of hypertension; pulmonary hypertension; heart failure; myocardial infarction; coronary spasm; unstable angina; percutaneous transluminal coronary angioplasty; ischemias of the heart; impairments of the renal system; edemas; renal vasospasm; necrosis of the renal cortex; hyponatremia; hypokalemia; Schwartz-Bartter syndrome; impairments of the gastrointestinal tract; gastritic vasospasm; hepatocirrhosis; gastric and intestinal ulcers; emesis; emesis related to chemotherapy; travel sickness; affective disorders; anxiety disorders and stress-dependent anxiety disorders; memory and cognitive impairments such as Alzheimer's disease, mild cognitive impairment and cognitive impairment associated with schizophrenia; psychoses and psychotic disorders; Cushing's syndrome and other stress-dependent diseases; sleep disorders; depressive disorders, such as major depression, seasonal depression, bipolar disorders, treatment-resistant depression, dysthymic disorders or childhood onset mood disorders; vasomotor symptoms, thermoregulatory dysfunctions; drug or pharmaceutical dependencies, dependencies mediated by other factors; stress caused by withdrawal of one or more factors mediating the dependence; stress-induced relapses into drug or pharmaceutical dependencies and/or dependencies mediated by other factors; drug-use disorders; schizophrenia and psychosis; and delaying micturition
 37. The method of claim 35, wherein the vasopressin-related diseases is selected from the group consisting of depressive disorders; anxiety disorders and stress-dependent anxiety disorders; drug or pharmaceutical dependencies; and dependencies mediated by alcohol use disorder, alcohol intoxication, alcohol withdrawal and unspecified alcohol-related disorder. 